title,page_link,pdf_link,issue_date,fda_organization,topic,status,docket_number,comment,closing_comment
"510(k) Third Party Review Program and Third Party Emergency Use Authorization (EUA) Review:  Guidance for Industry, Food and Drug Administration Staff, and Third Party Review Organizations",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/510k-third-party-review-program-and-third-party-emergency-use-authorization-eua-review,https://www.fda.gov/media/85284/download,2024-11-21,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Administrative / Procedural']",Final,FDA-2016-D-2565,No,
Frequently Asked Questions — Developing Potential Cellular and Gene Therapy Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/frequently-asked-questions-developing-potential-cellular-and-gene-therapy-products,https://www.fda.gov/media/183631/download,2024-11-18,['Center for Biologics Evaluation and Research'],['Gene Therapy'],Draft,FDA-2024-D-4311,No,
Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-safety-assessment-oligonucleotide-based-therapeutics,https://www.fda.gov/media/183496/download,2024-11-15,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Draft,FDA-2024-D-4624,Yes,2025-01-14
Guidance for Industry: FDA's Voluntary Qualified Importer Program,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-fdas-voluntary-qualified-importer-program,https://www.fda.gov/media/92196/download,2024-11-14,"['Center for Veterinary Medicine','Office of Inspections and Investigations','Human Foods Program']",['Import'],Final,FDA-2011-N-0144,No,
CPG Sec 540.525 Scombrotoxin (Histamine)-forming Fish and Fishery Products – Decomposition and Histamine (CPG 7108.24),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540525-scombrotoxin-histamine-forming-fish-and-fishery-products-decomposition-and-histamine,https://www.fda.gov/media/182955/download,2024-11-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Seafood/Seafood Product']",Final,FDA-2021-D-0367,No,
Study Data Technical Conformance Guide - Technical Specifications Document,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/study-data-technical-conformance-guide-technical-specifications-document,https://www.fda.gov/media/153632/download,2024-10-31,['Center for Drug Evaluation and Research'],,Final,FDA-2014-D-0092,No,2014-05-07
M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m13a-bioequivalence-immediate-release-solid-oral-dosage-forms,https://www.fda.gov/media/165049/download,2024-10-30,['Center for Drug Evaluation and Research'],['ICH-Multidisciplinary'],Final,FDA-2023-D-0093,No,2023-04-03
CVM GFI #293 - FDA Enforcement Policy for AAFCO-Defined Animal Feed Ingredients,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-293-fda-enforcement-policy-aafco-defined-animal-feed-ingredients,https://www.fda.gov/media/180441/download,2024-10-24,['Center for Veterinary Medicine'],"['Postmarket','Premarket','Animal Food Additives','Labeling']",Final,FDA-2024-D-2977,No,2024-09-09
"Guidance for Industry: Insanitary Conditions in the Preparation, Packing, and Holding of Tattoo Inks and the Risk of Microbial Contamination",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-insanitary-conditions-preparation-packing-and-holding-tattoo-inks-and-risk,https://www.fda.gov/media/183019/download,2024-10-22,['Office of the Commissioner'],['Tattoos'],Final,FDA-2023-D-1083,No,2023-09-11
Drug Interaction Information in Human Prescription Drug and Biological Product Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-interaction-information-human-prescription-drug-and-biological-product-labeling,https://www.fda.gov/media/182893/download,2024-10-21,['Center for Drug Evaluation and Research'],"['Labeling','Clinical - Pharmacology']",Draft,FDA-2024-D-3903,Yes,2025-01-21
Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/review-drug-master-files-advance-certain-anda-submissions-under-gdufa,https://www.fda.gov/media/162019/download,2024-10-17,['Center for Drug Evaluation and Research'],"['User Fees','Chemistry, Manufacturing, and Controls (CMC)','Generic Drugs','Pharmaceutical Quality','Drug Competition Action Plan']",Final,FDA-2022-D-2061,No,
Postoperative Nausea and Vomiting: Developing Drugs for Prevention,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postoperative-nausea-and-vomiting-developing-drugs-prevention,https://www.fda.gov/media/182757/download,2024-10-17,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2024-D-3993,Yes,2024-12-17
"Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-development-blood-collection-processing-and-storage-systems-manufacture-blood,https://www.fda.gov/media/182751/download,2024-10-17,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Draft,FDA-2024-D-2732,No,
Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-long-term-clinical-neurodevelopmental-safety-studies-neonatal-product-development,https://www.fda.gov/media/165239/download,2024-10-17,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research','Office of the Commissioner']","['Clinical - Medical','Pediatric Product Development']",Final,FDA-2022-D-0112,No,
Core Patient-Reported Outcomes in Cancer Clinical Trials:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/core-patient-reported-outcomes-cancer-clinical-trials,https://www.fda.gov/media/149994/download,2024-10-17,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Clinical Trials','Clinical - Medical']",Final,FDA-2020-D-2303,No,2021-08-09
Requests for Reconsideration at the Division Level Under GDUFA,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-reconsideration-division-level-under-gdufa,https://www.fda.gov/media/108398/download,2024-10-16,['Center for Drug Evaluation and Research'],"['User Fees','Generic Drugs']",Final,FDA-2017-D-5868,No,2024-03-11
CVM GFI #284 Using Relative Supersaturation to Support “Urinary Tract Health” Claims for Adult Maintenance Cat Food,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-284-using-relative-supersaturation-support-urinary-tract-health-claims-adult-maintenance-cat,https://www.fda.gov/media/173985/download,2024-10-15,['Center for Veterinary Medicine'],"['Animal Feed','Labeling']",Final,FDA-2023-D-4095,No,2024-02-28
Endosseous Dental Implants and Endosseous Dental Implant Abutments - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/endosseous-dental-implants-and-endosseous-dental-implant-abutments-performance-criteria-safety-and,https://www.fda.gov/media/182616/download,2024-10-15,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Dental']",Final,FDA-2024-D-4409,No,
Temporary Policies for Compounding Certain Parenteral Drug Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/temporary-policies-compounding-certain-parenteral-drug-products,https://www.fda.gov/media/182632/download,2024-10-11,['Center for Drug Evaluation and Research'],['Compounding'],Final,FDA-2024-D-4774,No,
"Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations:  Questions and Answers",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-systems-electronic-records-and-electronic-signatures-clinical-investigations-questions,https://www.fda.gov/media/166215/download,2024-10-01,"['Center for Drug Evaluation and Research','Office of the Commissioner']",['Administrative / Procedural'],Final,FDA-2017-D-1105,No,2023-05-15
CVM GFI #116 (VICH GL23 (R2)) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Genotoxicity Testing (Revision 2),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-116-vich-gl23-r2-studies-evaluate-safety-residues-veterinary-drugs-human-food-genotoxicity,https://www.fda.gov/media/70134/download,2024-09-30,['Center for Veterinary Medicine'],"['Human Food Safety','VICH']",Draft,FDA-2000-D-0598,Yes,2024-11-29
Air Powered Dental Handpieces and Air Motors - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/air-powered-dental-handpieces-and-air-motors-performance-criteria-safety-and-performance-based,https://www.fda.gov/media/182279/download,2024-09-30,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Dental']",Final,FDA-2024-D-4168,No,
Dental Cements - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dental-cements-performance-criteria-safety-and-performance-based-pathway,https://www.fda.gov/media/182280/download,2024-09-30,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Dental']",Final,FDA-2024-D-4171,No,
Dental Ceramics - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dental-ceramics-performance-criteria-safety-and-performance-based-pathway,https://www.fda.gov/media/182281/download,2024-09-30,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Dental']",Final,FDA-2024-D-4169,No,
Dental Impression Materials - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dental-impression-materials-performance-criteria-safety-and-performance-based-pathway,https://www.fda.gov/media/182282/download,2024-09-30,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Dental']",Final,FDA-2024-D-4170,No,
Clarification of Radiation Control Regulations For Manufacturers of Diagnostic X-Ray Equipment:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clarification-radiation-control-regulations-manufacturers-diagnostic-x-ray-equipment,https://www.fda.gov/media/119827/download,2024-09-27,['Center for Devices and Radiological Health'],"['Export','Import','Labeling','Radiology']",Final,FDA-2018-D-4115,No,
Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-considerations-human-radiolabeled-mass-balance-studies,https://www.fda.gov/media/158178/download,2024-09-26,['Center for Drug Evaluation and Research'],['Clinical - Pharmacology'],Final,FDA-2022-D-0113,No,2022-08-04
"Small Entity Compliance Guide: Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-standards-growing-harvesting-packing-and-holding-produce-human,https://www.fda.gov/media/107298/download,2024-09-25,['Human Foods Program'],['Produce'],Final,FDA-2011-N-0921,No,
An Acceptable Circular of Information for the Use of Human Blood and Blood Components:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acceptable-circular-information-use-human-blood-and-blood-components,https://www.fda.gov/media/86898/download,2024-09-25,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2002-D-0223,No,
"Basic Safety and Essential Performance of Medical Electrical Equipment, Medical Electrical Systems, and Laboratory Medical Equipment - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Program: Draft Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/basic-safety-and-essential-performance-medical-electrical-equipment-medical-electrical-systems-and-0,https://www.fda.gov/media/182020/download,2024-09-23,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Premarket'],Draft,FDA-2019-D-3805,Yes,2024-12-23
"Biocompatibility Testing of Medical Devices - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Program : Draft Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biocompatibility-testing-medical-devices-standards-specific-information-accreditation-scheme-0,https://www.fda.gov/media/182026/download,2024-09-23,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Premarket'],Draft,FDA-2019-D-3805,Yes,2024-12-23
"The Accreditation Scheme for Conformity Assessment (ASCA) Program: Draft Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/basic-safety-and-essential-performance-medical-electrical-equipment-medical-electrical-systems-and-0,https://www.fda.gov/media/182020/download,2024-09-23,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Premarket'],Draft,FDA-2019-D-3805,Yes,2024-12-23
Chemical Analysis for Biocompatibility Assessment of Medical Devices: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemical-analysis-biocompatibility-assessment-medical-devices,https://www.fda.gov/media/181952/download,2024-09-20,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','Chemistry, Manufacturing, and Controls (CMC)']",Draft,FDA-2024-D-4165,Yes,2024-12-19
Conducting Clinical Trials With Decentralized Elements,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/conducting-clinical-trials-decentralized-elements,https://www.fda.gov/media/167696/download,2024-09-18,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']",['Clinical - Medical'],Final,FDA-2022-D-2870,No,2023-08-01
Integrating Randomized Controlled Trials for Drug and Biological Products Into Routine Clinical Practice: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/integrating-randomized-controlled-trials-drug-and-biological-products-routine-clinical-practice,https://www.fda.gov/media/181871/download,2024-09-18,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Real World Data / Real World Evidence (RWD/RWE)'],Draft,FDA-2024-D-2052,Yes,2024-12-17
"CVM GFI #227 Chemistry, Manufacturing, and Controls (CMC) Technical Section Filing Strategies",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-227-chemistry-manufacturing-and-controls-cmc-technical-section-filing-strategies,https://www.fda.gov/media/89527/download,2024-09-17,['Center for Veterinary Medicine'],"['Premarket','Animal Drugs','Chemistry, Manufacturing, and Controls (CMC)','Investigational New Animal Drug (INAD)','New Animal Drug Application (NADA)']",Draft,FDA-2014-D-1492,No,2024-11-18
Data Standards Catalog,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-standards-catalog,,2024-09-16,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research','Human Foods Program','Center for Veterinary Medicine']",,Final,,No,
Considerations for Generating Clinical Evidence from Oncology Multiregional Clinical Development Programs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-generating-clinical-evidence-oncology-multiregional-clinical-development-programs,https://www.fda.gov/media/181824/download,2024-09-16,[],['Clinical - Medical'],Draft,FDA-2024-D-3163,No,2024-11-18
Enforcement Policy for Required Warnings for Cigarette Packages and Advertisements,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-required-warnings-cigarette-packages-and-advertisements,https://www.fda.gov/media/181776/download,2024-09-13,['Center for Tobacco Products'],,Final,FDA-2024-D-3742,No,
Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-certain-human-pharmaceutical-product-applications,https://www.fda.gov/media/135373/download,2024-09-13,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Electronic Submissions'],Final,FDA-2014-N-1006,No,
Submission of Plans for Cigarette Packages and Cigarette Advertisements (Revised),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-plans-cigarette-packages-and-cigarette-advertisements-revised,https://www.fda.gov/media/133839/download,2024-09-12,['Center for Tobacco Products'],,Final,FDA-2019-D-5364,No,
Required Warnings for Cigarette Packages and Advertisements: Small Entity Compliance Guide (Revised):  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/required-warnings-cigarette-packages-and-advertisements-small-entity-compliance-guide-revised,https://www.fda.gov/media/136185/download,2024-09-12,['Center for Tobacco Products'],,Final,FDA-2020-D-0988,No,
ANDA Submissions | Amendments to Abbreviated New Drug Applications Under GDUFA:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/anda-submissions-amendments-abbreviated-new-drug-applications-under-gdufa,https://www.fda.gov/media/89258/download,2024-09-11,['Center for Drug Evaluation and Research'],"['User Fees','Drug Competition Action Plan','Generic Drugs']",Final,FDA-2017-D-5670,No,
"Appeal Options Available to Mammography Facilities Concerning Adverse Accreditation Decisions, Suspension/Revocation of Certificates, or Patient and Referring Provider Notification Orders:  Guidance for Mammography Facilities and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/appeal-options-available-mammography-facilities-concerning-adverse-accreditation-decisions,https://www.fda.gov/media/140242/download,2024-09-10,['Center for Devices and Radiological Health'],"['Investigation & Enforcement','Administrative / Procedural','Radiological Health','Radiology']",Final,FDA-2020-D-1317,No,
Withdrawn Guidances (Biologics),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/withdrawn-guidances-biologics,,2024-09-06,['Center for Biologics Evaluation and Research'],,Final,,No,
"Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle: Draft Guidance for Industry, Food and Drug Administration Staff, and Other Interested Parties",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/incorporating-voluntary-patient-preference-information-over-total-product-life-cycle,https://www.fda.gov/media/181509/download,2024-09-06,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",,Draft,FDA-2015-D-1580,Yes,2024-12-05
Control of Nitrosamine Impurities in Human Drugs:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/control-nitrosamine-impurities-human-drugs,https://www.fda.gov/media/141720/download,2024-09-05,['Center for Drug Evaluation and Research'],"['Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,FDA-2020-D-1530,No,
Bioresearch Monitoring Technical Conformance Guide,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioresearch-monitoring-technical-conformance-guide,https://www.fda.gov/media/85061/download,2024-09-03,['Center for Drug Evaluation and Research'],['Electronic Submissions'],Final,FDA-2018-D-1216,No,
Voluntary Malfunction Summary Reporting (VMSR) Program for Manufacturers:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/voluntary-malfunction-summary-reporting-vmsr-program-manufacturers,https://www.fda.gov/media/163692/download,2024-08-29,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']",,Final,FDA-2022-D-2873,No,
CVM GFI #63 (VICH GL1) Validation of Analytical Procedures: Definition and Terminology,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-63-vich-gl1-validation-analytical-procedures-definition-and-terminology,https://www.fda.gov/media/70168/download,2024-08-28,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)','VICH']",Final,FDA-2021-D-0614,No,
CVM GFI #64 (VICH  GL2) Validation of Analytical Procedures: Methodology,,,2024-08-28,[],"['Chemistry, Manufacturing, and Controls (CMC)','VICH']",Final,FDA-2021-D-0616,No,
Mammography Quality Standards Act and Regulation Amendments: Small Entity Compliance Guide:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/mammography-quality-standards-act-and-regulation-amendments-small-entity-compliance-guide,https://www.fda.gov/media/181152/download,2024-08-26,['Center for Devices and Radiological Health'],,Final,FDA-2013-N-0134,No,
Electronic Submission Template for Medical Device De Novo Requests:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-submission-template-medical-device-de-novo-requests,https://www.fda.gov/media/172450/download,2024-08-23,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']","['Premarket','Electronic Submissions']",Final,FDA-2023-D-3788,No,
"FDA and Industry Procedures for Section 513(g) Requests for Information under the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-and-industry-procedures-section-513g-requests-information-under-federal-food-drug-and-cosmetic,https://www.fda.gov/media/78456/download,2024-08-23,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']","['Premarket','Administrative / Procedural','Labeling']",Final,FDA-2010-D-0153,No,
Predetermined Change Control Plans for Medical Devices: Draft Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/predetermined-change-control-plans-medical-devices,https://www.fda.gov/media/180978/download,2024-08-22,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Premarket'],Draft,FDA-2024-D-2338,Yes,2024-11-20
Product-Specific Guidance Meetings Between FDA and ANDA Applicants Under GDUFA:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-specific-guidance-meetings-between-fda-and-anda-applicants-under-gdufa,https://www.fda.gov/media/165468/download,2024-08-20,['Center for Drug Evaluation and Research'],"['Drug Competition Action Plan','Generic Drugs']",Final,FDA-2023-D-0044,No,
Acceptable Media for Electronic Product User Manuals:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acceptable-media-electronic-product-user-manuals,https://www.fda.gov/media/78332/download,2024-08-19,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Draft Guidance for Industry: Voluntary Sodium Reduction Goals (Edition 2),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-voluntary-sodium-reduction-goals-edition-2,https://www.fda.gov/media/180784/download,2024-08-15,['Human Foods Program'],,Draft,FDA-2014-D-0055,Yes,2025-01-13
CVM GFI #294 - Animal Food Ingredient Consultation (AFIC),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-294-animal-food-ingredient-consultation-afic,https://www.fda.gov/media/180442/download,2024-08-09,['Center for Veterinary Medicine'],"['Premarket','Animal Food Additives','Labeling','Safety - Issues, Errors, and Problems']",Draft,FDA-2024-D-2978,No,2024-09-09
Bacillus Calmette-Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biological Products for Treatment : Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bacillus-calmette-guerin-unresponsive-nonmuscle-invasive-bladder-cancer-developing-drugs-and,https://www.fda.gov/media/101468/download,2024-08-08,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Draft,FDA-2018-D-0342,No,
Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases:  Guidance for Industry; Availability,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/optimizing-dosage-human-prescription-drugs-and-biological-products-treatment-oncologic-diseases,https://www.fda.gov/media/164555/download,2024-08-08,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",,Final,FDA-2022-D-2827,No,
M12 Drug Interaction Studies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m12-drug-interaction-studies,https://www.fda.gov/media/161199/download,2024-08-02,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Multidisciplinary'],Final,FDA-2022-D-1527,No,
M12 Drug Interaction Studies: Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m12-drug-interaction-studies-questions-and-answers,https://www.fda.gov/media/180488/download,2024-08-02,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Multidisciplinary'],Final,FDA-2022-D-1527,No,
FDA Regional Implementation Guide for E2B(R3) Electronic Transmission of Individual Case Safety Reports for Drug and Biological Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-regional-implementation-guide-e2br3-electronic-transmission-individual-case-safety-reports-drug,https://www.fda.gov/media/180748/download,2024-08-01,['Center for Drug Evaluation and Research'],['ICH-Safety'],Final,FDA-2016-D-1280,No,
"CVM GFI #100 (VICH GL18 (R2)) Impurities: Residual Solvents in New Veterinary Medicinal Products, Active Substances and Excipients (Revision 2)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-100-vich-gl18-r2-impurities-residual-solvents-new-veterinary-medicinal-products-active,https://www.fda.gov/media/70410/download,2024-07-25,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)','VICH']",Final,FDA-1999-D-2955,No,2022-09-16
Providing Over-the-Counter Monograph Submissions in Electronic Format,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-over-counter-monograph-submissions-electronic-format,https://www.fda.gov/media/161822/download,2024-07-25,['Center for Drug Evaluation and Research'],['Electronic Submissions'],Final,FDA-2022-D-2059,No,
Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-data-assessing-electronic-health-records-and-medical-claims-data-support-regulatory,https://www.fda.gov/media/152503/download,2024-07-25,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Real World Data / Real World Evidence (RWD/RWE)'],Final,FDA-2020-D-2307,No,
Container Closure System and Component Changes: Glass Vials and Stoppers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/container-closure-system-and-component-changes-glass-vials-and-stoppers,https://www.fda.gov/media/167925/download,2024-07-24,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",,Final,FDA-2017-D-6821,No,
Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postapproval-manufacturing-changes-biosimilar-and-interchangeable-biosimilar-products-questions-and,https://www.fda.gov/media/180206/download,2024-07-23,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Current Good Manufacturing Practice (CGMP)'],Draft,FDA-2024-D-2581,No,2024-09-23
Pediatric Inflammatory Bowel Disease:  Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-inflammatory-bowel-disease-developing-drugs-treatment,https://www.fda.gov/media/180126/download,2024-07-19,['Center for Drug Evaluation and Research'],"['Clinical - Medical','Pediatric Product Development']",Draft,FDA-2024-D-2682,No,2024-09-17
Recommendations for Investigational and Licensed COVID-19 Convalescent Plasma:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-investigational-and-licensed-covid-19-convalescent-plasma,https://www.fda.gov/media/180209/download,2024-07-19,['Center for Biologics Evaluation and Research'],"['Blood','Infectious Disease Treatment','Coronavirus','Blood Products']",Final,FDA-2024-D-2442,No,
Blood Pressure and Pulse Donor Eligibility Requirements – Compliance Policy:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/blood-pressure-and-pulse-donor-eligibility-requirements-compliance-policy,https://www.fda.gov/media/158609/download,2024-07-17,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2022-D-0362,No,
Application User Fees for Combination Products:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/application-user-fees-combination-products,https://www.fda.gov/media/76413/download,2024-07-16,['Office of the Commissioner'],"['User Fees','Combination Products','Pediatric Product Development']",Final,FDA-2004-D-0371,No,
Drugs for the Treatment of Partial Onset Seizures: Extrapolation of Efficacy from Adults to Pediatric Patients  1 Month of Age and Older,,,2024-07-15,[],"['Clinical - Pharmacology','Pediatric Product Development']",Final,FDA-2018-D-0178,No,
Dental Composite Resin Devices - Premarket Notification (510(k)) Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dental-composite-resin-devices-premarket-notification-510k-submissions,https://www.fda.gov/media/179983/download,2024-07-12,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Dental']",Draft,FDA-2024-D-2511,No,2024-09-10
Dental Curing Lights - Premarket Notification (510(k)) Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dental-curing-lights-premarket-notification-510k-submissions,https://www.fda.gov/media/179991/download,2024-07-12,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Dental']",Draft,FDA-2024-D-2512,No,2024-09-10
Clinical Considerations for Studies of Devices Intended to Treat Opioid Use Disorder:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-considerations-studies-devices-intended-treat-opioid-use-disorder,https://www.fda.gov/media/170561/download,2024-07-11,['Center for Devices and Radiological Health'],,Final,FDA-2023-D-0466,No,
Addressing Misinformation About Medical Devices and Prescription Drugs:  Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/addressing-misinformation-about-medical-devices-and-prescription-drugs-questions-and-answers,https://www.fda.gov/media/179827/download,2024-07-08,"['Center for Veterinary Medicine','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research']",['Advertising'],Draft,FDA-2014-D-0447,No,
"Purpose and Content of Use-Related Risk Analyses for Drugs, Biological Products, and Combination Products",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/purpose-and-content-use-related-risk-analyses-drugs-biological-products-and-combination-products,https://www.fda.gov/media/179858/download,2024-07-08,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research','Office of the Commissioner']",,Draft,FDA-2024-D-2484,No,2024-09-09
"M14 General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies That Utilize Real-World Data for Safety Assessment of Medicines",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m14-general-principles-plan-design-and-analysis-pharmacoepidemiological-studies-utilize-real-world,https://www.fda.gov/media/179795/download,2024-07-05,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Multidisciplinary'],Draft,FDA-2024-D-2754,No,2024-09-03
Essential Drug Delivery Outputs for Devices Intended to Deliver Drugs and Biological Products: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/essential-drug-delivery-outputs-devices-intended-deliver-drugs-and-biological-products,https://www.fda.gov/media/179545/download,2024-06-28,"['Office of the Commissioner','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research']","['Combination Products','Pediatric Product Development']",Draft,FDA-2024-D-2560,No,2024-09-30
CVM GFI #276 Effectiveness of Anthelmintics:  Specific Recommendations for Products Proposed for the Prevention of Heartworm Disease in Dogs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-276-effectiveness-anthelmintics-specific-recommendations-products-proposed-prevention,https://www.fda.gov/media/163319/download,2024-06-26,['Center for Veterinary Medicine'],"['Premarket','Anthelmintics','Investigational New Animal Drug (INAD)','Target Animal – Effectiveness']",Final,FDA-2022-D-2899,No,2023-05-01
CVM GFI #283 Priority Zoonotic Animal Drug Designation and Review Process,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-283-priority-zoonotic-animal-drug-designation-and-review-process,https://www.fda.gov/media/174635/download,2024-06-26,['Center for Veterinary Medicine'],"['Premarket','Animal Drugs','Investigational New Animal Drug (INAD)','New Animal Drug Application (NADA)']",Final,FDA-2023-D-3740,No,2024-02-16
Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies,https://www.fda.gov/media/179593/download,2024-06-26,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Office of the Commissioner','Office of the Commissioner']",['Pediatric Product Development'],Draft,FDA-2021-D-0789,No,2024-09-26
Laboratory Developed Tests: Small Entity Compliance Guide:  Guidance for Laboratory Manufacturers and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/laboratory-developed-tests-small-entity-compliance-guide,https://www.fda.gov/media/179543/download,2024-06-25,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['IVDs (In Vitro Diagnostic Devices)'],Final,FDA-2023-N-2177,No,
"CVM GFI #288 Chemistry, Manufacturing, and Controls in Support of Recombinant Protein Products for Veterinary Medicinal Use",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-288-chemistry-manufacturing-and-controls-support-recombinant-protein-products-veterinary,https://www.fda.gov/media/179274/download,2024-06-24,['Center for Veterinary Medicine'],"['Premarket','Biotechnology','Chemistry, Manufacturing, and Controls (CMC)','Investigational New Animal Drug (INAD)','New Animal Drug Application (NADA)']",Draft,FDA-2024-D-1668,No,2024-08-23
"CVM GFI #292 Chemistry, Manufacturing, and Controls Considerations for Type A Medicated Articles",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-292-chemistry-manufacturing-and-controls-considerations-type-medicated-articles,https://www.fda.gov/media/179219/download,2024-06-24,['Center for Veterinary Medicine'],"['Premarket','Chemistry, Manufacturing, and Controls (CMC)','Current Good Manufacturing Practice (CGMP)','Generic Animal Drugs','Investigational New Animal Drug (INAD)','New Animal Drug Application (NADA)']",Draft,FDA-2024-D-1202,No,2024-08-23
CVM GFI #278 Human User Safety in New and Abbreviated New Animal Drug Applications,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-278-human-user-safety-new-and-abbreviated-new-animal-drug-applications,https://www.fda.gov/media/166696/download,2024-06-21,['Center for Veterinary Medicine'],"['Premarket','Animal Drugs','Investigational New Animal Drug (INAD)','New Animal Drug Application (NADA)','Labeling','Safety - Issues, Errors, and Problems','Pharmacology/Toxicology']",Final,FDA-2023-D-0592,No,2023-06-05
"CVM GFI #279 Demonstrating Bioequivalence for Type A Medicated Articles Containing Active Pharmaceutical Ingredient(s) Considered to be Poorly Soluble in Aqueous Media, That Exhibit Little to No Systemic Bioavailability, and Are Locally Acting",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-279-demonstrating-bioequivalence-type-medicated-articles-containing-active-pharmaceutical,https://www.fda.gov/media/168684/download,2024-06-21,['Center for Veterinary Medicine'],"['Premarket','Generic Animal Drugs','Investigational New Animal Drug (INAD)','New Animal Drug Application (NADA)']",Final,FDA-2023-D-1275,No,2023-10-16
Considerations in Demonstrating Interchangeability With a Reference Product: Update,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-demonstrating-interchangeability-reference-product-update,https://www.fda.gov/media/179456/download,2024-06-21,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Biosimilars'],Draft,FDA-2017-D-0154,No,2024-08-20
"Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/circumstances-constitute-delaying-denying-limiting-or-refusing-drug-or-device-inspection,https://www.fda.gov/media/86328/download,2024-06-20,"['Office of Inspections and Investigations','Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Center for Veterinary Medicine','Center for Devices and Radiological Health']","['Postmarket','Investigation & Enforcement']",Final,FDA-2013-D-0710,No,
Facility Readiness:  Goal Date Decisions Under GDUFA,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/facility-readiness-goal-date-decisions-under-gdufa,https://www.fda.gov/media/162018/download,2024-06-18,['Center for Drug Evaluation and Research'],['Generic Drugs'],Final,FDA-2022-D-1981,No,
Diabetic Foot Infections: Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diabetic-foot-infections-developing-drugs-treatment,https://www.fda.gov/media/173006/download,2024-06-17,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2023-D-4067,No,
Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-considerations-development-oligonucleotide-therapeutics,https://www.fda.gov/media/159414/download,2024-06-14,['Center for Drug Evaluation and Research'],['Clinical - Pharmacology'],Final,FDA-2022-D-0235,No,2022-09-25
Standardized Format for Electronic Submission for Marketing Applications Content for the Planning of Bioresearch Monitoring (BIMO) Inspections for Center of Biologics Evaluation and Research Submissions,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/standardized-format-electronic-submission-marketing-applications-content-planning-bioresearch,https://www.fda.gov/media/179136/download,2024-06-05,['Center for Biologics Evaluation and Research'],['Electronic Submissions'],Draft,FDA-2024-D-2221,No,2024-08-05
Processes and Practices Applicable to Bioresearch Monitoring Inspections: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/processes-and-practices-applicable-bioresearch-monitoring-inspections,https://www.fda.gov/media/179027/download,2024-06-05,"['Office of Inspections and Investigations','Office of the Commissioner','Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Human Foods Program','Center for Tobacco Products','Center for Veterinary Medicine']","['Clinical Trials','Compliance','Postmarket','Premarket','Investigation & Enforcement','Inspection','International','Administrative / Procedural','Bioequivalence','Biopharmaceutics','Biosimilars','Investigational New Drug Application (INDA)','Food & Color Additives','Generic Drugs','HUD/HDE','Investigational Device Exemption (IDE)','Premarket Approval (PMA)','IVDs (In Vitro Diagnostic Devices)','Investigational New Animal Drug (INAD)','New Animal Drug Application (NADA)','Vaccines']",Draft,FDA-2023-D-5021,No,2024-08-05
Platform Technology Designation Program for Drug Development,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/platform-technology-designation-program-drug-development,https://www.fda.gov/media/178938/download,2024-05-28,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",,Draft,FDA-2024-D-1829,No,2024-07-29
CVM GFI #115 (VICH GL22) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Reproduction Toxicity Testing (Revision 1),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-115-vich-gl22-studies-evaluate-safety-residues-veterinary-drugs-human-food-reproduction,https://www.fda.gov/media/70128/download,2024-05-23,['Center for Veterinary Medicine'],"['Human Food Safety','VICH']",Draft,FDA-2000-D-0784,No,2024-07-22
"Remanufacturing of Medical Devices:  Guidance for Industry, Entities That Perform Servicing or Remanufacturing, and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/remanufacturing-medical-devices,https://www.fda.gov/media/150141/download,2024-05-10,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Labeling'],Final,FDA-2018-N-3741,No,
REMS Logic Model: A Framework to Link Program Design With Assessment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rems-logic-model-framework-link-program-design-assessment,https://www.fda.gov/media/178291/download,2024-05-07,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Safety - Issues, Errors, and Problems']",Draft,FDA-2024-D-1032,No,2024-08-05
CVM GFI #290 (VICH GL61) – Pharmaceutical Development,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-290-vich-gl61-pharmaceutical-development,https://www.fda.gov/media/178155/download,2024-05-06,['Center for Veterinary Medicine'],"['Premarket','Postmarket','Chemistry, Manufacturing, and Controls (CMC)','Quality','Generic Animal Drugs','Investigational New Animal Drug (INAD)','New Animal Drug Application (NADA)','VICH']",Draft,FDA-2024-D-1133,No,2024-07-05
Consideration of Enforcement Policies for Tests During a Section 564 Declared Emergency: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/consideration-enforcement-policies-tests-during-section-564-declared-emergency,https://www.fda.gov/media/178123/download,2024-05-06,['Center for Devices and Radiological Health'],"['Outbreak','IVDs (In Vitro Diagnostic Devices)']",Draft,FDA-2023-D-5365,No,2024-07-05
Enforcement Policy for Certain In Vitro Diagnostic Devices for Immediate Public Health Response in the Absence of a Declaration under Section 564: Draft Guidance for Laboratory Manufacturers and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-certain-in-vitro-diagnostic-devices-immediate-public-health-response-absence,https://www.fda.gov/media/178122/download,2024-05-06,['Center for Devices and Radiological Health'],"['Outbreak','IVDs (In Vitro Diagnostic Devices)']",Draft,FDA-2024-D-0083,No,2024-07-05
CVM GFI #187A Heritable Intentional Genomic Alterations in Animals: Risk-Based Approach,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-187a-heritable-intentional-genomic-alterations-animals-risk-based-approach,https://www.fda.gov/media/74614/download,2024-05-02,['Center for Veterinary Medicine'],['Biotechnology'],Final,FDA-2008-D-0394,No,2017-04-19
CVM GFI #187B Heritable Intentional Genomic Alterations in Animals: The Approval Process,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-187b-heritable-intentional-genomic-alterations-animals-approval-process,https://www.fda.gov/media/150658/download,2024-05-02,['Center for Veterinary Medicine'],"['Premarket','Biotechnology','Investigational New Animal Drug (INAD)','New Animal Drug Application (NADA)']",Draft,FDA-2019-D-2648,No,2024-07-31
Recognition and Use of a Standard for Uniform Blood and Blood Component Container Labels:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recognition-and-use-standard-uniform-blood-and-blood-component-container-labels,https://www.fda.gov/media/72586/download,2024-04-30,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-1998-D-0067,No,
CVM GFI #120 Veterinary Feed Directive Regulation Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-120-veterinary-feed-directive-regulation-questions-and-answers,https://www.fda.gov/media/70173/download,2024-04-29,['Center for Veterinary Medicine'],['Animal Feed'],Final,FDA-2010-N-0155,No,2019-05-28
Small Entity Compliance Guide: Revocation of Uses of Partially Hydrogenated Oils in Foods,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-revocation-uses-partially-hydrogenated-oils-foods,https://www.fda.gov/media/178185/download,2024-04-29,['Human Foods Program'],,Final,FDA-2024-D-1669,No,
Considerations for the Use of Human-and Animal-Derived Materials in the Manufacture of Cell and Gene Therapy and Tissue-Engineered Medical Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-human-and-animal-derived-materials-manufacture-cell-and-gene-therapy-and-tissue,https://www.fda.gov/media/178022/download,2024-04-29,['Center for Biologics Evaluation and Research'],"['Gene Therapy','Tissue','Xenotransplantation']",Draft,FDA-2024-D-1244,No,
Content and Format of Composition Statement and Corresponding Statement of Ingredients in Labeling in NDAs and ANDAs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-format-composition-statement-and-corresponding-statement-ingredients-labeling-ndas-and,https://www.fda.gov/media/178099/download,2024-04-29,['Center for Drug Evaluation and Research'],"['Electronic Submissions','Drug Competition Action Plan','Generic Drugs']",Draft,FDA-2024-D-1461,No,2024-06-28
CVM GFI #287 - Raw Data for Safety and Effectiveness Studies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-287-raw-data-safety-and-effectiveness-studies,https://www.fda.gov/media/177901/download,2024-04-29,['Center for Veterinary Medicine'],"['Premarket','Environmental Safety','Human Food Safety','Investigational New Animal Drug (INAD)','New Animal Drug Application (NADA)','Target Animal – Effectiveness','Target Animal – Safety']",Draft,FDA-2024-D-1613,No,2024-06-28
Safety Testing of Human Allogeneic Cells Expanded for Use in Cell-Based Medical Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-testing-human-allogeneic-cells-expanded-use-cell-based-medical-products,https://www.fda.gov/media/178113/download,2024-04-29,['Center for Biologics Evaluation and Research'],['Gene Therapy'],Draft,FDA-2024-D-1243,No,
"Cancer Clinical Trial Eligibility Criteria: Laboratory Values: Draft Guidance for Industry, IRBs, and Clinical Investigators",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-laboratory-values,https://www.fda.gov/media/178013/download,2024-04-25,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical Trials'],Draft,FDA-2024-D-1402,No,2024-06-25
"Cancer Clinical Trial Eligibility Criteria: Performance Status: Draft Guidance for Industry, IRBs, and Clinical Investigators",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-performance-status,https://www.fda.gov/media/178018/download,2024-04-25,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical Trials'],Draft,FDA-2024-D-1377,No,2024-06-25
"Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications: Draft Guidance for Industry, IRBs, and Clinical Investigators",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-washout-periods-and-concomitant-medications,https://www.fda.gov/media/178016/download,2024-04-25,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical Trials'],Draft,FDA-2024-D-1376,No,2024-06-25
Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products Questions and Answers Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/promotional-labeling-and-advertising-considerations-prescription-biological-reference-and-biosimilar,https://www.fda.gov/media/134862/download,2024-04-24,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",,Draft,FDA-2019-D-5473,No,2024-06-25
Data Integrity for In Vivo Bioavailability and Bioequivalence Studies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-integrity-in-vivo-bioavailability-and-bioequivalence-studies,https://www.fda.gov/media/177404/download,2024-04-03,['Center for Drug Evaluation and Research'],['Generic Drugs'],Draft,FDA-2024-D-1245,No,2024-07-03
Draft Guidance for Industry: New Dietary Ingredient Notification Master Files for Dietary Supplements,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-new-dietary-ingredient-notification-master-files-dietary-supplements,https://www.fda.gov/media/177097/download,2024-04-03,['Human Foods Program'],,Draft,FDA-2024-D-0706,No,2024-06-03
Draft Guidance for Industry: New Dietary Ingredient Notifications and Related Issues,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-new-dietary-ingredient-notifications-and-related-issues,https://www.fda.gov/media/99538/download,2024-04-03,['Human Foods Program'],,Draft,FDA-2011-D-0376,No,2016-12-12
Electronic Submission of Expedited Safety Reports From IND-Exempt BA/BE Studies Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-submission-expedited-safety-reports-ind-exempt-babe-studies-guidance-industry,https://www.fda.gov/media/177371/download,2024-04-01,['Center for Drug Evaluation and Research'],"['Electronic Submissions','Generic Drugs']",Final,FDA-2022-D-1173,No,
Providing Regulatory Submissions in Electronic Format: IND Safety Reports Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-ind-safety-reports-guidance-industry,https://www.fda.gov/media/132079/download,2024-04-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Electronic Submissions'],Final,FDA-2019-D-3953,No,
Animal Studies for Dental Bone Grafting Material Devices - Premarket Notification (510(k)) Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/animal-studies-dental-bone-grafting-material-devices-premarket-notification-510k-submissions,https://www.fda.gov/media/177340/download,2024-03-29,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Dental']",Draft,FDA-2024-D-1242,No,2024-05-28
Handling and Retention of Bioavailability BA and Bioequivalence BE Testing Samples: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/handling-and-retention-bioavailability-ba-and-bioequivalence-be-testing-samples,https://www.fda.gov/media/71393/download,2024-03-27,['Center for Drug Evaluation and Research'],"['Generic Drugs','Good Clinical Practice (GCP)']",Draft,FDA-2002-D-0176,No,2024-05-28
Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-evidence-considerations-regarding-non-interventional-studies-drug-and-biological-products,https://www.fda.gov/media/177128/download,2024-03-21,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Real World Data / Real World Evidence (RWD/RWE)'],Draft,FDA-2023-D-5470,No,2024-06-18
Controlled Correspondence Related to Generic Drug Development,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/controlled-correspondence-related-generic-drug-development,https://www.fda.gov/media/164111/download,2024-03-18,['Center for Drug Evaluation and Research'],"['Drug Competition Action Plan','Generic Drugs']",Final,FDA-2014-D-1167,No,
"CVM GFI #285 - Manufacture of Batches in Support of Original NADAs, ANADAs, and CNADAs",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-285-manufacture-batches-support-original-nadas-anadas-and-cnadas,https://www.fda.gov/media/176991/download,2024-03-18,['Center for Veterinary Medicine'],"['Premarket','Current Good Manufacturing Practice (CGMP)','Chemistry, Manufacturing, and Controls (CMC)','Generic Animal Drugs','New Animal Drug Application (NADA)','Investigational New Animal Drug (INAD)']",Draft,FDA-2024-D-1054,No,2024-05-17
"Pharmacokinetics in Patients with Impaired Renal Function — Study Design, Data Analysis, and Impact on Dosing",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacokinetics-patients-impaired-renal-function-study-design-data-analysis-and-impact-dosing,https://www.fda.gov/media/78573/download,2024-03-15,['Center for Drug Evaluation and Research'],['Clinical - Pharmacology'],Final,FDA-2010-D-0133,No,2020-12-03
Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program - Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program-draft-guidance,https://www.fda.gov/media/177009/download,2024-03-15,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','Administrative / Procedural']",Draft,FDA-2018-D-1774,No,2024-05-14
Evaluation of Thermal Effects of Medical Devices that Produce Tissue Heating and/or Cooling: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-thermal-effects-medical-devices-produce-tissue-heating-andor-cooling,https://www.fda.gov/media/177004/download,2024-03-15,['Center for Devices and Radiological Health'],,Draft,FDA-2024-D-0664,No,2024-05-14
Annual Reportable Labeling Changes for New Drug Applications and Abbreviated New Drug Applications for Nonprescription Drug Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/annual-reportable-labeling-changes-new-drug-applications-and-abbreviated-new-drug-applications,https://www.fda.gov/media/176915/download,2024-03-13,['Center for Drug Evaluation and Research'],['Labeling'],Draft,FDA-2023-D-5616,No,2024-05-13
E2D(R1) Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2dr1-post-approval-safety-data-definitions-and-standards-management-and-reporting-individual-case,https://www.fda.gov/media/176977/download,2024-03-13,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Efficacy'],Draft,FDA-2024-D-0803,No,
Select Updates for the Premarket Cybersecurity Guidance: Section 524B of the FD&C Act: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/select-updates-premarket-cybersecurity-guidance-section-524b-fdc-act,https://www.fda.gov/media/176944/download,2024-03-13,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Premarket'],Draft,FDA-2021-D-1158,No,2024-05-13
Early Alzheimer’s Disease: Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/early-alzheimers-disease-developing-drugs-treatment,https://www.fda.gov/media/110903/download,2024-03-12,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Clinical - Medical'],Draft,FDA-2013-D-0077,No,2024-06-10
Q14 Analytical Procedure Development,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q14-analytical-procedure-development,https://www.fda.gov/media/161202/download,2024-03-07,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-2022-D-1503,No,
Q2(R2) Validation of Analytical Procedures,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q2r2-validation-analytical-procedures,https://www.fda.gov/media/161201/download,2024-03-06,['Center for Drug Evaluation and Research'],['ICH-Quality'],Final,FDA-2022-D-1503,No,
Guidance for Industry: New Dietary Ingredient Notification Procedures and Timeframes - Dietary Supplements,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-new-dietary-ingredient-notification-procedures-and-timeframes-dietary-supplements,https://www.fda.gov/media/176512/download,2024-03-05,['Human Foods Program'],['Ingredients'],Final,FDA-2023-D-5280,No,
"Key Information and Facilitating Understanding in Informed Consent Guidance for Sponsors, Investigators, and Institutional Review Boards",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/key-information-and-facilitating-understanding-informed-consent-guidance-sponsors-investigators-and,https://www.fda.gov/media/176663/download,2024-03-01,"['Center for Drug Evaluation and Research','Office of the Commissioner']",['Administrative / Procedural'],Draft,FDA-2022-D-2997,No,2024-04-30
Clinical Pharmacology Considerations for Antibody-Drug Conjugates  Guidance for Industry:  Guidance for Industry,,,2024-03-01,[],['Clinical - Pharmacology'],Final,FDA-2021-D-1051,No,
Reporting Amount of Listed Drugs and Biological Products Technical Conformance Guide:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reporting-amount-listed-drugs-and-biological-products-technical-conformance-guide,https://www.fda.gov/media/153612/download,2024-02-26,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Center for Veterinary Medicine']",['Administrative / Procedural'],Final,FDA-2021-D-1031,No,
Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment :  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drugs,https://www.fda.gov/media/167275/download,2024-02-22,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Infectious Disease','Coronavirus','Clinical - Medical']",Final,FDA-2020-D-1824,No,
Select Updates for the Medical Device User Fee Small Business Qualification and Certification Guidance: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/select-updates-medical-device-user-fee-small-business-qualification-and-certification-guidance,https://www.fda.gov/media/176439/download,2024-02-22,['Center for Devices and Radiological Health'],['User Fees'],Draft,FDA-2018-D-1873,No,2024-04-22
Guidance for Industry: Foods Derived from Plants Produced Using Genome Editing,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-foods-derived-plants-produced-using-genome-editing,https://www.fda.gov/media/176427/download,2024-02-21,['Human Foods Program'],['Bioengineering / GMOs'],Final,FDA-2019-D-4658,No,
Charging for Investigational Drugs Under an IND: Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/charging-investigational-drugs-under-ind-questions-and-answers,https://www.fda.gov/media/176308/download,2024-02-14,['Center for Drug Evaluation and Research'],,Final,FDA-2013-D-0447,No,
Use of Data Monitoring Committees in Clinical Trials,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-data-monitoring-committees-clinical-trials,https://www.fda.gov/media/176107/download,2024-02-13,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research']",['Clinical - Medical'],Draft,FDA-2001-D-0219,No,2024-04-15
Advanced Manufacturing Technologies Designation Program,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/advanced-manufacturing-technologies-designation-program,https://www.fda.gov/media/174651/download,2024-02-12,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Draft,FDA-2023-D-4974,No,2024-03-13
Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&C Act,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/notifying-fda-discontinuance-or-interruption-manufacturing-finished-products-or-active,https://www.fda.gov/media/166837/download,2024-02-06,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Administrative / Procedural'],Draft,FDA-2020-D-1057,No,2023-06-05
Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the FD&C Act,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reporting-amount-listed-drugs-and-biological-products-under-section-510j3-fdc-act,https://www.fda.gov/media/175933/download,2024-02-05,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2021-D-1031,No,
Draft Guidance for Industry: Recommendations for Collecting Representative Samples for Food Testing Used as Evidence for Release of Certain Fish and Fishery Products Subject to Detention Without Physical Examination (DWPE) and Removal of a Foreign Manufacturer’s Goods from DWPE,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-recommendations-collecting-representative-samples-food-testing-used-evidence,https://www.fda.gov/media/175948/download,2024-02-05,['Human Foods Program'],['Seafood/Seafood Product'],Draft,FDA-2023-D-5303,No,2024-06-25
Conducting Remote Regulatory Assessments Questions and Answers: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/conducting-remote-regulatory-assessments-questions-and-answers,https://www.fda.gov/media/160173/download,2024-02-02,['Office of Inspections and Investigations'],"['Compliance','Investigation & Enforcement','Inspection','Electronic Submissions','Regulation','Administration','Records','Import']",Draft,FDA-2022-D-0810,No,
Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-development-chimeric-antigen-receptor-car-t-cell-products,https://www.fda.gov/media/156896/download,2024-01-31,['Center for Biologics Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmacology/Toxicology','Gene Therapy']",Final,FDA-2021-D-0404,No,
CVM GFI #188 Data Elements for Submission of Veterinary Adverse Event Reports to the Center for Veterinary Medicine,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-188-data-elements-submission-veterinary-adverse-event-reports-center-veterinary-medicine,https://www.fda.gov/media/79105/download,2024-01-31,['Center for Veterinary Medicine'],['Adverse Event Reporting'],Final,FDA-2010-D-0241,No,
CVM GFI #214 (VICH GL35) Pharmacovigilance of Veterinary Medicinal Products Electronic Standards for Transfer of Data,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-214-vich-gl35-pharmacovigilance-veterinary-medicinal-products-electronic-standards-transfer,https://www.fda.gov/media/81045/download,2024-01-31,['Center for Veterinary Medicine'],"['Adverse Event Reporting','VICH']",Final,FDA-2011-D-0588,No,
Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/collection-race-and-ethnicity-data-clinical-trials-and-clinical-studies-fda-regulated-medical,https://www.fda.gov/media/175746/download,2024-01-30,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research','Office of the Commissioner','Office of the Commissioner','Office of the Commissioner','Office of the Commissioner']","['Clinical - Medical','Pediatric Product Development']",Draft,FDA-2016-D-3561,No,2024-04-29
Draft Guidance for Industry: Hazard Analysis and Risk-Based Preventive Controls for Human Food,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-hazard-analysis-and-risk-based-preventive-controls-human-food,https://www.fda.gov/media/100002/download,2024-01-30,['Human Foods Program'],,Draft,FDA-2016-D-2343,No,2024-08-02
Human Gene Therapy Products Incorporating Human Genome Editing:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-products-incorporating-human-genome-editing,https://www.fda.gov/media/156894/download,2024-01-29,['Center for Biologics Evaluation and Research'],['Gene Therapy'],Final,FDA-2021-D-0398,No,
CVM GFI #286 (VICH GL60) - Good Manufacturing Practice for Active Pharmaceutical Ingredients Used in Veterinary Medicinal Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-286-vich-gl60-good-manufacturing-practice-active-pharmaceutical-ingredients-used-veterinary,https://www.fda.gov/media/175603/download,2024-01-25,['Center for Veterinary Medicine'],"['Postmarket','Premarket','Compliance','Current Good Manufacturing Practice (CGMP)','Chemistry, Manufacturing, and Controls (CMC)','Generic Animal Drugs','Investigational New Animal Drug (INAD)','New Animal Drug Application (NADA)','VICH']",Draft,FDA-2023-D-4761,No,2024-03-25
ANDA Submissions – Amendments and Requests for Final Approval to Tentatively Approved ANDAs:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/anda-submissions-amendments-and-requests-final-approval-tentatively-approved-andas,https://www.fda.gov/media/119718/download,2024-01-24,['Center for Drug Evaluation and Research'],"['Drug Competition Action Plan','Generic Drugs']",Final,FDA-2018-D-4726,No,
Revising ANDA  Labeling Following  Revision of the RLD  Labeling Guidance for Industry:  Guidance for Industry,,,2024-01-24,[],['Generic Drugs'],Final,FDA-2022-D-0092,No,2022-03-25
Characterization of Metallic Coatings and/or Calcium Phosphate Coatings on Orthopedic Devices: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/characterization-metallic-coatings-andor-calcium-phosphate-coatings-orthopedic-devices,https://www.fda.gov/media/175564/download,2024-01-23,['Center for Devices and Radiological Health'],"['Premarket','Orthopedic']",Draft,FDA-2023-D-5430,No,2024-03-22
Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q5ar2-viral-safety-evaluation-biotechnology-products-derived-cell-lines-human-or-animal-origin,https://www.fda.gov/media/163115/download,2024-01-10,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-2022-D-2512,No,
Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-and-review-sterility-information-premarket-notification-510k-submissions-devices-labeled,https://www.fda.gov/media/74445/download,2024-01-08,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']","['Premarket','510(k)']",Final,FDA-2008-D-0611,No,
Reformulating Drug Products That Contain Carbomers Manufactured With Benzene,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reformulating-drug-products-contain-carbomers-manufactured-benzene,https://www.fda.gov/media/175083/download,2023-12-28,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2023-D-5408,No,
Potency Assurance for Cellular and Gene Therapy Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/potency-assurance-cellular-and-gene-therapy-products,https://www.fda.gov/media/175132/download,2023-12-27,['Center for Biologics Evaluation and Research'],['Gene Therapy'],Draft,FDA-2023-D-4299,No,2024-03-27
Quality Considerations for Topical Ophthalmic Drug Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-considerations-topical-ophthalmic-drug-products,https://www.fda.gov/media/172937/download,2023-12-27,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Draft,FDA-2023-D-4177,No,2024-02-26
"Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format Final Rule Questions and Answers",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/direct-consumer-prescription-drug-advertisements-presentation-major-statement-clear-conspicuous-and,https://www.fda.gov/media/175074/download,2023-12-26,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Advertising'],Final,FDA-2009-N-0582,No,
Rare Diseases: Considerations for the Development of Drugs and Biological Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-diseases-considerations-development-drugs-and-biological-products,https://www.fda.gov/media/119757/download,2023-12-26,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Rare Diseases','Pediatric Product Development']",Final,FDA-2015-D-2818,No,
"CVM GFI #61 Special Considerations, Incentives, and Programs to Support the Approval of New Animal Drugs for Minor Uses and for Minor Species",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-61-special-considerations-incentives-and-programs-support-approval-new-animal-drugs-minor,https://www.fda.gov/media/70157/download,2023-12-22,['Center for Veterinary Medicine'],"['Premarket','Aquaculture','Investigational New Animal Drug (INAD)']",Final,FDA-1997-D-0444,No,2021-01-11
Digital Health Technologies for Remote Data Acquisition in Clinical Investigations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/digital-health-technologies-remote-data-acquisition-clinical-investigations,https://www.fda.gov/media/155022/download,2023-12-22,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research']",['Clinical - Medical'],Final,FDA-2021-D-1128,No,
Real-World Data: Assessing Registries To Support Regulatory Decision-Making for Drug and Biological Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-data-assessing-registries-support-regulatory-decision-making-drug-and-biological-products,https://www.fda.gov/media/154449/download,2023-12-22,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Real World Data / Real World Evidence (RWD/RWE)','Clinical - Medical']",Final,FDA-2021-D-1146,No,
Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-monoclonal-antibody-products-targeting-sars-cov-2-emergency-use-authorization,https://www.fda.gov/media/146173/download,2023-12-21,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-2020-D-1136,No,
Master Protocols for Drug and Biological Product Development,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-drug-and-biological-product-development,https://www.fda.gov/media/174976/download,2023-12-21,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Draft,FDA-2023-D-5259,No,2024-02-22
Data Standards for Drug and Biological Product Submissions Containing Real-World Data:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-standards-drug-and-biological-product-submissions-containing-real-world-data,https://www.fda.gov/media/153341/download,2023-12-21,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Real World Data / Real World Evidence (RWD/RWE)'],Final,FDA-2021-D-0548,No,2022-01-21
Guidance for Industry:  Registration and Listing of Cosmetic Product Facilities and Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-registration-and-listing-cosmetic-product-facilities-and-products,https://www.fda.gov/media/170732/download,2023-12-18,['Office of the Commissioner'],,Final,FDA-2023-D-1716,No,
Clinical Pharmacology Considerations for Peptide Drug Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-considerations-peptide-drug-products,https://www.fda.gov/media/171901/download,2023-12-14,['Center for Drug Evaluation and Research'],['Clinical - Pharmacology'],Draft,FDA-2023-D-3391,No,2023-12-11
Draft: Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-use-real-world-evidence-support-regulatory-decision-making-medical-devices,https://www.fda.gov/media/174819/download,2023-12-14,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Postmarket','Real World Data / Real World Evidence (RWD/RWE)','Premarket']",Draft,FDA-2023-D-4395,No,2024-02-20
Draft Guidance for Industry: Menu Labeling Supplemental Guidance (Edition 2),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-menu-labeling-supplemental-guidance-edition-2,https://www.fda.gov/media/174528/download,2023-12-13,['Human Foods Program'],"['Labeling','Nutrition']",Draft,FDA-2011-F-0172,No,2024-02-12
Presenting Quantitative Efficacy and Risk Information in  Direct-to-Consumer (DTC) Promotional Labeling and Advertisements,,,2023-12-12,[],['Advertising'],Final,FDA-2018-D-2613,No,
"Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interim-policy-compounding-using-bulk-drug-substances-under-section-503a-federal-food-drug-and-0,https://www.fda.gov/media/174456/download,2023-12-07,['Center for Drug Evaluation and Research'],['Compounding'],Draft,FDA-2015-D-3517,No,2024-01-08
"Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act - Revision 2",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interim-policy-compounding-using-bulk-drug-substances-under-section-503b-federal-food-drug-and-0,https://www.fda.gov/media/174453/download,2023-12-07,['Center for Drug Evaluation and Research'],['Compounding'],Draft,FDA-2015-D-3539,No,2024-01-08
Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/verification-systems-under-drug-supply-chain-security-act-certain-prescription-drugs,https://www.fda.gov/media/117950/download,2023-12-07,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2018-D-3462,No,
CVM GFI #199 Animal Generic Drug User Fees and Fee Waivers and Reductions,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-199-animal-generic-drug-user-fees-and-fee-waivers-and-reductions,https://www.fda.gov/media/76498/download,2023-12-04,['Center for Veterinary Medicine'],['User Fees'],Final,FDA-2009-D-0189,No,
Small Entity Compliance Guide: Milk and Cream Products and Yogurt Products; Final Rule to Revoke the Standards for Lowfat Yogurt and Nonfat Yogurt and To Amend the Standard for Yogurt,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-milk-and-cream-products-and-yogurt-products-final-rule-revoke,https://www.fda.gov/media/174050/download,2023-11-27,['Human Foods Program'],['Dairy'],Final,FDA-2023-D-4722,No,
COVID-19: Developing Drugs and Biological Products for Treatment or Prevention:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-developing-drugs-and-biological-products-treatment-or-prevention,https://www.fda.gov/media/167274/download,2023-11-24,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Infectious Disease','Coronavirus','Clinical - Medical']",Final,FDA-2020-D-1370,No,
Translation of Good Laboratory Practice Study Reports: Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/translation-good-laboratory-practice-study-reports-questions-and-answers,https://www.fda.gov/media/173989/download,2023-11-21,['Center for Drug Evaluation and Research'],,Draft,FDA-2023-D-4719,No,2024-02-20
Assessing the Credibility of Computational Modeling and Simulation in Medical Device Submissions:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-credibility-computational-modeling-and-simulation-medical-device-submissions,https://www.fda.gov/media/154985/download,2023-11-17,['Center for Devices and Radiological Health'],"['Premarket','Digital Health']",Final,FDA-2021-D-0980,No,2022-03-24
Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing of a Device Under Section 506J of the FD&C Act:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/notifying-fda-permanent-discontinuance-or-interruption-manufacturing-device-under-section-506j-fdc,https://www.fda.gov/media/155245/download,2023-11-17,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Postmarket'],Final,FDA-2022-D-0053,No,
Select Updates for the 506J Guidance: 506J Device List and Additional Notifications: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/select-updates-506j-guidance-506j-device-list-and-additional-notifications,https://www.fda.gov/media/173800/download,2023-11-17,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Postmarket'],Draft,FDA-2022-D-0053,No,2024-02-15
Guidance for Industry: Compliance Policy for Cosmetic Product Facility Registration and Cosmetic Product Listing,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-compliance-policy-cosmetic-product-facility-registration-and-cosmetic-product,https://www.fda.gov/media/173606/download,2023-11-08,['Office of the Commissioner'],,Final,FDA-2023-D-1716,No,
Real-Time Oncology Review (RTOR) :  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-time-oncology-review-rtor,https://www.fda.gov/media/173641/download,2023-11-07,[],,Final,FDA-2022-D-0823,No,
Submitting Clinical Trial Datasets and Documentation for Clinical Outcome Assessments Using Item Response Theory,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-clinical-trial-datasets-and-documentation-clinical-outcome-assessments-using-item,https://www.fda.gov/media/173587/download,2023-11-06,['Center for Drug Evaluation and Research'],,Final,FDA-2018-D-1216,No,
Submitting Patient-Reported Outcome Data in Cancer Clinical Trials,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-patient-reported-outcome-data-cancer-clinical-trials,https://www.fda.gov/media/173581/download,2023-11-06,['Center for Drug Evaluation and Research'],,Final,FDA-2018-D-1216,No,
Enforcement Policy for Clinical Electronic Thermometers:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-clinical-electronic-thermometers,https://www.fda.gov/media/136698/download,2023-11-03,['Center for Devices and Radiological Health'],"['Premarket','Postmarket','Device & Drug Safety']",Final,FDA-2023-N-4372,No,
Process to Request a Review of FDA's Decision Not to Issue Certain Export Certificates for Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/process-request-review-fdas-decision-not-issue-certain-export-certificates-devices,https://www.fda.gov/media/115432/download,2023-11-03,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Postmarket','Export','Import']",Final,FDA-2018-D-2310,No,
Enforcement Policy for Certain Supplements for Approved Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) Submissions:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-certain-supplements-approved-premarket-approval-pma-or-humanitarian-device,https://www.fda.gov/media/138265/download,2023-11-02,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']","['HUD/HDE','Premarket Approval (PMA)']",Final,FDA-2023-D-4595,No,
Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/remote-interactive-evaluations-drug-manufacturing-and-bioresearch-monitoring-facilities,https://www.fda.gov/media/173286/download,2023-10-26,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Center for Veterinary Medicine']","['Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Draft,FDA-2023-D-4416,No,2023-12-26
Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/communications-firms-health-care-providers-regarding-scientific-information-unapproved-uses,https://www.fda.gov/media/173172/download,2023-10-24,"['Center for Veterinary Medicine','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research','Office of the Commissioner']",['Administrative / Procedural'],Draft,FDA-2008-D-0053,No,2024-01-05
Topical Dermatologic Corticosteroids:  In Vivo Bioequivalence,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/topical-dermatologic-corticosteroids-in-vivo-bioequivalence-0,https://www.fda.gov/media/162457/download,2023-10-24,['Center for Drug Evaluation and Research'],"['Drug Competition Action Plan','Generic Drugs']",Draft,FDA-2022-D-2170,No,
Development and Licensure of Vaccines to Prevent COVID-19:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19,https://www.fda.gov/media/139638/download,2023-10-19,['Center for Biologics Evaluation and Research'],"['Infectious Disease','Coronavirus','Vaccines']",Final,FDA-2020-D-1137,No,
Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/voluntary-consensus-standards-recognition-program-regenerative-medicine-therapies,https://www.fda.gov/media/159237/download,2023-10-19,['Center for Biologics Evaluation and Research'],['Tissue'],Final,FDA-2022-D-0745,No,
Enforcement Policy for Non-Invasive Remote Monitoring Devices Used to Support Patient Monitoring:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-non-invasive-remote-monitoring-devices-used-support-patient-monitoring,https://www.fda.gov/media/136290/download,2023-10-19,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Labeling']",Final,FDA-2023-D-4356,No,
Demonstrating the Substantial Equivalence of a New Tobacco Product: Responses to Frequently Asked Questions (Revised):  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/demonstrating-substantial-equivalence-new-tobacco-product-responses-frequently-asked-questions,https://www.fda.gov/media/173089/download,2023-10-18,['Center for Tobacco Products'],,Final,FDA-2011-D-0147,No,
"Establishing That a Tobacco Product Was Commercially Marketed in the United States as of February 15, 2007 (Revised):  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/establishing-tobacco-product-was-commercially-marketed-united-states-february-15-2007-revised,https://www.fda.gov/media/173091/download,2023-10-18,['Center for Tobacco Products'],,Final,FDA-2011-D-0125,No,
Benefit-Risk Assessment for New Drug and Biological Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/benefit-risk-assessment-new-drug-and-biological-products,https://www.fda.gov/media/152544/download,2023-10-17,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Clinical - Medical'],Final,FDA-2020-D-2316,No,
"Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-policy-regarding-blood-and-blood-component-donation-suitability-donor-eligibility-and,https://www.fda.gov/media/158608/download,2023-10-17,['Center for Biologics Evaluation and Research'],"['Blood','Coronavirus','Blood Products']",Final,FDA-2022-D-0588,No,
Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-testing-alcohol-ethanol-and-isopropyl-alcohol-methanol,https://www.fda.gov/media/173005/download,2023-10-17,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Center for Veterinary Medicine']",['Current Good Manufacturing Practice (CGMP)'],Final,FDA-2020-D-2016,No,
Guidance for Industry: Prior Notice of Imported Food Questions and Answers (Edition 4),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-prior-notice-imported-food-questions-and-answers-edition-4,https://www.fda.gov/media/161541/download,2023-10-13,"['Human Foods Program','Office of Inspections and Investigations','Center for Veterinary Medicine']",['Import'],Final,FDA-2011-N-0179,No,2023-10-13
Investigational COVID-19 Convalescent Plasma:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-covid-19-convalescent-plasma,https://www.fda.gov/media/136798/download,2023-10-13,['Center for Biologics Evaluation and Research'],"['Blood','Infectious Disease','Coronavirus','Blood Products']",Final,FDA-2020-D-1825,No,
Submission of Premarket Notifications for Magnetic Resonance Diagnostic Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-premarket-notifications-magnetic-resonance-diagnostic-devices,https://www.fda.gov/media/92921/download,2023-10-10,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Radiological Health','Radiology']",Final,FDA-2015-D-2148,No,
Testing and Labeling Medical Devices for Safety in the Magnetic Resonance (MR) Environment:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/testing-and-labeling-medical-devices-safety-magnetic-resonance-mr-environment,https://www.fda.gov/media/74201/download,2023-10-10,['Center for Devices and Radiological Health'],"['Premarket','Labeling','Safety - Issues, Errors, and Problems']",Final,FDA-2019-D-2837,No,
Stimulant Use Disorders: Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/stimulant-use-disorders-developing-drugs-treatment,https://www.fda.gov/media/172703/download,2023-10-05,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2023-D-1848,No,2023-12-04
Human Prescription Drug and Biological Products--Labeling for Dosing Based on Weight or Body Surface Area for Ready-to-Use Containers--“Dose Banding”,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-prescription-drug-and-biological-products-labeling-dosing-based-weight-or-body-surface-area,https://www.fda.gov/media/172571/download,2023-10-02,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Labeling'],Final,FDA-2022-D-0219,No,
Electronic Submission Template for Medical Device 510(k) Submissions:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-submission-template-medical-device-510k-submissions,https://www.fda.gov/media/152429/download,2023-10-02,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",,Final,FDA-2021-D-0872,No,
Antimicrobial Susceptibility Test (AST) System Devices – Updating Breakpoints in Device Labeling:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antimicrobial-susceptibility-test-ast-system-devices-updating-breakpoints-device-labeling,https://www.fda.gov/media/172463/download,2023-09-29,['Center for Devices and Radiological Health'],['Antimicrobial Resistance'],Final,FDA-2023-D-4045,No,
Technical Considerations for Medical Devices with Physiologic Closed-Loop Control Technology:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-considerations-medical-devices-physiologic-closed-loop-control-technology,https://www.fda.gov/media/154994/download,2023-09-29,['Center for Devices and Radiological Health'],"['Premarket','Combination Products','Clinical - Medical','Digital Health']",Final,FDA-2021-D-0996,No,2022-02-22
"Guidance for Industry: Standards for the Growing, Harvesting, Packing, and Holding of Sprouts for Human Consumption",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-standards-growing-harvesting-packing-and-holding-sprouts-human-consumption,https://www.fda.gov/media/172400/download,2023-09-28,['Human Foods Program'],['Produce'],Final,FDA-2017-D-0175,No,
"Draft Guidance for Industry: Standards for the Growing, Harvesting, Packing, and Holding of Sprouts for Human Consumption",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-standards-growing-harvesting-packing-and-holding-sprouts-human-consumption,https://www.fda.gov/media/172400/download,2023-09-28,['Human Foods Program'],['Vegetable Products'],Draft,FDA-2017-D-0175,No,2024-03-27
"Graft-versus-Host Diseases: Developing Drugs, Biological Products, and Certain Devices for Prevention or Treatment",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/graft-versus-host-diseases-developing-drugs-biological-products-and-certain-devices-prevention-or,https://www.fda.gov/media/172524/download,2023-09-28,[],,Draft,FDA-2023-D-3900,No,2023-11-28
Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions,https://www.fda.gov/media/119933/download,2023-09-27,['Center for Devices and Radiological Health'],"['Premarket','Digital Health']",Final,FDA-2021-D-1158,No,
CVM GFI #273 Defining Durations of Use for Approved Medically Important Antimicrobial Drugs Fed to Food-Producing Animals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-273-defining-durations-use-approved-medically-important-antimicrobial-drugs-fed-food,https://www.fda.gov/media/172362/download,2023-09-26,['Center for Veterinary Medicine'],"['Premarket','Antimicrobial Resistance','Labeling','New Animal Drug Application (NADA)']",Draft,FDA-2023-D-2925,No,2024-01-05
Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/alternative-tools-assessing-drug-manufacturing-facilities-identified-pending-applications,https://www.fda.gov/media/172290/download,2023-09-22,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Draft,FDA-2023-D-3031,No,2023-11-21
Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formal-meetings-between-fda-and-sponsors-or-applicants-pdufa-products,https://www.fda.gov/media/172311/download,2023-09-22,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Administrative / Procedural'],Draft,FDA-2017-D-6530,No,2023-12-21
Considerations for the Conduct of Clinical Trials of Medical Products During Major Disruptions Due to Disasters and Public Health Emergencies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-conduct-clinical-trials-medical-products-during-major-disruptions-due-disasters-and,https://www.fda.gov/media/172258/download,2023-09-21,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']",['Emergencies'],Final,FDA-2023-D-3550,No,
Guidance for Industry: Returning Refrigerated Transport Vehicles and Refrigerated Storage Units to Food Uses After Using Them to  Preserve Human Remains,,,2023-09-20,[],['Transportation'],Final,FDA-2020-D-1139,No,
Demonstrating Substantial Evidence of Effectiveness With One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/demonstrating-substantial-evidence-effectiveness-one-adequate-and-well-controlled-clinical,https://www.fda.gov/media/172166/download,2023-09-19,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Office of the Commissioner']",['Clinical - Medical'],Draft,FDA-2023-D-2318,No,2023-12-18
Regulatory Considerations for Prescription Drug Use-Related Software,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-prescription-drug-use-related-software,https://www.fda.gov/media/172165/download,2023-09-19,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']",['Labeling'],Draft,FDA-2023-D-2482,No,2023-12-18
Labeling for Biosimilar and Interchangeable Biosimilar Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-biosimilar-and-interchangeable-biosimilar-products,https://www.fda.gov/media/172170/download,2023-09-18,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Biosimilars'],Draft,FDA-2016-D-0643,No,2023-11-17
Biosimilarity and Interchangeability:  Additional Draft Q&As on Biosimilar Development and the BPCI Act (Revision 1): Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biosimilarity-and-interchangeability-additional-draft-qas-biosimilar-development-and-bpci-act,https://www.fda.gov/media/172169/download,2023-09-18,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Biosimilars','Prescription Drugs']",Draft,FDA-2011-D-0611,No,
CVM GFI #282 Informed Consent Forms for Studies that Enroll Client-Owned Companion Animals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-282-informed-consent-forms-studies-enroll-client-owned-companion-animals,https://www.fda.gov/media/172056/download,2023-09-15,['Center for Veterinary Medicine'],"['Premarket','Investigational New Animal Drug (INAD)','New Animal Drug Application (NADA)','Target Animal – Effectiveness']",Draft,FDA-2023-D-2654,No,2023-11-14
Annual Status Report Information and Other Submissions for Postmarketing Requirements and Commitments: Using Forms FDA 3988 and FDA 3989 Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/annual-status-report-information-and-other-submissions-postmarketing-requirements-and-commitments,https://www.fda.gov/media/172038/download,2023-09-15,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",,Final,FDA-2018-N-3771,No,
Fostering Medical Device Improvement: FDA Activities and Engagement with the Voluntary Improvement Program:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fostering-medical-device-improvement-fda-activities-and-engagement-voluntary-improvement-program,https://www.fda.gov/media/158180/download,2023-09-15,['Center for Devices and Radiological Health'],"['Postmarket','Current Good Manufacturing Practice (CGMP)']",Final,FDA-2022-D-0109,No,
Medical Devices with Indications Associated with Weight Loss - Clinical Study and Benefit-Risk Considerations: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-devices-indications-associated-weight-loss-clinical-study-and-benefit-risk-considerations,https://www.fda.gov/media/172084/download,2023-09-15,['Center for Devices and Radiological Health'],"['Premarket','Gastroenterology-Urology']",Draft,FDA-2019-N-4060,No,2023-11-14
Medical Devices with Indications Associated with Weight Loss - Non-Clinical Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-devices-indications-associated-weight-loss-non-clinical-recommendations,https://www.fda.gov/media/172063/download,2023-09-15,['Center for Devices and Radiological Health'],"['Premarket','Gastroenterology-Urology']",Draft,FDA-2019-N-4060,No,2023-11-14
Breakthrough Devices Program:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/breakthrough-devices-program,https://www.fda.gov/media/162413/download,2023-09-14,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",,Final,FDA-2017-D-5966,No,
Institutional Review Board (IRB) Review of Individual Patient Expanded Access Submissions for Investigational Drugs and Biological Products:   Guidance for IRBs and Clinical Investigators,,,2023-09-11,[],['Good Clinical Practice (GCP)'],Final,FDA-2023-D-3452,No,
Endogenous Cushing’s Syndrome: Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/endogenous-cushings-syndrome-developing-drugs-treatment,https://www.fda.gov/media/171900/download,2023-09-08,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2023-D-3518,No,2023-11-07
"Use of International Standard ISO 10993-1, ""Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process"" :  Guidance for Industry and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-international-standard-iso-10993-1-biological-evaluation-medical-devices-part-1-evaluation-and,https://www.fda.gov/media/142959/download,2023-09-08,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','510(k)','Premarket Approval (PMA)','Investigational Device Exemption (IDE)','HUD/HDE','Safety - Issues, Errors, and Problems']",Final,FDA-2013-D-0350,No,
Application of Human Factors Engineering Principles for Combination Products: Questions and Answers:  Guidance for Industry and  FDA Staff,,,2023-09-07,[],['Combination Products'],Final,FDA-2015-D-4848,No,2016-05-03
Best Practices for Selecting a Predicate Device to Support a Premarket Notification [510(k)] Submission: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-selecting-predicate-device-support-premarket-notification-510k-submission,https://www.fda.gov/media/171838/download,2023-09-07,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','510(k)']",Draft,FDA-2023-D-3134,No,2023-12-06
Evidentiary Expectations for 510(k) Implant Devices: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evidentiary-expectations-510k-implant-devices,https://www.fda.gov/media/171835/download,2023-09-07,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','510(k)']",Draft,FDA-2023-D-3132,No,2023-12-06
Recommendations for the Use of Clinical Data in Premarket Notification [510(k)] Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-use-clinical-data-premarket-notification-510k-submissions,https://www.fda.gov/media/171837/download,2023-09-07,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','510(k)']",Draft,FDA-2023-D-3133,No,2023-12-06
"DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dscsa-standards-interoperable-exchange-information-tracing-certain-human-finished-prescription-drugs,https://www.fda.gov/media/171796/download,2023-09-06,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Administrative / Procedural'],Final,FDA-2014-D-1981,No,
Post-Warning Letter Meetings Under GDUFA,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/post-warning-letter-meetings-under-gdufa,https://www.fda.gov/media/171785/download,2023-09-05,['Center for Drug Evaluation and Research'],['Generic Drugs'],Draft,FDA-2023-D-3370,No,2023-11-06
Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium avium Complex:  Developing Drugs for Treatment :  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nontuberculous-mycobacterial-pulmonary-disease-caused-mycobacterium-avium-complex-developing-drugs,https://www.fda.gov/media/171783/download,2023-09-05,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2021-D-0544,No,
Enforcement Policy for Face Masks and Barrier Face Coverings During the Coronavirus Disease (COVID-19) Public Health Emergency :  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-face-masks-and-barrier-face-coverings-during-coronavirus-disease-covid-19-public,https://www.fda.gov/media/136449/download,2023-09-05,['Center for Devices and Radiological Health'],"['Premarket','Coronavirus','Labeling']",Final,FDA-2020-D-1138,No,
Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product—Compliance Policies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/wholesale-distributor-verification-requirement-saleable-returned-drug-product-and-dispenser-0,https://www.fda.gov/media/171677/download,2023-09-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Administrative / Procedural'],Final,FDA-2019-D-4212,No,
Civil Money Penalties and No-Tobacco-Sale Orders For Tobacco Retailers (*Revised):  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/civil-money-penalties-and-no-tobacco-sale-orders-tobacco-retailers-revised,https://www.fda.gov/media/80888/download,2023-08-31,['Center for Tobacco Products'],['No-tobacco-sale order (NTSO)'],Final,FDA-2010-D-0431,No,
Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug,https://www.fda.gov/media/171667/download,2023-08-30,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Real World Data / Real World Evidence (RWD/RWE)','Clinical - Medical']",Final,FDA-2021-D-1214,No,
Enhanced Drug Distribution Security at the Package Level Under the Drug Supply Chain Security Act:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhanced-drug-distribution-security-package-level-under-drug-supply-chain-security-act,https://www.fda.gov/media/171666/download,2023-08-30,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Administrative / Procedural'],Final,FDA-2020-D-2024,No,
"Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act--Compliance Policies",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhanced-drug-distribution-security-requirements-under-section-582g1-federal-food-drug-and-cosmetic,https://www.fda.gov/media/171592/download,2023-08-28,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Administrative / Procedural'],Final,FDA-2023-D-1909,No,
Guidance for Industry: The Seafood List FDA’s Guide to Determine Acceptable Seafood Names,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-seafood-list-fdas-guide-determine-acceptable-seafood-names,https://www.fda.gov/media/171514/download,2023-08-22,['Human Foods Program'],['Seafood/Seafood Product'],Final,FDA-1994-D-0221,No,
"Informed Consent:  Guidance for IRBs, Clinical Investigators, and Sponsors",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/informed-consent,https://www.fda.gov/media/88915/download,2023-08-15,"['Office of the Commissioner','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Good Clinical Practice (GCP)','Pediatric Product Development']",Final,FDA-2006-D-0031,No,
Classification Categories for Certain Supplements Under BsUFA III,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/classification-categories-certain-supplements-under-bsufa-iii,https://www.fda.gov/media/170906/download,2023-08-11,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Biosimilars'],Draft,FDA-2023-D-1954,No,2023-10-10
Formal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formal-meetings-between-fda-and-sponsors-or-applicants-bsufa-products-guidance-industry,https://www.fda.gov/media/113913/download,2023-08-11,['Center for Drug Evaluation and Research'],"['Administrative / Procedural','Biosimilars']",Draft,FDA-2018-D-1922,No,2023-10-10
Off-The-Shelf Software Use in Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/shelf-software-use-medical-devices,https://www.fda.gov/media/71794/download,2023-08-11,['Center for Devices and Radiological Health'],"['Premarket','Digital Health']",Final,FDA-2019-D-3598,No,
Postmarketing Approaches to Obtain Data on Populations Underrepresented in Clinical Trials for Drugs and Biological Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-approaches-obtain-data-populations-underrepresented-clinical-trials-drugs-and,https://www.fda.gov/media/170899/download,2023-08-10,[],['Clinical - Medical'],Draft,FDA-2022-D-2629,No,
QTc Information in Human Prescription Drug and Biological Product Labeling: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/qtc-information-human-prescription-drug-and-biological-product-labeling,https://www.fda.gov/media/170814/download,2023-08-08,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Labeling'],Draft,FDA-2023-D-2439,No,2023-10-10
Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommended-acceptable-intake-limits-nitrosamine-drug-substance-related-impurities,https://www.fda.gov/media/170794/download,2023-08-07,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Final,FDA-2020-D-1530,No,
"Waivers, Exceptions, and Exemptions from the Requirements of Section 582 of the Federal Food, Drug, and Cosmetic Act",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/waivers-exceptions-and-exemptions-requirements-section-582-federal-food-drug-and-cosmetic-act,https://www.fda.gov/media/113342/download,2023-08-04,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Administrative / Procedural'],Final,FDA-2018-D-1434,No,
"PDUFA Waivers, Reductions, and Refunds for Fixed- Combinations and Single-Entity Versions of Previously Approved Antiretrovirals under PEPFAR",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pdufa-waivers-reductions-and-refunds-fixed-combinations-and-single-entity-versions-previously,https://www.fda.gov/media/170813/download,2023-08-03,['Center for Drug Evaluation and Research'],['User Fees'],Draft,FDA-2018-D-1635,No,2023-10-02
Fixed-Combinations and Single-Entity Versions of Previously Approved Antiretrovirals for the Treatment or Prevention of Human Immunodeficiency Virus-One Under the President’s Emergency Plan for Acquired Immunodeficiency Syndrome Relief,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fixed-combinations-and-single-entity-versions-previously-approved-antiretrovirals-treatment-or,https://www.fda.gov/media/72248/download,2023-08-01,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Draft,FDA-2004-D-0301,No,2023-11-01
Assessing User Fees Under the Biosimilar User Fee Amendments of 2022:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-user-fees-under-biosimilar-user-fee-amendments-2022,https://www.fda.gov/media/170634/download,2023-07-31,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['User Fees'],Final,FDA-2017-D-6209,No,
Hydrogen Peroxide-Based Contact Lens Care Products: Consumer Labeling Recommendations - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hydrogen-peroxide-based-contact-lens-care-products-consumer-labeling-recommendations-premarket,https://www.fda.gov/media/160909/download,2023-07-27,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Labeling','Ophthalmic']",Final,FDA-2022-D-0986,No,
CDER’s Program for the Recognition of Voluntary Consensus Standards Related to Pharmaceutical Quality,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cders-program-recognition-voluntary-consensus-standards-related-pharmaceutical-quality,https://www.fda.gov/media/121305/download,2023-07-26,['Center for Drug Evaluation and Research'],"['Administrative / Procedural','Drug Competition Action Plan']",Final,FDA-2018-D-4417,No,
Guidance for Industry | M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-m7r2-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals,https://www.fda.gov/media/170461/download,2023-07-25,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Multidisciplinary'],Final,FDA-2022-D-0055,No,
M7(R2) ADDENDUM: APPLICATION OF THE PRINCIPLES OF THE ICH M7 GUIDELINE TO CALCULATION OF COMPOUND-SPECIFIC ACCEPTABLE INTAKES:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m7r2-addendum-application-principles-ich-m7-guideline-calculation-compound-specific-acceptable,https://www.fda.gov/media/170459/download,2023-07-25,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Multidisciplinary'],Final,FDA-2022-D-0055,No,
Questions and Answers | M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/questions-and-answers-m7r2-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals,https://www.fda.gov/media/170460/download,2023-07-25,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Multidisciplinary'],Final,FDA-2020-N-1790,No,
"Qualification of Medical Device Development Tools:  Guidance for Industry, Tool Developers, and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/qualification-medical-device-development-tools,https://www.fda.gov/media/87134/download,2023-07-17,['Center for Devices and Radiological Health'],"['Premarket','Administrative / Procedural','Digital Health']",Final,FDA-2013-D-1279,No,
"Postmarketing Studies and Clinical Trials:  Determining Good Cause for Noncompliance with Section 505(o)(3)(E)(ii) of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-studies-and-clinical-trials-determining-good-cause-noncompliance-section-505o3eii,https://www.fda.gov/media/170187/download,2023-07-14,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",,Draft,FDA-2023-D-0559,No,2023-09-12
Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacturing-changes-and-comparability-human-cellular-and-gene-therapy-products,https://www.fda.gov/media/170198/download,2023-07-13,['Center for Biologics Evaluation and Research'],['Gene Therapy'],Draft,FDA-2023-D-2436,No,2023-11-13
Temporary Policy Regarding Accredited Third-Party Certification Program Onsite Observation and Certificate Duration Requirements Due to COVID-19 :  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/temporary-policy-regarding-accredited-third-party-certification-program-onsite-observation-and,https://www.fda.gov/media/137248/download,2023-07-13,"['Human Foods Program','Center for Veterinary Medicine','Office of Inspections and Investigations']","['Infectious Disease','Coronavirus']",Final,FDA-2023-D-2827,No,
Temporary Policy Regarding Preventive Controls and FSVP Food Supplier Verification Onsite Audit Requirements Due to COVID-19:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/temporary-policy-regarding-preventive-controls-and-fsvp-food-supplier-verification-onsite-audit,https://www.fda.gov/media/136142/download,2023-07-13,['Human Foods Program'],"['Infectious Disease','Coronavirus']",Final,FDA-2023-D-2828,No,
Inborn Errors of Metabolism That Use Dietary Management: Considerations for Optimizing and Standardizing Diet in Clinical Trials for Drug Product Development: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/inborn-errors-metabolism-use-dietary-management-considerations-optimizing-and-standardizing-diet,https://www.fda.gov/media/114764/download,2023-07-12,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Clinical - Medical','Pediatric Product Development']",Draft,FDA-2018-D-2647,No,2023-09-11
Chronic Rhinosinusitis with Nasal Polyps: Developing Drugs for Treatment :  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chronic-rhinosinusitis-nasal-polyps-developing-drugs-treatment,https://www.fda.gov/media/154724/download,2023-06-28,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Clinical - Medical','Pediatric Product Development']",Final,FDA-2021-D-1096,No,
Patient-Matched Guides to Orthopedic Implants: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-matched-guides-orthopedic-implants,https://www.fda.gov/media/169792/download,2023-06-28,['Center for Devices and Radiological Health'],"['Premarket','Orthopedic']",Draft,FDA-2023-D-2370,No,2023-08-28
"Prohibition on Wholesaling Under Section 503B of the Federal Food, Drug, and Cosmetic Act",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prohibition-wholesaling-under-section-503b-federal-food-drug-and-cosmetic-act,https://www.fda.gov/media/169838/download,2023-06-27,['Center for Drug Evaluation and Research'],['Compounding'],Draft,FDA-2023-D-0939,No,2023-08-28
"Formal Dispute Resolution and Administrative Hearings of Final Administrative Orders Under Section 505G of the Federal Food, Drug, and Cosmetic Act",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formal-dispute-resolution-and-administrative-hearings-final-administrative-orders-under-section-505g,https://www.fda.gov/media/169628/download,2023-06-23,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Draft,FDA-2023-D-2204,No,2023-08-22
Psychedelic Drugs: Considerations for Clinical Investigations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations,https://www.fda.gov/media/169694/download,2023-06-23,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2023-D-1987,No,2023-08-25
Alternative Procedures for the Manufacture of Cold-Stored Platelets Intended for the Treatment of Active Bleeding when Conventional Platelets Are Not Available or Their Use Is Not Practical:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/alternative-procedures-manufacture-cold-stored-platelets-intended-treatment-active-bleeding-when,https://www.fda.gov/media/169714/download,2023-06-23,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2023-D-2034,No,
Drug-Drug Interaction Assessment for Therapeutic Proteins Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-drug-interaction-assessment-therapeutic-proteins-guidance-industry,https://www.fda.gov/media/140909/download,2023-06-22,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Clinical - Pharmacology'],Final,FDA-2020-D-1480,No,2020-11-09
"Oncology Drug Products Used with Certain In Vitro Diagnostic Tests: Pilot Program:  Guidance for Industry, Clinical Laboratories, and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/oncology-drug-products-used-certain-in-vitro-diagnostic-tests-pilot-program,https://www.fda.gov/media/169616/download,2023-06-20,"['Center for Drug Evaluation and Research','Center for Devices and Radiological Health']",,Final,FDA-2022-D-2275,No,
CVM GFI #171 - Demonstrating Bioequivalence for Soluble Powder Oral Dosage Form Products and Type A Medicated Articles Containing Active Pharmaceutical Ingredients Considered to Be Soluble in Aqueous Media,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-171-demonstrating-bioequivalence-soluble-powder-oral-dosage-form-products-and-type-medicated,https://www.fda.gov/media/131173/download,2023-06-16,['Center for Veterinary Medicine'],"['Premarket','Aquaculture','Generic Animal Drugs','Investigational New Animal Drug (INAD)','New Animal Drug Application (NADA)']",Final,FDA-2019-D-3764,No,2019-11-29
Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/implementation-acceptable-full-length-and-abbreviated-donor-history-questionnaires-and-accompanying-0,https://www.fda.gov/media/124172/download,2023-06-14,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2016-D-1342,No,
Content of Premarket Submissions for Device Software Functions:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-premarket-submissions-device-software-functions,https://www.fda.gov/media/153781/download,2023-06-14,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research','Office of the Commissioner','Center for Drug Evaluation and Research']","['Premarket','Digital Health']",Final,FDA-2021-D-0775,No,
Assessing User Fees Under the Generic Drug User Fee Amendments of 2022,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-user-fees-under-generic-drug-user-fee-amendments-2022,https://www.fda.gov/media/132138/download,2023-06-09,['Center for Drug Evaluation and Research'],"['User Fees','Generic Drugs']",Final,FDA-2012-D-0880,No,
Clinical Drug Interaction Studies With Combined Oral Contraceptives Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-combined-oral-contraceptives-guidance-industry,https://www.fda.gov/media/143849/download,2023-06-08,['Center for Drug Evaluation and Research'],['Clinical - Pharmacology'],Final,FDA-2020-D-1848,No,2021-02-22
E6(R3) GOOD CLINICAL PRACTICE (GCP),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp,https://www.fda.gov/media/169090/download,2023-06-06,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Efficacy'],Draft,FDA-2023-D-1955,No,2023-09-05
Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-evaluation-immunotoxic-potential-pharmaceuticals,https://www.fda.gov/media/169117/download,2023-06-05,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Final,FDA-2019-D-5607,No,
Cover Letter Attachments for Controlled Correspondences and ANDA Submissions:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cover-letter-attachments-controlled-correspondences-and-anda-submissions,https://www.fda.gov/media/154762/download,2023-06-05,['Center for Drug Evaluation and Research'],['Generic Drugs'],Final,FDA-2021-D-0861,No,
Interstitial Cystitis/Bladder Pain Syndrome: Establishing Drug Development Programs for Treatment: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interstitial-cystitisbladder-pain-syndrome-establishing-drug-development-programs-treatment,https://www.fda.gov/media/169118/download,2023-06-02,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2019-D-4656,No,2023-08-04
Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program,https://www.fda.gov/media/114034/download,2023-06-02,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Administrative / Procedural','Investigational Device Exemption (IDE)']",Final,FDA-2018-D-1774,No,
Guidance for Industry: Action Level for Inorganic Arsenic in Apple Juice,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-action-level-inorganic-arsenic-apple-juice,https://www.fda.gov/media/86110/download,2023-06-01,['Human Foods Program'],"['Arsenic','Juice']",Final,FDA-2012-D-0322,No,
Migraine:  Developing Drugs for Preventive Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/migraine-developing-drugs-preventive-treatment,https://www.fda.gov/media/168871/download,2023-06-01,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2022-D-1729,No,2023-08-01
Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adjusting-covariates-randomized-clinical-trials-drugs-and-biological-products,https://www.fda.gov/media/148910/download,2023-05-26,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",,Final,FDA-2019-D-0934,No,
Non-Clinical Performance Assessment of Tissue Containment Systems Used During Power Morcellation Procedures:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-clinical-performance-assessment-tissue-containment-systems-used-during-power-morcellation,https://www.fda.gov/media/159294/download,2023-05-26,['Center for Devices and Radiological Health'],"['Premarket','Clinical - Medical','General & Plastic Surgery','Obstetrical & Gynecological']",Final,FDA-2022-D-0737,No,
Diabetes Mellitus: Efficacy Endpoints for Clinical Trials Investigating Antidiabetic Drugs and Biological Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diabetes-mellitus-efficacy-endpoints-clinical-trials-investigating-antidiabetic-drugs-and-biological,https://www.fda.gov/media/168475/download,2023-05-25,['Center for Drug Evaluation and Research'],"['Clinical - Medical','Pediatric Product Development']",Draft,FDA-2023-D-0625,No,2023-08-24
Generally Accepted Scientific Knowledge in Applications for Drug and Biological Products:  Nonclinical Information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/generally-accepted-scientific-knowledge-applications-drug-and-biological-products-nonclinical,https://www.fda.gov/media/168408/download,2023-05-24,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Pharmacology/Toxicology'],Draft,FDA-2023-D-1618,No,2023-07-24
Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Questions and Answers:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-whole-slide-imaging-nonclinical-toxicology-studies-questions-and-answers,https://www.fda.gov/media/168431/download,2023-05-24,"['Center for Veterinary Medicine','Office of Inspections and Investigations','Human Foods Program']",['Pharmacology/Toxicology'],Final,FDA-2021-D-1268,No,
Small Entity Compliance Guide: Requirements for Additional Traceability Records for Certain Foods: What You Need to Know About the FDA Regulation,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-requirements-additional-traceability-records-certain-foods-what-you,https://www.fda.gov/media/168142/download,2023-05-18,['Human Foods Program'],,Final,FDA-2023-D-1336,No,
Pediatric Drug Development Under the Pediatric Research Equity Act and the Best Pharmaceuticals for Children Act:  Scientific Considerations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-drug-development-under-pediatric-research-equity-act-and-best-pharmaceuticals-children-act,https://www.fda.gov/media/168202/download,2023-05-17,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Administrative / Procedural','Pediatric Product Development']",Draft,FDA-2005-D-0460,No,2023-07-17
Pediatric Drug Development:  Regulatory Considerations — Complying With the Pediatric Research Equity Act and Qualifying for Pediatric Exclusivity Under the Best Pharmaceuticals for Children Act,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-drug-development-regulatory-considerations-complying-pediatric-research-equity-act-and,https://www.fda.gov/media/168201/download,2023-05-17,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Administrative / Procedural','Pediatric Product Development']",Draft,FDA-2005-D-0460,No,2023-07-17
CVM GFI #271 Reporting and Mitigating Animal Drug Shortages,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-271-reporting-and-mitigating-animal-drug-shortages,https://www.fda.gov/media/137722/download,2023-05-12,['Center for Veterinary Medicine'],"['Postmarket','Coronavirus','Animal Drugs','Chemistry, Manufacturing, and Controls (CMC)']",Final,FDA-2020-D-1140,No,
Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Blood and Blood Components:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/implementation-acceptable-full-length-and-abbreviated-donor-history-questionnaires-and-accompanying,https://www.fda.gov/media/124193/download,2023-05-11,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2016-D-1342,No,
Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-evaluating-donor-eligibility-using-individual-risk-based-questions-reduce-risk-human,https://www.fda.gov/media/164829/download,2023-05-11,['Center for Biologics Evaluation and Research'],"['Blood','Coronavirus','HIV/AIDS','Blood Products']",Final,FDA-2015-D-1211,No,
CPG Sec 555.250 DRAFT: Major Food Allergen Labeling and Cross-contact,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555250-draft-major-food-allergen-labeling-and-cross-contact,https://www.fda.gov/media/168000/download,2023-05-09,['Human Foods Program'],['Investigation & Enforcement'],Draft,FDA-2023-D-1103,No,2023-07-17
"Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/testing-glycerin-propylene-glycol-maltitol-solution-hydrogenated-starch-hydrolysate-sorbitol,https://www.fda.gov/media/167974/download,2023-05-08,['Center for Drug Evaluation and Research'],['Compliance'],Final,FDA-2023-D-1573,No,
Q9(R1) Quality Risk Management,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q9r1-quality-risk-management,https://www.fda.gov/media/167721/download,2023-05-03,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-2022-D-0705,No,
Assessing User Fees Under the Prescription Drug User Fee Amendments of 2022,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-user-fees-under-prescription-drug-user-fee-amendments-2022,https://www.fda.gov/media/167877/download,2023-05-01,['Center for Drug Evaluation and Research'],['User Fees'],Final,FDA-2017-D-6821,No,
Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/smoking-cessation-and-related-indications-developing-nicotine-replacement-therapy-drug-products,https://www.fda.gov/media/167599/download,2023-05-01,['Center for Drug Evaluation and Research'],"['Clinical - Medical','Pediatric Product Development']",Final,FDA-2019-D-0297,No,
S12 NONCLINICAL BIODISTRIBUTION CONSIDERATIONS FOR GENE THERAPY PRODUCTS:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s12-nonclinical-biodistribution-considerations-gene-therapy-products,https://www.fda.gov/media/167605/download,2023-05-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Safety'],Final,FDA-2021-D-0875,No,
CVM GFI #108 Registering with CVM’s Electronic Submission System,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-108-registering-cvms-electronic-submission-system,https://www.fda.gov/media/70064/download,2023-04-26,['Center for Veterinary Medicine'],['Electronic Submissions'],Final,FDA-1992-S-0039,No,
Acute Radiation Syndrome: Developing Drugs for Prevention and Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acute-radiation-syndrome-developing-drugs-prevention-and-treatment,https://www.fda.gov/media/167172/download,2023-04-19,['Center for Drug Evaluation and Research'],"['Animal Rule','Pediatric Product Development']",Draft,FDA-2023-D-1146,No,2023-07-19
"Guidance for Industry: Transition from Temporary Policy During the COVID-19 Public Health Emergency Regarding the Qualified Exemption from the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-transition-temporary-policy-during-covid-19-public-health-emergency-regarding,https://www.fda.gov/media/166928/download,2023-04-14,['Human Foods Program'],['Produce'],Final,FDA-2023-D-1031,No,
Peripheral Percutaneous Transluminal Angioplasty (PTA) and Specialty Catheters - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/peripheral-percutaneous-transluminal-angioplasty-pta-and-specialty-catheters-premarket-notification,https://www.fda.gov/media/134016/download,2023-04-14,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Cardiovascular','Labeling']",Final,FDA-2019-D-5422,No,
CVM GFI #170 Animal Drug User Fees and Fee Waivers and Reductions,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-170-animal-drug-user-fees-and-fee-waivers-and-reductions,https://www.fda.gov/media/69918/download,2023-04-13,['Center for Veterinary Medicine'],['User Fees'],Final,FDA-2004-D-0369,No,2017-01-03
Over-the-Counter Monograph Order Requests: Format and Content,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/over-counter-monograph-order-requests-format-and-content,https://www.fda.gov/media/167035/download,2023-04-13,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Draft,FDA-2023-D-1188,No,2023-06-12
Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-irritation-and-sensitization-potential-transdermal-and-topical-delivery-systems-andas,https://www.fda.gov/media/167073/download,2023-04-13,['Center for Drug Evaluation and Research'],"['Drug Competition Action Plan','Generic Drugs']",Draft,FDA-2018-D-3546,No,2023-06-12
Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-adhesion-transdermal-and-topical-delivery-systems-andas-draft-guidance-industry,https://www.fda.gov/media/167043/download,2023-04-12,['Center for Drug Evaluation and Research'],"['Drug Competition Action Plan','Generic Drugs']",Draft,FDA-2016-D-1254,No,2023-06-12
A Risk-Based Approach to Monitoring of Clinical Investigations Questions and Answers:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/risk-based-approach-monitoring-clinical-investigations-questions-and-answers,https://www.fda.gov/media/121479/download,2023-04-12,"['Office of Inspections and Investigations','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research','Office of the Commissioner']",['Administrative / Procedural'],Final,FDA-2019-D-0362,No,
Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory,https://www.fda.gov/media/166830/download,2023-04-05,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']",['Administrative / Procedural'],Draft,FDA-2023-D-0026,No,2023-07-05
Guidance for Industry: Labeling of Certain Beers Subject to the Labeling Jurisdiction of the Food and Drug Administration,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-labeling-certain-beers-subject-labeling-jurisdiction-food-and-drug-administration,https://www.fda.gov/media/90473/download,2023-04-04,['Human Foods Program'],['Labeling'],Final,FDA-2009-D-0268,No,
Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-submission-recommendations-predetermined-change-control-plan-artificial,https://www.fda.gov/media/166704/download,2023-04-03,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research','Office of the Commissioner']","['Premarket','Digital Health']",Draft,FDA-2022-D-2628,No,2023-07-03
CVM GFI #281 Infectious Otitis Externa Drugs for Topical Use in Dogs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-281-infectious-otitis-externa-drugs-topical-use-dogs,https://www.fda.gov/media/166404/download,2023-03-31,['Center for Veterinary Medicine'],"['Premarket','Animal Drugs','Investigational New Animal Drug (INAD)','New Animal Drug Application (NADA)','Target Animal – Effectiveness','Target Animal – Safety','Labeling']",Draft,FDA-2023-D-0606,No,2023-05-30
Registration and Product Listing for Owners and Operators of Domestic Tobacco Product Establishments:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/registration-and-product-listing-owners-and-operators-domestic-tobacco-product-establishments,https://www.fda.gov/media/78165/download,2023-03-31,['Center for Tobacco Products'],,Final,FDA-2009-D-0508,No,2014-04-07
Tobacco Health Document Submission (Revised):  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/tobacco-health-document-submission-revised,https://www.fda.gov/media/78616/download,2023-03-31,['Center for Tobacco Products'],['Tobacco Health documents'],Final,FDA-2009-D-0600,No,2010-04-20
Identification of Medicinal Products —  Implementation and Use,,,2023-03-30,[],['Electronic Submissions'],Final,FDA-2023-D-0266,No,
"Research Involving Children as Subjects and Not Otherwise Approvable by an Institutional Review Board: Process for Referrals to Food and Drug Administration and Office for Human Research Protections: Draft Guidance for Institutional Review Boards, Investigators, and Sponsors",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/research-involving-children-subjects-and-not-otherwise-approvable-institutional-review-board-process,https://www.fda.gov/media/166731/download,2023-03-30,['Office of the Commissioner'],['Pediatric Product Development'],Draft,FDA-2022-D-0142,No,2023-05-30
"Orthopedic Non-Spinal Bone Plates, Screws, and Washers - Premarket Notification (510(k)) Submissions: Draft Guidance for Industry and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orthopedic-non-spinal-bone-plates-screws-and-washers-premarket-notification-510k-submissions,https://www.fda.gov/media/166507/download,2023-03-29,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Orthopedic']",Draft,FDA-2023-D-0488,No,2023-05-30
General Considerations for Animal Studies Intended to Evaluate Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-considerations-animal-studies-intended-evaluate-medical-devices,https://www.fda.gov/media/93963/download,2023-03-28,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Premarket Approval (PMA)','Investigational Device Exemption (IDE)','HUD/HDE']",Final,FDA-2015-D-3419,No,
Soft (Hydrophilic) Daily Wear Contact Lenses - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/soft-hydrophilic-daily-wear-contact-lenses-performance-criteria-safety-and-performance-based-pathway,https://www.fda.gov/media/135629/download,2023-03-28,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Ophthalmic']",Final,FDA-2019-D-4843,No,
"Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) Related to Coronavirus Disease 2019 (COVID-19):  Guidance for Industry, Other Stakeholders, and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/transition-plan-medical-devices-issued-emergency-use-authorizations-euas-related-coronavirus-disease,https://www.fda.gov/media/155039/download,2023-03-27,['Center for Devices and Radiological Health'],"['Premarket','Postmarket','Coronavirus']",Final,FDA-2021-D-1149,No,
"Transition Plan for Medical Devices That Fall Within Enforcement Policies Issued During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency:  Guidance for Industry, Other Stakeholders, and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/transition-plan-medical-devices-fall-within-enforcement-policies-issued-during-coronavirus-disease,https://www.fda.gov/media/155038/download,2023-03-27,['Center for Devices and Radiological Health'],"['Premarket','Postmarket','Coronavirus']",Final,FDA-2021-D-1118,No,
Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-considerations-support-accelerated-approval-oncology-therapeutics,https://www.fda.gov/media/166431/download,2023-03-24,[],,Draft,FDA-2023-D-0110,No,2023-05-26
Draft Guidance for Industry: Questions and Answers About Dietary Guidance Statements in Food Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-questions-and-answers-about-dietary-guidance-statements-food-labeling,https://www.fda.gov/media/166342/download,2023-03-24,['Human Foods Program'],"['Labeling','Nutrition']",Draft,FDA-2023-D-1027,No,2023-09-25
Pharmacogenomic Data Submissions,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacogenomic-data-submissions-0,https://www.fda.gov/media/166258/download,2023-03-17,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Administrative / Procedural'],Draft,FDA-2022-D-2856,No,2023-06-20
"FDA Deems Certain Tobacco Products Subject to FDA Authority, Sales and Distribution Restrictions, and Health Warning Requirements for Packages and Advertisements:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-deems-certain-tobacco-products-subject-fda-authority-sales-and-distribution-restrictions-and,https://www.fda.gov/media/143049/download,2023-03-17,['Center for Tobacco Products'],,Final,FDA-2014-N-0189,No,
Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products - Small Entity Compliance Guide:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/further-amendments-general-regulations-food-and-drug-administration-incorporate-tobacco-products,https://www.fda.gov/media/83261/download,2023-03-17,['Center for Tobacco Products'],,Final,FDA-2011-N-0121,No,2012-03-28
"Interpretation of and Compliance Policy for Certain Label Requirement; Applicability of Certain Federal Food, Drug, and Cosmetic Act Requirements to Vape Shops:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interpretation-and-compliance-policy-certain-label-requirement-applicability-certain-federal-food,https://www.fda.gov/media/102420/download,2023-03-17,['Center for Tobacco Products'],['Labeling'],Final,FDA-2017-D-0120,No,
Listing of Ingredients in Tobacco Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/listing-ingredients-tobacco-products,https://www.fda.gov/media/101162/download,2023-03-17,['Center for Tobacco Products'],,Final,FDA-2009-D-0524,No,2009-12-01
Premarket Tobacco Product Applications for Electronic Nicotine Delivery Systems (ENDS):  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-tobacco-product-applications-electronic-nicotine-delivery-systems-ends,https://www.fda.gov/media/127853/download,2023-03-17,['Center for Tobacco Products'],"['Electronic Nicotine Delivery Systems (ENDS)','Product Application and Review']",Final,FDA-2015-D-2496,No,
Prohibition of Distributing Free Samples of Tobacco Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prohibition-distributing-free-samples-tobacco-products,https://www.fda.gov/media/118928/download,2023-03-17,['Center for Tobacco Products'],['Free samples'],Final,FDA-2017-D-0113,No,
Determination of the Period Covered by a No-Tobacco-Sale Order and Compliance With an Order:  Guidance for Tobacco Retailers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/determination-period-covered-no-tobacco-sale-order-and-compliance-order,https://www.fda.gov/media/93328/download,2023-03-17,['Center for Tobacco Products'],['No-tobacco-sale order (NTSO)'],Final,FDA-2015-D-0404,No,
CVM GFI #106 The Use of Published Literature in Support of New Animal Drug Approvals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-106-use-published-literature-support-new-animal-drug-approvals,https://www.fda.gov/media/70056/download,2023-03-16,['Center for Veterinary Medicine'],"['Premarket','Chemistry, Manufacturing, and Controls (CMC)','Clinical - Antimicrobial','Clinical - Pharmacology','Safety - Issues, Errors, and Problems','Antimicrobial Resistance','New Animal Drug Application (NADA)','Target Animal – Effectiveness','Target Animal – Safety','Investigational New Animal Drug (INAD)','Minor Use/ Minor Species (MUMS)']",Final,FDA-2021-D-1155,No,2022-06-21
Definitions of Suspect Product and Illegitimate Product for Verification Obligations Under the Drug Supply Chain Security Act Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/definitions-suspect-product-and-illegitimate-product-verification-obligations-under-drug-supply,https://www.fda.gov/media/111468/download,2023-03-16,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Administrative / Procedural'],Final,FDA-2018-D-0338,No,
Guidance for Industry: Frequently Asked Questions About Medical Foods - Third Edition,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-frequently-asked-questions-about-medical-foods-third-edition,https://www.fda.gov/media/97726/download,2023-03-15,['Human Foods Program'],['Labeling'],Final,FDA-2013-D-0880,No,
Development of Local Anesthetic Drug Products With Prolonged Duration of Effect,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-local-anesthetic-drug-products-prolonged-duration-effect,https://www.fda.gov/media/166210/download,2023-03-15,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2023-D-0608,No,2023-06-14
"Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications  Guidance for Industry:  Guidance for Industry",,,2023-03-10,[],['Clinical - Pharmacology'],Final,FDA-2020-D-1794,No,2021-02-26
Guidance for Industry: Labeling of Infant Formula,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-labeling-infant-formula,https://www.fda.gov/media/99701/download,2023-03-06,['Human Foods Program'],"['Infant Formula & Foods','Labeling']",Final,FDA-2013-S-0610,No,
Potency Assay Considerations for Monoclonal Antibodies and Other Therapeutic Proteins Targeting Viral Pathogens,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/potency-assay-considerations-monoclonal-antibodies-and-other-therapeutic-proteins-targeting-viral,https://www.fda.gov/media/165746/download,2023-03-01,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Draft,FDA-2023-D-0202,No,2023-05-01
Q13 Continuous Manufacturing of Drug Substances and Drug Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q13-continuous-manufacturing-drug-substances-and-drug-products,https://www.fda.gov/media/165775/download,2023-03-01,['Center for Drug Evaluation and Research'],['ICH-Quality'],Final,FDA-2021-D-1047,No,
Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/neovascular-age-related-macular-degeneration-developing-drugs-treatment,https://www.fda.gov/media/165606/download,2023-02-24,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Clinical - Medical'],Draft,FDA-2022-D-0073,No,2023-05-30
Guidance for Industry and Food and Drug Administration Staff - Assembler's Guide to Diagnostic X-Ray Equipment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-food-and-drug-administration-staff-assemblers-guide-diagnostic-x-ray-equipment,https://www.fda.gov/media/80801/download,2023-02-21,['Center for Devices and Radiological Health'],,Final,FDA-2018-D-4115,No,
"Performance Standard for Diagnostic X-Ray Systems and Their Major Components (21CFR 1020.30, 1020.31, 1020.32, 1020.33); Small Entity Compliance Guide",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/performance-standard-diagnostic-x-ray-systems-and-their-major-components-21cfr-102030-102031-102032,https://www.fda.gov/media/73941/download,2023-02-21,['Center for Devices and Radiological Health'],['Radiology'],Final,FDA-2001-N-0178,No,
Laser Products - Conformance with IEC 60825-1 Ed. 3 and IEC 60601-2-22 Ed. 3.1 (Laser Notice No. 56):  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/laser-products-conformance-iec-60825-1-ed-3-and-iec-60601-2-22-ed-31-laser-notice-no-56,https://www.fda.gov/media/110120/download,2023-02-21,['Center for Devices and Radiological Health'],"['Export','Import','Laser Notice','Radiological Health','Radiology']",Final,FDA-2017-D-7011,No,
Marketing Clearance of Diagnostic Ultrasound Systems and Transducers :  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-clearance-diagnostic-ultrasound-systems-and-transducers,https://www.fda.gov/media/71100/download,2023-02-21,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Radiological Health','Radiology']",Final,FDA-2017-D-5372,No,
Medical X-Ray Imaging Devices Conformance with IEC Standards:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-x-ray-imaging-devices-conformance-iec-standards,https://www.fda.gov/media/99466/download,2023-02-21,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Radiological Health','Radiology']",Final,FDA-2016-D-2049,No,
Policy Clarification and Premarket Notification [510(k)] Submissions for Ultrasonic Diathermy Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-clarification-and-premarket-notification-510k-submissions-ultrasonic-diathermy-devices,https://www.fda.gov/media/107094/download,2023-02-21,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Physical Medicine']",Final,FDA-2017-D-4764,No,2017-10-30
Draft Guidance for Industry: Labeling of Plant-Based Milk Alternatives and Voluntary Nutrient Statements,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-labeling-plant-based-milk-alternatives-and-voluntary-nutrient-statements,https://www.fda.gov/media/165420/download,2023-02-10,['Human Foods Program'],"['Labeling','Nutrition']",Draft,FDA-2023-D-0451,No,2023-07-31
"Compounding Certain Ibuprofen Oral Suspension Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compounding-certain-ibuprofen-oral-suspension-products-under-section-503b-federal-food-drug-and,https://www.fda.gov/media/164693/download,2023-02-09,['Center for Drug Evaluation and Research'],['Compounding'],Final,FDA-2023-D-0169,No,
Draft Guidance for Industry:  Protein Efficiency Ratio (PER) Rat Bioassay Studies to Demonstrate that a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-protein-efficiency-ratio-rat-bioassay-studies-demonstrate-new-infant-formula,https://www.fda.gov/media/165173/download,2023-02-09,['Human Foods Program'],['Infant Formula & Foods'],Draft,FDA-2022-D-2424,No,2023-05-11
Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-design-and-conduct-externally-controlled-trials-drug-and-biological-products,https://www.fda.gov/media/164960/download,2023-02-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Real World Data / Real World Evidence (RWD/RWE)'],Draft,FDA-2022-D-2983,No,2023-05-02
Early Lyme Disease as Manifested by Erythema Migrans:  Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/early-lyme-disease-manifested-erythema-migrans-developing-drugs-treatment,https://www.fda.gov/media/164949/download,2023-01-31,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Draft,FDA-2022-D-2315,No,2023-04-03
"Surveying, Leveling, and Alignment Laser Products:  Guidance for Industry and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/surveying-leveling-and-alignment-laser-products,https://www.fda.gov/media/88325/download,2023-01-31,['Center for Devices and Radiological Health'],"['Laser Notice','Radiological Health']",Final,FDA-2014-D-0435,No,
CVM GFI #272 Practices to Prevent Unsafe Contamination of Animal Feed from Drug Carryover,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-272-practices-prevent-unsafe-contamination-animal-feed-drug-carryover,https://www.fda.gov/media/157979/download,2023-01-30,['Center for Veterinary Medicine'],"['Animal Feed','Current Good Manufacturing Practice (CGMP)','Safety - Issues, Errors, and Problems']",Final,FDA-2022-D-0173,No,2022-08-08
Acromegaly:  Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acromegaly-developing-drugs-treatment,https://www.fda.gov/media/164858/download,2023-01-30,['Center for Drug Evaluation and Research'],['Clinical - Pharmacology'],Draft,FDA-2022-D-2658,No,2023-03-31
CVM GFI #152 Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-152-evaluating-safety-antimicrobial-new-animal-drugs-regard-their-microbiological-effects,https://www.fda.gov/media/69949/download,2023-01-27,['Center for Veterinary Medicine'],"['Antimicrobial Resistance','Human Food Safety']",Draft,FDA-1998-D-0038,No,2023-05-19
Draft Guidance for Industry: Action Levels for Lead in Food Intended for Babies and Young Children,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-action-levels-lead-food-intended-babies-and-young-children,https://www.fda.gov/media/164684/download,2023-01-24,['Human Foods Program'],"['Infant Formula & Foods','Lead']",Draft,FDA-2022-D-0278,No,2023-05-08
Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cannabis-and-cannabis-derived-compounds-quality-considerations-clinical-research-guidance-industry,https://www.fda.gov/media/164690/download,2023-01-23,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2020-D-1079,No,
Mpox: Development of Drugs and Biological Products; Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/mpox-development-drugs-and-biological-products-guidance-industry,https://www.fda.gov/media/164642/download,2023-01-19,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2022-D-2395,No,2023-03-21
Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dosage-and-administration-section-labeling-human-prescription-drug-and-biological-products-content,https://www.fda.gov/media/72142/download,2023-01-12,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Labeling'],Draft,FDA-2007-D-0201,No,2023-03-14
Policy for Coronavirus Disease-2019 Tests (Revised):  Guidance for Developers and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-revised,https://www.fda.gov/media/135659/download,2023-01-12,['Center for Devices and Radiological Health'],"['Premarket','Coronavirus','CLIA (Clinical Laboratory Improvement Amendments)','Immunology & Microbiology','IVDs (In Vitro Diagnostic Devices)']",Final,FDA-2020-D-0987,No,
Photobiomodulation (PBM) Devices - Premarket Notification [510(k)] Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/photobiomodulation-pbm-devices-premarket-notification-510k-submissions,https://www.fda.gov/media/164417/download,2023-01-12,['Center for Devices and Radiological Health'],,Draft,FDA-2022-D-3116,No,2023-03-13
Policy for Evaluating Impact of Viral Mutations on COVID-19 Tests (Revised):  Guidance for Test Developers and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-evaluating-impact-viral-mutations-covid-19-tests-revised,https://www.fda.gov/media/146171/download,2023-01-12,['Center for Devices and Radiological Health'],"['Premarket','Coronavirus','IVDs (In Vitro Diagnostic Devices)']",Final,FDA-2020-D-0987,No,
Guidance for Industry: Foreign Supplier Verification Programs for Importers of Food for Humans and Animals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-foreign-supplier-verification-programs-importers-food-humans-and-animals,https://www.fda.gov/media/118241/download,2023-01-10,"['Center for Veterinary Medicine','Office of Inspections and Investigations','Human Foods Program']",['Import'],Final,FDA-2017-D-5225,No,
Format and Content of a REMS Document Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/format-and-content-rems-document-guidance-industry,https://www.fda.gov/media/77846/download,2023-01-04,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Safety - Issues, Errors, and Problems']",Final,FDA-2009-D-0461,No,2017-12-11
REMS Document Technical Conformance Guide,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rems-document-technical-conformance-guide,https://www.fda.gov/media/164344/download,2023-01-04,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Safety - Issues, Errors, and Problems']",Final,,No,
M11 Clinical Electronic Structured Harmonised Protocol,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m11-clinical-electronic-structured-harmonised-protocol,https://www.fda.gov/media/164112/download,2022-12-21,['Center for Drug Evaluation and Research'],['ICH-Multidisciplinary'],Draft,FDA-2022-D-3054,No,2023-02-21
M11 Technical Specification: Clinical Electronic Structured Harmonised Protocol,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m11-technical-specification-clinical-electronic-structured-harmonised-protocol,https://www.fda.gov/media/164116/download,2022-12-21,['Center for Drug Evaluation and Research'],['ICH-Multidisciplinary'],Draft,FDA-2022-D-3054,No,
M11 Template: Clinical Electronic Structured Harmonised Protocol,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m11-template-clinical-electronic-structured-harmonised-protocol,https://www.fda.gov/media/164117/download,2022-12-21,['Center for Drug Evaluation and Research'],['ICH-Multidisciplinary'],Draft,FDA-2022-D-3054,No,
Guidance for Industry: Best Practices for Convening a GRAS Panel,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-best-practices-convening-gras-panel,https://www.fda.gov/media/109006/download,2022-12-20,"['Center for Veterinary Medicine','Human Foods Program']",['GRAS'],Final,FDA-2017-D-0085,No,2018-05-15
Pulmonary Tuberculosis: Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pulmonary-tuberculosis-developing-drugs-treatment,https://www.fda.gov/media/87194/download,2022-12-14,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Draft,FDA-2013-D-1319,No,2023-02-13
Failure to Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/failure-respond-anda-complete-response-letter-within-regulatory-timeframe-guidance-industry,https://www.fda.gov/media/160166/download,2022-12-14,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['User Fees','Drug Competition Action Plan','Generic Drugs']",Final,FDA-2020-D-1548,No,
Content of Human Factors Information in Medical Device Marketing Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-human-factors-information-medical-device-marketing-submissions,https://www.fda.gov/media/163694/download,2022-12-09,['Center for Devices and Radiological Health'],,Draft,FDA-2015-D-4599,No,2023-03-09
Homeopathic Drug Products Guidance for FDA Staff and Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/homeopathic-drug-products-guidance-fda-staff-and-industry,https://www.fda.gov/media/163755/download,2022-12-07,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Compliance','Administrative / Procedural']",Final,FDA-2017-D-6580,No,
Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-reduce-risk-transfusion-transmitted-malaria,https://www.fda.gov/media/163737/download,2022-12-07,['Center for Biologics Evaluation and Research'],"['Laboratory Methods','Blood','Infectious Disease','Coronavirus','Blood Products']",Final,FDA-2000-D-0187,No,
Small Volume Parenteral Drug Products and Pharmacy Bulk Packages for Parenteral Nutrition: Aluminum Content and Labeling Recommendations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-volume-parenteral-drug-products-and-pharmacy-bulk-packages-parenteral-nutrition-aluminum,https://www.fda.gov/media/163799/download,2022-12-06,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2022-D-2301,No,2023-02-06
Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) Blocking Antibodies for Treatment of Patients with Cancer:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacokinetic-based-criteria-supporting-alternative-dosing-regimens-programmed-cell-death-receptor,https://www.fda.gov/media/151745/download,2022-12-06,['Center for Drug Evaluation and Research'],['Clinical - Pharmacology'],Final,FDA-2021-D-0691,No,
E19 A Selective Approach to Safety Data Collection in Specific Late-Stage Pre-Approval or Post-Approval Clinical Trials,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e19-selective-approach-safety-data-collection-specific-late-stage-pre-approval-or-post-approval,https://www.fda.gov/media/163670/download,2022-12-05,['Center for Drug Evaluation and Research'],,Final,FDA-2019-D-1828,No,
ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-pre-submission-facility-correspondence-related-prioritized-generic-drug-submissions,https://www.fda.gov/media/163643/download,2022-12-02,['Center for Drug Evaluation and Research'],,Draft,FDA-2017-D-3101,No,
Statistical Approaches to Establishing Bioequivalence,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-approaches-establishing-bioequivalence-0,https://www.fda.gov/media/163638/download,2022-12-02,['Center for Drug Evaluation and Research'],"['Biopharmaceutics','Generic Drugs']",Draft,FDA-2001-D-0197,No,
"Clinical Investigator Administrative Actions - Disqualification:  Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-investigator-administrative-actions-disqualification,https://www.fda.gov/media/164561/download,2022-12-01,['Office of the Commissioner'],['Good Clinical Practice (GCP)'],Final,FDA-2010-D-0265,No,
Guidance for Industry: Questions and Answers Regarding Food Allergen Labeling (Edition 5),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-questions-and-answers-regarding-food-allergen-labeling-edition-5,https://www.fda.gov/media/163454/download,2022-11-29,['Human Foods Program'],"['Allergens','Labeling']",Final,FDA-2022-D-0099,No,
Draft Guidance for Industry: Questions and Answers Regarding Food Allergen Labeling (Edition 5),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-questions-and-answers-regarding-food-allergen-labeling-edition-5,https://www.fda.gov/media/163454/download,2022-11-29,['Human Foods Program'],"['Allergens','Labeling']",Draft,FDA-2022-D-0099,No,2023-01-29
Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-regarding-investigational-new-drug-requirements-use-fecal-microbiota,https://www.fda.gov/media/86440/download,2022-11-28,['Center for Biologics Evaluation and Research'],['Vaccines'],Final,FDA-2013-D-0811,No,
Compounding Certain Beta-Lactam Products in Shortage Under Section 503A of the Federal Food Drug and Cosmetic Act,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compounding-certain-beta-lactam-products-shortage-under-section-503a-federal-food-drug-and-cosmetic,https://www.fda.gov/media/163367/download,2022-11-18,['Center for Drug Evaluation and Research'],,Final,FDA-2022-D-2922,No,
"Referencing the Definition of ""Device"" in the Federal Food, Drug, and Cosmetic Act in Guidance, Regulatory Documents, Communications, and Other Public Documents:  Guidance for Industry and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/referencing-definition-device-federal-food-drug-and-cosmetic-act-guidance-regulatory-documents,https://www.fda.gov/media/154866/download,2022-11-14,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",,Final,FDA-2021-D-0997,No,
Sameness Evaluations in an ANDA — Active Ingredients,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sameness-evaluations-anda-active-ingredients,https://www.fda.gov/media/163018/download,2022-11-08,['Center for Drug Evaluation and Research'],"['Drug Competition Action Plan','Generic Drugs']",Draft,FDA-2022-D-0697,No,2023-01-08
M10 Bioanalytical Method Validation and Study Sample Analysis,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m10-bioanalytical-method-validation-and-study-sample-analysis,https://www.fda.gov/media/162903/download,2022-11-04,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Clinical - Medical','ICH-Multidisciplinary']",Final,FDA-2019-D-1469,No,
Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/studying-multiple-versions-cellular-or-gene-therapy-product-early-phase-clinical-trial,https://www.fda.gov/media/152536/download,2022-11-04,['Center for Biologics Evaluation and Research'],"['Clinical Trials','Gene Therapy']",Final,FDA-2021-D-0776,No,
Cross Labeling Oncology Drugs in Combination Regimens,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cross-labeling-oncology-drugs-combination-regimens,https://www.fda.gov/media/162806/download,2022-11-02,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Clinical - Medical'],Final,FDA-2020-D-2107,No,
S1B(R1) Addendum to S1B Testing for Carcinogenicity of Pharmaceuticals:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s1br1-addendum-s1b-testing-carcinogenicity-pharmaceuticals,https://www.fda.gov/media/152777/download,2022-11-02,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Safety'],Final,FDA-2021-D-0669,No,
Assessing User Fees Under the Over-the-Counter Monograph Drug User Fee Program,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-user-fees-under-over-counter-monograph-drug-user-fee-program,https://www.fda.gov/media/162759/download,2022-11-01,['Center for Drug Evaluation and Research'],['User Fees'],Draft,2021-709,No,
Expanded Access to Investigational Drugs for Treatment Use:  Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expanded-access-investigational-drugs-treatment-use-questions-and-answers-0,https://www.fda.gov/media/162793/download,2022-11-01,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Draft,FDA-2013-D-0446,No,2023-01-03
"Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) - Small Entity Compliance Guide:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulation-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-small-entity-compliance,https://www.fda.gov/media/70689/download,2022-11-01,['Center for Biologics Evaluation and Research'],['Tissue'],Final,FDA-2022-D-0563,No,
Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials; Draft Guidance for Industry; Availability,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/measuring-growth-and-evaluating-pubertal-development-pediatric-clinical-trials-draft-guidance,https://www.fda.gov/media/162725/download,2022-10-31,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Clinical - Medical','Pediatric Product Development']",Draft,FDA-2022-D-0760,No,2023-01-03
"Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clostridioides-difficile-infection-developing-drugs-treatment-reduction-recurrence-and-prevention,https://www.fda.gov/media/162692/download,2022-10-27,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Draft,FDA-2022-D-1261,No,2022-12-27
Developing and Responding to Deficiencies in Accordance with the Least Burdensome Provisions:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-and-responding-deficiencies-accordance-least-burdensome-provisions,https://www.fda.gov/media/71735/download,2022-10-26,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','Premarket Approval (PMA)']",Final,FDA-2017-D-5711,No,
In Vitro Permeation Test Studies for Topical Drug Products Submitted in ANDAs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/in-vitro-permeation-test-studies-topical-drug-products-submitted-andas,https://www.fda.gov/media/162475/download,2022-10-21,['Center for Drug Evaluation and Research'],['Generic Drugs'],Draft,FDA-2022-D-1862,No,
In Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/in-vitro-release-test-studies-topical-drug-products-submitted-andas,https://www.fda.gov/media/162476/download,2022-10-21,['Center for Drug Evaluation and Research'],['Generic Drugs'],Draft,FDA-2022-D-1859,No,
Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/physicochemical-and-structural-q3-characterization-topical-drug-products-submitted-andas,https://www.fda.gov/media/162471/download,2022-10-21,['Center for Drug Evaluation and Research'],['Generic Drugs'],Draft,FDA-2022-D-1864,No,
Human Gene Therapy for Neurodegenerative Diseases:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-neurodegenerative-diseases,https://www.fda.gov/media/144886/download,2022-10-21,['Center for Biologics Evaluation and Research'],"['Gene Therapy','Pediatric Product Development']",Final,FDA-2020-D-2101,No,
Multiple Endpoints in Clinical Trials:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/multiple-endpoints-clinical-trials,https://www.fda.gov/media/162416/download,2022-10-21,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Clinical - Medical'],Final,FDA-2016-D-4460,No,
"CVM GFI #253 Current Good Manufacturing Practice for Animal Cells, Tissues, and Cell- and Tissue-Based Products",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-253-current-good-manufacturing-practice-animal-cells-tissues-and-cell-and-tissue-based,https://www.fda.gov/media/147150/download,2022-10-20,['Center for Veterinary Medicine'],"['Premarket','Animal Cell-Based Products','Chemistry, Manufacturing, and Controls (CMC)','Current Good Manufacturing Practice (CGMP)','Investigational New Animal Drug (INAD)','New Animal Drug Application (NADA)']",Final,FDA-2021-D-0399,No,2021-11-22
"CVM GFI #254 Donor Eligibility for Animal Cells, Tissues, and Cell- and Tissue-Based Products",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-254-donor-eligibility-animal-cells-tissues-and-cell-and-tissue-based-products,https://www.fda.gov/media/147151/download,2022-10-20,['Center for Veterinary Medicine'],"['Premarket','Animal Cell-Based Products','Chemistry, Manufacturing, and Controls (CMC)','Current Good Manufacturing Practice (CGMP)','Investigational New Animal Drug (INAD)','New Animal Drug Application (NADA)']",Final,FDA-2021-D-0401,No,2021-11-22
Guidance for Industry: Refusal of Inspection by a Foreign Food Establishment or Foreign Government,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-refusal-inspection-foreign-food-establishment-or-foreign-government,https://www.fda.gov/media/109635/download,2022-10-20,"['Center for Veterinary Medicine','Office of Inspections and Investigations','Human Foods Program']",['Inspection'],Final,FDA-2017-D-6528,No,
"CVM GFI #258 Use of Tracers in Animal Food, Type A Medicated Articles, and Medicated Feeds",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-258-use-tracers-animal-food-type-medicated-articles-and-medicated-feeds,https://www.fda.gov/media/156527/download,2022-10-19,['Center for Veterinary Medicine'],"['Animal Food Additives','Chemistry, Manufacturing, and Controls (CMC)','Labeling','Investigational New Animal Drug (INAD)','New Animal Drug Application (NADA)']",Final,FDA-2021-D-1246,No,2022-05-02
Small Entity Compliance Guide: Laboratory Accreditation for Analyses of Foods - What You Need to Know,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-laboratory-accreditation-analyses-foods-what-you-need-know,https://www.fda.gov/media/162315/download,2022-10-19,"['Human Foods Program','Center for Veterinary Medicine','Office of Inspections and Investigations']",,Final,FDA-2022-D-1126,No,
Tissue Agnostic Drug Development in Oncology: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/tissue-agnostic-drug-development-oncology,https://www.fda.gov/media/162346/download,2022-10-17,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",,Draft,FDA-2022-D-0286,No,
Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment:  Guidance for Industry; Availability,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acute-myeloid-leukemia-developing-drugs-and-biological-products-treatment-0,https://www.fda.gov/media/162362/download,2022-10-17,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Pediatric Product Development'],Final,FDA-2020-D-1298,No,
"Characterizing, Collecting, and Reporting Immune-Mediated Adverse Reactions in Cancer Immunotherapeutic Clinical Trials: Draft Guidance for Industry; Availability",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/characterizing-collecting-and-reporting-immune-mediated-adverse-reactions-cancer-immunotherapeutic,https://www.fda.gov/media/162341/download,2022-10-17,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",,Draft,FDA-2022-D-1744,No,
ANDA Submissions – Prior Approval Supplements Under GDUFA:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/anda-submissions-prior-approval-supplements-under-gdufa,https://www.fda.gov/media/89263/download,2022-10-14,['Center for Drug Evaluation and Research'],"['User Fees','Drug Competition Action Plan','Generic Drugs']",Final,FDA-2014-D-0901,No,
"Comparability Protocols for Postapproval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/comparability-protocols-postapproval-changes-chemistry-manufacturing-and-controls-information-nda,https://www.fda.gov/media/162263/download,2022-10-13,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2016-D-0973,No,
"Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarket-surveillance-under-section-522-federal-food-drug-and-cosmetic-act,https://www.fda.gov/media/81015/download,2022-10-07,['Center for Devices and Radiological Health'],,Final,FDA-2011-D-0514,No,
Procedures for Handling Post-Approval Studies Imposed by PMA Order:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/procedures-handling-post-approval-studies-imposed-pma-order,https://www.fda.gov/media/71327/download,2022-10-07,['Center for Devices and Radiological Health'],,Final,FDA-2005-D-0027,No,
Competitive Generic Therapies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/competitive-generic-therapies,https://www.fda.gov/media/136063/download,2022-10-05,['Center for Drug Evaluation and Research'],"['Drug Competition Action Plan','Generic Drugs']",Final,FDA-2019-D-0065,No,
Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formal-meetings-between-fda-and-anda-applicants-complex-products-under-gdufa-guidance-industry,https://www.fda.gov/media/107626/download,2022-10-05,['Center for Drug Evaluation and Research'],"['User Fees','Drug Competition Action Plan','Generic Drugs']",Final,FDA-2017-D-5739,No,
Post-Complete Response Letter Clarification Teleconferences Between FDA and ANDA Applicants Under GDUFA Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/post-complete-response-letter-clarification-teleconferences-between-fda-and-anda-applicants-under,https://www.fda.gov/media/108337/download,2022-10-05,['Center for Drug Evaluation and Research'],"['User Fees','Generic Drugs']",Final,FDA-2017-D-5928,No,
Information Requests and Discipline Review Letters Under the Generic Drug User Fee Amendments:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/information-requests-and-discipline-review-letters-under-generic-drug-user-fee-amendments,https://www.fda.gov/media/109915/download,2022-10-05,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['User Fees','Generic Drugs']",Final,FDA-2017-D-6752,No,
User Fees and Refunds for De Novo Classification Requests :  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/user-fees-and-refunds-de-novo-classification-requests,https://www.fda.gov/media/107658/download,2022-10-05,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','User Fees','Administrative / Procedural']",Final,FDA-2017-D-5713,No,
User Fees and Refunds for Premarket Approval Applications and Device Biologics License Applications:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/user-fees-and-refunds-premarket-approval-applications-and-device-biologics-license-applications,https://www.fda.gov/media/85712/download,2022-10-05,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','User Fees']",Final,FDA-2009-D-0051,No,
User Fees and Refunds for Premarket Notification Submissions (510(k)s):  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/user-fees-and-refunds-premarket-notification-submissions-510ks,https://www.fda.gov/media/85591/download,2022-10-05,['Center for Devices and Radiological Health'],"['Premarket','User Fees','510(k)']",Final,FDA-2003-D-0198,No,
User Fees for 513(g) Requests for Information:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/user-fees-513g-requests-information,https://www.fda.gov/media/78463/download,2022-10-05,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','User Fees']",Final,FDA-2010-D-0144,No,
"Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/size-shape-and-other-physical-attributes-generic-tablets-and-capsules,https://www.fda.gov/media/161902/download,2022-10-03,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2013-N-1434,No,
FDA and Industry Actions on De Novo Classification Requests: Effect on FDA Review Clock and Goals:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-and-industry-actions-de-novo-classification-requests-effect-fda-review-clock-and-goals,https://www.fda.gov/media/107652/download,2022-10-03,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']","['Premarket','Administrative / Procedural']",Final,FDA-2017-D-5712,No,
FDA and Industry Actions on Premarket Approval Applications (PMAs): Effect on FDA Review Clock and Goals:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-and-industry-actions-premarket-approval-applications-pmas-effect-fda-review-clock-and-goals,https://www.fda.gov/media/73504/download,2022-10-03,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','Premarket Approval (PMA)']",Final,FDA-2003-D-0378,No,
FDA and Industry Actions on Premarket Notification (510(k)) Submissions: Effect on FDA Review Clock and Goals:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-and-industry-actions-premarket-notification-510k-submissions-effect-fda-review-clock-and-goals,https://www.fda.gov/media/73507/download,2022-10-03,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']","['Premarket','510(k)']",Final,FDA-2003-D-0033,No,
Guidance for Industry: Infant Formula Transition Plan for Exercise of Enforcement Discretion,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-infant-formula-transition-plan-exercise-enforcement-discretion,https://www.fda.gov/media/161904/download,2022-09-29,['Human Foods Program'],['Infant Formula & Foods'],Final,FDA-2022-D-0814,No,
Clinical Performance Assessment: Considerations for Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data in Premarket Notification (510(k)) Submissions:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-performance-assessment-considerations-computer-assisted-detection-devices-applied-radiology,https://www.fda.gov/media/77642/download,2022-09-28,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Digital Health','Radiology','Labeling']",Final,FDA-2009-D-0503,No,
Clinical Decision Support Software:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-decision-support-software,https://www.fda.gov/media/109618/download,2022-09-28,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Administrative / Procedural','Digital Health']",Final,FDA-2017-D-6569,No,
Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data - Premarket Notification [510(k)] Submissions:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/computer-assisted-detection-devices-applied-radiology-images-and-radiology-device-data-premarket,https://www.fda.gov/media/77635/download,2022-09-28,['Center for Devices and Radiological Health'],"['Premarket','Radiology']",Final,FDA-2009-D-0503,No,
Display Devices for Diagnostic Radiology:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/display-devices-diagnostic-radiology,https://www.fda.gov/media/95527/download,2022-09-28,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Labeling','Radiological Health','Radiology']",Final,FDA-2016-D-0270,No,
"Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices:  Guidance for Industry and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-device-data-systems-medical-image-storage-devices-and-medical-image-communications-devices,https://www.fda.gov/media/88572/download,2022-09-28,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Digital Health'],Final,FDA-2014-D-0798,No,
Policy for Device Software Functions and Mobile Medical Applications:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-device-software-functions-and-mobile-medical-applications,https://www.fda.gov/media/80958/download,2022-09-28,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','Digital Health']",Final,FDA-2011-D-0530,No,
"Ethical Considerations for Clinical Investigations of Medical Products Involving Children: Draft Guidance for Industry, Sponsors, and IRBs",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ethical-considerations-clinical-investigations-medical-products-involving-children,https://www.fda.gov/media/161740/download,2022-09-26,"['Office of the Commissioner','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research']","['Clinical - Medical','Pediatric Product Development']",Draft,FDA-2022-D-0738,No,
Exemption and Exclusion From Certain Requirements of the Drug Supply Chain Security Act for the Distribution of FDA-Approved Naloxone Products During the Opioid Public Health Emergency Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exemption-and-exclusion-certain-requirements-drug-supply-chain-security-act-distribution-fda,https://www.fda.gov/media/161750/download,2022-09-22,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2022-D-1847,No,
How To Obtain a Covered Product Authorization,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/how-obtain-covered-product-authorization,https://www.fda.gov/media/161730/download,2022-09-21,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Draft,FDA-2022-D-1358,No,2022-11-21
Q3D(R2) – Guideline for Elemental Impurities:  International Council for Harmonisation; Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q3dr2-guideline-elemental-impurities,https://www.fda.gov/media/148474/download,2022-09-14,['Center for Drug Evaluation and Research'],['ICH-Quality'],Final,FDA-2013-D-1156,No,
Computer Software Assurance for Production and Quality System Software: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/computer-software-assurance-production-and-quality-system-software,https://www.fda.gov/media/161521/download,2022-09-13,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Postmarket','Current Good Manufacturing Practice (CGMP)','Digital Health']",Draft,FDA-2022-D-0795,No,2022-11-14
Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-documents-using-real-world-data-and-real-world-evidence-fda-drug-and-biological-products,https://www.fda.gov/media/124795/download,2022-09-09,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Real World Data / Real World Evidence (RWD/RWE)','Administrative / Procedural']",Final,FDA-2019-D-1263,No,
"Quantitative Labeling of Sodium, Potassium, and Phosphorus for Human Over-the-Counter and Prescription Drug Products",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quantitative-labeling-sodium-potassium-and-phosphorus-human-over-counter-and-prescription-drug,https://www.fda.gov/media/161194/download,2022-09-08,['Center for Drug Evaluation and Research'],['Labeling'],Draft,FDA-2021-D-0528,No,2022-11-08
Statement of Identity and Strength — Content and Format of Labeling for Human Nonprescription Drug Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statement-identity-and-strength-content-and-format-labeling-human-nonprescription-drug-products,https://www.fda.gov/media/161186/download,2022-09-08,['Center for Drug Evaluation and Research'],['Labeling'],Draft,FDA-2022-D-1837,No,2022-11-08
"General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-clinical-pharmacology-considerations-pediatric-studies-drugs-including-biological-products,https://www.fda.gov/media/90358/download,2022-09-07,['Center for Drug Evaluation and Research'],"['Clinical - Pharmacology','Pediatric Product Development']",Draft,FDA-2013-D-1275,No,2022-12-07
Meetings with Industry and Investigators on the Research and Development of Tobacco Products (Revised):  Guidance for Industry and Investigators,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/meetings-industry-and-investigators-research-and-development-tobacco-products-revised,https://www.fda.gov/media/83420/download,2022-09-07,['Center for Tobacco Products'],,Final,FDA-2012-D-0429,No,
"Policy for Monkeypox Tests to Address the Public Health Emergency:  Guidance for Laboratories, Commercial Manufacturers and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-monkeypox-tests-address-public-health-emergency,https://www.fda.gov/media/161443/download,2022-09-07,['Center for Devices and Radiological Health'],,Final,FDA-2022-D-1908,No,
E11A Pediatric Extrapolation,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e11a-pediatric-extrapolation,https://www.fda.gov/media/161190/download,2022-08-26,['Center for Drug Evaluation and Research'],['Pediatric Product Development'],Draft,FDA-2022-D-1562,No,
E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers :  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e14-and-s7b-clinical-and-nonclinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic,https://www.fda.gov/media/161198/download,2022-08-26,['Center for Drug Evaluation and Research'],"['ICH-Efficacy','ICH-Safety']",Final,FDA-2020-D-1791,No,
Tobacco Products: Principles for Designing and Conducting Tobacco Product Perception and Intention Studies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/tobacco-products-principles-designing-and-conducting-tobacco-product-perception-and-intention,https://www.fda.gov/media/143322/download,2022-08-23,['Center for Tobacco Products'],,Final,FDA-2019-D-4188,No,
Replacement Reagent and Instrument Family Policy for In Vitro Diagnostic Devices:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/replacement-reagent-and-instrument-family-policy-in-vitro-diagnostic-devices,https://www.fda.gov/media/111186/download,2022-08-17,['Center for Devices and Radiological Health'],['Laboratory Tests'],Final,FDA-2017-D-6765,No,
Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-requirements-hearing-aid-devices-and-personal-sound-amplification-products,https://www.fda.gov/media/87330/download,2022-08-17,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-1380,No,
CVM GFI #109 (VICH GL15) Effectiveness of Anthelmintics: Specific Recommendations for Equines,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-109-vich-gl15-effectiveness-anthelmintics-specific-recommendations-equines,https://www.fda.gov/media/70072/download,2022-08-12,['Center for Veterinary Medicine'],"['Anthelmintics','Target Animal – Effectiveness','VICH']",Draft,FDA-2022-D-1494,No,2022-10-11
CVM GFI #110 (VICH GL16) Effectiveness of Anthelmintics: Specific Recommendations for Porcines,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-110-vich-gl16-effectiveness-anthelmintics-specific-recommendations-porcines,https://www.fda.gov/media/70080/download,2022-08-12,['Center for Veterinary Medicine'],"['Anthelmintics','Target Animal – Effectiveness','VICH']",Draft,FDA-2022-D-1494,No,2022-10-11
CVM GFI #111 (VICH GL19) Effectiveness of Anthelmintics: Specific Recommendations for Canines,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-111-vich-gl19-effectiveness-anthelmintics-specific-recommendations-canines,https://www.fda.gov/media/70091/download,2022-08-12,['Center for Veterinary Medicine'],"['Anthelmintics','Target Animal – Effectiveness','VICH']",Draft,FDA-2022-D-1494,No,2022-10-11
CVM GFI #113 (VICH GL20) Effectiveness of Anthelmintics: Specific Recommendations for Felines,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-113-vich-gl20-effectiveness-anthelmintics-specific-recommendations-felines,https://www.fda.gov/media/70104/download,2022-08-12,['Center for Veterinary Medicine'],"['Anthelmintics','Target Animal – Effectiveness','VICH']",Draft,FDA-2022-D-1494,No,2022-10-11
CVM GFI #114 (VICH GL21) Effectiveness of Anthelmintics: Specific Recommendations for Chickens Gallus gallus,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-114-vich-gl21-effectiveness-anthelmintics-specific-recommendations-chickens-gallus-gallus,https://www.fda.gov/media/70118/download,2022-08-12,['Center for Veterinary Medicine'],"['Anthelmintics','Target Animal – Effectiveness']",Draft,FDA-2022-D-1494,No,2022-10-11
CVM GFI #90 (VICH GL7) Effectiveness of Anthelmintics: General Recommendations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-90-vich-gl7-effectiveness-anthelmintics-general-recommendations,https://www.fda.gov/media/70349/download,2022-08-12,['Center for Veterinary Medicine'],"['Anthelmintics','Target Animal – Effectiveness','VICH']",Draft,FDA-2022-D-1494,No,2022-10-11
CVM GFI #95 (VICH GL12) Effectiveness of Anthelmintics:  Specific Recommendations for Bovines,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-95-vich-gl12-effectiveness-anthelmintics-specific-recommendations-bovines,https://www.fda.gov/media/70377/download,2022-08-12,['Center for Veterinary Medicine'],"['Anthelmintics','Target Animal – Effectiveness','VICH']",Draft,FDA-2022-D-1494,No,2022-10-11
CVM GFI #96 (VICH GL13) Effectiveness of Anthelmintics:  Specific Recommendations for Ovines,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-96-vich-gl13-effectiveness-anthelmintics-specific-recommendations-ovines,https://www.fda.gov/media/70383/download,2022-08-12,['Center for Veterinary Medicine'],"['Anthelmintics','Target Animal – Effectiveness','VICH']",Draft,FDA-2022-D-1494,No,2022-10-11
CVM GFI #97 (VICH GL14) Effectiveness of Anthelmintics:  Specific Recommendations for Caprines,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-97-vich-gl14-effectiveness-anthelmintics-specific-recommendations-caprines,https://www.fda.gov/media/70391/download,2022-08-12,['Center for Veterinary Medicine'],"['Anthelmintics','Target Animal – Effectiveness','VICH']",Draft,FDA-2022-D-1494,No,2022-10-11
CVM GFI #256 - Compounding Animal Drugs from Bulk Drug Substances,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-256-compounding-animal-drugs-bulk-drug-substances,https://www.fda.gov/media/132567/download,2022-08-10,['Center for Veterinary Medicine'],['Compounding'],Final,FDA-2018-D-4533,No,2020-10-15
"Guidance for Industry: Questions and Answers Regarding the Final Rule on Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation (Layers with Access to Areas Outside the Poultry House)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-regarding-final-rule-prevention-salmonella-enteritidis-shell-0,https://www.fda.gov/media/86276/download,2022-08-10,['Human Foods Program'],"['Egg/Egg Product','Transportation']",Final,FDA-2000-N-0190,No,2013-09-23
Guidance for Industry: Policy Regarding N-acetyl-L-cysteine,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-policy-regarding-n-acetyl-l-cysteine,https://www.fda.gov/media/157784/download,2022-08-01,['Human Foods Program'],,Final,FDA-2022-D-0490,No,
Changes to Disposable Manufacturing Materials:  Questions and Answers Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-disposable-manufacturing-materials-questions-and-answers-guidance-industry,https://www.fda.gov/media/160300/download,2022-07-29,"['Center for Veterinary Medicine','Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Pharmaceutical Quality'],Final,FDA-2017-D-6821,No,
Laser-Assisted In Situ Keratomileusis (LASIK) Lasers - Patient Labeling Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/laser-assisted-situ-keratomileusis-lasik-lasers-patient-labeling-recommendations,https://www.fda.gov/media/160239/download,2022-07-28,['Center for Devices and Radiological Health'],"['Labeling','Ophthalmic','Premarket Approval (PMA)']",Draft,FDA-2022-D-1253,No,2022-11-25
General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-clinical-pharmacology-considerations-neonatal-studies-drugs-and-biological-products-guidance,https://www.fda.gov/media/129532/download,2022-07-27,['Center for Drug Evaluation and Research'],"['Clinical - Pharmacology','Pediatric Product Development']",Final,FDA-2019-D-3132,No,
Cancer Clinical Trial Eligibility Criteria: Available Therapy in Non-Curative Settings:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-available-therapy-non-curative-settings,https://www.fda.gov/media/150244/download,2022-07-27,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Clinical Trials','Clinical - Medical']",Final,FDA-2020-D-1802,No,2021-08-24
"Unique Device Identification: Policy Regarding Compliance Dates for Class I and Unclassified Devices, Direct Marking, and Global Unique Device Identification Database Requirements for Certain Devices:  Guidance for Industry and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/unique-device-identification-policy-regarding-compliance-dates-class-i-and-unclassified-devices,https://www.fda.gov/media/110564/download,2022-07-25,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']","['Labeling','UDI']",Final,FDA-2017-D-6841,No,
Orange Book Questions and Answers Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orange-book-questions-and-answers-guidance-industry,https://www.fda.gov/media/160167/download,2022-07-22,['Center for Drug Evaluation and Research'],['Generic Drugs'],Final,FDA-2020-D-1068,No,
Evaluation of Therapeutic Equivalence,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-therapeutic-equivalence,https://www.fda.gov/media/160054/download,2022-07-21,['Center for Drug Evaluation and Research'],"['Drug Competition Action Plan','Generic Drugs']",Draft,FDA-2022-D-0528,No,2022-09-19
Instructions for Use — Patient Labeling for Human Prescription Drug and Biological Products — Content and Format,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/instructions-use-patient-labeling-human-prescription-drug-and-biological-products-content-and-format,https://www.fda.gov/media/128446/download,2022-07-15,['Center for Biologics Evaluation and Research'],['Labeling'],Final,FDA-2019-D-1615,No,
CVM GFI #245 Hazard Analysis and Risk-Based Preventive Controls for Food for Animals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-245-hazard-analysis-and-risk-based-preventive-controls-food-animals,https://www.fda.gov/media/110477/download,2022-07-08,['Center for Veterinary Medicine'],['Animal Feed'],Final,FDA-2018-D-0388,No,2018-07-23
Identifying Trading Partners Under the Drug Supply Chain Security Act,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/identifying-trading-partners-under-drug-supply-chain-security-act,https://www.fda.gov/media/159621/download,2022-07-05,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Draft,FDA-2017-D-1956,No,2022-09-05
"Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome,https://www.fda.gov/media/159500/download,2022-06-29,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Draft,FDA-2022-D-1385,No,2022-09-28
Bladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bladder-cancer-developing-drugs-and-biologics-adjuvant-treatment,https://www.fda.gov/media/159509/download,2022-06-28,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Premarket','Clinical - Medical']",Final,FDA-2020-D-1497,No,2020-12-01
Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/renal-cell-carcinoma-developing-drugs-and-biologics-adjuvant-treatment,https://www.fda.gov/media/159510/download,2022-06-27,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Premarket','Clinical - Medical']",Final,FDA-2020-D-1496,No,2020-12-01
Considerations for Rescinding Breakthrough Therapy Designation,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-rescinding-breakthrough-therapy-designation,https://www.fda.gov/media/159359/download,2022-06-24,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Administrative / Procedural'],Draft,FDA-2021-D-1152,No,2022-08-23
Providing Regulatory Submissions in Alternate Electronic Format Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-alternate-electronic-format-guidance-industry,https://www.fda.gov/media/159388/download,2022-06-24,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Electronic Submissions'],Final,FDA-2020-D-0420,No,
Non-Penicillin Beta-Lactam Drugs:  A CGMP Framework for Preventing Cross-Contamination: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-penicillin-beta-lactam-drugs-cgmp-framework-preventing-cross-contamination-0,https://www.fda.gov/media/159358/download,2022-06-24,['Center for Drug Evaluation and Research'],"['Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Draft,FDA-2011-D-0104,No,2022-08-23
Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-effects-food-drugs-inds-and-ndas-clinical-pharmacology-considerations,https://www.fda.gov/media/121313/download,2022-06-23,['Center for Drug Evaluation and Research'],['Clinical - Pharmacology'],Final,FDA-2018-D-4368,No,
FDA Oversight of Food Covered by Systems Recognition Arrangements,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-oversight-food-covered-systems-recognition-arrangements,https://www.fda.gov/media/150676/download,2022-06-21,"['Office of Inspections and Investigations','Human Foods Program']","['Export','Import','Investigational Use']",Final,FDA-2019-D-1997,No,
Technical Performance Assessment of Quantitative Imaging in Radiological Device Premarket Submissions:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-performance-assessment-quantitative-imaging-radiological-device-premarket-submissions,https://www.fda.gov/media/123271/download,2022-06-16,['Center for Devices and Radiological Health'],"['Premarket','Radiological Health']",Final,FDA-2019-D-1470,No,
Electromagnetic Compatibility (EMC) of Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electromagnetic-compatibility-emc-medical-devices,https://www.fda.gov/media/94758/download,2022-06-06,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Investigational Device Exemption (IDE)','Radiological Health','Radiology','Safety - Issues, Errors, and Problems']",Final,FDA-2015-D-3787,No,
Guidance for Industry: Fish and Fishery Products Hazards and Controls,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-fish-and-fishery-products-hazards-and-controls,,2022-06-01,['Human Foods Program'],['Seafood/Seafood Product'],Final,FDA-2011-D-0287,No,
Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues Guidance for Industry:  Clinical/Medical,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/advanced-prostate-cancer-developing-gonadotropin-releasing-hormone-analogues-guidance-industry,https://www.fda.gov/media/129027/download,2022-05-27,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-2019-D-2808,No,
Importation of Prescription Drugs Final Rule Questions and Answers; Small Entity Compliance Guide,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/importation-prescription-drugs-final-rule-questions-and-answers-small-entity-compliance-guide,https://www.fda.gov/media/158659/download,2022-05-25,['Center for Drug Evaluation and Research'],['Import'],Final,FDA-2021-D-0958,No,
Antibacterial Therapies for Patients With an Unmet Medical Need for the Treatment of Serious Bacterial Diseases – Questions and Answers (Revision 1),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antibacterial-therapies-patients-unmet-medical-need-treatment-serious-bacterial-diseases-questions,https://www.fda.gov/media/158589/download,2022-05-24,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Draft,FDA-2013-D-0744,No,2022-07-24
Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-reduce-possible-risk-transmission-creutzfeldt-jakob-disease-and-variant-creutzfeldt,https://www.fda.gov/media/124156/download,2022-05-23,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2012-D-0307,No,
Draft Guidance for Industry: Policy Regarding Certain New Dietary Ingredients and Dietary Supplements Subject to the Requirement for Pre-market Notification,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-policy-regarding-certain-new-dietary-ingredients-and-dietary-supplements,https://www.fda.gov/media/158369/download,2022-05-19,['Human Foods Program'],,Draft,FDA-2022-D-0281,No,2022-07-19
Risk Management Plans to Mitigate the Potential for Drug Shortages,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/risk-management-plans-mitigate-potential-drug-shortages,https://www.fda.gov/media/158487/download,2022-05-19,['Center for Drug Evaluation and Research'],"['Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Draft,FDA-2022-D-0277,No,2022-07-19
Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-considerations-container-labels-and-carton-labeling-design-minimize-medication-errors,https://www.fda.gov/media/158522/download,2022-05-18,['Center for Drug Evaluation and Research'],"['Safety - Issues, Errors, and Problems']",Final,FDA-2013-D-0401,No,
Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production - Level 2 revision:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision,https://www.fda.gov/media/158416/download,2022-05-16,['Center for Drug Evaluation and Research'],"['Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,FDA-1998-D-0019,No,
Guidance for Industry: Reducing Microbial Food Safety Hazards in the Production of Seed for Sprouting,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-reducing-microbial-food-safety-hazards-production-seed-sprouting,https://www.fda.gov/media/127972/download,2022-05-13,['Human Foods Program'],['Produce'],Final,FDA-2018-D-4534,No,2019-08-26
CVM GFI #3 General Principles for Evaluating the Human Food Safety of New Animal Drugs Used In Food-Producing Animals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-3-general-principles-evaluating-human-food-safety-new-animal-drugs-used-food-producing,https://www.fda.gov/media/70028/download,2022-05-10,['Center for Veterinary Medicine'],['Human Food Safety'],Final,FDA-2005-D-0155,No,2016-09-19
Benefit-Risk Considerations for Product Quality Assessments,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/benefit-risk-considerations-product-quality-assessments,https://www.fda.gov/media/158204/download,2022-05-09,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Draft,FDA-2022-D-0168,No,2022-07-10
Feasibility and Early Feasibility Clinical Studies for Certain Medical Devices Intended to Therapeutically Improve Glycemic Control in Patients with Type 2 Diabetes Mellitus:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/feasibility-and-early-feasibility-clinical-studies-certain-medical-devices-intended-therapeutically,https://www.fda.gov/media/148765/download,2022-05-06,['Center for Devices and Radiological Health'],"['Premarket','Gastroenterology-Urology','Investigational Device Exemption (IDE)']",Final,FDA-2021-D-0131,No,
Use of Circulating Tumor Deoxyribonucleic Acid for Early-Stage Solid Tumor Drug Development; Draft Guidance for Industry; Availability,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-circulating-tumor-deoxyribonucleic-acid-early-stage-solid-tumor-drug-development-draft-guidance,https://www.fda.gov/media/158072/download,2022-05-02,[],,Draft,Docket No. FDA-2022-D-0084,No,
Guidance for Industry: Infant Formula Enforcement Discretion Policy,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-infant-formula-enforcement-discretion-policy,https://www.fda.gov/media/158476/download,2022-05-01,['Human Foods Program'],['Infant Formula & Foods'],Final,FDA-2022-D-0814,No,
E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification; and Appendix to the Implementation Guide — Backwards and Forwards Compatibility,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2br3-electronic-transmission-individual-case-safety-reports-implementation-guide-data-elements-and,https://www.fda.gov/media/81904/download,2022-04-29,['Center for Drug Evaluation and Research'],['ICH-Efficacy'],Final,FDA-2011-D-0720,No,
E2B(R3) The Electronic Transmission of Individual Case Safety Reports Implementation Guide —Appendix to the Implementation Guide — Backwards and Forwards Compatibility,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2br3-electronic-transmission-individual-case-safety-reports-implementation-guide-appendix,https://www.fda.gov/media/81913/download,2022-04-29,['Center for Drug Evaluation and Research'],['ICH-Safety'],Final,FDA-2011-D-0720,No,
Electronic Submission of IND Safety Reports Technical Conformance Guide :  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-submission-ind-safety-reports-technical-conformance-guide,https://www.fda.gov/media/132078/download,2022-04-29,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Electronic Submissions'],Final,FDA-2018-D-1216,No,
Crohn’s Disease:  Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/crohns-disease-developing-drugs-treatment,https://www.fda.gov/media/158001/download,2022-04-28,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Draft,FDA-2022-D-0091,No,2022-06-28
Draft Guidance for Industry: Questions and Answers on the Accredited Third-Party Certification Program,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-questions-and-answers-accredited-third-party-certification-program,https://www.fda.gov/media/157965/download,2022-04-28,"['Center for Veterinary Medicine','Office of Inspections and Investigations','Human Foods Program']",['Import'],Draft,FDA-2022-D-0370,No,2022-07-28
Ulcerative Colitis:  Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ulcerative-colitis-developing-drugs-treatment,https://www.fda.gov/media/158016/download,2022-04-28,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Draft,FDA-2022-D-0140,No,2022-06-28
Guidance for Industry: Compliance with Providing an Acceptable Unique Facility Identifier for the Foreign Supplier Verification Programs for Food Importers Regulation,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-compliance-providing-acceptable-unique-facility-identifier-foreign-supplier,https://www.fda.gov/media/111885/download,2022-04-27,"['Center for Veterinary Medicine','Human Foods Program']",['Import'],Final,FDA-2011-N-0143,No,
Providing Submissions in Electronic Format — Postmarketing Safety Reports,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-submissions-electronic-format-postmarketing-safety-reports,https://www.fda.gov/media/71176/download,2022-04-27,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Electronic Submissions'],Final,FDA-2001-D-0067,No,
Draft Guidance for Industry: Action Levels for Lead in Juice,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-action-levels-lead-juice,https://www.fda.gov/media/157949/download,2022-04-27,['Human Foods Program'],"['Juice','Lead']",Draft,FDA-2019-D-5609,No,2022-06-28
"Drug Products, Including Biological Products, that Contain Nanomaterials - Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-products-including-biological-products-contain-nanomaterials-guidance-industry,https://www.fda.gov/media/157812/download,2022-04-21,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2017-D-0759,No,2018-03-13
Refuse to Accept Policy for 510(k)s:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/refuse-accept-policy-510ks,https://www.fda.gov/media/83888/download,2022-04-21,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','510(k)','Administrative / Procedural']",Final,FDA-2012-D-0523,No,
"Draft Guidance for FDA Staff and Stakeholders: Evaluating the Public Health Importance of Food Allergens Other Than the Major Food Allergens Listed in the Federal Food, Drug, and Cosmetic Act",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-fda-staff-and-stakeholders-evaluating-public-health-importance-food-allergens-other,https://www.fda.gov/media/157637/download,2022-04-18,['Human Foods Program'],"['Allergens','Labeling']",Draft,FDA-2021-N-0553,No,2022-08-17
Bioavailability Studies Submitted in NDAs or INDs – General Considerations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioavailability-studies-submitted-ndas-or-inds-general-considerations,https://www.fda.gov/media/121311/download,2022-04-15,['Center for Drug Evaluation and Research'],['Clinical - Pharmacology'],Final,FDA-2018-D-4367,No,2019-05-28
Celiac Disease: Developing Drugs for Adjunctive Treatment to a Gluten-Free Diet,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/celiac-disease-developing-drugs-adjunctive-treatment-gluten-free-diet,https://www.fda.gov/media/157682/download,2022-04-15,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Draft,FDA-2021-D-1238,No,2022-06-14
"Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic Use: Draft Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-waiver-requests-ph-adjusters-generic-drug-products-intended-parenteral-ophthalmic-or,https://www.fda.gov/media/157655/download,2022-04-14,['Center for Drug Evaluation and Research'],['Generic Drugs'],Draft,FDA-2022-D-0108,No,
Guidance for Industry: Reconditioning of Fish and Fishery Products by Segregation,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-reconditioning-fish-and-fishery-products-segregation,https://www.fda.gov/media/130658/download,2022-04-13,['Human Foods Program'],['Seafood/Seafood Product'],Final,FDA-2019-D-3324,No,
Denture Base Resins - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/denture-base-resins-performance-criteria-safety-and-performance-based-pathway,https://www.fda.gov/media/151777/download,2022-04-13,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2021-D-0603,No,
Facet Screw Systems - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/facet-screw-systems-performance-criteria-safety-and-performance-based-pathway,https://www.fda.gov/media/151776/download,2022-04-13,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2021-D-0604,No,
Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-and-non-electronic-format-promotional-labeling-and,https://www.fda.gov/media/128163/download,2022-04-11,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Electronic Submissions'],Final,FDA-2015-D-1163,No,
Orthopedic Fracture Fixation Plates - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orthopedic-fracture-fixation-plates-performance-criteria-safety-and-performance-based-pathway,https://www.fda.gov/media/157491/download,2022-04-11,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2022-D-0552,No,
Surgical Sutures - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/surgical-sutures-performance-criteria-safety-and-performance-based-pathway,https://www.fda.gov/media/157490/download,2022-04-11,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2022-D-0552,No,
E8(R1) General Considerations for Clinical Studies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e8r1-general-considerations-clinical-studies,https://www.fda.gov/media/157560/download,2022-04-08,['Center for Drug Evaluation and Research'],['ICH-Efficacy'],Final,FDA-2019-D-3049,No,
Chronic Hepatitis B Virus Infection: Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chronic-hepatitis-b-virus-infection-developing-drugs-treatment,https://www.fda.gov/media/117977/download,2022-04-07,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2018-D-3903,No,
Certain Ophthalmic Products: Policy Regarding Compliance With 21 CFR Part 4  Guidance for Industry:  Guidance for Industry,,,2022-03-22,[],['Combination Products'],Final,FDA-2022-D-0192,No,
"Guidance for Industry: Current Good Manufacturing Practice and Preventive Controls, Foreign Supplier Verification Programs, Intentional Adulteration, and Produce Safety Regulations: Enforcement Policy Regarding Certain Provisions",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-current-good-manufacturing-practice-and-preventive-controls-foreign-supplier,https://www.fda.gov/media/156729/download,2022-03-11,"['Human Foods Program','Center for Veterinary Medicine','Office of Inspections and Investigations']",,Final,FDA-2021-D-0563,No,
"Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C:  Guidance for Industry and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/initiation-voluntary-recalls-under-21-cfr-part-7-subpart-c,https://www.fda.gov/media/123664/download,2022-03-04,"['Center for Veterinary Medicine','Office of Inspections and Investigations','Human Foods Program','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research','Center for Tobacco Products']","['Recalls','Investigation & Enforcement']",Final,FDA-2018-D-2074,No,
Inclusion of Older Adults in Cancer Clinical Trials:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/inclusion-older-adults-cancer-clinical-trials,https://www.fda.gov/media/156616/download,2022-03-02,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Clinical - Medical'],Final,FDA-2019-D-5572,No,
Center for Devices and Radiological Health (CDRH) Appeals Processes:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/center-devices-and-radiological-health-cdrh-appeals-processes,https://www.fda.gov/media/128444/download,2022-03-02,['Center for Devices and Radiological Health'],['Administrative / Procedural'],Final,FDA-2011-D-0893,No,
Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expansion-cohorts-use-first-human-clinical-trials-expedite-development-oncology-drugs-and-biologics,https://www.fda.gov/media/115172/download,2022-03-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Administrative / Procedural','Biosimilars']",Final,FDA-2018-D-2777,No,
Master Protocols:  Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-efficient-clinical-trial-design-strategies-expedite-development-oncology-drugs-and,https://www.fda.gov/media/120721/download,2022-03-01,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Administrative / Procedural','Pediatric Product Development','Biosimilars']",Final,FDA-2018-D-3292,No,2018-11-30
Pre-Launch Activities Importation Requests (PLAIR):  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pre-launch-activities-importation-requests-plair,https://www.fda.gov/media/86243/download,2022-03-01,"['Office of the Commissioner','Center for Drug Evaluation and Research']","['Administrative / Procedural','Biosimilars']",Final,FDA-2013-D-0836,No,
"Patient-Focused Drug Development: Methods to Identify What Is Important to Patients:  Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-methods-identify-what-important-patients,https://www.fda.gov/media/131230/download,2022-02-25,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2019-D-4247,No,2019-12-30
Guidance for Industry and FDA Staff: Model Accreditation Standards for Third-Party Certification Body Accreditation for Food Safety Audits,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-staff-model-accreditation-standards-third-party-certification-body,https://www.fda.gov/media/92999/download,2022-02-24,['Human Foods Program'],['Import'],Final,FDA-2011-N-0146,No,
Development of Non-Opioid Analgesics for Acute Pain; Draft Guidance for Industry: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-non-opioid-analgesics-acute-pain-draft-guidance-industry,https://www.fda.gov/media/156063/download,2022-02-09,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2021-N-0556,No,2022-04-11
Drug Product Tracing: The Effect of Section 585 of the FD&C Act,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-product-tracing-effect-section-585-fdc-act,https://www.fda.gov/media/89954/download,2022-02-03,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Administrative / Procedural'],Final,FDA-2014-D-1411,No,
Population Pharmacokinetics:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/population-pharmacokinetics,https://www.fda.gov/media/128793/download,2022-02-03,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Pharmacology'],Final,FDA-2019-D-2398,No,
Assessment of Pressor Effects of Drugs Guidance for Industry: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessment-pressor-effects-drugs-guidance-industry,https://www.fda.gov/media/113477/download,2022-02-03,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2018-D-1636,No,
Immunogenicity Information in Human Prescription Therapeutic Protein and Select Drug Product Labeling--Content and Format: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-information-human-prescription-therapeutic-protein-and-select-drug-product-labeling,https://www.fda.gov/media/155871/download,2022-02-03,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Labeling'],Draft,FDA-2021-D-1041,No,2022-04-05
Formal Meetings Between the Food and Drug Administration and Sponsors or Requestors of Over-the-Counter Monograph Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formal-meetings-between-food-and-drug-administration-and-sponsors-or-requestors-over-counter,https://www.fda.gov/media/155864/download,2022-02-01,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Draft,FDA-2022-D-0080,No,
Good ANDA Submission Practices Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-anda-submission-practices-guidance-industry,https://www.fda.gov/media/110689/download,2022-01-26,['Center for Drug Evaluation and Research'],"['Drug Competition Action Plan','Generic Drugs']",Final,FDA-2017-D-6854,No,
Principles of Premarket Pathways for Combination Products:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/principles-premarket-pathways-combination-products,https://www.fda.gov/media/119958/download,2022-01-26,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research','Office of the Commissioner']",['Combination Products'],Final,FDA-2019-D-0078,No,2019-05-07
"Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation:  Guidance for Industry and Food and Drug Administration Staff, And Other Stakeholders",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/principles-selecting-developing-modifying-and-adapting-patient-reported-outcome-instruments-use,https://www.fda.gov/media/141565/download,2022-01-26,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','Postmarket']",Final,FDA-2020-D-1564,No,
"Patient Engagement in the Design and Conduct of Medical Device Clinical Studies:  Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-engagement-design-and-conduct-medical-device-clinical-studies,https://www.fda.gov/media/130917/download,2022-01-26,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','Good Clinical Practice (GCP)']",Final,FDA-2019-D-3846,No,
CVM GFI #159 (VICH GL36) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish a Microbiological ADI,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-159-vich-gl36-studies-evaluate-safety-residues-veterinary-drugs-human-food-general-approach,https://www.fda.gov/media/75205/download,2022-01-21,['Center for Veterinary Medicine'],"['Human Food Safety','VICH']",Final,FDA-2003-D-0433,No,
Technical Specifications for Submitting Clinical Trial Data Sets for Treatment of Noncirrhotic Nonalcoholic Steatohepatitis (NASH):  Guidance for Industry Technical Specifications Document,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-specifications-submitting-clinical-trial-data-sets-treatment-noncirrhotic-nonalcoholic,https://www.fda.gov/media/151870/download,2022-01-21,['Center for Drug Evaluation and Research'],,Final,FDA-2018-D-1216,No,
Collecting and Providing 702(b) Portions of FDA Official Samples: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/collecting-and-providing-702b-portions-fda-official-samples,https://www.fda.gov/media/155621/download,2022-01-01,"['Center for Drug Evaluation and Research','Center for Veterinary Medicine','Office of Inspections and Investigations','Center for Biologics Evaluation and Research','Human Foods Program']","['Allergenics','Blood Products','Allergens','Animal Feed','Combination Products','Current Good Manufacturing Practice (CGMP)','Chemistry, Manufacturing, and Controls (CMC)','Human Food Safety']",Draft,FDA-2021-D-0593,No,
Pathology Peer Review in Nonclinical Toxicology Studies: Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pathology-peer-review-nonclinical-toxicology-studies-questions-and-answers,https://www.fda.gov/media/129533/download,2021-12-27,"['Center for Biologics Evaluation and Research','Center for Veterinary Medicine','Center for Devices and Radiological Health','Human Foods Program','Center for Drug Evaluation and Research']",['Pharmacology/Toxicology'],Final,FDA-2019-D-2330,No,
Non-Clinical and Clinical Investigation of Devices Used for the Treatment of Benign Prostatic Hyperplasia (BPH):  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-clinical-and-clinical-investigation-devices-used-treatment-benign-prostatic-hyperplasia-bph,https://www.fda.gov/media/79397/download,2021-12-27,['Center for Devices and Radiological Health'],"['Premarket','Gastroenterology-Urology','Good Clinical Practice (GCP)']",Final,FDA-2020-D-1118,No,
Arthroscopy Pump Tubing Sets Intended for Multiple Patient Use - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/arthroscopy-pump-tubing-sets-intended-multiple-patient-use-premarket-notification-510k-submissions,https://www.fda.gov/media/134667/download,2021-12-23,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Orthopedic']",Final,FDA-2019-D-5606,No,
Guidance for Industry: Juice HACCP and the FDA Food Safety Modernization Act,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-juice-haccp-and-fda-food-safety-modernization-act,https://www.fda.gov/media/106711/download,2021-12-21,['Human Foods Program'],"['HACCP','Juice']",Final,FDA-2017-D-3716,No,
Guidance for Industry: Low-Acid Foods Packaged in Hermetically Sealed Containers (LACF) Regulation and the FDA Food Safety Modernization Act,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-low-acid-foods-packaged-hermetically-sealed-containers-lacf-regulation-and-fda,https://www.fda.gov/media/106721/download,2021-12-21,['Human Foods Program'],['Canned Foods'],Final,FDA-2017-D-3716,No,
Guidance for Industry: Seafood HACCP and the FDA Food Safety Modernization Act,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-seafood-haccp-and-fda-food-safety-modernization-act,https://www.fda.gov/media/106733/download,2021-12-21,['Human Foods Program'],"['HACCP','Seafood/Seafood Product']",Final,FDA-2017-D-3716,No,
Validation and Verification of Analytical Testing Methods Used for Tobacco Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/validation-and-verification-analytical-testing-methods-used-tobacco-products,https://www.fda.gov/media/155033/download,2021-12-21,['Center for Tobacco Products'],,Draft,FDA-2021-D-0756,No,
Inspection of Injectable Products for Visible Particulates: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/inspection-injectable-products-visible-particulates,https://www.fda.gov/media/154868/download,2021-12-16,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Center for Veterinary Medicine']","['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Draft,FDA-2021-D-0241,No,2022-02-15
Q3C(R8) Impurities: Guidance for Residual Solvents   Guidance for Industry:  Guidance for Industry,,,2021-12-10,[],['ICH-Quality'],Final,FDA-2020-D-1301,No,
Bowel Cleansing for Colonoscopy:  Efficacy and Safety Considerations for Developing New Products : Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bowel-cleansing-colonoscopy-efficacy-and-safety-considerations-developing-new-products,https://www.fda.gov/media/154760/download,2021-12-10,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2021-D-0406,No,2022-02-10
CMC Postapproval Manufacturing Changes for Specified Biological Products To Be Documented in Annual Reports,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cmc-postapproval-manufacturing-changes-specified-biological-products-be-documented-annual-reports,https://www.fda.gov/media/106935/download,2021-12-09,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2017-D-2802,No,
Development of Anti-Infective Drug Products for the Pediatric Population :  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-anti-infective-drug-products-pediatric-population,https://www.fda.gov/media/139586/download,2021-12-09,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Clinical - Medical','Pediatric Product Development']",Final,FDA-2020-D-1518,No,
Tobacco Product User Fees: Responses to Frequently Asked Questions,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/tobacco-product-user-fees-responses-frequently-asked-questions,https://www.fda.gov/media/154697/download,2021-12-08,['Center for Tobacco Products'],,Final,FDA-2021-D-0373,No,
IND Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Clinical Recommendations: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-submissions-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or-life,https://www.fda.gov/media/154663/download,2021-12-08,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2021-D-1140,No,2022-02-07
"Investigational New Drug Application Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases:  Chemistry, Manufacturing, and Controls Recommendations, Guidance for Sponsor-Investigators : Draft Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-new-drug-application-submissions-individualized-antisense-oligonucleotide-drug,https://www.fda.gov/media/154664/download,2021-12-07,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)']",Draft,FDA-2021-D-1139,No,2022-02-07
Manufacture of Blood Components Using a Pathogen Reduction Device in Blood Establishments: Questions and Answers:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacture-blood-components-using-pathogen-reduction-device-blood-establishments-questions-and,https://www.fda.gov/media/153786/download,2021-11-03,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products','Product Safety']",Final,FDA-2017-D-6784,No,
Guidance for Industry: Temporary Permits for Interstate Shipment of Experimental Packs of Food Varying from the Requirements of Definitions and Standards of Identity,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-temporary-permits-interstate-shipment-experimental-packs-food-varying-requirements,https://www.fda.gov/media/153639/download,2021-11-01,['Human Foods Program'],['Labeling'],Final,FDA-2016-D-4484,No,
Guidance for Industry: Preparation of Food Contact Substance Notifications (Toxicology Recommendations),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-preparation-food-contact-substance-notifications-toxicology-recommendations,https://www.fda.gov/media/153239/download,2021-10-20,['Human Foods Program'],"['Food & Color Additives','Food Contact Substances (FCS)','Ingredients']",Final,FDA-1999-D-0062,No,
Guidance for Industry:  Preparation of Food Contact  Substance Notifications (Administrative),,,2021-10-18,[],"['Food & Color Additives','Food Contact Substances (FCS)','Ingredients']",Final,FDA-2000-D-0138,No,
"Guidance for Industry: Voluntary Sodium Reduction Goals:  Target Mean and Upper Bound Concentrations for Sodium in Commercially Processed, Packaged, and Prepared Foods",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-voluntary-sodium-reduction-goals,https://www.fda.gov/media/98264/download,2021-10-13,['Human Foods Program'],['Nutrition'],Final,FDA-2014-D-0055,No,
Surgical Staplers and Staples for Internal Use - Labeling Recommendations:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/surgical-staplers-and-staples-internal-use-labeling-recommendations,https://www.fda.gov/media/123572/download,2021-10-08,['Center for Devices and Radiological Health'],"['Device & Drug Safety','General & Plastic Surgery','Labeling','Device & Drug Safety']",Final,FDA-2019-D-1262,No,
CVM GFI #265 Use of Data from Foreign Investigational Studies to Support Effectiveness of New Animal Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-265-use-data-foreign-investigational-studies-support-effectiveness-new-animal-drugs,https://www.fda.gov/media/138159/download,2021-10-06,['Center for Veterinary Medicine'],"['Premarket','Investigational New Animal Drug (INAD)','New Animal Drug Application (NADA)','Target Animal – Effectiveness']",Final,FDA-2020-D-1396,No,2020-10-13
CVM GFI #266 Use of Real-World Data and Real-World Evidence to Support Effectiveness of New Animal Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-266-use-real-world-data-and-real-world-evidence-support-effectiveness-new-animal-drugs,https://www.fda.gov/media/139953/download,2021-10-06,['Center for Veterinary Medicine'],"['Premarket','Investigational New Animal Drug (INAD)','New Animal Drug Application (NADA)','Target Animal – Effectiveness']",Final,FDA-2020-D-1400,No,2020-10-13
CVM GFI #267 Biomarkers and Surrogate Endpoints in Clinical Studies to Support Effectiveness of New Animal Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-267-biomarkers-and-surrogate-endpoints-clinical-studies-support-effectiveness-new-animal,https://www.fda.gov/media/138160/download,2021-10-06,['Center for Veterinary Medicine'],"['Premarket','Investigational New Animal Drug (INAD)','New Animal Drug Application (NADA)','Target Animal – Effectiveness']",Final,FDA-2020-D-1402,No,2020-10-13
CVM GFI #268 Adaptive and Other Innovative Designs for Effectiveness Studies of New Animal Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-268-adaptive-and-other-innovative-designs-effectiveness-studies-new-animal-drugs,https://www.fda.gov/media/139971/download,2021-10-06,['Center for Veterinary Medicine'],"['Premarket','Investigational New Animal Drug (INAD)','New Animal Drug Application (NADA)','Target Animal – Effectiveness']",Final,FDA-2020-D-1401,No,2020-10-13
"Hospital and Health System Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hospital-and-health-system-compounding-under-section-503a-federal-food-drug-and-cosmetic-act,https://www.fda.gov/media/97353/download,2021-10-06,['Center for Drug Evaluation and Research'],['Compounding'],Draft,FDA-2016-D-0271,No,
Acceptance Review for De Novo Classification Requests:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acceptance-review-de-novo-classification-requests,https://www.fda.gov/media/152657/download,2021-10-05,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Premarket'],Final,FDA-2017-D-6069,No,
De Novo Classification Process (Evaluation of Automatic Class III Designation):  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/de-novo-classification-process-evaluation-automatic-class-iii-designation,https://www.fda.gov/media/72674/download,2021-10-05,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','Administrative / Procedural']",Final,FDA-2011-D-0689,No,
Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interpreting-sameness-gene-therapy-products-under-orphan-drug-regulations,https://www.fda.gov/media/134731/download,2021-09-29,"['Center for Biologics Evaluation and Research','Office of the Commissioner']",['Gene Therapy'],Final,FDA-2019-D-5392,No,2020-07-28
Investigator Responsibilities – Safety Reporting for Investigational Drugs and Devices: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigator-responsibilities-safety-reporting-investigational-drugs-and-devices,https://www.fda.gov/media/152530/download,2021-09-29,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research']",['Device & Drug Safety'],Draft,FDA-2021-D-0368,No,2021-11-29
Microbiological Quality Considerations in Non-Sterile Drug Manufacturing: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/microbiological-quality-considerations-non-sterile-drug-manufacturing,https://www.fda.gov/media/152527/download,2021-09-29,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Draft,FDA-2021-D-0432,No,2021-12-29
Questions and Answers on Quality Related Controlled Correspondence Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/questions-and-answers-quality-related-controlled-correspondence-guidance-industry,https://www.fda.gov/media/152281/download,2021-09-20,['Center for Drug Evaluation and Research'],['Pharmaceutical Quality'],Final,FDA-2017-D-6821,No,
Questions and Answers on Biosimilar Development and the BPCI Act Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/questions-and-answers-biosimilar-development-and-bpci-act-guidance-industry,https://www.fda.gov/media/119258/download,2021-09-17,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Biosimilars'],Final,FDA-2011-D-0611,No,
New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 3): Draft New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 3).”,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/new-and-revised-draft-qas-biosimilar-development-and-bpci-act-revision-3,https://www.fda.gov/media/119278/download,2021-09-17,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Biosimilars'],Draft,FDA-2011-D-0611,No,2021-11-17
Q2(R1) Validation of Analytical Procedures: Text and Methodology  Guidance for Industry:  Guidance for Industry,,,2021-09-16,[],,Final,FDA-2017-D-6821,No,
Withdrawn CDER Product Specific Guidances,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/withdrawn-cder-product-specific-guidances,https://www.fda.gov/media/90032/download,2021-09-09,['Center for Drug Evaluation and Research'],"['Generic Drugs','Labeling']",Final,FDA-2007-D-0369,No,
Guidance for Industry: Microbiological Considerations for Antimicrobial Agents Used in Food Applications,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-microbiological-considerations-antimicrobial-agents-used-food-applications,https://www.fda.gov/media/83078/download,2021-09-01,['Human Foods Program'],['Food & Color Additives'],Final,FDA-2007-D-0207,No,
Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioequivalence-studies-pharmacokinetic-endpoints-drugs-submitted-under-abbreviated-new-drug,https://www.fda.gov/media/87219/download,2021-08-20,['Center for Drug Evaluation and Research'],"['Biopharmaceutics','Generic Drugs']",Draft,FDA-2013-D-1464,No,
FDA Export Certification:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-export-certification,https://www.fda.gov/media/151701/download,2021-08-20,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Human Foods Program','Center for Veterinary Medicine']","['Export','Import']",Final,,No,
Notifying FDA of Fatalities Related to Blood Collection or Transfusion:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/notifying-fda-fatalities-related-blood-collection-or-transfusion,https://www.fda.gov/media/70676/download,2021-08-20,['Center for Biologics Evaluation and Research'],"['Application & Approvals','Blood Products']",Final,FDA-2002-D-0010,No,
Development and Submission of Near Infrared Analytical Procedures,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-submission-near-infrared-analytical-procedures,https://www.fda.gov/media/91343/download,2021-08-06,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2015-D-0868,No,
Nonmetastatic Castration-Resistant Prostate Cancer: Considerations for Metastasis-Free Survival Endpoint in Clinical Trials,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonmetastatic-castration-resistant-prostate-cancer-considerations-metastasis-free-survival-endpoint,https://www.fda.gov/media/117792/download,2021-08-06,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Final,FDA-2018-D-3931,No,
Rabies:  Developing Monoclonal Antibody Cocktails for the Passive Immunization Component of Post-Exposure Prophylaxis Guidance for Industry: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rabies-developing-monoclonal-antibody-cocktails-passive-immunization-component-post-exposure,https://www.fda.gov/media/151102/download,2021-07-28,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Draft,FDA-2021-D-0519,No,2021-10-27
Field Alert Report Submission: Questions and Answers Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/field-alert-report-submission-questions-and-answers-guidance-industry,https://www.fda.gov/media/114549/download,2021-07-22,"['Office of Inspections and Investigations','Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Investigation & Enforcement','Chemistry, Manufacturing, and Controls (CMC)','Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,FDA-2018-D-2326,No,
Guidance for Industry: Use of Recycled Plastics in Food Packaging (Chemistry Considerations),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-use-recycled-plastics-food-packaging-chemistry-considerations,https://www.fda.gov/media/150792/download,2021-07-15,['Human Foods Program'],"['Food & Color Additives','Food Contact Substances (FCS)']",Final,FDA-2020-D-1456,No,
CVM GFI #261 - Eligibility Criteria for Expanded Conditional Approval of New Animal Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-261-eligibility-criteria-expanded-conditional-approval-new-animal-drugs,https://www.fda.gov/media/130706/download,2021-07-14,['Center for Veterinary Medicine'],"['Premarket','User Fees','Antimicrobial Resistance','New Animal Drug Application (NADA)','Target Animal – Effectiveness']",Final,FDA-2019-D-3361,No,2020-01-28
Technical Considerations for Non-Clinical Assessment of Medical Devices Containing Nitinol:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-considerations-non-clinical-assessment-medical-devices-containing-nitinol,https://www.fda.gov/media/123272/download,2021-07-09,['Center for Devices and Radiological Health'],"['Premarket','Animal Cell-Based Products']",Final,FDA-2019-D-1261,No,
Unique Device Identification System: Form and Content of the Unique Device Identifier (UDI):  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/unique-device-identification-system-form-and-content-unique-device-identifier-udi,https://www.fda.gov/media/99084/download,2021-07-07,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']","['Labeling','UDI']",Final,FDA-2016-D-1853,No,
Evaluating Cancer Drugs in Patients with Central Nervous System Metastases:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluating-cancer-drugs-patients-central-nervous-system-metastases,https://www.fda.gov/media/141507/download,2021-07-01,"['Center for Drug Evaluation and Research','Office of the Commissioner']",['Clinical - Medical'],Final,FDA-2020-D-0938,No,2020-10-26
Assessment of Adhesion for Topical and Transdermal Systems Submitted in New Drug Applications : Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessment-adhesion-topical-and-transdermal-systems-submitted-new-drug-applications,https://www.fda.gov/media/150509/download,2021-07-01,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2020-D-2323,No,
Sponsor Responsibilities - Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sponsor-responsibilities-safety-reporting-requirements-and-safety-assessment-ind-and,https://www.fda.gov/media/150356/download,2021-06-25,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Device & Drug Safety','Safety - Issues, Errors, and Problems']",Draft,FDA-2020-D-2099,No,2021-09-24
Providing Regulatory Submissions in Electronic Format -- Standardized Study Data,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-standardized-study-data,https://www.fda.gov/media/82716/download,2021-06-22,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Electronic Submissions'],Final,FDA-2012-D-0097,No,
"Chemistry, Manufacturing, and Controls Changes to an Approved Application: Certain Biological Products:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemistry-manufacturing-and-controls-changes-approved-application-certain-biological-products,https://www.fda.gov/media/109615/download,2021-06-21,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",,Final,FDA-1995-D-0288,No,
Premenopausal Women with Breast Cancer: Developing Drugs for Treatment:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premenopausal-women-breast-cancer-developing-drugs-treatment,https://www.fda.gov/media/142638/download,2021-06-17,['Center for Biologics Evaluation and Research'],['Clinical - Medical'],Final,FDA-2020-D-1553,No,2020-12-07
CVM GFI #263 Recommendations for Sponsors of Medically Important Antimicrobial Drugs Approved for Use in Animals to Voluntarily Bring Under Veterinary Oversight All Products That Continue to be Available Over-the-Counter,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-263-recommendations-sponsors-medically-important-antimicrobial-drugs-approved-use-animals,https://www.fda.gov/media/130610/download,2021-06-11,['Center for Veterinary Medicine'],"['Premarket','Antimicrobial Resistance','Labeling','New Animal Drug Application (NADA)']",Final,FDA-2019-D-3614,No,2019-12-24
Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-supply-chain-security-act-implementation-identification-suspect-product-and-notification,https://www.fda.gov/media/88790/download,2021-06-03,"['Office of Inspections and Investigations','Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Administrative / Procedural'],Final,FDA-2014-D-0609,No,
Product Identifiers under the Drug Supply Chain Security Act - Questions and Answers:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-identifiers-under-drug-supply-chain-security-act-questions-and-answers,https://www.fda.gov/media/116304/download,2021-06-03,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Labeling'],Final,FDA-2018-D-3175,No,
Oral Drug Products Administered Via Enteral Feeding Tube: In Vitro Testing and Labeling Recommendations: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/oral-drug-products-administered-enteral-feeding-tube-in-vitro-testing-and-labeling-recommendations,https://www.fda.gov/media/149688/download,2021-06-02,"['Center for Drug Evaluation and Research','Center for Devices and Radiological Health']","['Chemistry, Manufacturing, and Controls (CMC)','Labeling','Pharmaceutical Quality']",Draft,FDA-2021-D-0391,No,2021-08-02
CPG Sec 555.400 Aflatoxins in Human Food,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555400-aflatoxins-human-food,https://www.fda.gov/media/149666/download,2021-06-01,"['Office of Inspections and Investigations','Human Foods Program']",['Investigation & Enforcement'],Final,FDA-2021-D-0242,No,
CPG Sec 570.200 Aflatoxins in Brazil Nuts,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-570200-aflatoxins-brazil-nuts,https://www.fda.gov/media/72053/download,2021-06-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Nuts & Nut Products']",Final,FDA-2021-D-0243,No,
CPG Sec 570.375 Aflatoxins in Peanuts and Peanut Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-570375-aflatoxins-peanuts-and-peanut-products,https://www.fda.gov/media/72073/download,2021-06-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Nuts & Nut Products']",Final,FDA-2021-D-0244,No,
CPG Sec 570.500 Aflatoxins in Pistachio Nuts,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-570500-aflatoxins-pistachio-nuts,https://www.fda.gov/media/72084/download,2021-06-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Nuts & Nut Products']",Final,FDA-2021-D-0245,No,
Bispecific Antibody Development Programs Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bispecific-antibody-development-programs-guidance-industry,https://www.fda.gov/media/123313/download,2021-05-24,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2019-D-0621,No,
FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD&C Act:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fdara-implementation-guidance-pediatric-studies-molecularly-targeted-oncology-drugs-amendments-sec,https://www.fda.gov/media/133440/download,2021-05-24,['Center for Drug Evaluation and Research'],"['Clinical Trials','Administrative / Procedural','Pediatric Product Development']",Final,FDA-2019-D-4751,No,2020-02-12
ICH Q12: Implementation Considerations for FDA-Regulated Products: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ich-q12-implementation-considerations-fda-regulated-products,https://www.fda.gov/media/148947/download,2021-05-20,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']","['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Draft,FDA-2021-D-0166,No,2021-10-12
Implanted Brain-Computer Interface (BCI) Devices for Patients with Paralysis or Amputation - Non-clinical Testing and Clinical Considerations:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/implanted-brain-computer-interface-bci-devices-patients-paralysis-or-amputation-non-clinical-testing,https://www.fda.gov/media/120362/download,2021-05-20,['Center for Devices and Radiological Health'],"['Premarket','Investigational Device Exemption (IDE)','Neurological']",Final,FDA-2014-N-1130,No,
Peripheral Vascular Atherectomy Devices - Premarket Notification [510(k)] Submissions:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/peripheral-vascular-atherectomy-devices-premarket-notification-510k-submissions,https://www.fda.gov/media/114852/download,2021-05-20,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Cardiovascular','Labeling']",Final,FDA-2018-D-2494,No,
ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-certain-highly-purified-synthetic-peptide-drug-products-refer-listed-drugs-rdna-origin,https://www.fda.gov/media/107622/download,2021-05-19,['Center for Drug Evaluation and Research'],"['User Fees','Drug Competition Action Plan','Generic Drugs']",Final,FDA-2017-D-5767,No,
Chemotherapy-Induced Nausea and Vomiting: Developing Drugs for Prevention Guidance for Industry: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemotherapy-induced-nausea-and-vomiting-developing-drugs-prevention-guidance-industry,https://www.fda.gov/media/148829/download,2021-05-19,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2021-D-0351,No,2021-07-19
"Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs  Frequently Asked Questions  Statement of Investigator  (Form FDA 1572) (Revision 1): Draft Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs  Frequently Asked Questions  Statement of Investigator  (Form FDA 1572) (Revision 1)",,,2021-05-19,[],['Administrative / Procedural'],Draft,FDA-2008-D-0406,No,2021-07-15
COVID-19: Master Protocols Evaluating Drugs and Biological Products for Treatment or Prevention:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-master-protocols-evaluating-drugs-and-biological-products-treatment-or-prevention,https://www.fda.gov/media/148739/download,2021-05-17,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",,Final,FDA-2021-D-0409,No,
M9 Biopharmaceutics Classification System-Based Biowaivers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m9-biopharmaceutics-classification-system-based-biowaivers,https://www.fda.gov/media/148472/download,2021-05-11,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['ICH-Multidisciplinary'],Final,FDA-2018-D-3614,No,
Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Annex,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q12-technical-and-regulatory-considerations-pharmaceutical-product-lifecycle-management-annex,https://www.fda.gov/media/148477/download,2021-05-11,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-2018-D-1609,No,
E9(R1) Statistical Principles for Clinical Trials: Addendum: Estimands and Sensitivity Analysis in Clinical Trials:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e9r1-statistical-principles-clinical-trials-addendum-estimands-and-sensitivity-analysis-clinical,https://www.fda.gov/media/148473/download,2021-05-11,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Efficacy'],Final,FDA-2017-D-6113,No,
Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q12-technical-and-regulatory-considerations-pharmaceutical-product-lifecycle-management-guidance,https://www.fda.gov/media/148476/download,2021-05-11,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-2018-D-1609,No,
S5(R3) Detection of Reproductive and Developmental Toxicity for Human Pharmaceuticals :  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s5r3-detection-reproductive-and-developmental-toxicity-human-pharmaceuticals,https://www.fda.gov/media/148475/download,2021-05-11,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Safety'],Final,FDA-2017-D-5138,No,
Qualified Infectious Disease Product Designation Questions and Answers:  Guidance for Industy,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/qualified-infectious-disease-product-designation-questions-and-answers,https://www.fda.gov/media/148480/download,2021-05-11,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2017-D-7001,No,
S11 Nonclinical Safety Testing In Support of Development of Pediatric Pharmaceuticals :  International Council for Harmonisation; Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s11-nonclinical-safety-testing-support-development-pediatric-pharmaceuticals,https://www.fda.gov/media/148478/download,2021-05-11,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['ICH-Safety','Pediatric Product Development']",Final,FDA-2018-D-4524,No,
Submitting Nonclinical Datasets for Evaluation of Rodent Carcinogenicity Studies of Pharmaceuticals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-nonclinical-datasets-evaluation-rodent-carcinogenicity-studies-pharmaceuticals,https://www.fda.gov/media/169654/download,2021-05-01,['Center for Drug Evaluation and Research'],,Final,,No,
Nonclinical Testing of Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases Guidance for Sponsor-Investigators: Draft Guidance for Sponsor-Investigators,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-testing-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or,https://www.fda.gov/media/147876/download,2021-04-26,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Draft,FDA-2021-D-0320,No,
Guidance for Industry: Enforcement Policy for Providing an Acceptable Unique Facility Identifier (UFI) for the 2020 Food Facility Registration Biennial Renewal Period,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-enforcement-policy-providing-acceptable-unique-facility-identifier-ufi-2020-food,https://www.fda.gov/media/143997/download,2021-03-30,['Human Foods Program'],['Registration'],Final,FDA-2012-D-1002,No,
Manufacturing Considerations for Licensed and Investigational Cellular and Gene Therapy Products During COVID-19 Public Health Emergency:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacturing-considerations-licensed-and-investigational-cellular-and-gene-therapy-products-during,https://www.fda.gov/media/145301/download,2021-01-19,['Center for Biologics Evaluation and Research'],"['Coronavirus','Gene Therapy']",Final,FDA-2020-D-1137,No,
Safer Technologies Program for Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safer-technologies-program-medical-devices,https://www.fda.gov/media/130815/download,2021-01-06,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','510(k)','Premarket Approval (PMA)']",Final,FDA-2019-D-4048,No,
Mouse Embryo Assay for Assisted Reproduction Technology Devices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/mouse-embryo-assay-assisted-reproduction-technology-devices,https://www.fda.gov/media/127874/download,2021-01-05,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Premarket Approval (PMA)','Investigational Device Exemption (IDE)','Obstetrical & Gynecological']",Final,FDA-2019-D-2105,No,
IND Submissions for Individualized Antisense Oligonucleotide Drug Products: Administrative and Procedural Recommendations Guidance for Sponsor-Investigators: Draft Guidance for Sponsor-Investigators,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-submissions-individualized-antisense-oligonucleotide-drug-products-administrative-and-procedural,https://www.fda.gov/media/144872/download,2021-01-04,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Draft,FDA-2020-D-2199,No,2021-03-04
Consumer Antiseptic  Rub Final Rule Questions and Answers Guidance for Industry:  Guidance for Industry,,,2020-12-30,[],['Over-the-Counter Drugs'],Final,FDA-2016-N-0124,No,
Product Labeling for Laparoscopic Power Morcellators:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-labeling-laparoscopic-power-morcellators,https://www.fda.gov/media/90012/download,2020-12-30,['Center for Devices and Radiological Health'],"['Postmarket','Premarket','510(k)','Labeling','Safety - Issues, Errors, and Problems','Obstetrical & Gynecological','General & Plastic Surgery']",Final,FDA-2014-D-1804,No,
Providing Regulatory Submissions in Electronic Format --Content of the Risk Evaluation and Mitigation Strategies Document Using Structured Product Labeling:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-content-risk-evaluation-and-mitigation-strategies,https://www.fda.gov/media/107302/download,2020-12-23,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Electronic Submissions','Generic Drugs']",Final,FDA-2017-D-4303,No,
Guidance for Industry: The Use of an Alternate Name for Potassium Chloride in Food Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-use-alternate-name-potassium-chloride-food-labeling,https://www.fda.gov/media/125081/download,2020-12-17,['Human Foods Program'],['Labeling'],Final,FDA-2019-D-0892,No,
Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bacterial-risk-control-strategies-blood-collection-establishments-and-transfusion-services-enhance,https://www.fda.gov/media/123448/download,2020-12-17,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-2014-D-1814,No,
Dry Eye: Developing Drugs for Treatment Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dry-eye-developing-drugs-treatment-guidance-industry,https://www.fda.gov/media/144594/download,2020-12-16,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2020-D-2214,No,2021-03-17
Interacting with the FDA on Complex Innovative Trial Designs for Drugs and Biological Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interacting-fda-complex-innovative-trial-designs-drugs-and-biological-products,https://www.fda.gov/media/130897/download,2020-12-16,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Clinical - Medical'],Final,FDA-2019-D-3679,No,
CVM GFI #262 Pre-Submission Consultation Process for Animal Food Additive Petitions or Generally Recognized as Safe (GRAS) Notices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-262-pre-submission-consultation-process-animal-food-additive-petitions-or-generally,https://www.fda.gov/media/134995/download,2020-12-11,['Center for Veterinary Medicine'],"['Animal Food Additives','Generally Recognized as Safe (GRAS)']",Final,FDA-2020-D-0064,No,2020-04-13
Magnetic Resonance (MR) Receive-only Coil - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/magnetic-resonance-mr-receive-only-coil-performance-criteria-safety-and-performance-based-pathway,https://www.fda.gov/media/133250/download,2020-12-11,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Radiology']",Final,FDA-2019-D-1650,No,
Orthopedic Non-Spinal Metallic Bone Screws and Washers - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orthopedic-non-spinal-metallic-bone-screws-and-washers-performance-criteria-safety-and-performance,https://www.fda.gov/media/130866/download,2020-12-11,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Orthopedic']",Final,FDA-2019-D-1652,No,
Spinal Plating Systems - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/spinal-plating-systems-performance-criteria-safety-and-performance-based-pathway,https://www.fda.gov/media/130867/download,2020-12-11,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Orthopedic']",Final,FDA-2019-D-1647,No,
Best Practices in Developing Proprietary Names for Human Prescription Drug Products; Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-developing-proprietary-names-human-prescription-drug-products-guidance-industry,https://www.fda.gov/media/88496/download,2020-12-08,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Safety - Issues, Errors, and Problems']",Final,FDA-2014-D-0622,No,
Best Practices in Developing Proprietary Names for Human Nonprescription Drug Products; Draft Guidance for Industry: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-developing-proprietary-names-human-nonprescription-drug-products-draft-guidance,https://www.fda.gov/media/144257/download,2020-12-08,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Safety - Issues, Errors, and Problems']",Draft,FDA-2020-D-0770,No,2021-02-08
Requesting FDA Feedback on Combination Products :  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requesting-fda-feedback-combination-products,https://www.fda.gov/media/133768/download,2020-12-04,"['Office of the Commissioner','Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research','Center for Devices and Radiological Health']","['Combination Products','Over-the-Counter Drugs']",Final,FDA-2019-D-4739,No,2020-02-24
"Recommendations for Screening, Testing, and Management of Blood Donors and Blood and Blood Components Based on Screening Tests for Syphilis:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-screening-testing-and-management-blood-donors-and-blood-and-blood-components-based,https://www.fda.gov/media/85283/download,2020-12-02,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-2003-D-0128,No,
Compliance Policy Guide CPG Sec. 110.650 Weekly Entry Filing Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-policy-guide-cpg-sec-110650-weekly-entry-filing-guidance-industry-and-fda-staff,https://www.fda.gov/media/144074/download,2020-11-30,['Office of Inspections and Investigations'],"['Compliance','Export','Import']",Final,FDA-2019-D-3904,No,
CVM GFI #242 In-Use Stability Studies and Associated Labeling Statements for Multiple-Dose Injectable Animal Drug Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-242-use-stability-studies-and-associated-labeling-statements-multiple-dose-injectable-animal,https://www.fda.gov/media/102469/download,2020-11-27,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)','New Animal Drug Application (NADA)','Investigational New Animal Drug (INAD)']",Final,FDA-2016-D-4437,No,2017-03-06
Qualification Process for Drug Development Tools Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/qualification-process-drug-development-tools-guidance-industry-and-fda-staff,https://www.fda.gov/media/133511/download,2020-11-24,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Administrative / Procedural','Clinical - Medical','Drug Development Tools']",Final,FDA-2010-D-0529,No,
CVM GFI #255 Elemental Impurities in Animal Drug Products Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-255-elemental-impurities-animal-drug-products-questions-and-answers,https://www.fda.gov/media/111953/download,2020-11-23,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)']",Final,FDA-2018-D-0943,No,2018-05-29
Public Availability of Lists of Retail Consignees to Effectuate Certain Human and Animal Food Recalls:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/public-availability-lists-retail-consignees-effectuate-certain-human-and-animal-food-recalls,https://www.fda.gov/media/116401/download,2020-11-20,"['Center for Veterinary Medicine','Office of Inspections and Investigations','Human Foods Program']","['Recalls','Retail Food Protection']",Final,FDA-2018-D-1752,No,2018-11-26
CVM GFI #197 Documenting Electronic Data Files and Statistical Analysis Programs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-197-documenting-electronic-data-files-and-statistical-analysis-programs,https://www.fda.gov/media/75077/download,2020-11-13,['Center for Veterinary Medicine'],"['Target Animal – Effectiveness','Target Animal – Safety','Investigational New Animal Drug (INAD)']",Final,FDA-2009-D-0052,No,2018-07-20
"Certificates of Confidentiality:  Guidance for Sponsors, Sponsor-Investigators, Researchers, Industry, and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/certificates-confidentiality,https://www.fda.gov/media/132966/download,2020-11-13,"['Office of the Commissioner','Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Tobacco Products','Human Foods Program','Center for Veterinary Medicine','Office of the Commissioner']","['Research','Good Clinical Practice (GCP)']",Final,FDA-2019-D-3592,No,2020-01-08
Draft Guidance for Industry: Voluntary Disclosure of Sesame as an Allergen,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-voluntary-disclosure-sesame-allergen,https://www.fda.gov/media/143521/download,2020-11-10,['Human Foods Program'],['Allergens'],Draft,FDA-2020-D-0530,No,2021-02-25
Regulatory Considerations for Microneedling Products:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-microneedling-products,https://www.fda.gov/media/107708/download,2020-11-10,['Center for Devices and Radiological Health'],"['Premarket','General & Plastic Surgery']",Final,FDA-2017-D-4792,No,
"Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial,https://www.fda.gov/media/127712/download,2020-11-09,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Clinical - Medical','Pediatric Product Development']",Final,FDA-2019-D-1264,No,
Assessing User Fees Under the Prescription Drug User Fee Amendments of 2017 Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-user-fees-under-prescription-drug-user-fee-amendments-2017-guidance-industry,https://www.fda.gov/media/108233/download,2020-11-09,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['User Fees'],Final,FDA-2017-D-5913,No,
Insanitary Conditions at Compounding Facilities Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/insanitary-conditions-compounding-facilities-guidance-industry,https://www.fda.gov/media/124948/download,2020-11-06,['Center for Drug Evaluation and Research'],"['Administrative / Procedural','Compounding']",Final,FDA-2016-D-2268,No,
Guidance for Industry: Prior Notice of Imported Food Contingency Plan for System Outages,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-prior-notice-imported-food-contingency-plan-system-outages,https://www.fda.gov/media/143799/download,2020-11-01,['Office of Inspections and Investigations'],['Import'],Final,FDA-2004-D-0042,No,
Nonclinical Testing of Orally Inhaled Nicotine-Containing Drug Products Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-testing-orally-inhaled-nicotine-containing-drug-products-guidance-industry,https://www.fda.gov/media/115150/download,2020-10-28,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Final,FDA-2018-D-2583,No,
Referencing Approved Drug Products in ANDA Submissions Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/referencing-approved-drug-products-anda-submissions-guidance-industry,https://www.fda.gov/media/102360/download,2020-10-27,['Center for Drug Evaluation and Research'],['Generic Drugs'],Final,FDA-2017-D-0114,No,
Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product—Compliance Policies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/wholesale-distributor-verification-requirement-saleable-returned-drug-product-and-dispenser-0,https://www.fda.gov/media/171677/download,2020-10-22,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Administrative / Procedural'],Final,FDA-2019-D-4212.,No,
Guidance for Industry: The Declaration of Allulose and Calories from Allulose on Nutrition and Supplement Facts Labels,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-declaration-allulose-and-calories-allulose-nutrition-and-supplement-facts-labels,https://www.fda.gov/media/123342/download,2020-10-16,['Human Foods Program'],"['Labeling','Nutrition Label']",Final,FDA-2019-D-0725,No,
Guidance for Industry: U.S. Agent Voluntary Identification System (VIS) for Food Facility Registration,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-us-agent-voluntary-identification-system-vis-food-facility-registration,https://www.fda.gov/media/142968/download,2020-10-16,['Human Foods Program'],['Registration'],Final,FDA-2012-D-1002,No,
Testing for Biotin Interference in In Vitro Diagnostic Devices:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/testing-biotin-interference-in-vitro-diagnostic-devices,https://www.fda.gov/media/127915/download,2020-10-16,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']","['Blood','Blood Products','IVDs (In Vitro Diagnostic Devices)']",Final,FDA-2019-D-1876,No,
Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Treatment Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/opioid-use-disorder-endpoints-demonstrating-effectiveness-drugs-treatment-guidance-industry,https://www.fda.gov/media/114948/download,2020-10-01,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-2018-D-2382,No,
"Importation of Certain FDA- Approved Human Prescription Drugs, Including Biological Products, and Combination Products under Section 801(d)(1)(B) of the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/importation-certain-fda-approved-human-prescription-drugs-including-biological-products-and,https://www.fda.gov/media/142474/download,2020-10-01,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research','Office of Inspections and Investigations','Office of the Commissioner']","['Investigation & Enforcement','Labeling','Chemistry, Manufacturing, and Controls (CMC)','Combination Products','Pharmaceutical Quality']",Final,FDA-2019-D-5743,No,2020-02-21
"The Use of Physiologically Based Pharmacokinetic Analyses — Biopharmaceutics Applications for Oral Drug Product Development, Manufacturing Changes, and Controls : Draft Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-physiologically-based-pharmacokinetic-analyses-biopharmaceutics-applications-oral-drug-product,https://www.fda.gov/media/142500/download,2020-09-30,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Draft,FDA-2020-D-1517,No,2020-11-30
"Saline, Silicone Gel, and Alternative Breast Implants:  Guidance for Industry and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/saline-silicone-gel-and-alternative-breast-implants,https://www.fda.gov/media/71081/download,2020-09-29,['Center for Devices and Radiological Health'],"['Premarket','General & Plastic Surgery','Labeling']",Final,FDA-2004-D-0124,No,
Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/blood-glucose-monitoring-test-systems-prescription-point-care-use,https://www.fda.gov/media/119829/download,2020-09-29,['Center for Devices and Radiological Health'],"['Premarket','CLIA (Clinical Laboratory Improvement Amendments)','IVDs (In Vitro Diagnostic Devices)','General Hospital & Personal Use','Clinical Chemistry & Clinical Toxicology']",Final,FDA-2013-D-1445,No,
Breast Implants - Certain Labeling Recommendations to Improve Patient Communication:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/breast-implants-certain-labeling-recommendations-improve-patient-communication,https://www.fda.gov/media/131885/download,2020-09-29,['Center for Devices and Radiological Health'],"['Premarket','General & Plastic Surgery','Labeling']",Final,FDA-2019-D-4467,No,2019-12-23
Self-Monitoring Blood Glucose Test Systems for Over-the-Counter Use:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/self-monitoring-blood-glucose-test-systems-over-counter-use,https://www.fda.gov/media/87721/download,2020-09-29,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Clinical Chemistry & Clinical Toxicology','Over-the-Counter Drugs']",Final,FDA-2013-D-1446,No,
"Basic Safety and Essential Performance of Medical Electrical Equipment, Medical Electrical Systems, and Laboratory Medical Equipment - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program:  Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/basic-safety-and-essential-performance-medical-electrical-equipment-medical-electrical-systems-and,https://www.fda.gov/media/142385/download,2020-09-25,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']",['Premarket'],Final,FDA-2019-D-3805,No,
"Biocompatibility Testing of Medical Devices - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program:  Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biocompatibility-testing-medical-devices-standards-specific-information-accreditation-scheme,https://www.fda.gov/media/142388/download,2020-09-25,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']",['Premarket'],Final,FDA-2019-D-3805,No,
"The Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program:  Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/basic-safety-and-essential-performance-medical-electrical-equipment-medical-electrical-systems-and,https://www.fda.gov/media/142385/download,2020-09-25,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']",['Premarket'],Final,FDA-2019-D-3805,No,
Eosinophilic Esophagitis: Developing Drugs for Treatment Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/eosinophilic-esophagitis-developing-drugs-treatment-guidance-industry,https://www.fda.gov/media/120089/download,2020-09-15,['Center for Drug Evaluation and Research'],"['Clinical - Medical','Pediatric Product Development']",Final,FDA-2019-D-0177,No,
Geriatric Information in Human Prescription Drug and Biological Product Labeling Guidance for Industry: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/geriatric-information-human-prescription-drug-and-biological-product-labeling-guidance-industry,https://www.fda.gov/media/142162/download,2020-09-15,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Labeling'],Draft,FDA-2020-D-1621,No,2020-11-16
Recognition and Withdrawal of Voluntary Consensus Standards:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recognition-and-withdrawal-voluntary-consensus-standards,https://www.fda.gov/media/71995/download,2020-09-15,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']",['Administrative / Procedural'],Final,FDA-2018-D-2936,No,
CVM GFI #191 Changes to Approved NADAs - New NADAs vs. Category II Supplemental NADAs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-191-changes-approved-nadas-new-nadas-vs-category-ii-supplemental-nadas,https://www.fda.gov/media/70423/download,2020-08-27,['Center for Veterinary Medicine'],['New Animal Drug Application (NADA)'],Final,FDA-2008-D-0614,No,
Acute Myeloid Leukemia:  Developing Drugs and Biological Products for Treatment: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acute-myeloid-leukemia-developing-drugs-and-biological-products-treatment,https://www.fda.gov/media/140821/download,2020-08-17,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Draft,FDA-2020-D-1298,No,2020-10-13
Conventional Foley Catheters - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/conventional-foley-catheters-performance-criteria-safety-and-performance-based-pathway,https://www.fda.gov/media/130865/download,2020-08-14,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Gastroenterology-Urology']",Final,FDA-2019-D-1651,No,
Cutaneous Electrodes for Recording Purposes - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cutaneous-electrodes-recording-purposes-performance-criteria-safety-and-performance-based-pathway,https://www.fda.gov/media/130864/download,2020-08-14,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Neurological']",Final,FDA-2019-D-1649,No,
"Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank:  Guidance for Responsible Parties, Submitters of Certain Applications and Submissions to FDA, and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/civil-money-penalties-relating-clinicaltrialsgov-data-bank,https://www.fda.gov/media/113361/download,2020-08-14,"['Office of Inspections and Investigations','Office of the Commissioner','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Investigation & Enforcement','Good Clinical Practice (GCP)']",Final,FDA-2018-D-0787,No,
Male Breast Cancer: Developing Drugs for Treatment:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/male-breast-cancer-developing-drugs-treatment,https://www.fda.gov/media/130061/download,2020-08-12,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Final,FDA-2019-D-2966,No,2019-10-28
"Marketing Status Notifications Under Section 506I of the Federal Food, Drug, and Cosmetic Act",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-status-notifications-under-section-506i-federal-food-drug-and-cosmetic-act,https://www.fda.gov/media/120095/download,2020-08-10,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2018-D-4615,No,
Limited Population Pathway for Antibacterial and Antifungal Drugs Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/limited-population-pathway-antibacterial-and-antifungal-drugs-guidance-industry,https://www.fda.gov/media/113729/download,2020-08-05,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Administrative / Procedural'],Final,FDA-2018-D-2032,No,
Guidance for Industry: Action Level for Inorganic Arsenic in Rice Cereals for Infants,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-action-level-inorganic-arsenic-rice-cereals-infants,https://www.fda.gov/media/97234/download,2020-08-04,['Human Foods Program'],"['Arsenic','Infant Formula & Foods']",Final,FDA-2016-D-1099,No,
CPG Sec. 280.100 -  Stability Requirements -  Licensed In Vitro Diagnostic Products,,,2020-07-31,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 280.110-  Microbiological Control Requirements-Licensed Anti-Human Globulin and Blood Grouping Reagents,,,2020-07-31,[],['Investigation & Enforcement'],Final,,No,
Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Initial Pediatric Study Plans,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-study-plans-content-and-process-submitting-initial-pediatric-study-plans-and-amended,https://www.fda.gov/media/86340/download,2020-07-31,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Administrative / Procedural','Pediatric Product Development']",Final,FDA-2013-D-0814,No,
Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pathological-complete-response-neoadjuvant-treatment-high-risk-early-stage-breast-cancer-use,https://www.fda.gov/media/83507/download,2020-07-29,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-2012-D-0432,No,
Expiration Dating of Unit-Dose Repackaged Solid Oral Dosage Form Drug Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expiration-dating-unit-dose-repackaged-solid-oral-dosage-form-drug-products,https://www.fda.gov/media/70985/download,2020-07-29,['Center for Drug Evaluation and Research'],"['Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,FDA-2017-D-0829,No,
"Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products-Content and Format: Draft Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pregnancy-lactation-and-reproductive-potential-labeling-human-prescription-drug-and-biological,https://www.fda.gov/media/90160/download,2020-07-29,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Labeling'],Draft,FDA-2014-D-1551,No,2020-09-29
Multiple Function Device Products: Policy and Considerations:  Guidance for Industry and Food and Drug Administration,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/multiple-function-device-products-policy-and-considerations,https://www.fda.gov/media/112671/download,2020-07-29,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research','Office of the Commissioner','Center for Drug Evaluation and Research']","['Postmarket','Premarket','Combination Products','Digital Health']",Final,FDA-2018-D-1339,No,
Setting Endotoxin Limits During Development of Investigational Oncology Drugs and Biological Products Guidance for Industry: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/setting-endotoxin-limits-during-development-investigational-oncology-drugs-and-biological-products,https://www.fda.gov/media/140410/download,2020-07-28,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Draft,FDA-2020-D-1294,No,2020-10-28
"Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use:  Guidance for Industry and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal,https://www.fda.gov/media/109176/download,2020-07-20,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']","['Cellular & Gene Therapy','Tissue']",Final,FDA-2017-D-6146,No,
Clinical Investigations for Prostate Tissue Ablation Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-investigations-prostate-tissue-ablation-devices,https://www.fda.gov/media/128263/download,2020-07-15,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Investigational Device Exemption (IDE)','Gastroenterology-Urology','Good Clinical Practice (GCP)']",Final,FDA-2019-D-2223,No,
"Providing Regulatory Submissions for Medical Devices in Electronic Format - Submissions Under Section 745A(b) of the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-medical-devices-electronic-format-submissions-under-section-745ab,https://www.fda.gov/media/131064/download,2020-07-15,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Electronic Submissions'],Final,FDA-2019-D-3769,No,
CPG Sec 540.750 - Use of The Seafood List to Determine Acceptable Seafood Names,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540750-use-seafood-list-determine-acceptable-seafood-names,https://www.fda.gov/media/139978/download,2020-07-13,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Seafood/Seafood Product']",Final,FDA-2016-D-3004,No,
Cancer Clinical Trial Eligibility Criteria: Brain Metastases,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-brain-metastases,https://www.fda.gov/media/121317/download,2020-07-10,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Clinical - Medical'],Final,FDA-2019-D-0357,No,
Cancer Clinical Trial Eligibility Criteria: Minimum Age Considerations for Inclusion of Pediatric Patients,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-minimum-age-considerations-inclusion-pediatric-patients,https://www.fda.gov/media/121318/download,2020-07-10,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Clinical - Medical','Pediatric Product Development']",Final,FDA-2019-D-0358,No,
"Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-patients-hiv-hepatitis-b-virus-or-hepatitis-c-virus,https://www.fda.gov/media/121319/download,2020-07-10,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Clinical - Medical'],Final,FDA-2019-D-0363,No,
Cancer Clinical Trial Eligibility Criteria: Patients with Organ Dysfunction or Prior or Concurrent Malignancies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-patients-organ-dysfunction-or-prior-or-concurrent,https://www.fda.gov/media/123745/download,2020-07-10,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Clinical - Medical'],Final,FDA-2019-D-0359,No,
Review and Update of Device Establishment Inspection Processes and Standards:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/review-and-update-device-establishment-inspection-processes-and-standards,https://www.fda.gov/media/139466/download,2020-06-29,"['Office of Inspections and Investigations','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Administrative / Procedural'],Final,FDA-2019-D-0914,No,2020-06-26
CVM GFI #240 Proprietary Names for New Animal Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-240-proprietary-names-new-animal-drugs,https://www.fda.gov/media/111947/download,2020-06-01,['Center for Veterinary Medicine'],"['Administrative / Procedural','Advertising','Labeling','New Animal Drug Application (NADA)']",Final,FDA-2018-D-0626,No,2018-05-11
Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During a Pandemic,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-adverse-event-reporting-medical-products-and-dietary-supplements-during-pandemic,https://www.fda.gov/media/72498/download,2020-05-11,"['Human Foods Program','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research']","['Safety - Issues, Errors, and Problems']",Final,FDA-2008-D-0610,No,
Classification of Posterior Cervical Screw Systems: Small Entity Compliance Guide:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/classification-posterior-cervical-screw-systems-small-entity-compliance-guide,https://www.fda.gov/media/137500/download,2020-05-04,['Center for Devices and Radiological Health'],"['Orthopedic','Premarket Approval (PMA)']",Final,FDA-2015-N-3785,No,
Enforcement Priorities for Electronic Nicotine Delivery System (ENDS) and Other Deemed Products on the Market Without Premarket Authorization:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market,https://www.fda.gov/media/133880/download,2020-04-29,['Center for Tobacco Products'],"['Electronic Nicotine Delivery Systems (ENDS)','Product Application and Review']",Final,FDA-2019-D-0661,No,2019-04-15
eCopy Program for Medical Device Submissions:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ecopy-program-medical-device-submissions,https://www.fda.gov/media/83522/download,2020-04-27,['Center for Devices and Radiological Health'],"['Premarket','User Fees','Administrative / Procedural','Investigational Device Exemption (IDE)']",Final,FDA-2018-N-0628,No,
Nonbinding Feedback After Certain FDA Inspections of Device Establishments:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonbinding-feedback-after-certain-fda-inspections-device-establishments,https://www.fda.gov/media/120260/download,2020-04-22,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Postmarket'],Final,FDA-2018-D-4711,No,2019-04-20
"Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted under a BLA, NDA or ANDA: Draft Guidance for Industry and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-considerations-demonstrating-reliability-emergency-use-injectors-submitted-under-bla-nda,https://www.fda.gov/media/137158/download,2020-04-21,"['Office of the Commissioner','Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']",['Combination Products'],Draft,FDA-2019-D-5573,No,2020-06-22
CVM GFI #259 (VICH GL58) Stability Testing of New Veterinary Drug Substances and Medicinal Products in Climatic Zones III and IV,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-259-vich-gl58-stability-testing-new-veterinary-drug-substances-and-medicinal-products,https://www.fda.gov/media/119840/download,2020-04-14,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)','VICH']",Final,FDA-2018-D-4662,No,2019-02-26
Developing and Labeling In vitro Companion Diagnostic Devices for a Specific Group of Oncology Therapeutic Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-and-labeling-in-vitro-companion-diagnostic-devices-specific-group-oncology-therapeutic,https://www.fda.gov/media/120340/download,2020-04-13,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research']","['Premarket','Labeling']",Final,FDA-2018-D-3380,No,2019-02-05
Fees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the FD&C Act,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fees-human-drug-compounding-outsourcing-facilities-under-sections-503b-and-744k-fdc-act,https://www.fda.gov/media/136683/download,2020-04-03,['Center for Drug Evaluation and Research'],"['User Fees','Compounding']",Final,FDA-2014-D-0329,No,
Center for Devices and Radiological Health (CDRH) Appeals Processes: Questions and Answers About 517A:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/center-devices-and-radiological-health-cdrh-appeals-processes-questions-and-answers-about-517a,https://www.fda.gov/media/128447/download,2020-03-27,['Center for Devices and Radiological Health'],"['510(k)','Premarket Approval (PMA)','Administrative / Procedural']",Final,FDA-2013-D-0501,No,
CPG Section 110.800 Post Detention Sampling Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-section-110800-post-detention-sampling-guidance-industry,https://www.fda.gov/media/137109/download,2020-03-24,['Office of Inspections and Investigations'],['Investigation & Enforcement'],Final,,No,
Restricted Delivery Systems: Flow Restrictors for Oral Liquid Drug Products Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/restricted-delivery-systems-flow-restrictors-oral-liquid-drug-products-guidance-industry,https://www.fda.gov/media/136170/download,2020-03-17,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']",['Device & Drug Safety'],Draft,FDA-2020-D-0567,No,2020-05-18
Biological Product Deviation Reporting for Blood and Plasma Establishments:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biological-product-deviation-reporting-blood-and-plasma-establishments,https://www.fda.gov/media/70694/download,2020-03-12,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2001-D-0007,No,
Type 2 Diabetes Mellitus: Evaluating the Safety of New Drugs for Improving Glycemic Control Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/type-2-diabetes-mellitus-evaluating-safety-new-drugs-improving-glycemic-control-guidance-industry,https://www.fda.gov/media/135936/download,2020-03-10,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2019-N-6084,No,2020-06-08
Premarket Notification (510(k)) Submissions for Electrosurgical Devices for General Surgery:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-notification-510k-submissions-electrosurgical-devices-general-surgery,https://www.fda.gov/media/87995/download,2020-03-09,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Clinical - Medical','Good Clinical Practice (GCP)','Labeling','General & Plastic Surgery']",Final,FDA-2014-D-0217,No,
Contact Dermatitis From Topical Drug Products for Cutaneous Application: Human Safety Assessment Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/contact-dermatitis-topical-drug-products-cutaneous-application-human-safety-assessment-guidance,https://www.fda.gov/media/135888/download,2020-03-06,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2020-D-0043,No,2020-05-08
The “Deemed to be a License” Provision of the BPCI Act: Questions and Answers :  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/deemed-be-license-provision-bpci-act-questions-and-answers,https://www.fda.gov/media/135838/download,2020-03-04,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Administrative / Procedural'],Final,FDA-2015-D-4750.,No,
Bone Anchors - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bone-anchors-premarket-notification-510k-submissions,https://www.fda.gov/media/72235/download,2020-03-03,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Orthopedic']",Final,FDA-2016-D-4436,No,
"Product Recalls, Including Removals and Corrections:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-recalls-including-removals-and-corrections,https://www.fda.gov/media/136987/download,2020-03-02,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research','Human Foods Program','Center for Tobacco Products','Center for Veterinary Medicine']",['Recalls'],Final,,No,
CVM GFI #264 Standardized Medicated Feed Assay Limits,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-264-standardized-medicated-feed-assay-limits,https://www.fda.gov/media/135515/download,2020-02-27,['Center for Veterinary Medicine'],"['Animal Feed','Chemistry, Manufacturing, and Controls (CMC)','Current Good Manufacturing Practice (CGMP)','Target Animal – Safety','Target Animal – Effectiveness','Human Food Safety','Investigational New Animal Drug (INAD)']",Draft,FDA-2019-D-5664,No,2020-06-26
Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-clinical-laboratory-improvement-amendments-1988-clia-waiver-applications,https://www.fda.gov/media/109582/download,2020-02-26,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['CLIA (Clinical Laboratory Improvement Amendments)'],Final,FDA-2017-D-5570,No,
Recommendations for Dual 510(k) and CLIA Waiver by Application Studies:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-dual-510k-and-clia-waiver-application-studies,https://www.fda.gov/media/109574/download,2020-02-26,['Center for Devices and Radiological Health'],"['Premarket','Postmarket','CLIA (Clinical Laboratory Improvement Amendments)','510(k)']",Final,FDA-2017-D-5625,No,
Specifications for Preparing and Submitting Electronic ICSRs and ICSR Attachments,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/specifications-preparing-and-submitting-electronic-icsrs-and-icsr-attachments,https://www.fda.gov/media/132096/download,2020-02-14,['Center for Drug Evaluation and Research'],"['Safety - Issues, Errors, and Problems']",Final,None found,No,
Supplemental Draft Guidance for Industry: Mitigation Strategies to Protect Food Against Intentional Adulteration,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supplemental-draft-guidance-industry-mitigation-strategies-protect-food-against-intentional,https://www.fda.gov/media/135122/download,2020-02-13,['Human Foods Program'],,Draft,FDA-2018-D-1398,No,
Biosimilars and Interchangeable Biosimilars:  Licensure for Fewer Than All Conditions of Use for Which the Reference Product Has Been Licensed Guidance for Industry: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biosimilars-and-interchangeable-biosimilars-licensure-fewer-all-conditions-use-which-reference,https://www.fda.gov/media/134932/download,2020-02-07,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Biosimilars'],Draft,FDA-2019-D-5270,No,2020-04-06
Use of Serological Tests to Reduce the Risk of Transfusion-Transmitted Human T-Lymphotropic Virus Types I and II (HTLV-I/II):  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-serological-tests-reduce-risk-transfusion-transmitted-human-t-lymphotropic-virus-types-i-and-ii,https://www.fda.gov/media/124062/download,2020-02-05,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-2018-D-3324,No,
Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Developing Drugs for Treatment Guidance for Industry: Draft Guidance for Industy,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/mucopolysaccharidosis-type-iii-sanfilippo-syndrome-developing-drugs-treatment-guidance-industry,https://www.fda.gov/media/134893/download,2020-02-04,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Clinical - Medical'],Draft,FDA-2019-D-5404,No,2020-05-05
Small Entity Compliance Guide: Revision of the Nutrition and Supplement Facts Labels,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-revision-nutrition-and-supplement-facts-labels,https://www.fda.gov/media/134505/download,2020-02-03,['Human Foods Program'],"['Labeling','Nutrition Label']",Final,FDA-2012-N-1210,No,
Long Term Follow-up After Administration of Human Gene Therapy Products:   Guidance for Industry,,,2020-01-28,[],['Cellular & Gene Therapy'],Final,FDA-2018-D-2173,No,2018-10-10
"Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs):  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemistry-manufacturing-and-control-cmc-information-human-gene-therapy-investigational-new-drug,https://www.fda.gov/media/113760/download,2020-01-28,['Center for Biologics Evaluation and Research'],"['Cellular & Gene Therapy','Gene Therapy']",Final,2008-D-0205,No,2018-10-10
Human Gene Therapy for Hemophilia:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-hemophilia,https://www.fda.gov/media/113799/download,2020-01-28,['Center for Biologics Evaluation and Research'],"['Cellular & Gene Therapy','Gene Therapy']",Final,FDA 2018-D-2238,No,2018-10-18
Human Gene Therapy for Rare Diseases:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-rare-diseases,https://www.fda.gov/media/113807/download,2020-01-28,['Center for Biologics Evaluation and Research'],"['Cellular & Gene Therapy','Gene Therapy','Pediatric Product Development']",Final,FDA-2018-D-2258,No,2018-10-10
Human Gene Therapy for Retinal Disorders:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-retinal-disorders,https://www.fda.gov/media/124641/download,2020-01-28,['Center for Biologics Evaluation and Research'],"['Cellular & Gene Therapy','Gene Therapy','Pediatric Product Development']",Final,FDA-2018-D-2236,No,2018-10-10
Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/testing-retroviral-vector-based-human-gene-therapy-products-replication-competent-retrovirus-during,https://www.fda.gov/media/113790/download,2020-01-28,['Center for Biologics Evaluation and Research'],"['Cellular & Gene Therapy','Gene Therapy']",Final,FDA-1999-D-0081,No,2018-10-10
Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hematologic-malignancies-regulatory-considerations-use-minimal-residual-disease-development-drug-and,https://www.fda.gov/media/134605/download,2020-01-24,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Final,FDA-2018-D-3090,No,
Current Good Manufacturing Practice—Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act Guidance for Industry: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-manufacturing-practice-guidance-human-drug-compounding-outsourcing-facilities-under,https://www.fda.gov/media/88905/download,2020-01-22,['Center for Drug Evaluation and Research'],"['Compounding','Pharmaceutical Quality','Current Good Manufacturing Practice (CGMP)']",Draft,FDA-2014-D-0779,No,2019-02-11
"Guidance for Industry: Serving Sizes of Foods That Can Reasonably Be Consumed At One Eating Occasion, Reference Amounts Customarily Consumed, Serving Size-Related Issues, Dual-Column Labeling, and Miscellaneous Topics",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-serving-sizes-foods-can-reasonably-be-consumed-one-eating-occasion-reference,https://www.fda.gov/media/133699/download,2019-12-30,['Human Foods Program'],"['Labeling','Nutrition Label']",Final,FDA-2018-D-1459,No,
Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/demonstrating-substantial-evidence-effectiveness-human-drug-and-biological-products,https://www.fda.gov/media/133660/download,2019-12-20,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Clinical - Medical'],Draft,FDA-2019-D-4964,No,2020-03-19
Recommended Content and Format of Non-Clinical Bench Performance Testing Information in Premarket Submissions:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommended-content-and-format-non-clinical-bench-performance-testing-information-premarket,https://www.fda.gov/media/113230/download,2019-12-20,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Premarket'],Final,FDA-2018-D-1329,No,
Submitting Study Datasets for Vaccines to the Office of Vaccines Research and Review:  Guidance for Industry; Technical Specifications Document,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-study-datasets-vaccines-office-vaccines-research-and-review,https://www.fda.gov/media/112581/download,2019-12-20,['Center for Biologics Evaluation and Research'],"['Electronic Submissions','Administrative / Procedural']",Final,FDA-2018-D-1216,No,
Considerations for the Development of Dried Plasma Products Intended for Transfusion:   Guidance for Industry,,,2019-12-19,[],"['Blood','Blood Products']",Final,FDA-2018-D-3759,No,2019-01-28
Bridging for Drug-Device and Biologic-Device Combination Products: Draft  Guidance for Industry,,,2019-12-19,[],['Combination Products'],Draft,FDA-2019-D-5585,No,2020-02-18
"Guidance for Industry: Nutrition and Supplement Facts Labels Questions and Answers Related to the Compliance Date, Added Sugars, and Declaration of Quantitative Amounts of Vitamins and Minerals",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-nutrition-and-supplement-facts-labels-questions-and-answers-related-compliance,https://www.fda.gov/media/117402/download,2019-12-16,['Human Foods Program'],"['Labeling','Nutrition Label']",Final,FDA-2016-D-4414,No,
"30-Day Notices, 135-Day Premarket Approval (PMA) Supplements and 75-Day Humanitarian Device Exemption (HDE) Supplements for Manufacturing Method or Process Changes:  Guidance for Industry and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/30-day-notices-135-day-premarket-approval-pma-supplements-and-75-day-humanitarian-device-exemption,https://www.fda.gov/media/72663/download,2019-12-16,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']","['Premarket','Administrative / Procedural','Device & Drug Safety','HUD/HDE','Premarket Approval (PMA)']",Final,FDA-1998-D-0281,No,
Real-Time Premarket Approval Application (PMA) Supplements:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-time-premarket-approval-application-pma-supplements,https://www.fda.gov/media/73126/download,2019-12-16,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','Administrative / Procedural','Device & Drug Safety','Premarket Approval (PMA)']",Final,FDA-2017-D-5971,No,
Acceptance and Filing Reviews for Premarket Approval Applications (PMAs):  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acceptance-and-filing-reviews-premarket-approval-applications-pmas,https://www.fda.gov/media/83408/download,2019-12-16,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','Administrative / Procedural','Premarket Approval (PMA)']",Final,FDA-2012-D-0524,No,
Annual Reports for Approved Premarket Approval Applications (PMA) :  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/annual-reports-approved-premarket-approval-applications-pma,https://www.fda.gov/media/73391/download,2019-12-16,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','Administrative / Procedural','Device & Drug Safety','Premarket Approval (PMA)']",Final,FDA-2006-D-0039,No,
Chapter 2 - Biologics,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chapter-2-biologics,,2019-12-13,['Center for Biologics Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
Development of Locally Applied Corticosteroid Products for the Short-Term Treatment of Symptoms Associated with Internal or External Hemorrhoids Guidance for Industry: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-locally-applied-corticosteroid-products-short-term-treatment-symptoms-associated,https://www.fda.gov/media/133256/download,2019-12-09,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2019-D-4433,No,2020-02-07
Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry,https://www.fda.gov/media/78495/download,2019-12-02,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Biostatistics','Clinical - Medical']",Final,FDA-2018-D-3124,No,
"CPG Sec. 230.150 Blood Donor Classification Statement, Paid or Volunteer Donor",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-230150-blood-donor-classification-statement-paid-or-volunteer-donor,https://www.fda.gov/media/75039/download,2019-12-01,['Office of Regulatory Affairs'],"['Investigation & Enforcement','Blood Products']",Final,,No,
Compliance Policy for Limited Modifications to Certain Marketed Tobacco Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-policy-limited-modifications-certain-marketed-tobacco-products,https://www.fda.gov/media/133009/download,2019-11-26,['Center for Tobacco Products'],['Compliance'],Final,FDA-2019-D-5324,No,
Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-immunogenicity-considerations-biosimilar-and-interchangeable-insulin-products,https://www.fda.gov/media/133014/download,2019-11-25,['Center for Drug Evaluation and Research'],['Biosimilars'],Draft,FDA-2019-D-5255,No,2020-01-28
Transdermal and Topical Delivery Systems - Product Development and Quality Considerations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/transdermal-and-topical-delivery-systems-product-development-and-quality-considerations,https://www.fda.gov/media/132674/download,2019-11-21,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality','Drug Competition Action Plan']",Draft,FDA-2019-D-4447,No,2020-02-19
Smallpox (Variola Virus) Infection: Developing Drugs for Treatment or Prevention Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/smallpox-variola-virus-infection-developing-drugs-treatment-or-prevention-guidance-industry,https://www.fda.gov/media/132623/download,2019-11-18,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2018-D-1835,No,
Drug Master Files Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-master-files-guidance-industry,https://www.fda.gov/media/131861/download,2019-11-15,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Draft,FDA-2019-D-3989,No,2019-12-20
Chronic Hepatitis D Virus Infection: Developing Drugs for Treatment  Guidance for Industry,,,2019-11-01,[],['Clinical - Antimicrobial'],Draft,FDA-2019-D-4042,No,2020-01-01
Type V DMFs for CDER-Led Combination Products Using Device Constituent Parts With Electronics or Software Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/type-v-dmfs-cder-led-combination-products-using-device-constituent-parts-electronics-or-software,https://www.fda.gov/media/132043/download,2019-10-29,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Draft,FDA-2019-D-4258,No,2019-12-30
"Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry: Draft Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-studies-and-clinical-trials-implementation-section-505o3-federal-food-drug-and-0,https://www.fda.gov/media/148646/download,2019-10-25,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Safety - Issues, Errors, and Problems']",Draft,FDA-2009-D-0283,No,
Identification of Manufacturing Establishments in Applications Submitted to CBER and CDER Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/identification-manufacturing-establishments-applications-submitted-cber-and-cder-questions-and,https://www.fda.gov/media/131911/download,2019-10-22,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2017-D-6821,No,
"Prescription Drug User Fee Act Waivers, Reductions, and Refunds for Drug and Biological Products Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prescription-drug-user-fee-act-waivers-reductions-and-refunds-drug-and-biological-products-guidance,https://www.fda.gov/media/131797/download,2019-10-17,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['User Fees'],Final,2019-22690,No,
Investigational In Vitro Diagnostics in Oncology Trials: Streamlined Submission Process for Study Risk Determination Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-in-vitro-diagnostics-oncology-trials-streamlined-submission-process-study-risk,https://www.fda.gov/media/112605/download,2019-10-10,"['Center for Drug Evaluation and Research','Center for Devices and Radiological Health']",['Administrative / Procedural'],Final,FDA-2018-D-0944,No,
"Coronary, Peripheral, and Neurovascular Guidewires - Performance Tests and Recommended Labeling:  Guidance for Industry and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/coronary-peripheral-and-neurovascular-guidewires-performance-tests-and-recommended-labeling,https://www.fda.gov/media/113959/download,2019-10-10,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Cardiovascular','Neurological']",Final,FDA-2018-D-1775,No,
"Intravascular Catheters, Wires, and Delivery Systems with Lubricious Coatings - Labeling Considerations:  Guidance for Industry and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/intravascular-catheters-wires-and-delivery-systems-lubricious-coatings-labeling-considerations,https://www.fda.gov/media/113951/download,2019-10-10,['Center for Devices and Radiological Health'],"['510(k)','Premarket Approval (PMA)','Labeling','Neurological','Cardiovascular']",Final,FDA-2018-D-1788,No,
Investigational Enzyme Replacement Therapy Products:  Nonclinical Assessment:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-enzyme-replacement-therapy-products-nonclinical-assessment,https://www.fda.gov/media/131295/download,2019-10-03,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Final,FDA-2015-D-1246,No,2020-01-02
Further Testing of Donations that are Reactive on a Licensed Donor Screening Test for Antibodies to Hepatitis C Virus:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/further-testing-donations-are-reactive-licensed-donor-screening-test-antibodies-hepatitis-c-virus,https://www.fda.gov/media/116353/download,2019-10-02,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2018-D-3197,No,2018-12-24
Changes to Existing Medical Software Policies Resulting from Section 3060 of the 21st Century Cures Act:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-existing-medical-software-policies-resulting-section-3060-21st-century-cures-act,https://www.fda.gov/media/109622/download,2019-09-27,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Postmarket','Premarket','Digital Health']",Final,FDA-2017-D-6294,No,
General Wellness: Policy for Low Risk Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-wellness-policy-low-risk-devices,https://www.fda.gov/media/90652/download,2019-09-27,['Center for Devices and Radiological Health'],"['Premarket','Digital Health']",Final,FDA-2014-N-1039,No,
Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/amyotrophic-lateral-sclerosis-developing-drugs-treatment-guidance-industry,https://www.fda.gov/media/130964/download,2019-09-24,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-2013-N-0035,No,
Wholesale Distributor Verification Requirement for Saleable Returned Drug Product—Compliance Policy Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/wholesale-distributor-verification-requirement-saleable-returned-drug-product-compliance-policy,https://www.fda.gov/media/143208/download,2019-09-20,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Office of Regulatory Affairs']",['Administrative / Procedural'],Final,FDA-2019-D-4212,No,
Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/endosseous-dental-implants-and-endosseous-dental-implant-abutments-performance-criteria-safety-and,https://www.fda.gov/media/182616/download,2019-09-20,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2018-D-1387,No,
"Citizen Petitions and Petitions for Stay of Action Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/citizen-petitions-and-petitions-stay-action-subject-section-505q-federal-food-drug-and-cosmetic-act,https://www.fda.gov/media/130878/download,2019-09-19,['Center for Drug Evaluation and Research'],"['Administrative / Procedural','Drug Competition Action Plan']",Final,FDA-2009-D-0008,No,
The Abbreviated 510(k) Program:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/abbreviated-510k-program,https://www.fda.gov/media/72646/download,2019-09-13,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','510(k)']",Final,FDA-2019-D-4015,No,
The Special 510(k) Program:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/special-510k-program,https://www.fda.gov/media/116418/download,2019-09-13,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','510(k)','Administrative / Procedural']",Final,FDA-2018-D-3304,No,
Humanitarian Device Exemption (HDE) Program:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/humanitarian-device-exemption-hde-program,https://www.fda.gov/media/74307/download,2019-09-06,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','Good Clinical Practice (GCP)','HUD/HDE','Premarket Approval (PMA)']",Final,FDA-2014-D-0223,No,
Humanitarian Use Device (HUD) Designations :  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/humanitarian-use-device-hud-designations,https://www.fda.gov/media/130442/download,2019-09-05,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']","['Premarket','Good Clinical Practice (GCP)']",Final,FDA-2014-D-0223,No,
Evaluation of Internal Standard Responses During Chromatographic Bioanalysis: Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-internal-standard-responses-during-chromatographic-bioanalysis-questions-and-answers,https://www.fda.gov/media/130451/download,2019-09-04,['Center for Drug Evaluation and Research'],['Biopharmaceutics'],Final,FDA-2009-D-0008,No,
Guidance for Industry: Policy Related to Cranberry Products with Added Flavorings,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-policy-related-cranberry-products-added-flavorings,https://www.fda.gov/media/130373/download,2019-08-30,['Human Foods Program'],"['Labeling','Nutrition Label']",Final,FDA-2018-D-0075,No,
"Consideration of Uncertainty in Making Benefit-Risk Determinations in Medical Device Premarket Approvals, De Novo Classifications, and Humanitarian Device Exemptions:  Guidance for Industry and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/consideration-uncertainty-making-benefit-risk-determinations-medical-device-premarket-approvals-de,https://www.fda.gov/media/115672/download,2019-08-30,['Center for Devices and Radiological Health'],"['Postmarket','Premarket Approval (PMA)','HUD/HDE']",Final,FDA-2018-D-3130,No,
Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/factors-consider-when-making-benefit-risk-determinations-medical-device-premarket-approval-and-de,https://www.fda.gov/media/99769/download,2019-08-30,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','Premarket Approval (PMA)']",Final,FDA-2011-D-0577,No,
Placebos and Blinding in Randomized Controlled Cancer Clinical Trials for Drug and Biological Products Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/placebos-and-blinding-randomized-controlled-cancer-clinical-trials-drug-and-biological-products,https://www.fda.gov/media/130326/download,2019-08-29,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Final,FDA-2018-D-3092,No,
CVM GFI #257 (VICH GL57) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Species: Marker Residue Depletion Studies to Establish Product Withdrawal Periods in Aquatic Species,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-257-vich-gl57-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food,https://www.fda.gov/media/114760/download,2019-08-19,['Center for Veterinary Medicine'],"['Human Food Safety','VICH','Minor Use/ Minor Species (MUMS)']",Final,FDA-2018-D-2354,No,2018-09-24
"Guidance for Industry: Converting Units of Measure for Folate, Niacin, and Vitamins A, D, and E on the Nutrition and Supplement Facts Labels",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-converting-units-measure-folate-niacin-and-vitamins-d-and-e-nutrition-and,https://www.fda.gov/media/129863/download,2019-08-15,['Human Foods Program'],"['Labeling','Nutrition Label']",Final,FDA-2016-D-4484,No,
Osteoporosis:  Nonclinical Evaluation of Drugs Intended for Treatment Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/osteoporosis-nonclinical-evaluation-drugs-intended-treatment-guidance-industry,https://www.fda.gov/media/129899/download,2019-08-15,['Center for Drug Evaluation and Research'],"['Clinical - Medical','Pharmacology/Toxicology']",Final,FDA-2016-D-1273,No,
Child-Resistant Packaging Statements in Drug Product Labeling Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/child-resistant-packaging-statements-drug-product-labeling-guidance-industry,https://www.fda.gov/media/129881/download,2019-08-13,['Center for Drug Evaluation and Research'],['Labeling'],Final,FDA-2017-D-2163,No,
Gastroparesis: Clinical Evaluation of Drugs for Treatment Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/gastroparesis-clinical-evaluation-drugs-treatment-guidance-industry,https://www.fda.gov/media/129880/download,2019-08-13,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2015-D-2479,No,2019-10-14
Fabry Disease: Developing Drugs for Treatment Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fabry-disease-developing-drugs-treatment-guidance-industry,https://www.fda.gov/media/129690/download,2019-08-07,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2019-D-2973,No,2019-11-06
Oncology Therapeutic Radiopharmaceuticals: Nonclinical Studies and Labeling Recommendations Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/oncology-therapeutic-radiopharmaceuticals-nonclinical-studies-and-labeling-recommendations-guidance,https://www.fda.gov/media/129547/download,2019-08-02,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Final,FDA-2018-D-1772,No,
Bacterial Vaginosis: Developing Drugs for Treatment Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bacterial-vaginosis-developing-drugs-treatment-guidance-industry,https://www.fda.gov/media/129530/download,2019-08-01,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2016-D-1659,No,
Uncomplicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/uncomplicated-urinary-tract-infections-developing-drugs-treatment-guidance-industry,https://www.fda.gov/media/129531/download,2019-08-01,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2018-D-1562,No,
Vulvovaginal Candidiasis:  Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/vulvovaginal-candidiasis-developing-drugs-treatment,https://www.fda.gov/media/129537/download,2019-08-01,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2016-D-1662,No,
Rare Pediatric Disease Priority Review Vouchers: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-pediatric-disease-priority-review-vouchers,https://www.fda.gov/media/90014/download,2019-07-30,"['Center for Biologics Evaluation and Research','Office of the Commissioner']","['Rare Diseases','Administrative / Procedural','Pediatric Product Development']",Draft,FDA-2014-D-1461,No,2019-09-28
Delayed Graft Function in Kidney Transplantation: Developing Drugs for Prevention Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/delayed-graft-function-kidney-transplantation-developing-drugs-prevention-guidance-industry,https://www.fda.gov/media/129320/download,2019-07-29,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Clinical - Medical'],Final,FDA-2017-D-0198,No,
Metal Expandable Biliary Stents - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/metal-expandable-biliary-stents-premarket-notification-510k-submissions,https://www.fda.gov/media/72693/download,2019-07-26,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Gastroenterology-Urology']",Final,FDA-2018-D-1771,No,
Providing Regulatory Submissions in Electronic Format--Submission of Manufacturing Establishment Information Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-submission-manufacturing-establishment,,2019-07-23,['Center for Drug Evaluation and Research'],,Draft,,No,
CVM GFI #181 Blue Bird Medicated Feed Labels,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-181-blue-bird-medicated-feed-labels,https://www.fda.gov/media/70452/download,2019-07-23,['Center for Veterinary Medicine'],"['Animal Feed','Labeling']",Final,FDA-2008-D-0165,No,
Postmarketing Safety Reporting for Combination Products:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-safety-reporting-combination-products,https://www.fda.gov/media/111788/download,2019-07-22,"['Office of the Commissioner','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Combination Products'],Final,FDA-2008-N-0424,No,2018-06-19
Submitting Next Generation Sequencing Data to the Division of Antiviral Products Guidance for Industry Technical Specifications Document,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-next-generation-sequencing-data-division-antiviral-products-guidance-industry-technical,https://www.fda.gov/media/129126/download,2019-07-18,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']",['Clinical - Antimicrobial'],Final,FDA-2017-D-6821,No,
Establishing Effectiveness and Safety for Hormonal Drug Products Intended to Prevent Pregnancy Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/establishing-effectiveness-and-safety-hormonal-drug-products-intended-prevent-pregnancy-guidance,https://www.fda.gov/media/128792/download,2019-07-12,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2019-D-2153,No,2019-09-11
Using the Inactive Ingredient Database Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/using-inactive-ingredient-database-guidance-industry,https://www.fda.gov/media/128687/download,2019-07-11,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Drug Competition Action Plan','Pharmaceutical Quality']",Draft,FDA-2019-D-2397,No,2019-10-09
"Live Case Presentations During Investigational Device Exemption (IDE) Clinical Trials:  Guidance for Institutional Review Boards, Industry, Clinical Investigators, and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/live-case-presentations-during-investigational-device-exemption-ide-clinical-trials,https://www.fda.gov/media/88454/download,2019-07-11,['Center for Devices and Radiological Health'],"['Premarket','Good Clinical Practice (GCP)','Pediatric Product Development','Investigational Device Exemption (IDE)']",Final,FDA-2014-D-0331,No,
Harmonizing Compendial Standards With Drug Application Approval Using the USP Pending Monograph Process Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/harmonizing-compendial-standards-drug-application-approval-using-usp-pending-monograph-process,https://www.fda.gov/media/128689/download,2019-07-10,"['Center for Drug Evaluation and Research','Center for Veterinary Medicine']","['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality','Drug Competition Action Plan']",Draft,FDA-2019-D-1768,No,2019-09-10
Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/risk-evaluation-and-mitigation-strategies-modifications-and-revisions-guidance-industry,https://www.fda.gov/media/128651/download,2019-07-09,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Device & Drug Safety'],Final,FDA-2014-D-1747,No,
Compliance Policy for Certain Compounding of Oral Oxitriptan (5-HTP) Drug Products for Patients With Tetrahydrobiopterin (BH4) Deficiency Immediately in Effect Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-policy-certain-compounding-oral-oxitriptan-5-htp-drug-products-patients,https://www.fda.gov/media/128603/download,2019-07-08,['Center for Drug Evaluation and Research'],['Compounding'],Final,FDA-2019-D-2733,No,
Drug Abuse and Dependence Section of Labeling for Human Prescription Drug and Biological Products —  Content and Format   Guidance for Industry,,,2019-07-01,[],['Labeling'],Draft,FDA-2019-D-1917,No,2019-09-02
Epidermolysis Bullosa:  Developing Drugs for Treatment of Cutaneous Manifestations; Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/epidermolysis-bullosa-developing-drugs-treatment-cutaneous-manifestations-guidance-industry,https://www.fda.gov/media/128419/download,2019-06-28,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Final,FDA-2018-D-2016,No,
Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/treatment-heart-failure-endpoints-drug-development-guidance-industry,https://www.fda.gov/media/128372/download,2019-06-28,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Clinical - Medical'],Draft,FDA-2019-D-2314,No,2019-08-27
E19 OPTIMISATION OF SAFETY DATA COLLECTION,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e19-optimisation-safety-data-collection,https://www.fda.gov/media/128313/download,2019-06-27,['Center for Drug Evaluation and Research'],['ICH-Efficacy'],Draft,FDA-2019-D-1828,No,2019-08-26
M10 BIOANALYTICAL METHOD VALIDATION,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m10-bioanalytical-method-validation-and-study-sample-analysis,https://www.fda.gov/media/162903/download,2019-06-26,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Clinical - Medical','ICH-Multidisciplinary']",Draft,FDA-2019-D-1469,No,2019-08-26
Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/opioid-analgesic-drugs-considerations-benefit-risk-assessment-framework-guidance-industry,https://www.fda.gov/media/128150/download,2019-06-20,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2019-D-1536,No,2019-08-20
ANDA Submissions — Content and Format of Abbreviated New Drug Applications:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/anda-submissions-content-and-format-abbreviated-new-drug-applications,https://www.fda.gov/media/128127/download,2019-06-20,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['User Fees','Generic Drugs']",Final,FDA-2014-D-0725,No,
Guidance for Industry: Determining the Number of Employees for Purposes of the “Small Business” Definition in Parts 117 and 507,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-determining-number-employees-purposes-small-business-definition-parts-117-and-507,https://www.fda.gov/media/111951/download,2019-06-19,"['Center for Veterinary Medicine','Human Foods Program']",,Final,FDA-2018-D-0671,No,
"Guidance for Industry: Declaration of Added Sugars on Honey, Maple Syrup, Other Single-Ingredient Sugars and Syrups, and Certain Cranberry Products",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-declaration-added-sugars-honey-maple-syrup-other-single-ingredient-sugars-and,https://www.fda.gov/media/127928/download,2019-06-18,['Human Foods Program'],"['Labeling','Nutrition Label']",Final,FDA-2018-D-0075,No,
Nonalcoholic Steatohepatitis with Compensated Cirrhosis: Developing Drugs for Treatment Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonalcoholic-steatohepatitis-compensated-cirrhosis-developing-drugs-treatment-guidance-industry,https://www.fda.gov/media/127738/download,2019-06-07,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2019-D-1516,No,2019-08-06
"Draft Guidance for Industry: Evaluating Alternate Curricula for the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-evaluating-alternate-curricula-standards-growing-harvesting-packing-and,https://www.fda.gov/media/126868/download,2019-06-03,['Human Foods Program'],['Produce'],Draft,FDA-2019-D-2131,No,2019-10-02
CPG Sec. 651.100  Ethylenediamine Dihydroiodide (EDDI),,,2019-06-01,[],"['Investigation & Enforcement','Animal Drugs']",Final,FDA-2021-D-0628,No,
Formal Dispute Resolution: Sponsor Appeals Above the Division Level Guidance for Industry and Review Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formal-dispute-resolution-sponsor-appeals-above-division-level-guidance-industry-and-review-staff,https://www.fda.gov/media/126910/download,2019-05-30,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Administrative / Procedural'],Final,FDA-2013-D-0221,No,
Section 503A Bulks List Final Rule Questions and Answers; Small Entity Compliance Guide;:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/section-503a-bulks-list-final-rule-questions-and-answers-small-entity-compliance-guide,https://www.fda.gov/media/126110/download,2019-05-24,['Center for Drug Evaluation and Research'],"['Administrative / Procedural','Compounding']",Final,FDA-2019-D-2011,No,
Development of Therapeutic Protein Biosimilars:  Comparative Analytical Assessment and Other Quality-Related Considerations   Guidance for Industry,,,2019-05-22,[],['Biosimilars'],Draft,FDA-2019-D-2102,No,
Considerations in Demonstrating Interchangeability With a Reference Product Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-demonstrating-interchangeability-reference-product-guidance-industry,https://www.fda.gov/media/124907/download,2019-05-14,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Biosimilars'],Final,FDA-2017-D-0154,No,
Determining Whether to Submit an ANDA or a 505(b)(2) Application,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/determining-whether-submit-anda-or-505b2-application,https://www.fda.gov/media/124848/download,2019-05-10,['Center for Drug Evaluation and Research'],"['Drug Competition Action Plan','Generic Drugs']",Final,FDA-2017-D-5974,No,
Maximal Usage Trials for Topically Applied Active Ingredients Being Considered for Inclusion in an Over-The-Counter Monograph: Study Elements and Considerations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/maximal-usage-trials-topically-applied-active-ingredients-being-considered-inclusion-over-counter,https://www.fda.gov/media/125080/download,2019-05-10,['Center for Drug Evaluation and Research'],"['Clinical - Pharmacology','Pediatric Product Development','Over-the-Counter Drugs']",Final,FDA-2018-D-1456,No,
Oncology Pharmaceuticals: Reproductive Toxicity Testing and Labeling Recommendations Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/oncology-pharmaceuticals-reproductive-toxicity-testing-and-labeling-recommendations-guidance,https://www.fda.gov/media/124829/download,2019-05-10,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Final,FDA-2017-D-2165,No,
Clinical Lactation Studies: Considerations for Study Design,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-lactation-studies-considerations-study-design,https://www.fda.gov/media/124749/download,2019-05-09,['Center for Drug Evaluation and Research'],"['Clinical - Medical','Clinical - Pharmacology']",Draft,FDA-2018-D-4525.,No,
Postapproval Pregnancy Safety Studies Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postapproval-pregnancy-safety-studies-guidance-industry,https://www.fda.gov/media/124746/download,2019-05-09,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Draft,FDA-2018-D-4693,No,2019-07-08
Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-reducing-risk-transfusion-transmitted-babesiosis,https://www.fda.gov/media/114847/download,2019-05-09,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2018-D-2478,No,
Guidance for Industry: Preparation of Food Contact Notifications for Food Contact Substances in Contact with Infant Formula and/or Human Milk,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-preparation-food-contact-notifications-food-contact-substances-contact-infant,https://www.fda.gov/media/124714/download,2019-05-08,['Human Foods Program'],"['Milk/Milk Product','Food & Color Additives','Infant Formula & Foods']",Final,FDA-2016-D-1814,No,
Classification and Requirements for Laser Illuminated Projectors (LIPs) (Laser Notice No. 57):  Guidance for Industry and Food and Drug Administration,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/classification-and-requirements-laser-illuminated-projectors-lips-laser-notice-no-57,https://www.fda.gov/media/90796/download,2019-05-08,['Center for Devices and Radiological Health'],['Radiological Health'],Final,FDA-2014-D-2245,No,
Policy Clarification for Certain Fluoroscopic Equipment Requirements:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-clarification-certain-fluoroscopic-equipment-requirements,https://www.fda.gov/media/89919/download,2019-05-08,['Center for Devices and Radiological Health'],['Radiological Health'],Final,FDA-2014-D-1344,No,
Utilizing Animal Studies to Evaluate Organ Preservation Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/utilizing-animal-studies-evaluate-organ-preservation-devices,https://www.fda.gov/media/107701/download,2019-05-08,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Gastroenterology-Urology']",Final,FDA-2017-D-4886,No,
Attention Deficit Hyperactivity Disorder: Developing Stimulant Drugs for Treatment Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/attention-deficit-hyperactivity-disorder-developing-stimulant-drugs-treatment-guidance-industry,https://www.fda.gov/media/124334/download,2019-05-06,['Center for Drug Evaluation and Research'],"['Clinical - Medical','Pediatric Product Development','Over-the-Counter Drugs']",Draft,FDA-2019-D-0849,No,2019-07-03
Characterization of Ultrahigh Molecular Weight Polyethylene (UHMWPE) Used in Orthopedic Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/characterization-ultrahigh-molecular-weight-polyethylene-uhmwpe-used-orthopedic-devices,https://www.fda.gov/media/95791/download,2019-04-26,['Center for Devices and Radiological Health'],"['510(k)','Premarket Approval (PMA)','Investigational Device Exemption (IDE)','Orthopedic']",Final,FDA-2016-D-0363,No,2016-05-12
Unique Device Identification: Convenience Kits :  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/unique-device-identification-convenience-kits,https://www.fda.gov/media/95120/download,2019-04-26,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']","['Labeling','UDI']",Final,FDA-2015-D-4048,No,2016-04-05
Extending Expiration Dates of Doxycycline Tablets and Capsules in Strategic Stockpiles :  Guidance for Government Public Health and Emergency Response Stakeholders,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/extending-expiration-dates-doxycycline-tablets-and-capsules-strategic-stockpiles,https://www.fda.gov/media/123805/download,2019-04-24,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,2019-08349,No,
Compliance Policy for Combination Product Postmarketing Safety Reporting:  Immediately in Effect Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-policy-combination-product-postmarketing-safety-reporting,https://www.fda.gov/media/111795/download,2019-04-20,"['Office of the Commissioner','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Combination Products'],Final,FDA-2008-N-0424,No,
REMS: FDA’s Application of Statutory Factors in Determining When a REMS Is Necessary Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rems-fdas-application-statutory-factors-determining-when-rems-necessary-guidance-industry,https://www.fda.gov/media/100307/download,2019-04-04,['Center for Drug Evaluation and Research'],,Final,2019-06663,No,
FDA’s Application of Statutory Factors in Determining When a REMS Is Necessary,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rems-fdas-application-statutory-factors-determining-when-rems-necessary-guidance-industry,https://www.fda.gov/media/100307/download,2019-04-04,['Center for Drug Evaluation and Research'],"['Safety - Issues, Errors, and Problems']",Final,FDA-2016-D-2730,No,
Pediatric Information Incorporated Into Human Prescription Drug and Biological Products Labeling Good Review Practice,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-information-incorporated-human-prescription-drug-and-biological-products-labeling-good,https://www.fda.gov/media/84949/download,2019-03-28,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Labeling','Pediatric Product Development']",Final,FDA-2013-D-0169,No,
"Guidance for Industry: Enforcement Policy for Entities Growing, Harvesting, Packing, or Holding Hops, Wine Grapes, Pulse Crops, and Almonds",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-enforcement-policy-entities-growing-harvesting-packing-or-holding-hops-wine-grapes,https://www.fda.gov/media/122904/download,2019-03-27,['Human Foods Program'],,Final,FDA-2019-D-1266,No,
Standards Development and the Use of Standards in Regulatory Submissions Reviewed in the Center for Biologics Evaluation and Research:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/standards-development-and-use-standards-regulatory-submissions-reviewed-center-biologics-evaluation,https://www.fda.gov/media/124694/download,2019-03-25,['Center for Biologics Evaluation and Research'],"['Compliance','Administrative / Procedural']",Final,FDA-2017-D-6535,No,
Rare Diseases: Natural History Studies for Drug Development: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-diseases-natural-history-studies-drug-development,https://www.fda.gov/media/122425/download,2019-03-25,"['Office of the Commissioner','Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Diseases & Conditions','Rare Diseases']",Draft,FDA-2019-D-0481,No,2019-05-24
Pediatric HIV Infection: Drug Development for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-hiv-infection-drug-development-treatment,https://www.fda.gov/media/113319/download,2019-03-20,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Clinical - Medical','Pediatric Product Development']",Final,FDA-2018-D-1638,No,
Human Immunodeficiency Virus-1 Infection:  Developing Systemic Drug Products for Pre-Exposure Prophylaxis,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-immunodeficiency-virus-1-infection-developing-systemic-drug-products-pre-exposure-prophylaxis,https://www.fda.gov/media/113940/download,2019-03-18,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2018-D-1918,No,
Severely Debilitating or Life-Threatening Hematologic Disorders: Nonclinical Development of Pharmaceuticals Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/severely-debilitating-or-life-threatening-hematologic-disorders-nonclinical-development,https://www.fda.gov/media/112750/download,2019-03-15,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Final,FDA-2018-D-1328,No,
Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enrichment-strategies-clinical-trials-support-approval-human-drugs-and-biological-products,https://www.fda.gov/media/121320/download,2019-03-15,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Clinical - Medical','Good Clinical Practice (GCP)']",Final,FDA-2012-D-1145,No,
Medical Devices Containing Materials Derived from Animal Sources (Except for In Vitro Diagnostic Devices):  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-devices-containing-materials-derived-animal-sources-except-in-vitro-diagnostic-devices,https://www.fda.gov/media/87251/download,2019-03-15,['Center for Devices and Radiological Health'],"['Premarket','Laboratory Tests']",Final,FDA-2013-D-1574,No,
Considerations for the Inclusion of Adolescent Patients in Adult Oncology Clinical Trials,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-inclusion-adolescent-patients-adult-oncology-clinical-trials,https://www.fda.gov/media/113499/download,2019-03-13,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Office of the Commissioner']","['Clinical - Medical','Pediatric Product Development']",Final,FDA-2018-D-1540,No,
"Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-bulk-drug-substances-nominated-use-compounding-under-section-503b-federal-food-drug-and,https://www.fda.gov/media/121315/download,2019-03-13,['Center for Drug Evaluation and Research'],['Compounding'],Final,FDA-2018-D-1067,No,
Guidance for Industry: Voluntary Labeling Indicating Whether Foods Have or Have Not Been Derived from Genetically Engineered Plants,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-voluntary-labeling-indicating-whether-foods-have-or-have-not-been-derived,https://www.fda.gov/media/120958/download,2019-03-11,['Human Foods Program'],"['Bioengineering / GMOs','Labeling']",Final,FDA-2000-D-0075,No,
Draft Guidance for Industry: Voluntary Labeling Indicating Whether Food Has or Has Not Been Derived From Genetically Engineered Atlantic Salmon,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-voluntary-labeling-indicating-whether-food-has-or-has-not-been-derived,https://www.fda.gov/media/120960/download,2019-03-11,"['Center for Veterinary Medicine','Human Foods Program']","['Bioengineering / GMOs','Labeling']",Draft,FDA-2015-D-4272,No,2016-01-25
Nonproprietary Naming of Biological Products: Update Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonproprietary-naming-biological-products-update-guidance-industry,https://www.fda.gov/media/121316/download,2019-03-08,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Labeling'],Draft,FDA-2013-D-1543,No,2019-05-07
Draft Guidance for Industry: Mitigation Strategies to Protect Food Against Intentional Adulteration,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supplemental-draft-guidance-industry-mitigation-strategies-protect-food-against-intentional,https://www.fda.gov/media/135122/download,2019-03-06,['Human Foods Program'],,Draft,FDA-2018-D-1398,No,2020-08-14
CPG Sec. 608.200  Prescription Use of Certain Injectable Animal Drugs,,,2019-03-01,[],"['Investigation & Enforcement','Animal Drugs']",Final,,No,
CPG Sec. 635.100  Large Volume Parenterals (LVPs) for Animal Use,,,2019-03-01,[],"['Investigation & Enforcement','Animal Drugs']",Final,,No,
CPG Sec. 653.100  Animal Grooming Aids,,,2019-03-01,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 665.300 Use of Type A Medicated Article Proprietary Names in the Names of Medicated Feeds,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-665300-use-type-medicated-article-proprietary-names-names-medicated-feeds,https://www.fda.gov/media/121190/download,2019-03-01,"['Center for Veterinary Medicine','Office of Regulatory Affairs']","['Investigation & Enforcement','Labeling','Medicated Feed']",Final,,No,
CPG Sec. 666.100  Alternate Feeding of Different Medicated Feeds,,,2019-03-01,[],"['Investigation & Enforcement','Medicated Feed']",Final,,No,
CPG Sec. 683.100  Action Levels for Aflatoxins in Animal Feeds,,,2019-03-01,[],"['Investigation & Enforcement','Animal Feed']",Final,,No,
Release of ORA Laboratory Analytical Results to the Responsible Party:  Guidance for Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/release-ora-laboratory-analytical-results-responsible-party,https://www.fda.gov/media/123137/download,2019-03-01,"['Center for Veterinary Medicine','Human Foods Program','Office of Inspections and Investigations','Center for Devices and Radiological Health','Center for Tobacco Products']","['Investigation & Enforcement','Administrative / Procedural']",Final,FDA-2019-D-1163,No,
Enforcement Policy for Certain Marketed Tobacco Products: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-certain-marketed-tobacco-products,https://www.fda.gov/media/120808/download,2019-02-28,['Center for Tobacco Products'],,Draft,FDA-2018-D-3244,No,2019-04-30
Providing Lot Release Protocol Submissions to the Center for Biologics Evaluation and Research (CBER) in Electronic Format:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-lot-release-protocol-submissions-center-biologics-evaluation-and-research-cber-electronic,https://www.fda.gov/media/120438/download,2019-02-22,['Center for Biologics Evaluation and Research'],"['Premarket','Administrative / Procedural']",Final,FDA-1998-D-0095,No,
Use of Investigational Tobacco Products: Draft Guidance for Industry and Investigators,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-investigational-tobacco-products,https://www.fda.gov/media/94052/download,2019-02-20,['Center for Tobacco Products'],,Draft,FDA-2014-D-1939,No,2019-04-21
Evaluation of Devices Used with Regenerative Medicine Advanced Therapies:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-devices-used-regenerative-medicine-advanced-therapies,https://www.fda.gov/media/120266/download,2019-02-15,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Office of the Commissioner']","['Combination Products','Gene Therapy']",Final,FDA-2017-D-6154,No,2018-02-15
Expedited Programs for Regenerative Medicine Therapies for Serious Conditions:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-regenerative-medicine-therapies-serious-conditions,https://www.fda.gov/media/120267/download,2019-02-15,['Center for Biologics Evaluation and Research'],"['Cellular & Gene Therapy','Gene Therapy']",Final,FDA-2017-D-6159,No,2018-02-15
"Public Warning-Notification of Recalls Under 21 CFR Part 7, Subpart C :  Guidance for Industry and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/public-warning-notification-recalls-under-21-cfr-part-7-subpart-c,https://www.fda.gov/media/110457/download,2019-02-08,"['Office of Regulatory Affairs','Center for Veterinary Medicine','Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Tobacco Products']","['Recalls','Investigation & Enforcement']",Final,FDA-2016-D-3548,No,2020-02-08
Intent to Exempt Certain Unclassified Medical Devices from Premarket Notification Requirements:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/intent-exempt-certain-unclassified-medical-devices-premarket-notification-requirements,https://www.fda.gov/media/89238/download,2019-02-08,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Anesthesiology','Physical Medicine','Orthopedic','Ophthalmic','Obstetrical & Gynecological','Neurological','Cardiovascular','General Hospital & Personal Use','General & Plastic Surgery','Gastroenterology-Urology','Ear','Nose & Throat','Dental']",Final,FDA-2014-D-0967,No,
Opioid Use Disorder: Developing Depot Buprenorphine Products for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/opioid-use-disorder-developing-depot-buprenorphine-products-treatment,https://www.fda.gov/media/120090/download,2019-02-07,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-2018-D-1334,No,
The Least Burdensome Provisions: Concept and Principles:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/least-burdensome-provisions-concept-and-principles,https://www.fda.gov/media/73188/download,2019-02-05,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Premarket'],Final,FDA-2017-D-6702,No,
Labeling for Human Prescription Drug and Biological Products Approved Under the Accelerated Approval Regulatory Pathway,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-human-prescription-drug-and-biological-products-approved-under-accelerated-approval,https://www.fda.gov/media/119755/download,2019-02-04,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Labeling'],Final,FDA-2014-D-0250,No,
Immunogenicity Testing of Therapeutic Protein Products —Developing and Validating Assays for Anti-Drug Antibody Detection,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug,https://www.fda.gov/media/119788/download,2019-02-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2009-D-0539,No,
REMS Assessment: Planning and Reporting,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rems-assessment-planning-and-reporting,https://www.fda.gov/media/119790/download,2019-02-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Administrative / Procedural'],Draft,FDA-2018-D-4628,No,2019-04-02
Survey Methodologies to Assess REMS Goals That Relate to Knowledge,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/survey-methodologies-assess-rems-goals-relate-knowledge,https://www.fda.gov/media/119789/download,2019-02-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Administrative / Procedural','Good Clinical Practice (GCP)']",Draft,FDA-2018-D-4629,No,
Coordinated Development of Antimicrobial Drugs and Antimicrobial Susceptibility Test Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/coordinated-development-antimicrobial-drugs-and-antimicrobial-susceptibility-test-devices,https://www.fda.gov/media/124382/download,2019-02-01,['Center for Devices and Radiological Health'],"['IVDs (In Vitro Diagnostic Devices)','Premarket Approval (PMA)','Testing']",Final,FDA-2016-D-2561,No,
Developing and Submitting Proposed Draft Guidance Relating to Patient Experience Data,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-and-submitting-proposed-draft-guidance-relating-patient-experience-data,https://www.fda.gov/media/119542/download,2018-12-21,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Administrative / Procedural','Generic Drugs']",Draft,FDA-2018-D-4455,No,2019-03-21
Labeling of Red Blood Cell Units with Historical Antigen Typing Results:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-red-blood-cell-units-historical-antigen-typing-results,https://www.fda.gov/media/119376/download,2018-12-20,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-2016-D-4308,No,
Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics,https://www.fda.gov/media/71195/download,2018-12-19,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Clinical - Medical'],Final,FDA-2005-D-0225,No,
Manufacturing Site Change Supplements: Content and Submission:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacturing-site-change-supplements-content-and-submission,https://www.fda.gov/media/124387/download,2018-12-17,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']","['Postmarket','Premarket Approval (PMA)']",Final,FDA-2015-N-3454,No,
Data Integrity and Compliance With Drug CGMP: Questions and Answers:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-integrity-and-compliance-drug-cgmp-questions-and-answers,https://www.fda.gov/media/119267/download,2018-12-13,"['Center for Veterinary Medicine','Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,FDA-2018-D-3984,No,
Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition and Innovation Act of 2009 :  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interpretation-deemed-be-license-provision-biologics-price-competition-and-innovation-act-2009,https://www.fda.gov/media/119272/download,2018-12-12,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Administrative / Procedural'],Final,FDA-2015-D-4750,No,
Biomarker Qualification: Evidentiary Framework: Draft Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biomarker-qualification-evidentiary-framework,https://www.fda.gov/media/122319/download,2018-12-12,['Center for Drug Evaluation and Research'],['Drug Development Tools'],Draft,FDA-2018-D-4267,No,2019-02-11
Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/noncirrhotic-nonalcoholic-steatohepatitis-liver-fibrosis-developing-drugs-treatment,https://www.fda.gov/media/119044/download,2018-12-04,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2018-D-3632,No,2019-02-04
Guidance for Industry and FDA: Establishing and Maintaining a List of U.S. Dairy Product Manufacturers/Processors with Interest in Exporting to Chile,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-establishing-and-maintaining-list-us-dairy-product-manufacturersprocessors,https://www.fda.gov/media/118782/download,2018-11-27,['Human Foods Program'],['Export'],Final,FDA-2006-N-0183,No,
"Guidance for Industry: Establishing and Maintaining a List of U.S. Milk and Milk Product, Seafood, Infant Formula, and Formula for Young Children Manufacturers/Processors with Interest in Exporting to China",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-establishing-and-maintaining-list-us-milk-and-milk-product-seafood-infant-formula,https://www.fda.gov/media/87676/download,2018-11-27,['Human Foods Program'],"['Export','Seafood/Seafood Product','Milk/Milk Product','Infant Formula & Foods']",Final,FDA-2016-D-4484,No,
CVM GFI #243 (VICH GL56) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Species: Study Design Recommendations for Residue Studies in Honey for Establishing Maximum Residue Limits and Withdrawal Periods,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-243-vich-gl56-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food,https://www.fda.gov/media/102492/download,2018-11-14,['Center for Veterinary Medicine'],"['Human Food Safety','VICH']",Final,FDA-2016-D-4461,No,2017-03-06
Hypertension: Developing Fixed-Dose Combination Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hypertension-developing-fixed-dose-combination-drugs-treatment,https://www.fda.gov/media/117975/download,2018-11-07,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-2018-D-3860,No,2019-01-26
Meta-Analyses of Randomized Controlled Clinical Trials to Evaluate the Safety of Human Drugs or Biological Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/meta-analyses-randomized-controlled-clinical-trials-evaluate-safety-human-drugs-or-biological,https://www.fda.gov/media/117976/download,2018-11-07,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Clinical - Medical','Device & Drug Safety']",Draft,FDA-2018-D-3710,No,2019-01-07
Guidance for Industry and FDA Staff: Questions and Answers Regarding Mandatory Food Recalls,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-staff-questions-and-answers-regarding-mandatory-food-recalls,https://www.fda.gov/media/117429/download,2018-11-06,"['Center for Veterinary Medicine','Office of Inspections and Investigations','Human Foods Program']",['Recalls'],Final,FDA-2015-D-0138,No,
Testicular Toxicity: Evaluation During Drug Development,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/testicular-toxicity-evaluation-during-drug-development,https://www.fda.gov/media/117948/download,2018-10-25,['Center for Drug Evaluation and Research'],"['Clinical - Medical','Pharmacology/Toxicology']",Final,FDA-2015-D-2306,No,
Draft Guidance for Industry: Guide to Minimize Food Safety Hazards of Fresh-cut Produce,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-guide-minimize-food-safety-hazards-fresh-cut-produce,https://www.fda.gov/media/117526/download,2018-10-22,['Human Foods Program'],"['Fruit/Fruit Product','Vegetable Products']",Draft,FDA-2018-D-3583,No,2019-04-22
"Draft Guidance for Industry: Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-standards-growing-harvesting-packing-and-holding-produce-human-consumption,https://www.fda.gov/media/117414/download,2018-10-22,['Human Foods Program'],"['Fruit/Fruit Product','Vegetable Products']",Draft,FDA-2018-D-3631,No,2019-04-22
Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-targeted-therapies-low-frequency-molecular-subsets-disease,https://www.fda.gov/media/117173/download,2018-10-16,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Pharmacology'],Final,FDA-2017-D-6617,No,
Rare Diseases: Early Drug Development and the Role of Pre-IND Meetings : Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-diseases-early-drug-development-and-role-pre-ind-meetings,https://www.fda.gov/media/117322/download,2018-10-16,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Rare Diseases','Pediatric Product Development']",Draft,FDA-2018-D-3268,No,2018-12-17
"Impact of Certain Provisions of the Revised Common Rule on FDA-Regulated Clinical Investigations:  Guidance for Sponsors, Investigators, and Institutional Review Boards",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/impact-certain-provisions-revised-common-rule-fda-regulated-clinical-investigations,https://www.fda.gov/media/117042/download,2018-10-11,['Office of the Commissioner'],['Good Clinical Practice (GCP)'],Final,FDA-2018-D-3551,No,
Atopic Dermatitis: Timing of Pediatric Studies During Development of Systemic Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/atopic-dermatitis-timing-pediatric-studies-during-development-systemic-drugs,https://www.fda.gov/media/117570/download,2018-10-03,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Clinical - Medical','Pediatric Product Development']",Final,FDA-2018-D-1175,No,
"Selection of the Appropriate Package Type Terms and Recommendations for Labeling Injectable Medical Products Packaged in Multiple-Dose, Single-Dose, and Single-Patient-Use Containers for Human Use:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/selection-appropriate-package-type-terms-and-recommendations-labeling-injectable-medical-products,https://www.fda.gov/media/117883/download,2018-10-03,"['Office of the Commissioner','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Chemistry, Manufacturing, and Controls (CMC)','Combination Products','Pharmaceutical Quality']",Final,FDA-2015-D-3438,No,
Contents of a Complete Submission for Threshold Analyses and Human Factors Submissions to Drug and Biologic Applications,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/contents-complete-submission-threshold-analyses-and-human-factors-submissions-drug-and-biologic,https://www.fda.gov/media/122971/download,2018-10-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Administrative / Procedural'],Draft,FDA-2018-D-3275,No,
Compliance Policy Guides Index,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-policy-guides-index,https://www.fda.gov/media/75894/download,2018-09-28,['Office of Regulatory Affairs'],['Investigation & Enforcement'],Final,,No,
Compounding and Repackaging of Radiopharmaceuticals By Outsourcing Facilities Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compounding-and-repackaging-radiopharmaceuticals-outsourcing-facilities-guidance-industry,https://www.fda.gov/media/102637/download,2018-09-26,['Center for Drug Evaluation and Research'],['Compounding'],Final,FDA-2016-D-4317,No,
Compounding and Repackaging of Radiopharmaceuticals by State-Licensed Nuclear Pharmacies and Federal Facilities Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compounding-and-repackaging-radiopharmaceuticals-state-licensed-nuclear-pharmacies-and-federal,https://www.fda.gov/media/102615/download,2018-09-26,['Center for Drug Evaluation and Research'],['Compounding'],Final,FDA-2016-D-4318,No,
Benefit-Risk Factors to Consider When Determining Substantial Equivalence in Premarket Notifications (510(k)) with Different Technological Characteristics:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/benefit-risk-factors-consider-when-determining-substantial-equivalence-premarket-notifications-510k,https://www.fda.gov/media/89019/download,2018-09-25,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['510(k)'],Final,FDA-2014-D-0900,No,
Good Review Management Principles and Practices for New Drug Applications and Biologics License Applications: Draft Guidance for Industry and Review Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-review-management-principles-and-practices-new-drug-applications-and-biologics-license,https://www.fda.gov/media/72259/download,2018-09-25,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Administrative / Procedural'],Draft,FDA-2018-D-3103,No,2018-11-23
Product Identifier Requirements Under the Drug Supply Chain Security Act – Compliance Policy Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-identifier-requirements-under-drug-supply-chain-security-act-compliance-policy-guidance,https://www.fda.gov/media/106198/download,2018-09-20,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,,No,
Heparin-Containing Medical Devices and Combination Products: Recommendations for Labeling and Safety Testing:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/heparin-containing-medical-devices-and-combination-products-recommendations-labeling-and-safety,https://www.fda.gov/media/93196/download,2018-09-20,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Premarket Approval (PMA)','HUD/HDE','Combination Products']",Final,FDA-2015-D-2167,No,
Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/grandfathering-policy-packages-and-homogenous-cases-product-without-product-identifier,https://www.fda.gov/media/109591/download,2018-09-19,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,,No,
Guía para la industria: Evaluación de la inocuidad de los cultivos alimentarios para el consumo humano afectados por las inundaciones,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guia-para-la-industria-evaluacion-de-la-inocuidad-de-los-cultivos-alimentarios-para-el-consumo,,2018-09-17,['Human Foods Program'],,Final,FDA-2011-D-0733,No,
Guidance for Industry: Determination of Status as a Qualified Facility,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-determination-status-qualified-facility,https://www.fda.gov/media/125438/download,2018-09-17,"['Center for Veterinary Medicine','Human Foods Program']",,Final,FDA-2016-D-1164,No,
Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/appropriate-use-voluntary-consensus-standards-premarket-submissions-medical-devices,https://www.fda.gov/media/71983/download,2018-09-14,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Postmarket','Premarket','Administrative / Procedural']",Final,FDA-2014-D-0456,No,
Postapproval Changes to Drug Substances Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postapproval-changes-drug-substances-guidance-industry,https://www.fda.gov/media/115733/download,2018-09-11,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Center for Veterinary Medicine']","['Chemistry, Manufacturing, and Controls (CMC)']",Draft,FDA-2018-D-3151,No,2018-11-09
Draft Guidance for Industry: Policy Regarding Quantitative Labeling of Dietary Supplements Containing Live Microbials,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-policy-regarding-quantitative-labeling-dietary-supplements-containing-live,https://www.fda.gov/media/115730/download,2018-09-07,['Human Foods Program'],,Draft,FDA-2011-D-0376,No,2018-11-06
Allergic Rhinitis: Developing Drug Products for Treatment Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/allergic-rhinitis-developing-drug-products-treatment-guidance-industry,https://www.fda.gov/media/71158/download,2018-09-06,['Center for Drug Evaluation and Research'],"['Clinical - Medical','Pediatric Product Development']",Final,FDA-2000-D-0277,No,
Nonallergic Rhinitis:  Developing Drug Products for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonallergic-rhinitis-developing-drug-products-treatment,https://www.fda.gov/media/95943/download,2018-09-06,['Center for Drug Evaluation and Research'],"['Clinical - Medical','Pediatric Product Development']",Final,FDA-2016-D-0236,No,
Physiologically Based Pharmacokinetic Analyses — Format and Content Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/physiologically-based-pharmacokinetic-analyses-format-and-content-guidance-industry,https://www.fda.gov/media/101469/download,2018-09-04,['Center for Drug Evaluation and Research'],['Clinical - Pharmacology'],Final,FDA-2016-D-3969,No,
Osteoarthritis: Structural Endpoints for the Development of Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/osteoarthritis-structural-endpoints-development-drugs,https://www.fda.gov/media/71132/download,2018-08-23,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research']",['Clinical - Medical'],Draft,FDA-2018-D-2896,No,2018-11-22
Quality Attribute Considerations for Chewable Tablets Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-attribute-considerations-chewable-tablets-guidance-industry,https://www.fda.gov/media/98598/download,2018-08-21,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2016-D-1490,No,
Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/microdose-radiopharmaceutical-diagnostic-drugs-nonclinical-study-recommendations,https://www.fda.gov/media/107641/download,2018-08-21,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Final,FDA-2017-D-5297,No,
Guidance for Industry: Questions and Answers Regarding Food Facility Registration (Seventh Edition),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-regarding-food-facility-registration-seventh-edition,https://www.fda.gov/media/85043/download,2018-08-20,"['Center for Veterinary Medicine','Office of Inspections and Investigations','Human Foods Program']",['Registration'],Final,FDA-2012-D-1002,No,
Draft Guidance for Industry: Supplemental Questions and Answers Regarding Food Facility Registration,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-supplemental-questions-and-answers-regarding-food-facility-registration,https://www.fda.gov/media/115080/download,2018-08-20,"['Center for Veterinary Medicine','Office of Inspections and Investigations','Human Foods Program']",['Registration'],Draft,FDA-2012-D-1002,No,2018-10-19
Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dissolution-testing-and-acceptance-criteria-immediate-release-solid-oral-dosage-form-drug-products,https://www.fda.gov/media/92988/download,2018-08-09,['Center for Drug Evaluation and Research'],['Biopharmaceutics'],Final,FDA-2018-D-2614,No,
Compliance Policy for Certain Labeling and Warning Statement Requirements for Cigars and Pipe Tobacco:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-policy-certain-labeling-and-warning-statement-requirements-cigars-and-pipe-tobacco,https://www.fda.gov/media/115103/download,2018-08-09,['Center for Tobacco Products'],"['Cigars','Cigarillos','Little Filtered Cigars','Pipe','Labeling']",Final,FDA-2018-D-3047,No,
Compliance Policy for Required Warning Statements on Small-Packaged Cigars:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-policy-required-warning-statements-small-packaged-cigars,https://www.fda.gov/media/102295/download,2018-08-09,['Center for Tobacco Products'],"['Cigars','Cigarillos','Little Filtered Cigars','Labeling']",Final,FDA-2017-D-0121,No,
Submission of Warning Plans for Cigars:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-warning-plans-cigars,https://www.fda.gov/media/102554/download,2018-08-09,['Center for Tobacco Products'],"['Cigars','Cigarillos','Little Filtered Cigars','Labeling']",Final,FDA-2016-D-2495,No,
Tobacco Retailer Training Programs:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/tobacco-retailer-training-programs,https://www.fda.gov/media/79013/download,2018-08-09,['Center for Tobacco Products'],['Training & Education'],Final,FDA-2010-D-0350,No,2019-08-16
Elemental Impurities in Drug Products Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/elemental-impurities-drug-products-guidance-industry,https://www.fda.gov/media/98847/download,2018-08-08,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2016-D-1692,No,
Q3C Tables and List Rev. 4,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q3c-tables-and-list-rev-4,https://www.fda.gov/media/133650/download,2018-08-01,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['ICH-Quality'],Final,,No,
"Medical Device User Fee Small Business Qualification and Certification:  Guidance for Industry, Food and Drug Administration Staff and Foreign Governments",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-device-user-fee-small-business-qualification-and-certification,https://www.fda.gov/media/93354/download,2018-08-01,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']","['User Fees','Administrative / Procedural']",Final,FDA-2018-D-1873,No,
"Slowly Progressive, Low-Prevalence Rare Diseases with Substrate Deposition That Results from Single Enzyme Defects: Providing Evidence of Effectiveness for Replacement or Corrective Therapies Guidance for Industry:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/slowly-progressive-low-prevalence-rare-diseases-substrate-deposition-results-single-enzyme-defects,https://www.fda.gov/media/136058/download,2018-07-27,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Rare Diseases','Pediatric Product Development']",Final,FDA-2018-D-2456,No,
Use of Liquids and/or Soft Foods as Vehicles for Drug Administration:  General Considerations for Selection and In Vitro Methods for Product Quality Assessments,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-liquids-andor-soft-foods-vehicles-drug-administration-general-considerations-selection-and-vitro,https://www.fda.gov/media/114872/download,2018-07-25,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Draft,FDA-2018-D-2544,No,2018-10-24
E17 General Principles for Planning and Design of Multi-Regional Clinical Trials,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e17-general-principles-planning-and-design-multi-regional-clinical-trials,https://www.fda.gov/media/99974/download,2018-07-19,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Efficacy'],Final,2018-15395,No,2016-11-08
Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-electronic-health-record-data-clinical-investigations-guidance-industry,https://www.fda.gov/media/97567/download,2018-07-19,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']",['Administrative / Procedural'],Final,FDA-2016-D-1224,No,
Real World Data / Real World Evidence RWD/RWE,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-data-real-world-evidence-rwdrwe,,2018-07-18,['Center for Drug Evaluation and Research'],['Real World Data / Real World Evidence (RWD/RWE)'],Final,,No,
Labeling for Biosimilar Products Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-biosimilar-products-guidance-industry,https://www.fda.gov/media/96894/download,2018-07-18,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Labeling'],Final,FDA-2016-D-0643,No,2018-10-18
Innovative Approaches for Nonprescription Drug Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/innovative-approaches-nonprescription-drug-products,https://www.fda.gov/media/114328/download,2018-07-18,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Draft,FDA-2018-D-2281,No,2018-10-17
Hypertension: Conducting Studies of Drugs to Treat Patients on a Background of Multiple Antihypertensive Drugs Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hypertension-conducting-studies-drugs-treat-patients-background-multiple-antihypertensive-drugs,https://www.fda.gov/media/114731/download,2018-07-13,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2018-D-2515,No,2018-10-12
Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products — Content and Format Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/indications-and-usage-section-labeling-human-prescription-drug-and-biological-products-content-and,https://www.fda.gov/media/114443/download,2018-07-06,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Labeling'],Draft,FDA-2018-D-1895,No,2018-10-05
CVM GFI #252 Small Entity Compliance Guide Antimicrobial Animal Drug Sales and Distribution Reporting,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-252-small-entity-compliance-guide-antimicrobial-animal-drug-sales-and-distribution-reporting,https://www.fda.gov/media/114144/download,2018-06-29,['Center for Veterinary Medicine'],"['Administrative / Procedural','Antimicrobial Resistance']",Final,FDA-2012-N-0447,No,
Major Depressive Disorder:  Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/major-depressive-disorder-developing-drugs-treatment,https://www.fda.gov/media/113988/download,2018-06-21,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2018-D-1919,No,2018-09-20
Guidance for Industry: The Declaration of Certain Isolated or Synthetic Non-Digestible Carbohydrates as Dietary Fiber on Nutrition and Supplement Facts Labels,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-declaration-certain-isolated-or-synthetic-non-digestible-carbohydrates-dietary,https://www.fda.gov/media/113663/download,2018-06-15,['Human Foods Program'],"['Labeling','Nutrition Label']",Final,FDA-2018-D-1323,No,
CVM GFI #246 Hazard Analysis and Risk-Based Preventive Controls for Food for Animals: Supply-Chain Program,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-246-hazard-analysis-and-risk-based-preventive-controls-food-animals-supply-chain-program,https://www.fda.gov/media/113923/download,2018-06-15,['Center for Veterinary Medicine'],"['Administrative / Procedural','Animal Feed']",Draft,FDA-2018-D-1861,No,2018-12-12
Logical Observation Identifiers Names and Codes for In Vitro Diagnostic Tests :  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/logical-observation-identifiers-names-and-codes-in-vitro-diagnostic-tests,https://www.fda.gov/media/113967/download,2018-06-15,['Center for Devices and Radiological Health'],"['Labeling','Laboratory Tests','IVDs (In Vitro Diagnostic Devices)','Digital Health']",Final,FDA-2017-D-6982,No,
Patient-Focused Drug Development:  Collecting Comprehensive and Representative Input,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-collecting-comprehensive-and-representative-input,https://www.fda.gov/media/139088/download,2018-06-13,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2018-D-1893,No,2018-09-12
Medical Product Communications That Are Consistent With the FDA-Required Labeling — Questions and Answers :  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-product-communications-are-consistent-fda-required-labeling-questions-and-answers,https://www.fda.gov/media/133619/download,2018-06-13,"['Center for Veterinary Medicine','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research','Office of the Commissioner']",['Administrative / Procedural'],Final,FDA-2016-D-2285,No,
"Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and Answers:  Guidance for Industry and Review Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-and-device-manufacturer-communications-payors-formulary-committees-and-similar-entities,https://www.fda.gov/media/133620/download,2018-06-13,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research','Office of the Commissioner']",['Administrative / Procedural'],Final,FDA-2016-D-1307,No,
Prescription Drug User Fee Act Waivers for Fixed-Combination Antiretroviral Drugs for the President’s Emergency Plan for AIDS Relief: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prescription-drug-user-fee-act-waivers-fixed-combination-antiretroviral-drugs-presidents-emergency,https://www.fda.gov/media/114038/download,2018-06-07,['Center for Drug Evaluation and Research'],['User Fees'],Draft,FDA-2018-D-1635,No,2018-08-06
Complicated Urinary Tract Infections:  Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/uncomplicated-urinary-tract-infections-developing-drugs-treatment-guidance-industry,https://www.fda.gov/media/129531/download,2018-06-01,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2012-D-0148,No,
Development of a Shared System REMS Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-shared-system-rems-guidance-industry,https://www.fda.gov/media/113869/download,2018-06-01,['Center for Drug Evaluation and Research'],"['Drug Competition Action Plan','Safety - Issues, Errors, and Problems']",Draft,FDA-2018-D-1041,No,2018-07-31
Small Entity Compliance Guide: Registration of Food Facilities,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-registration-food-facilities,https://www.fda.gov/media/85098/download,2018-05-29,"['Center for Veterinary Medicine','Human Foods Program']",['Registration'],Final,FDA-2012-D-1003,No,
Anthrax: Developing Drugs for Prophylaxis of Inhalational Anthrax Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/anthrax-developing-drugs-prophylaxis-inhalational-anthrax-guidance-industry,https://www.fda.gov/media/71320/download,2018-05-24,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2016-D-0412,No,
CVM GFI #132 Administrative Applications and the Phased Review Process,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-132-administrative-applications-and-phased-review-process,https://www.fda.gov/media/70029/download,2018-05-23,['Center for Veterinary Medicine'],['New Animal Drug Application (NADA)'],Final,FDA-2002-D-0147,No,
Acne Vulgaris:  Establishing Effectiveness of Drugs Intended for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acne-vulgaris-establishing-effectiveness-drugs-intended-treatment,https://www.fda.gov/media/71152/download,2018-05-22,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-2005-D-0461,No,
Bioanalytical Method Validation Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry,https://www.fda.gov/media/70858/download,2018-05-22,"['Center for Drug Evaluation and Research','Center for Veterinary Medicine']",['Biopharmaceutics'],Final,FDA-2013-D-1020,No,
Cytomegalovirus in Transplantation:  Developing Drugs to Treat or Prevent Disease,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cytomegalovirus-transplantation-developing-drugs-treat-or-prevent-disease,https://www.fda.gov/media/112942/download,2018-05-21,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2018-D-1711,No,2018-07-17
Establishing Effectiveness for Drugs Intended to Treat Male Hypogonadotropic Hypogonadism Attributed to Nonstructural Disorders Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/establishing-effectiveness-drugs-intended-treat-male-hypogonadotropic-hypogonadism-attributed,https://www.fda.gov/media/110004/download,2018-05-18,[],['Clinical - Medical'],Final,,No,
Institutional Review Board (IRB) Written Procedures:  Guidance for Institutions and IRBs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/institutional-review-board-irb-written-procedures,https://www.fda.gov/media/99271/download,2018-05-17,"['Office of Inspections and Investigations','Office of the Commissioner','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Investigation & Enforcement','Good Clinical Practice (GCP)']",Final,FDA-2016-D-1605,No,2016-09-30
Small Entity Compliance Guide: Extension and Clarification of Compliance Dates for Certain Provisions of Four Implementing Rules of the FDA Food Safety Modernization Act,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-extension-and-clarification-compliance-dates-certain-provisions-four,https://www.fda.gov/media/112982/download,2018-05-14,"['Center for Veterinary Medicine','Human Foods Program']",,Final,FDA-2018-D-1378,No,
"Facility Definition Under Section 503B of the Federal Food, Drug, and Cosmetic Act",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/facility-definition-under-section-503b-federal-food-drug-and-cosmetic-act,https://www.fda.gov/media/97359/download,2018-05-10,['Center for Drug Evaluation and Research'],['Compounding'],Final,,No,
S3A Guidance: Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies: Focus on Microsampling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s3a-guidance-note-guidance-toxicokinetics-assessment-systemic-exposure-toxicity-studies-focus,https://www.fda.gov/media/100027/download,2018-05-09,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Safety'],Final,FDA-2016-D-2513,No,
Complicated Intra-Abdominal Infections: Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/complicated-intra-abdominal-infections-developing-drugs-treatment,https://www.fda.gov/media/84691/download,2018-05-01,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2012-D-0973,No,
Guidance for Industry: Menu Labeling Supplemental Guidance,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-menu-labeling-supplemental-guidance-edition-2,https://www.fda.gov/media/174528/download,2018-05-01,['Human Foods Program'],"['Labeling','Nutrition']",Final,FDA-2011-F-0172,No,
Clinical Trial Imaging Endpoint Process Standards Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-imaging-endpoint-process-standards-guidance-industry,https://www.fda.gov/media/81172/download,2018-04-27,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Final,FDA-2011-D-0586,No,
Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Questions and Answers Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q7-good-manufacturing-practice-guidance-active-pharmaceutical-ingredients-questions-and-answers,https://www.fda.gov/media/112426/download,2018-04-20,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-2018-D-1176,No,
Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products--Quality Considerations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/metered-dose-inhaler-mdi-and-dry-powder-inhaler-dpi-drug-products-quality-considerations,https://www.fda.gov/media/70851/download,2018-04-19,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Draft,FDA-2018-D-1098,No,
Guidance for Industry: Highly Concentrated Caffeine in Dietary Supplements,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-highly-concentrated-caffeine-dietary-supplements,https://www.fda.gov/media/112363/download,2018-04-16,['Human Foods Program'],,Final,FDA–2018–D–1189,No,
Special Protocol Assessment Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/special-protocol-assessment-guidance-industry,https://www.fda.gov/media/97618/download,2018-04-16,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Administrative / Procedural'],Final,FDA-2016-D-1174,No,
"Considerations for Design, Development, and Analytical Validation of Next Generation Sequencing (NGS) - Based In Vitro Diagnostics (IVDs) Intended to Aid in the Diagnosis of Suspected Germline Diseases:  Guidance for Stakeholders and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-design-development-and-analytical-validation-next-generation-sequencing-ngs-based,https://www.fda.gov/media/99208/download,2018-04-13,['Center for Devices and Radiological Health'],,Final,FDA-2016-D-1270,No,
Use of Public Human Genetic Variant Databases to Support Clinical Validity for Genetic and Genomic-Based In Vitro Diagnostics :  Guidance for Stakeholders and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-public-human-genetic-variant-databases-support-clinical-validity-genetic-and-genomic-based-vitro,https://www.fda.gov/media/99200/download,2018-04-13,['Center for Devices and Radiological Health'],"['Premarket','Laboratory Tests','IVDs (In Vitro Diagnostic Devices)','Molecular and Clinical Genetics']",Final,FDA-2016-D-1233,No,
E11(R1) Addendum: Clinical Investigation of Medicinal Products in the Pediatric Population,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e11r1-addendum-clinical-investigation-medicinal-products-pediatric-population,https://www.fda.gov/media/101398/download,2018-04-11,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['ICH-Efficacy','Pediatric Product Development']",Final,FDA-2016-D-3848,No,
Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pregnant-women-scientific-and-ethical-considerations-inclusion-clinical-trials,https://www.fda.gov/media/112195/download,2018-04-09,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Draft,FDA-2018-D-1201,No,
"Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/liposome-drug-products-chemistry-manufacturing-and-controls-human-pharmacokinetics-and,https://www.fda.gov/media/70837/download,2018-04-05,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2016-D-2817,No,
Questions and Answers on Current Good Manufacturing Practices for Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/questions-and-answers-current-good-manufacturing-practices-drugs,,2018-03-30,"['Center for Veterinary Medicine','Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,FDA-2017-D-6821,No,
Chronic Obstructive Pulmonary Disease: Use of the St. George’s Respiratory Questionnaire as a PRO Assessment Tool Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chronic-obstructive-pulmonary-disease-use-st-georges-respiratory-questionnaire-pro-assessment-tool,https://www.fda.gov/media/71121/download,2018-03-26,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-2017-D-6821,No,
Guidance for Industry: Application of the Foreign Supplier Verification Program Regulation to the Importation of Live Animals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-application-foreign-supplier-verification-program-regulation-importation-live,https://www.fda.gov/media/112085/download,2018-03-22,['Human Foods Program'],['Import'],Final,FDA-2018-D-0721,No,
E18 Genomic Sampling and Management of Genomic Data Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e18-genomic-sampling-and-management-genomic-data-guidance-industry,https://www.fda.gov/media/98596/download,2018-03-02,"['Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['ICH-Efficacy'],Final,FDA-2016-D-1255,No,
Guidance for Industry: Proper Labeling of Honey and Honey Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-proper-labeling-honey-and-honey-products,https://www.fda.gov/media/110846/download,2018-03-02,['Human Foods Program'],"['Labeling','Nutrition Label']",Final,FDA-2006-P-0207,No,
Guidance for Industry: Reference Amounts Customarily Consumed (List of Products for Each Product Category),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-reference-amounts-customarily-consumed-list-products-each-product-category,https://www.fda.gov/media/102587/download,2018-03-02,['Human Foods Program'],"['Labeling','Nutrition Label']",Final,FDA-2016-D-4098,No,
Guidance for Industry: Scientific Evaluation of the Evidence on the Beneficial Physiological Effects of Isolated or Synthetic Non-Digestible Carbohydrates Submitted as a Citizen Petition (21 CFR 10.30),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-scientific-evaluation-evidence-beneficial-physiological-effects-isolated-or,https://www.fda.gov/media/101183/download,2018-03-02,['Human Foods Program'],"['Labeling','Nutrition Label']",Final,FDA-2016-D-3401,No,
"Guidance for Industry: Serving Sizes of Foods That Can Reasonably Be Consumed At One Eating Occasion; Dual-Column Labeling; Updating, Modifying, and Establishing Certain Reference Amounts Customarily Consumed; Serving Size for Breath Mints",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-serving-sizes-foods-can-reasonably-be-consumed-one-eating-occasion-dual-column,https://www.fda.gov/media/111144/download,2018-03-02,['Human Foods Program'],"['Labeling','Nutrition Label']",Final,FDA-2004-N-0258,No,
Standardization of Data and Documentation Practices for Product Tracing Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/standardization-data-and-documentation-practices-product-tracing-guidance-industry,https://www.fda.gov/media/111451/download,2018-03-02,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']",['Administrative / Procedural'],Draft,FDA-2018-D-0688,No,2018-05-01
E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r2-good-clinical-practice-integrated-addendum-ich-e6r1,https://www.fda.gov/media/93884/download,2018-03-01,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['ICH-Efficacy'],Final,FDA-2018-D-0719,No,
Q11 Development and Manufacture of Drug Substances--Questions and Answers (Chemical Entities and Biotechnological/Biological Entities),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q11-development-and-manufacture-drug-substances-questions-and-answers-chemical-entities-and,https://www.fda.gov/media/103162/download,2018-02-26,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-2011-D-0436,No,
Acceptance of Clinical Data to Support Medical Device Applications and Submissions: Frequently Asked Questions:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acceptance-clinical-data-support-medical-device-applications-and-submissions-frequently-asked,https://www.fda.gov/media/111346/download,2018-02-21,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']","['Premarket','Good Clinical Practice (GCP)','Investigational Device Exemption (IDE)']",Final,FDA-2013-N-0080,No,
Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/duchenne-muscular-dystrophy-and-related-dystrophinopathies-developing-drugs-treatment-guidance,https://www.fda.gov/media/92233/download,2018-02-16,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-2015-D-1884,No,
Migraine: Developing Drugs for Acute Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/migraine-developing-drugs-acute-treatment,https://www.fda.gov/media/89829/download,2018-02-16,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-2014-D-1540,No,
Standardized Format for Electronic Submission of NDA and BLA Content for the Planning of Bioresearch Monitoring (BIMO) Inspections for CDER Submissions Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/standardized-format-electronic-submission-nda-and-bla-content-planning-bioresearch-monitoring-bimo,https://www.fda.gov/media/85056/download,2018-02-16,['Center for Drug Evaluation and Research'],['Electronic Submissions'],Draft,FDA-2018-D-0481,No,
Regulatory Classification of Pharmaceutical Co-Crystals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-classification-pharmaceutical-co-crystals,https://www.fda.gov/media/81824/download,2018-02-15,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2011-D-0800,No,
How to Prepare a Pre-Request for Designation (Pre-RFD):  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/how-prepare-pre-request-designation-pre-rfd,https://www.fda.gov/media/102706/download,2018-02-14,['Office of the Commissioner'],['Combination Products'],Final,FDA-2017-D-0040,No,2017-04-13
"Microbiological Data for Systemic Antibacterial Drug Products — Development, Analysis, and Presentation",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/microbiological-data-systemic-antibacterial-drug-products-development-analysis-and-presentation,https://www.fda.gov/media/77442/download,2018-02-07,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2009-D-0408,No,
Payment and Reimbursement to Research Subjects:  Guidance for Institutional Review Boards and Clinical Investigators,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/payment-and-reimbursement-research-subjects,,2018-01-29,['Office of the Commissioner'],['Good Clinical Practice (GCP)'],Final,,No,
Guidance for Industry: Application of the Foreign Supplier Verification Program Regulation to Importers of Grain Raw Agricultural Commodities,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-application-foreign-supplier-verification-program-regulation-importers-grain-raw,https://www.fda.gov/media/110302/download,2018-01-25,"['Center for Veterinary Medicine','Office of Inspections and Investigations','Human Foods Program']",['Import'],Final,FDA-2017-D-6592,No,
Small Entity Compliance Guide: Foreign Supplier Verification Programs for Importers of Food for Humans and Animals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-foreign-supplier-verification-programs-importers-food-humans-and,https://www.fda.gov/media/110327/download,2018-01-25,['Human Foods Program'],['Import'],Final,FDA-2011-N-0143,No,
Draft Guidance for Industry: Considerations for Determining Whether a Measure Provides the Same Level of Public Health Protection as the Corresponding Requirement in 21 CFR part 112 or the Preventive Controls Requirements in part 117 or 507,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-considerations-determining-whether-measure-provides-same-level-public-health,https://www.fda.gov/media/110317/download,2018-01-25,['Human Foods Program'],,Draft,FDA-2017-D-0397,No,2018-05-25
"Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compounded-drug-products-are-essentially-copies-commercially-available-drug-product-under-section,https://www.fda.gov/media/98973/download,2018-01-19,['Center for Drug Evaluation and Research'],['Compounding'],Final,FDA-2016-D-1309,No,
"Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compounded-drug-products-are-essentially-copies-approved-drug-products-under-section-503b-federal,https://www.fda.gov/media/98964/download,2018-01-19,['Center for Drug Evaluation and Research'],['Compounding'],Final,FDA-2016-D-1267,No,
Product Title and Initial U.S. Approval in the Highlights of Prescribing Information for Human Prescription Drug and Biological Products — Content and Format Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-title-and-initial-us-approval-highlights-prescribing-information-human-prescription-drug-and,https://www.fda.gov/media/110453/download,2018-01-19,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Labeling'],Draft,FDA-2017-D-6969,No,2018-03-19
Material Threat Medical Countermeasure Priority Review Vouchers  - Draft Guidance for Industry: Draft Guidance for Industry,,,2018-01-19,[],['Emergencies'],Draft,FDA-2017-D-6880,No,2018-03-20
"Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/mixing-diluting-or-repackaging-biological-products-outside-scope-approved-biologics-license,https://www.fda.gov/media/90986/download,2018-01-18,['Center for Drug Evaluation and Research'],"['Compounding','Pharmaceutical Quality','Current Good Manufacturing Practice (CGMP)']",Final,,No,2017-03-13
"Guidance for Industry: Policy Regarding Certain Entities Subject to the Current Good Manufacturing Practice and Preventive Controls, Produce Safety, and/or Foreign Supplier Verification Programs",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-policy-regarding-certain-entities-subject-current-good-manufacturing-practice-and,https://www.fda.gov/media/110023/download,2018-01-05,"['Center for Veterinary Medicine','Human Foods Program']",,Final,FDA-2017-N-6908,No,
Labeling for Combined Hormonal Contraceptives Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-combined-hormonal-contraceptives-guidance-industry,https://www.fda.gov/media/110050/download,2018-01-02,['Center for Drug Evaluation and Research'],['Labeling'],Draft,FDA-2017-D-1846,No,2018-02-28
Best Practices for Communication Between IND Sponsors and FDA During Drug Development,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-communication-between-ind-sponsors-and-fda-during-drug-development,https://www.fda.gov/media/94850/download,2017-12-29,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2017-D-6564,No,
"Nucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV-1) and Hepatitis C Virus (HCV): Testing, Product Disposition, and Donor Deferral and Reentry:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nucleic-acid-testing-nat-human-immunodeficiency-virus-type-1-hiv-1-and-hepatitis-c-virus-hcv-testing,https://www.fda.gov/media/124144/download,2017-12-28,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-2005-D-0140,No,
Medical Device Accessories - Describing Accessories and Classification Pathways:   Guidance for Industry and FDA Staff,,,2017-12-20,[],"['Premarket','Administrative / Procedural','Digital Health']",Final,FDA-2015-D-0025,No,2015-04-10
Clarification of Orphan Designation of Drugs and  Biologics for Pediatric Subpopulations of Common Diseases:  Guidance for Industry,,,2017-12-19,[],"['Premarket','Pediatric Product Development']",Final,FDA-2017-D-6380.,No,2018-07-27
"Investigational IVDs Used in Clinical Investigations of Therapeutic Products: Draft Guidance for Industry, Food and Drug Administration Staff, Sponsors, and Institutional Review Boards",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-ivds-used-clinical-investigations-therapeutic-products,https://www.fda.gov/media/109464/download,2017-12-18,['Center for Devices and Radiological Health'],"['Good Clinical Practice (GCP)','Labeling','Investigational Device Exemption (IDE)','Investigational New Drug Application (INDA)','Laboratory Tests','IVDs (In Vitro Diagnostic Devices)']",Draft,FDA-2017-N-6356,No,2018-03-19
Systemic Antibacterial and Antifungal Drugs:  Susceptibility Test Interpretive Criteria Labeling for NDAs and ANDAs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/systemic-antibacterial-and-antifungal-drugs-susceptibility-test-interpretive-criteria-labeling-ndas,https://www.fda.gov/media/109839/download,2017-12-13,['Center for Drug Evaluation and Research'],['Labeling'],Final,FDA-2017-N-5925,No,
Refuse to File: NDA and BLA Submissions to CDER Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/refuse-file-nda-and-bla-submissions-cder-guidance-industry,https://www.fda.gov/media/109758/download,2017-12-13,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Draft,FDA-2017-D-6554,No,2018-03-12
"Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling-Final",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-name-placement-size-and-prominence-advertising-and-promotional-labeling-final,https://www.fda.gov/media/87202/download,2017-12-12,"['Center for Veterinary Medicine','Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Advertising'],Final,FDA-1999-D-4079,No,
Gluten in Drug Products and Associated Labeling Recommendations; Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/gluten-drug-products-and-associated-labeling-recommendations-draft-guidance-industry,https://www.fda.gov/media/116958/download,2017-12-12,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Labeling'],Draft,FDA-2017-D-6352,No,2018-03-12
Software as a Medical Device (SAMD): Clinical Evaluation:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/software-medical-device-samd-clinical-evaluation,https://www.fda.gov/media/100714/download,2017-12-08,['Center for Devices and Radiological Health'],"['Premarket','International']",Final,FDA-2016-D-2483,No,
Pediatric Rare Diseases--A Collaborative Approach for Drug Development Using Gaucher Disease as a Model; Draft Guidance for Industry: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-rare-diseases-collaborative-approach-drug-development-using-gaucher-disease-model-draft,https://www.fda.gov/media/109465/download,2017-12-07,['Center for Drug Evaluation and Research'],"['Rare Diseases','Pediatric Product Development']",Draft,FDA-2017-N-6476,No,2018-03-06
Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Blood and Blood Components:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-serological-tests-reduce-risk-transmission-trypanosoma-cruzi-infection-blood-and-blood,https://www.fda.gov/media/101270/download,2017-12-05,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2009-D-0137,No,2017-12-06
Technical Considerations for Additive Manufactured Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-considerations-additive-manufactured-medical-devices,https://www.fda.gov/media/97633/download,2017-12-05,['Center for Devices and Radiological Health'],"['Premarket','Biotechnology','510(k)','Premarket Approval (PMA)','Investigational Device Exemption (IDE)','HUD/HDE','Orthopedic','Tissue']",Final,FDA-2016-D-1210,No,2016-08-08
"FDA Categorization of Investigational Device Exemption (IDE) Devices to Assist the Centers for Medicare and Medicaid Services (CMS) with Coverage Decisions:  Guidance for Sponsors, Clinical Investigators, Industry, Institutional Review Boards, and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-categorization-investigational-device-exemption-ide-devices-assist-centers-medicare-and-medicaid,https://www.fda.gov/media/98578/download,2017-12-05,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Investigational Device Exemption (IDE)'],Final,FDA-2016-D-1159,No,
Pediatric Information for X-ray Imaging Device Premarket Notifications:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-information-x-ray-imaging-device-premarket-notifications,https://www.fda.gov/media/83281/download,2017-11-28,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Pediatric Product Development','Radiology']",Final,FDA-2012-D-0384,No,
Small Entity Compliance Guide: Sanitary Transportation of Human and Animal Food - What You Need to Know About the FDA Regulation,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-sanitary-transportation-human-and-animal-food-what-you-need-know-about,https://www.fda.gov/media/108944/download,2017-11-22,['Human Foods Program'],['Transportation'],Final,FDA-2013-N-0013,No,
General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-evaluating-abuse-deterrence-generic-solid-oral-opioid-drug-products-guidance,https://www.fda.gov/media/96643/download,2017-11-21,['Center for Drug Evaluation and Research'],"['Drug Competition Action Plan','Generic Drugs']",Final,FDA-2016-D-0785,No,
Unique Device Identification: Direct Marking of Devices :  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/unique-device-identification-direct-marking-devices,https://www.fda.gov/media/92100/download,2017-11-17,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Labeling','UDI']",Final,FDA-2015-D-2245,No,2015-09-24
Same Surgical Procedure Exception under 21 CFR 1271.15(b): Questions and Answers Regarding the Scope of the Exception,,,2017-11-16,[],"['Cellular & Gene Therapy','Tissue']",Final,FDA-2014-D-1584,No,
Guidance for Industry: Use of the Terms “Brown King Crab” and “Golden King Crab” in the Labeling of Human Food Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-use-terms-brown-king-crab-and-golden-king-crab-labeling-human-food-products,https://www.fda.gov/media/109182/download,2017-11-15,['Human Foods Program'],"['Labeling','Seafood/Seafood Product']",Final,,No,
Use of a Drug Master File for Shared System REMS Submissions Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-drug-master-file-shared-system-rems-submissions-guidance-industry,https://www.fda.gov/media/109124/download,2017-11-09,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Administrative / Procedural','Drug Competition Action Plan']",Draft,FDA-2017-D-6231,No,
Evaluating Drug Effects on the Ability to Operate a Motor Vehicle,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluating-drug-effects-ability-operate-motor-vehicle,https://www.fda.gov/media/90670/download,2017-11-08,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,,No,
Recurrent Herpes Labialis:  Developing Drugs for Treatment and Prevention,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recurrent-herpes-labialis-developing-drugs-treatment-and-prevention,https://www.fda.gov/media/99233/download,2017-11-08,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-2016-D-1504,No,
Chronic Hepatitis C Virus Infection:  Developing Direct-Acting Antiviral Drugs for Treatment Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chronic-hepatitis-c-virus-infection-developing-direct-acting-antiviral-drugs-treatment-guidance,https://www.fda.gov/media/79486/download,2017-11-07,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2013-D-1170,No,
Recommended Statement for Over-the-Counter Aspirin-Containing Drug Products Labeled With Cardiovascular Related Imagery Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommended-statement-over-counter-aspirin-containing-drug-products-labeled-cardiovascular-related,https://www.fda.gov/media/102479/download,2017-11-07,['Center for Drug Evaluation and Research'],['Compliance'],Final,FDA-2012-D-0529,No,
Guidance for Industry: Supply-Chain Program Requirements and Co-Manufacturer Supplier Approval and Verification for Human Food and Animal Food,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-supply-chain-program-requirements-and-co-manufacturer-supplier-approval-and,https://www.fda.gov/media/108732/download,2017-11-06,"['Center for Veterinary Medicine','Human Foods Program']",,Final,FDA-2017-D-5996,No,
ANDAs: Pre-Submission of Facility Information Related to Prioritized Generic Drug Applications (Pre-Submission Facility Correspondence) Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-pre-submission-facility-information-related-prioritized-generic-drug-applications-pre,https://www.fda.gov/media/105794/download,2017-11-03,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Generic Drugs','Pharmaceutical Quality','Drug Competition Action Plan']",Draft,FDA-2017-D-3101,No,2018-02-02
"Guidance for Industry: Regulatory Framework for Substances Intended for Use in Human Food or Animal Food on the Basis of the Generally Recognized as Safe (GRAS) Provision of the Federal Food, Drug, and Cosmetic Act",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-regulatory-framework-substances-intended-use-human-food-or-animal-food-basis,https://www.fda.gov/media/109117/download,2017-11-01,"['Center for Veterinary Medicine','Human Foods Program']",['GRAS'],Final,FDA-2016-D-4484,No,
Recommendations for the Submission of LOINC® Codes in Regulatory Applications to the U.S. Food and Drug Administration:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-submission-loincr-codes-regulatory-applications-us-food-and-drug-administration,https://www.fda.gov/media/109376/download,2017-11-01,['Center for Drug Evaluation and Research'],,Final,FDA-2017-D-6982,No,
Assessing User Fees Under the Generic Drug User Fee Amendments of 2017 Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-user-fees-under-generic-drug-user-fee-amendments-2017-guidance-industry,,2017-10-30,['Center for Drug Evaluation and Research'],"['User Fees','Generic Drugs']",Draft,FDA-2012-D-0880,No,
Manufacturers Sharing Patient-Specific Information from Medical Devices with Patients Upon Request:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacturers-sharing-patient-specific-information-medical-devices-patients-upon-request,https://www.fda.gov/media/98519/download,2017-10-30,['Center for Devices and Radiological Health'],['Postmarket'],Final,FDA-2016-D-1264,No,2016-08-09
Product Labeling for Certain Ultrasonic Surgical Aspirator Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-labeling-certain-ultrasonic-surgical-aspirator-devices,https://www.fda.gov/media/100882/download,2017-10-30,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Labeling','Safety - Issues, Errors, and Problems','Obstetrical & Gynecological','General & Plastic Surgery']",Final,FDA-2016-D-3275,No,2017-01-09
Pediatric Gastroesophageal Reflux Disease: Developing Drugs for Treatment Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-gastroesophageal-reflux-disease-developing-drugs-treatment-guidance-industry,https://www.fda.gov/media/108594/download,2017-10-26,['Center for Drug Evaluation and Research'],"['Clinical - Medical','Pediatric Product Development']",Draft,FDA-2017-D-5912,No,2018-01-26
Deciding When to Submit a 510(k) for a Change to an Existing Device:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/deciding-when-submit-510k-change-existing-device,https://www.fda.gov/media/99812/download,2017-10-25,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Labeling','Laboratory Tests','IVDs (In Vitro Diagnostic Devices)']",Final,FDA-2011-D-0453,No,2016-11-06
Deciding When to Submit a 510(k) for a Software Change to an Existing Device:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/deciding-when-submit-510k-software-change-existing-device,https://www.fda.gov/media/99785/download,2017-10-25,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Labeling','Laboratory Tests','IVDs (In Vitro Diagnostic Devices)','Digital Health']",Final,FDA-2016-D-2021,No,2016-11-06
CVM GFI #235 Current Good Manufacturing Practice Requirements for Food for Animals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-235-current-good-manufacturing-practice-requirements-food-animals,https://www.fda.gov/media/97464/download,2017-10-20,['Center for Veterinary Medicine'],"['Animal Feed','Current Good Manufacturing Practice (CGMP)']",Final,FDA-2016-D-1229,No,2016-11-23
Draft Guidance for Industry: Application of the “Solely Engaged” Exemptions in Parts 117 and 507,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-application-solely-engaged-exemptions-parts-117-and-507,https://www.fda.gov/media/108360/download,2017-10-20,"['Center for Veterinary Medicine','Human Foods Program']",['Registration'],Draft,FDA-2017-D-6133,No,2018-04-18
Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/respiratory-syncytial-virus-infection-developing-antiviral-drugs-prophylaxis-and-treatment-guidance,https://www.fda.gov/media/108437/download,2017-10-11,['Center for Drug Evaluation and Research'],"['Clinical - Antimicrobial','Pediatric Product Development']",Draft,,No,2017-12-11
Completeness Assessments for Type II API DMFs Under GDUFA Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/completeness-assessments-type-ii-api-dmfs-under-gdufa-guidance-industry,https://www.fda.gov/media/84217/download,2017-10-11,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['User Fees','Chemistry, Manufacturing, and Controls (CMC)','Generic Drugs','Pharmaceutical Quality']",Final,None found,No,
CVM GFI #236 Clarification of FDA and EPA Jurisdiction Over Mosquito-Related Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-236-clarification-fda-and-epa-jurisdiction-over-mosquito-related-products,https://www.fda.gov/media/102158/download,2017-10-05,['Center for Veterinary Medicine'],['New Animal Drug Application (NADA)'],Final,FDA-2016-D-4482,No,2017-02-21
Individual Patient Expanded Access Applications: Form FDA 3926,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/individual-patient-expanded-access-applications-form-fda-3926,https://www.fda.gov/media/91160/download,2017-10-03,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Administrative / Procedural'],Final,FDA-2015-D-0268,No,
M4 Organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m4-organization-common-technical-document-registration-pharmaceuticals-human-use-guidance-industry,https://www.fda.gov/media/71551/download,2017-10-03,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Multidisciplinary'],Final,FDA-2017-D-5139,No,
ANDA Submissions - Refuse-to-Receive Standards: Questions and Answers Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/anda-submissions-refuse-receive-standards-questions-and-answers-guidance-industry,https://www.fda.gov/media/107637/download,2017-10-03,['Center for Drug Evaluation and Research'],"['User Fees','Generic Drugs']",Draft,FDA-2017-D-5846,No,2018-01-02
"Waiver of IRB Requirements for Drug and Biological Product Studies:  Guidance For Sponsors, Clinical Investigators, and IRBs",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/waiver-irb-requirements-drug-and-biological-product-studies,https://www.fda.gov/media/75152/download,2017-10-03,['Office of the Commissioner'],['Good Clinical Practice (GCP)'],Final,,No,
Administrative Procedures for CLIA Categorization:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/administrative-procedures-clia-categorization,https://www.fda.gov/media/71065/download,2017-10-02,['Center for Devices and Radiological Health'],"['User Fees','Administrative / Procedural','CLIA (Clinical Laboratory Improvement Amendments)']",Final,FDA-2008-D-0228,No,
Advancement of Emerging Technology Applications for Pharmaceutical Innovation and Modernization Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/advancement-emerging-technology-applications-pharmaceutical-innovation-and-modernization-guidance,https://www.fda.gov/media/95444/download,2017-09-29,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2015-D-4644,No,
Classification of Products as Drugs and Devices and Additional Product Classification Issues:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/classification-products-drugs-and-devices-and-additional-product-classification-issues,https://www.fda.gov/media/80384/download,2017-09-25,['Office of the Commissioner'],['Combination Products'],Final,FDA-2011-D-0429,No,2011-09-01
Minutes of Institutional Review Board (IRB) Meetings:  Guidance for Institutions and IRBs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/minutes-institutional-review-board-irb-meetings,https://www.fda.gov/media/94686/download,2017-09-25,"['Office of Inspections and Investigations','Office of the Commissioner','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Investigation & Enforcement','Good Clinical Practice (GCP)','Pediatric Product Development']",Final,FDA-2015-D-3638,No,2016-01-04
Q4B Annex 2: Test for Extractable Volume of Parenteral Preparations General Chapter,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-2-test-extractable-volume-parenteral-preparations-general-chapter,https://www.fda.gov/media/71222/download,2017-09-18,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-2008-D-0081,No,
Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Human Papillomaviruses:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/establishing-performance-characteristics-in-vitro-diagnostic-devices-detection-or-detection-and-0,https://www.fda.gov/media/92930/download,2017-09-15,['Center for Devices and Radiological Health'],"['Premarket','Microbiology','Laboratory Tests','IVDs (In Vitro Diagnostic Devices)','Premarket Approval (PMA)']",Final,FDA-2009-D-0386,No,2015-11-12
"Evaluation and Reporting of Age-, Race-, and Ethnicity-Specific Data in Medical Device Clinical Studies:  Guidance for Industry and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-and-reporting-age-race-and-ethnicity-specific-data-medical-device-clinical-studies,https://www.fda.gov/media/98686/download,2017-09-12,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','510(k)','Premarket Approval (PMA)','Investigational Device Exemption (IDE)','HUD/HDE','Clinical - Medical','Good Clinical Practice (GCP)','Labeling','Pediatric Product Development','Laboratory Tests','IVDs (In Vitro Diagnostic Devices)','Physical Medicine','Orthopedic','Ophthalmic','Obstetrical & Gynecological','Neurological','Molecular and Clinical Genetics','Immunology & Microbiology','Cardiovascular','Hematology & Pathology','General Hospital & Personal Use','General & Plastic Surgery','Gastroenterology-Urology','Ear','Nose & Throat','Dental','Clinical Chemistry & Clinical Toxicology','Radiology','Radiological Health']",Final,FDA-2016-D-0734,No,2016-09-18
"Deviation Reporting for Human Cells, Tissues, and Cellular and Tissue-Based Products Regulated Solely Under Section 361 of the Public Health Service Act and 21 CFR Part 1271:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/deviation-reporting-human-cells-tissues-and-cellular-and-tissue-based-products-regulated-solely,https://www.fda.gov/media/107703/download,2017-09-06,['Center for Biologics Evaluation and Research'],"['Cellular & Gene Therapy','Tissue']",Final,FDA-2015-D-4386,No,
Design Considerations and Pre-market Submission Recommendations for Interoperable Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-considerations-and-pre-market-submission-recommendations-interoperable-medical-devices,https://www.fda.gov/media/95636/download,2017-09-06,['Center for Devices and Radiological Health'],"['510(k)','Anesthesiology','Neurological','Cardiovascular','General Hospital & Personal Use','Digital Health','Dental','Radiological Health']",Final,FDA-2015-D-4852,No,2016-04-28
Requalification of Donors Previously Deferred for a History of Viral Hepatitis after the 11th Birthday:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requalification-donors-previously-deferred-history-viral-hepatitis-after-11th-birthday,https://www.fda.gov/media/107384/download,2017-09-01,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2017-D-5152,No,
Procedures for Meetings of the Medical Devices Advisory Committee:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/procedures-meetings-medical-devices-advisory-committee,https://www.fda.gov/media/91429/download,2017-09-01,['Center for Devices and Radiological Health'],"['Premarket','Advisory Committees','510(k)','Premarket Approval (PMA)','HUD/HDE','Administrative / Procedural','Labeling','Safety - Issues, Errors, and Problems','Anesthesiology','Laboratory Tests','IVDs (In Vitro Diagnostic Devices)','Physical Medicine','Orthopedic','Ophthalmic','Obstetrical & Gynecological','Neurological','Molecular and Clinical Genetics','Immunology & Microbiology','Cardiovascular','Hematology & Pathology','General Hospital & Personal Use','General & Plastic Surgery','Gastroenterology-Urology','Ear','Nose & Throat','Dental','Clinical Chemistry & Clinical Toxicology','Radiology','Laser Notice']",Final,FDA-2015-D-0838,No,2015-05-29
Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices :   Guidance for Industry and Food and Drug Administration Staff,,,2017-08-31,[],"['Postmarket','Biostatistics','Adverse Event Reporting System (FAERS)','Real World Data / Real World Evidence (RWD/RWE)','Adverse Event Reporting','Antimicrobial Resistance','Anesthesiology','Physical Medicine','Orthopedic','Ophthalmic','Obstetrical & Gynecological','Neurological','Molecular and Clinical Genetics','Immunology & Microbiology','Cardiovascular']",Final,FDA-2016-D-2153,No,2016-10-25
Small Entity Compliance Guide: Mitigation Strategies to Protect Food Against Intentional Adulteration,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-mitigation-strategies-protect-food-against-intentional-adulteration,https://www.fda.gov/media/105742/download,2017-08-25,['Human Foods Program'],['Defense & Security'],Final,FDA-2013-N-1425,No,
CVM GFI #232 (VICH GL54) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish an Acute Reference Dose (ARfD),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-232-vich-gl54-studies-evaluate-safety-residues-veterinary-drugs-human-food-general-approach,https://www.fda.gov/media/92063/download,2017-08-23,['Center for Veterinary Medicine'],"['Human Food Safety','VICH']",Final,FDA-2015-D-1804,No,2015-07-31
CVM GFI #237 Oncology Drugs for Companion Animals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-237-oncology-drugs-companion-animals,https://www.fda.gov/media/98399/download,2017-08-23,['Center for Veterinary Medicine'],['Investigational New Animal Drug (INAD)'],Final,FDA-2016-D-1248,No,2016-08-09
Identifying Trading Partners Under the Drug Supply Chain Security Act Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/identifying-trading-partners-under-drug-supply-chain-security-act-guidance-industry,https://www.fda.gov/media/106961/download,2017-08-18,[],['Administrative / Procedural'],Draft,,No,2017-10-18
Guidance for Industry: Ultrafiltered Milk in the Production of Standardized Cheeses and Related Cheese Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-ultrafiltered-milk-production-standardized-cheeses-and-related-cheese-products,https://www.fda.gov/media/106876/download,2017-08-14,['Human Foods Program'],['Cheese/Cheese Product'],Final,FDA-2017-D-4713,No,
Antibacterial Therapies for Patients With an Unmet Medical Need for the Treatment of Serious Bacterial Diseases,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antibacterial-therapies-patients-unmet-medical-need-treatment-serious-bacterial-diseases-questions,https://www.fda.gov/media/158589/download,2017-08-02,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2013-D-0744,No,
Guidance for Industry: Clarification on Food Establishment Waiver from Requirements of the Sanitary Transportation of Human and Animal Food Rule,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-clarification-food-establishment-waiver-requirements-sanitary-transportation-human,https://www.fda.gov/media/107146/download,2017-08-01,"['Center for Veterinary Medicine','Human Foods Program']","['Sanitation','Transportation']",Final,FDA-2013-N-0013,No,
Consumer Antiseptic Wash Final Rule Questions and Answers:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/consumer-antiseptic-wash-final-rule-questions-and-answers,https://www.fda.gov/media/106652/download,2017-07-26,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Final,FDA-2017-D-3906,No,
ICH Q3C Maintenance Procedures for the Guidance for Industry Q3C Impurities: Residual Solvents,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ich-q3c-maintenance-procedures-guidance-industry-q3c-impurities-residual-solvents,,2017-07-25,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-2010-N-0327 (Cumene) FDA-2015-D-3474 (Triethylamine/Methylisobutylketone)  4 Guidances listed under this Document:Triethylamine/Methylisobutylketone - pdf on web Tetrahydrofuran (THF) - pdf ON web; Docket #2001B-0431 N-Methylpyrrolidone (NMP) - pdf ON,No,
PDEs for Triethylamine and for Methylisobutylketone,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pdes-triethylamine-and-methylisobutylketone,https://www.fda.gov/media/94385/download,2017-07-25,['Center for Drug Evaluation and Research'],['ICH-Efficacy'],Final,,No,
M4E(R2):  The CTD – Efficacy,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m4er2-ctd-efficacy,https://www.fda.gov/media/93569/download,2017-07-24,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Multidisciplinary'],Final,FDA-2015-D-3235,No,
Q3C Maintenance Procedures,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ich-q3c-maintenance-procedures-guidance-industry-q3c-impurities-residual-solvents,,2017-07-24,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,,No,
Current Good Manufacturing Practice for Medical Gases: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-manufacturing-practice-medical-gases,https://www.fda.gov/media/70973/download,2017-06-29,['Center for Drug Evaluation and Research'],"['Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Draft,FDA-2003-D-0431,No,2017-09-28
E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions and Answers (R3) Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e14-clinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic-potential-non-antiarrhythmic-1,https://www.fda.gov/media/71379/download,2017-06-28,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Efficacy'],Final,FDA-2004-D-0241,No,
"Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions:  Guidance for Sponsors, Industry, Researchers, Investigators, and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/form-fda-3674-certifications-accompany-drug-biological-product-and-device-applicationssubmissions,https://www.fda.gov/media/105405/download,2017-06-07,['Office of the Commissioner'],['Premarket'],Final,,No,
Guidance for Industry: Recognition of Acceptable Unique Facility Identifier (UFI) for the Foreign Supplier Verification Programs Regulation,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-recognition-acceptable-unique-facility-identifier-ufi-foreign-supplier,https://www.fda.gov/media/104622/download,2017-03-13,"['Center for Veterinary Medicine','Human Foods Program']",['Import'],Final,FDA-2011-N-0143,No,
Assessment of Abuse Potential of Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessment-abuse-potential-drugs,https://www.fda.gov/media/116739/download,2017-01-18,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-2010-D-0026,No,
Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/comparative-analyses-and-related-comparative-use-human-factors-studies-drug-device-combination,https://www.fda.gov/media/102349/download,2017-01-17,['Center for Drug Evaluation and Research'],['Generic Drugs'],Draft,FDA-2016-D-4412,No,2017-03-13
Draft Guidance for Industry: Control of Listeria monocytogenes in Ready-To-Eat Foods,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-control-listeria-monocytogenes-ready-eat-foods,https://www.fda.gov/media/102633/download,2017-01-17,['Human Foods Program'],['Listeria'],Draft,FDA-2008-D-0096,No,2017-07-26
2016 Medical Gas Container-Closure Rule Questions and Answers Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/2016-medical-gas-container-closure-rule-questions-and-answers-guidance-industry,https://www.fda.gov/media/102638/download,2017-01-17,['Center for Drug Evaluation and Research'],"['Current Good Manufacturing Practice (CGMP)','Labeling']",Final,,No,
Repackaging of Certain Human Drug Products by Pharmacies and Outsourcing Facilities:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/repackaging-certain-human-drug-products-pharmacies-and-outsourcing-facilities,https://www.fda.gov/media/90978/download,2017-01-13,['Center for Drug Evaluation and Research'],"['Compliance','Compounding','Pharmaceutical Quality','Current Good Manufacturing Practice (CGMP)']",Final,FDA-2014-D-1524,No,
Emergency Use Authorization of Medical Products and Related Authorities:  Guidance for Industry and Other Stakeholders,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-medical-products-and-related-authorities,https://www.fda.gov/media/97321/download,2017-01-13,['Office of the Commissioner'],"['Premarket','Emergencies']",Final,FDA-2016-D-1025,No,2016-06-04
"Factors to Consider When Making Benefit-Risk Determinations for Medical Device Investigational Device Exemptions:  Guidance for Investigational Device Exemption Sponsors, Sponsor-Investigators and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/factors-consider-when-making-benefit-risk-determinations-medical-device-investigational-device,https://www.fda.gov/media/92427/download,2017-01-13,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','Clinical - Medical','Investigational Device Exemption (IDE)']",Final,FDA-2015-D-1777,No,2015-09-16
Nonproprietary Naming of Biological Products Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonproprietary-naming-biological-products-guidance-industry,https://www.fda.gov/media/93218/download,2017-01-12,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Labeling'],Final,FDA-2013-D-1543,No,
Guidance for Industry 180-Day Exclusivity: Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-180-day-exclusivity-questions-and-answers,https://www.fda.gov/media/102650/download,2017-01-12,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Generic Drugs'],Draft,FDA-2016-D-4645,No,2017-03-12
Recommended Warning for Over-the-Counter Acetaminophen-Containing Drug Products and Labeling Statements Regarding Serious Skin Reactions,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommended-warning-over-counter-acetaminophen-containing-drug-products-and-labeling-statements,https://www.fda.gov/media/90572/download,2017-01-11,['Center for Drug Evaluation and Research'],"['Compliance','Current Good Manufacturing Practice (CGMP)','Over-the-Counter Drugs']",Final,FDA-2014-D-1862,No,
Current Good Manufacturing Practice Requirements for Combination Products:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-manufacturing-practice-requirements-combination-products,https://www.fda.gov/media/90425/download,2017-01-11,"['Office of Inspections and Investigations','Office of the Commissioner','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Investigation & Enforcement','Compounding','Pharmaceutical Quality','Current Good Manufacturing Practice (CGMP)']",Final,FDA-2015-D-0198,No,2015-03-30
Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers: Questions and Answers Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/annual-reporting-prescription-drug-wholesale-distributors-and-third-party-logistics-providers,https://www.fda.gov/media/102639/download,2017-01-10,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Draft,FDA-2016-D-4646,No,
"Recommendations for Assessment of Blood Donor Eligibility, Donor Deferral and Blood Product Management in Response to Ebola Virus:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-assessment-blood-donor-eligibility-donor-deferral-and-blood-product-management,https://www.fda.gov/media/94902/download,2017-01-10,['Center for Biologics Evaluation and Research'],"['Blood','Ebola','Blood Products']",Final,FDA-2014-D-2175,No,
"Electronic Drug Product Reporting for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act.”",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-drug-product-reporting-human-drug-compounding-outsourcing-facilities-under-section-503b,https://www.fda.gov/media/90173/download,2017-01-03,['Center for Drug Evaluation and Research'],"['Administrative / Procedural','Compounding']",Final,FDA-2013-N-1428,No,
Botanical Drug Development: Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/botanical-drug-development-guidance-industry,https://www.fda.gov/media/93113/download,2016-12-29,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2000-D-0103,No,
Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference  Product,,,2016-12-29,[],"['Biosimilars','Clinical - Pharmacology']",Final,FDA-2014-D-0234,No,
"Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prescription-requirement-under-section-503a-federal-food-drug-and-cosmetic-act-guidance-industry,https://www.fda.gov/media/97347/download,2016-12-29,['Center for Drug Evaluation and Research'],['Compounding'],Final,FDA-2016-D-0269,No,
ANDA Submissions -- Refuse-to-Receive Standards Rev.2,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/anda-submissions-refuse-receive-standards-rev2,https://www.fda.gov/media/86660/download,2016-12-28,['Center for Drug Evaluation and Research'],"['User Fees','Generic Drugs']",Final,FDA-2013-D-1120,No,
Postmarket Management of Cybersecurity in Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarket-management-cybersecurity-medical-devices,https://www.fda.gov/media/95862/download,2016-12-28,['Center for Devices and Radiological Health'],"['Postmarket','Premarket','510(k)','Premarket Approval (PMA)','Digital Health','Labeling','Safety - Issues, Errors, and Problems']",Final,FDA-2015-D-5105,No,
"Factors to Consider Regarding Benefit-Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions:  Guidance for Industry and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/factors-consider-regarding-benefit-risk-medical-device-product-availability-compliance-and,https://www.fda.gov/media/98657/download,2016-12-27,['Center for Devices and Radiological Health'],"['Postmarket','Recalls','Adverse Event Reporting System (FAERS)','510(k)','Premarket Approval (PMA)','Investigational Device Exemption (IDE)','HUD/HDE','Adverse Event Reporting','Combination Products','Safety - Issues, Errors, and Problems','Laser Notice']",Final,FDA-2016-D-1495,No,2016-09-14
Draft Guidance for Industry: Lead in Cosmetic Lip Products and Externally Applied Cosmetics: Recommended Maximum Level,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-lead-cosmetic-lip-products-and-externally-applied-cosmetics-recommended,https://www.fda.gov/media/99866/download,2016-12-22,['Office of the Commissioner'],,Draft,FDA-2014-D-2275,No,2017-02-21
"CVM GFI #234 Question-Based Review for the Chemistry, Manufacturing, and Controls Technical Section of Animal Drug Applications",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-234-question-based-review-chemistry-manufacturing-and-controls-technical-section-animal-drug,https://www.fda.gov/media/96718/download,2016-12-20,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)']",Final,FDA-2016-D-0620,No,2016-05-17
CVM GFI #224 (VICH GL52) Bioequivalence: Blood Level Bioequivalence Study,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-224-vich-gl52-bioequivalence-blood-level-bioequivalence-study,https://www.fda.gov/media/89840/download,2016-12-16,['Center for Veterinary Medicine'],"['Generic Animal Drugs','Generic Drugs','New Animal Drug Application (NADA)','VICH']",Final,FDA-2014-D-1352,No,2014-11-24
Civil Money Penalties and No-Tobacco-Sale Orders for Tobacco Retailers Responses to Frequently Asked Questions (*Revised):  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/civil-money-penalties-and-no-tobacco-sale-orders-tobacco-retailers-responses-frequently-asked,https://www.fda.gov/media/92558/download,2016-12-16,['Center for Tobacco Products'],['No-tobacco-sale order (NTSO)'],Final,FDA-2012-D-1083,No,
Gifts to FDA: Evaluation and Acceptance:  Guidance for the Public and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/gifts-fda-evaluation-and-acceptance,https://www.fda.gov/media/98917/download,2016-12-16,['Office of the Commissioner'],,Final,FDA-2015-D-4361,No,2016-09-12
"Use of Electronic Informed Consent in Clinical Investigations – Questions and Answers:  Guidance for Institutional Review Boards, Investigators, and Sponsors",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-electronic-informed-consent-clinical-investigations-questions-and-answers,https://www.fda.gov/media/116850/download,2016-12-15,"['Office of the Commissioner','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Administrative / Procedural'],Final,FDA-2015-D-0390,No,
"Public Notification of Emerging Postmarket Medical Device Signals (""Emerging Signals""):  Guidance for Industry and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/public-notification-emerging-postmarket-medical-device-signals-emerging-signals,https://www.fda.gov/media/95125/download,2016-12-14,['Center for Devices and Radiological Health'],"['Postmarket','Safety - Issues, Errors, and Problems']",Final,FDA-2015-D-4803,No,
"Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/source-animal-product-preclinical-and-clinical-issues-concerning-use-xenotransplantation-products,https://www.fda.gov/media/102126/download,2016-12-13,['Center for Biologics Evaluation and Research'],['Xenotransplantation'],Final,FDA-2000-D-0129,No,
Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products — Content and Format,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-labeling-human-prescription-drug-and-biological-products-content-and-format,https://www.fda.gov/media/74346/download,2016-12-05,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Labeling'],Final,FDA-2009-D-0095,No,
CPG Sec 615.115 Extralabel Use of Medicated Feeds for Minor Species,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-615115-extralabel-use-medicated-feeds-minor-species,https://www.fda.gov/media/71960/download,2016-12-01,['Center for Veterinary Medicine'],"['Investigation & Enforcement','Medicated Feed','Minor Use/ Minor Species (MUMS)']",Final,,No,
Providing Postmarket Periodic Safety Reports in the ICH E2C(R2) Format (Periodic Benefit-Risk Evaluation Report),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-postmarket-periodic-safety-reports-ich-e2cr2-format-periodic-benefit-risk-evaluation,https://www.fda.gov/media/85520/download,2016-11-29,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Safety - Issues, Errors, and Problems']",Final,FDA-2013-D-0349,No,
Mitigating the Risk of Cross-Contamination from Valves and Accessories Used for Irrigation Through Flexible Gastrointestinal Endoscopes:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/mitigating-risk-cross-contamination-valves-and-accessories-used-irrigation-through-flexible,https://www.fda.gov/media/90148/download,2016-11-29,['Center for Devices and Radiological Health'],"['Premarket','Gastroenterology-Urology']",Final,FDA-2014-D-2153,No,
Submission of Quality Metrics Data Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-quality-metrics-data-guidance-industry,https://www.fda.gov/media/93012/download,2016-11-25,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Chemistry, Manufacturing, and Controls (CMC)','Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Draft,FDA-2015-D-2537,No,2017-01-23
Nonprescription Sunscreen Drug Products – Format and Content of Data Submissions,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonprescription-sunscreen-drug-products-format-and-content-data-submissions,https://www.fda.gov/media/94249/download,2016-11-23,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Final,FDA-2015-D-4033,No,
Contract Manufacturing Arrangements for Drugs: Quality Agreements Guidance for Industry:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/contract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry,https://www.fda.gov/media/86193/download,2016-11-23,"['Center for Veterinary Medicine','Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Compliance','Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,FDA-2013-D-0558,No,
Nonprescription Sunscreen Drug Products – Safety and Effectiveness Data,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonprescription-sunscreen-drug-products-safety-and-effectiveness-data,https://www.fda.gov/media/94513/download,2016-11-22,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Final,FDA-2015-D-4021,No,
Safety Testing of Drug Metabolites,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-testing-drug-metabolites,https://www.fda.gov/media/72279/download,2016-11-22,['Center for Drug Evaluation and Research'],"['Device & Drug Safety','Pharmacology/Toxicology']",Final,FDA-2008-D-0065,No,
Generic Drug User Fee Amendments of 2012: Questions and Answers Related to User Fee Assessments:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/generic-drug-user-fee-amendments-2012-questions-and-answers-related-user-fee-assessments,https://www.fda.gov/media/84730/download,2016-11-22,['Center for Drug Evaluation and Research'],"['User Fees','Generic Drugs']",Final,FDA-2012-D-0880,No,
Non-Inferiority Clinical Trials,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-inferiority-clinical-trials,https://www.fda.gov/media/78504/download,2016-11-08,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Final,FDA-2010-D-0075,No,
Medical Device Reporting for Manufacturers :  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-device-reporting-manufacturers,https://www.fda.gov/media/86420/download,2016-11-08,['Center for Devices and Radiological Health'],"['Postmarket','Adverse Event Reporting System (FAERS)','Adverse Event Reporting']",Final,FDA-2013-D-0743,No,
Clinical Considerations for Investigational Device Exemptions (IDEs) for Neurological Devices Targeting Disease Progression and Clinical Outcomes:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-considerations-investigational-device-exemptions-ides-neurological-devices-targeting,https://www.fda.gov/media/96228/download,2016-11-07,['Center for Devices and Radiological Health'],"['Premarket','Advisory Committees','510(k)','Premarket Approval (PMA)','HUD/HDE','Clinical - Medical','Good Clinical Practice (GCP)','Labeling','Safety - Issues, Errors, and Problems','Laser Notice','Neurological']",Final,FDA-2016-D-0539,No,2016-06-05
"CVM GFI #241 Small Entity Compliance Guide – What You Need to Know About the FDA Regulation: Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals (21 CFR Part 507)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-241-small-entity-compliance-guide-what-you-need-know-about-fda-regulation-current-good,https://www.fda.gov/media/97470/download,2016-11-01,['Center for Veterinary Medicine'],['Animal Feed'],Final,FDA-2011-N-0922,No,
Guidance for Industry: Submitting Forms for Food Canning Establishment Registration and Food Process Filing to FDA in Electronic or Paper Format,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-submitting-forms-food-canning-establishment-registration-and-food-process-filing,https://www.fda.gov/media/93770/download,2016-11-01,['Human Foods Program'],"['Registration','Canned Foods']",Final,FDA-2013-D-1622,No,
"Revised Recommendations for Determining Eligibility of Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products Who Have Received Human-Derived Clotting Factor Concentrates:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/revised-recommendations-determining-eligibility-donors-human-cells-tissues-and-cellular-and-tissue,https://www.fda.gov/media/101401/download,2016-11-01,['Center for Biologics Evaluation and Research'],['Tissue'],Final,FDA-2016-D-3750,No,
"Small Entity Compliance Guide: What You Need to Know About Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-what-you-need-know-about-current-good-manufacturing-practice-hazard,https://www.fda.gov/media/100921/download,2016-10-31,['Human Foods Program'],,Final,FDA-2011-N-0920,No,
Labeling for Permanent Hysteroscopically-Placed Tubal Implants Intended for Sterilization:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-permanent-hysteroscopically-placed-tubal-implants-intended-sterilization,https://www.fda.gov/media/96315/download,2016-10-31,['Center for Devices and Radiological Health'],"['Postmarket','Biostatistics','Adverse Event Reporting System (FAERS)','510(k)','Adverse Event Reporting','Labeling','Gastroenterology-Urology']",Final,FDA-2016-D-0435,No,2016-04-29
"Draft Guidance for Industry: Describing a Hazard That Needs Control in Documents Accompanying the Food, as Required by Four Rules Implementing FSMA",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-describing-hazard-needs-control-documents-accompanying-food-required-four,https://www.fda.gov/media/100907/download,2016-10-30,"['Center for Veterinary Medicine','Human Foods Program','Office of the Commissioner']",,Draft,FDA-2016-D-2841,No,2017-05-01
Collection of Race and Ethnicity Data in Clinical Trials:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/collection-race-and-ethnicity-data-clinical-trials,https://www.fda.gov/media/75453/download,2016-10-26,"['Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research','Office of the Commissioner','Office of the Commissioner']","['Clinical - Medical','Good Clinical Practice (GCP)','Investigational Device Exemption (IDE)']",Final,FDA-2016-D-3561,No,
"Low Sexual Interest, Desire, and/or Arousal in Women: Developing Drugs for Treatment Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/low-sexual-interest-desire-andor-arousal-women-developing-drugs-treatment-guidance-industry,https://www.fda.gov/media/100833/download,2016-10-25,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2016-D-2817,No,2016-12-25
CPG Sec. 101.100 FDA Considerations for Recommending Charges for Causing the Introduction of Violative Products into Interstate Commerce,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-101100-fda-considerations-recommending-charges-causing-introduction-violative-products,https://www.fda.gov/media/100824/download,2016-10-17,['Office of Regulatory Affairs'],['Investigation & Enforcement'],Final,,No,
Sunscreen Innovation Act:  Section 586C(c) Advisory Committee Process,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sunscreen-innovation-act-section-586cc-advisory-committee-process,https://www.fda.gov/media/94237/download,2016-10-11,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Final,FDA-2015-D-3990,No,
Sunscreen Innovation Act: Withdrawal of a 586A Request or Pending Request Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sunscreen-innovation-act-withdrawal-586a-request-or-pending-request-guidance-industry,https://www.fda.gov/media/94523/download,2016-10-11,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Final,FDA-2015-D-4012,No,
Tropical Disease Priority Review Vouchers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/tropical-disease-priority-review-vouchers,https://www.fda.gov/media/129278/download,2016-10-06,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Administrative / Procedural','Over-the-Counter Drugs']",Final,FDA-2008-D-0530,No,
Head Lice Infestation: Developing Drugs for Topical Treatment Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/head-lice-infestation-developing-drugs-topical-treatment-guidance-industry,https://www.fda.gov/media/94903/download,2016-10-05,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,,No,
Guidance for Industry:  Frequently Asked Questions About GRAS for Substances Intended for Use in Human or Animal Food,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-frequently-asked-questions-about-gras-substances-intended-use-human-or-animal-food,https://www.fda.gov/media/101042/download,2016-09-30,"['Center for Veterinary Medicine','Human Foods Program']","['Food & Color Additives','GRAS']",Final,FDA-2020-D-1908,No,
Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q7-good-manufacturing-practice-guidance-active-pharmaceutical-ingredients-guidance-industry,https://www.fda.gov/media/71518/download,2016-09-30,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-1995-D-0288,No,
Guidance for Industry: Use of the Term “Healthy” in the Labeling of Human Food Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-use-term-healthy-labeling-human-food-products,https://www.fda.gov/media/100520/download,2016-09-28,['Human Foods Program'],['Labeling'],Final,FDA-2016-D-2335,No,
"Self-Identification of Generic Drug Facilities, Sites, and Organizations; Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/self-identification-generic-drug-facilities-sites-and-organizations-guidance-industry,https://www.fda.gov/media/83966/download,2016-09-23,['Center for Drug Evaluation and Research'],"['User Fees','Generic Drugs']",Final,FDA-2012-D-0881,No,
CVM GFI #233 Veterinary Feed Directive Common Format Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-233-veterinary-feed-directive-common-format-questions-and-answers,https://www.fda.gov/media/94752/download,2016-09-22,['Center for Veterinary Medicine'],"['Antimicrobial Resistance','Labeling','New Animal Drug Application (NADA)']",Final,FDA-2010-N-0155,No,2016-02-01
Reporting of Computational Modeling Studies in Medical Device Submissions:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reporting-computational-modeling-studies-medical-device-submissions,https://www.fda.gov/media/87586/download,2016-09-21,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Premarket Approval (PMA)','Investigational Device Exemption (IDE)']",Final,FDA-2013-D-1530,No,
Qualification of Biomarker Total Kidney Volume in Studies for Treatment of Autosomal Dominant Polycystic Kidney Disease Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/qualification-biomarker-total-kidney-volume-studies-treatment-autosomal-dominant-polycystic-kidney,https://www.fda.gov/media/93105/download,2016-09-16,['Center for Drug Evaluation and Research'],['Drug Development Tools'],Final,FDA-2015-D-2843,No,
Recommendations for Microbial Vectors Used for Gene Therapy:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-microbial-vectors-used-gene-therapy,https://www.fda.gov/media/94200/download,2016-09-16,['Center for Biologics Evaluation and Research'],"['Cellular & Gene Therapy','Gene Therapy']",Final,FDA-2015-D-3399,No,
ANDA Submissions — Refuse to Receive for Lack of Justification of Impurity Limits:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/anda-submissions-refuse-receive-lack-justification-impurity-limits,https://www.fda.gov/media/89932/download,2016-09-14,['Center for Drug Evaluation and Research'],"['User Fees','Generic Drugs']",Final,FDA-2014-D-1292,No,
Qualification of Biomarker Plasma Fibrinogen in Studies Examining Exacerbations and/or All-Cause Mortality in Patients With Chronic Obstructive Pulmonary Disease Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/qualification-biomarker-plasma-fibrinogen-studies-examining-exacerbations-andor-all-cause-mortality,https://www.fda.gov/media/92782/download,2016-09-13,['Center for Drug Evaluation and Research'],['Drug Development Tools'],Final,FDA-2015-D-2244,No,
Draft Guidance for Industry: Substantiation for Structure/Function Claims Made in Infant Formula Labels and Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-substantiation-structurefunction-claims-made-infant-formula-labels-and,https://www.fda.gov/media/99691/download,2016-09-09,['Human Foods Program'],"['Infant Formula & Foods','Labeling']",Draft,FDA-2016-D-2241,No,2017-02-21
"Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Living Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps):  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-nucleic-acid-tests-reduce-risk-transmission-west-nile-virus-living-donors-human-cells-tissues,https://www.fda.gov/media/87050/download,2016-09-08,['Center for Biologics Evaluation and Research'],"['Policy Making','Tissue']",Final,FDA-2013-D-1143,No,
CPG Sec. 150.200 Compliance Review of Private Laboratory Analytical Packages (PLAPs),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-150200-compliance-review-private-laboratory-analytical-packages-plaps,https://www.fda.gov/media/100067/download,2016-09-01,['Office of Inspections and Investigations'],['Investigation & Enforcement'],Final,,No,
Guidance for Industry: Necessity of the Use of Food Product Categories in Food Facility Registrations and Updates to Food Product Categories (2016 Edition),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-necessity-use-food-product-categories-food-facility-registrations-and-updates-food,https://www.fda.gov/media/84245/download,2016-09-01,"['Center for Veterinary Medicine','Human Foods Program']",['Registration'],Final,FDA-2012-D-0585,No,
"“Harmful and Potentially Harmful Constituents” in Tobacco Products as Used in Section 904(e) of the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/harmful-and-potentially-harmful-constituents-tobacco-products-used-section-904e-federal-food-drug,https://www.fda.gov/media/80109/download,2016-09-01,['Center for Tobacco Products'],,Final,FDA-2010-D-0281,No,2016-09-01
Guidance for the Submission of 510(k)s for Solid State X-ray Imaging Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-submission-510ks-solid-state-x-ray-imaging-devices,https://www.fda.gov/media/71798/download,2016-09-01,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Radiological Health','Radiology']",Final,FDA-1997-N-0389,No,
CVM GFI #239 Human Food By-Products For Use As Animal Food,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-239-human-food-products-use-animal-food,https://www.fda.gov/media/97467/download,2016-08-25,['Center for Veterinary Medicine'],"['Animal Feed','Current Good Manufacturing Practice (CGMP)']",Draft,FDA-2016-D-1220,No,2016-11-23
"Draft Guidance for Industry: Classification of Activities as Harvesting, Packing, Holding, or Manufacturing/Processing for Farms and Facilities",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-classification-activities-harvesting-packing-holding-or,https://www.fda.gov/media/99911/download,2016-08-25,['Human Foods Program'],,Draft,FDA-2016-D-2373,No,2017-02-21
"Patient Preference Information - Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling:  Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-preference-information-voluntary-submission-review-premarket-approval-applications,https://www.fda.gov/media/92593/download,2016-08-24,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",,Final,FDA-2015-D-1580,No,
Small Entity Compliance Guide: Calorie Labeling of Articles of Food in Vending Machines,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-calorie-labeling-articles-food-vending-machines,https://www.fda.gov/media/99885/download,2016-08-16,['Human Foods Program'],"['Labeling','Nutrition Label']",Final,FDA-2011-F-0171,No,
Draft Guidance for Industry: Calorie Labeling of Articles of Food in Vending Machines,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-calorie-labeling-articles-food-vending-machines,https://www.fda.gov/media/99814/download,2016-08-16,['Human Foods Program'],"['Labeling','Nutrition Label']",Draft,FDA-2011-F-0171,No,2016-09-30
Premarket Notification (510(k)) Submissions for Bipolar Electrosurgical Vessel Sealers for General Surgery:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-notification-510k-submissions-bipolar-electrosurgical-vessel-sealers-general-surgery,https://www.fda.gov/media/87987/download,2016-08-15,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Clinical - Medical','Good Clinical Practice (GCP)','Labeling','General & Plastic Surgery']",Final,FDA-2014-D-0218,No,
Determining Donor Eligibility for Autologous Donors of Blood and Blood Components Intended Solely for Autologous Use - Compliance Policy:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/determining-donor-eligibility-autologous-donors-blood-and-blood-components-intended-solely,https://www.fda.gov/media/99325/download,2016-08-01,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-2016-D-2071,No,
"Use of Nucleic Acid Tests to Reduce the Risk of Transmission of Hepatitis B Virus from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-nucleic-acid-tests-reduce-risk-transmission-hepatitis-b-virus-donors-human-cells-tissues-and,https://www.fda.gov/media/99642/download,2016-08-01,['Center for Biologics Evaluation and Research'],['Tissue'],Final,FDA-2015-D-5073,No,
Adaptive Designs for Medical Device Clinical Studies:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-designs-medical-device-clinical-studies,https://www.fda.gov/media/92671/download,2016-07-27,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','Good Clinical Practice (GCP)','Premarket Approval (PMA)','Investigational Device Exemption (IDE)','HUD/HDE']",Final,FDA-2015-D-1439,No,
E2C(R2) Periodic Benefit-Risk Evaluation Report – Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2cr2-periodic-benefit-risk-evaluation-report-questions-and-answers,https://www.fda.gov/media/99228/download,2016-07-19,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['ICH-Efficacy'],Final,FDA-2012-D-0315,No,
E2C(R2) Periodic Benefit-Risk Evaluation Report (PBRER),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2cr2-periodic-benefit-risk-evaluation-report-pbrer,https://www.fda.gov/media/83371/download,2016-07-18,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['ICH-Efficacy'],Final,FDA-2012-D-0315,No,
Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/principles-codevelopment-in-vitro-companion-diagnostic-device-therapeutic-product,https://www.fda.gov/media/99030/download,2016-07-15,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Premarket Approval (PMA)','Laboratory Tests','IVDs (In Vitro Diagnostic Devices)']",Draft,FDA-2016-D-1703,No,2016-10-13
Updating ANDA Labeling After the Marketing Application for the Reference Listed Drug Has Been Withdrawn Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/updating-anda-labeling-after-marketing-application-reference-listed-drug-has-been-withdrawn-guidance,https://www.fda.gov/media/99041/download,2016-07-11,['Center for Drug Evaluation and Research'],['Generic Drugs'],Draft,FDA-2016-D-1673,No,
Guidance for Industry: FDA's Policy on Declaring Small Amounts of Nutrients and Dietary Ingredients on Nutrition Labels,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-fdas-policy-declaring-small-amounts-nutrients-and-dietary-ingredients-nutrition,https://www.fda.gov/media/98834/download,2016-07-01,['Human Foods Program'],"['Labeling','Nutrition Label']",Final,FDA-2015-D-1839,No,
"Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/early-clinical-trials-live-biotherapeutic-products-chemistry-manufacturing-and-control-information,https://www.fda.gov/media/82945/download,2016-06-30,['Center for Biologics Evaluation and Research'],['Good Clinical Practice (GCP)'],Final,FDA-2010-D-0500,No,
"Procedures for Evaluating Appearance Issues and Granting Authorizations for Participation in FDA Advisory Committees: Draft Guidance for the Public, FDA Advisory Committee Members, and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/procedures-evaluating-appearance-issues-and-granting-authorizations-participation-fda-advisory,https://www.fda.gov/media/98852/download,2016-06-29,"['Human Foods Program','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research','Center for Tobacco Products','Office of the Commissioner','National Center for Toxicological Research','Office of the Commissioner']",['Advisory Committees'],Draft,FDA-2016-D-1399,No,2016-06-29
Leveraging Existing Clinical Data for Extrapolation to Pediatric Uses of Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/leveraging-existing-clinical-data-extrapolation-pediatric-uses-medical-devices,https://www.fda.gov/media/91889/download,2016-06-21,['Center for Devices and Radiological Health'],"['Premarket','Good Clinical Practice (GCP)','Pediatric Product Development','Premarket Approval (PMA)','HUD/HDE']",Final,FDA-2015-D-1376,No,2016-09-19
"CVM GFI #238 Modified Release Veterinary Parenteral Dosage Forms: Development, Evaluation, and Establishment of Specifications",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-238-modified-release-veterinary-parenteral-dosage-forms-development-evaluation-and,https://www.fda.gov/media/95426/download,2016-06-17,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)']",Final,FDA-2015-N-4563,No,2016-03-21
"Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interim-policy-compounding-using-bulk-drug-substances-under-section-503a-federal-food-drug-and,https://www.fda.gov/media/94398/download,2016-06-10,['Center for Drug Evaluation and Research'],"['Administrative / Procedural','Compounding','Device & Drug Safety']",Final,FDA-2015-D-3517,No,
"Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interim-policy-compounding-using-bulk-drug-substances-under-section-503b-federal-food-drug-and-0,https://www.fda.gov/media/174453/download,2016-06-10,['Center for Drug Evaluation and Research'],"['Administrative / Procedural','Compounding']",Final,FDA-2015-D-3539,No,
Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expanded-access-investigational-drugs-treatment-use-questions-and-answers,https://www.fda.gov/media/85675/download,2016-06-03,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Administrative / Procedural','Good Clinical Practice (GCP)']",Final,FDA-2013-D-0446,No,
Guidance for Industry: Ingredients Declared as Evaporated Cane Juice,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-ingredients-declared-evaporated-cane-juice,https://www.fda.gov/media/97827/download,2016-05-26,['Human Foods Program'],"['Juice','Labeling']",Final,FDA-2009-D-0430,No,
Considerations for Use of Histopathology and Its Associated Methodologies to Support Biomarker Qualification Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-histopathology-and-its-associated-methodologies-support-biomarker-qualification,https://www.fda.gov/media/82768/download,2016-05-16,['Center for Drug Evaluation and Research'],"['Administrative / Procedural','Good Clinical Practice (GCP)']",Final,FDA-2011-D-0872,No,
Requirements for the Submission of Data Needed to Calculate User Fees for Domestic Manufacturers and Importers of Tobacco Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requirements-submission-data-needed-calculate-user-fees-domestic-manufacturers-and-importers-tobacco,https://www.fda.gov/media/97683/download,2016-05-10,['Center for Tobacco Products'],['User Fees'],Final,FDA-2014-D-0917,No,
Tobacco Product Master Files:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/tobacco-product-master-files,https://www.fda.gov/media/97632/download,2016-05-10,['Center for Tobacco Products'],,Final,FDA-2015-D-2325,No,
Guidance for Industry: A Labeling Guide for Restaurants and Retail Establishments Selling Away-From-Home Foods - Part II,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-labeling-guide-restaurants-and-retail-establishments-selling-away-home-foods-part-0,https://www.fda.gov/media/93414/download,2016-05-05,['Human Foods Program'],['Labeling'],Final,FDA-2011-F-0172,No,
"CPG Sec 540.275 Crabmeat – Fresh and Frozen – Adulteration with Filth, Involving the Presence of Escherichia coli",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540275-crabmeat-fresh-and-frozen-adulteration-filth-involving-presence-escherichia-coli,https://www.fda.gov/media/97455/download,2016-04-30,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Seafood/Seafood Product']",Final,FDA-2014-D-1842,No,
CVM GFI #231 Distributor Labeling for New Animal Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-231-distributor-labeling-new-animal-drugs,https://www.fda.gov/media/93540/download,2016-04-20,['Center for Veterinary Medicine'],"['Administrative / Procedural','Advertising','Labeling','New Animal Drug Application (NADA)']",Final,FDA-2015-D-3056,No,2015-11-09
Technical Performance Assessment of Digital Pathology Whole Slide Imaging Devices :  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-performance-assessment-digital-pathology-whole-slide-imaging-devices,https://www.fda.gov/media/90791/download,2016-04-20,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Labeling','Laboratory Tests','IVDs (In Vitro Diagnostic Devices)']",Final,FDA-2015-D-0230,No,
Radiation Biodosimetry Medical Countermeasure Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/radiation-biodosimetry-medical-countermeasure-devices,https://www.fda.gov/media/90385/download,2016-04-18,['Center for Devices and Radiological Health'],"['Premarket','Emergencies','Laboratory Tests','IVDs (In Vitro Diagnostic Devices)','Radiological Health']",Final,FDA-2014-D-2065,No,2015-03-30
Guidance for Industry: Exempt Infant Formula Production,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-exempt-infant-formula-production,https://www.fda.gov/media/87996/download,2016-04-15,['Human Foods Program'],['Infant Formula & Foods'],Final,FDA-2014-D-0044,No,
Safety Considerations for Product Design to Minimize Medication Errors Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-considerations-product-design-minimize-medication-errors-guidance-industry,https://www.fda.gov/media/84903/download,2016-04-12,['Center for Drug Evaluation and Research'],"['Safety - Issues, Errors, and Problems']",Final,FDA-2012-D-1005,No,
Contents of a Complete Submission for the Evaluation of Proprietary Names,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/contents-complete-submission-evaluation-proprietary-names,https://www.fda.gov/media/72144/download,2016-04-11,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Labeling','Safety - Issues, Errors, and Problems']",Final,FDA-2008-D-0592,No,
"CVM GFI #156 Comparability Protocols - Chemistry, Manufacturing, and Controls Information for New Animal Drugs",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-156-comparability-protocols-chemistry-manufacturing-and-controls-information-new-animal,https://www.fda.gov/media/69943/download,2016-04-04,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)']",Final,FDA-2016-D-0938,No,
"CPG Sec. 690.150 Labeling and Marketing of Dog and Cat Food Diets Intended to Diagnose, Cure, Mitigate, Treat, or Prevent Diseases",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-690150-labeling-and-marketing-dog-and-cat-food-diets-intended-diagnose-cure-mitigate-treat,https://www.fda.gov/media/83998/download,2016-04-01,['Center for Veterinary Medicine'],"['Investigation & Enforcement','Labeling','Pet Food']",Final,FDA-2012-D-0755,No,2012-11-09
Assessment of Radiofrequency-Induced Heating in the Magnetic Resonance (MR) Environment for Multi-Configuration Passive Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessment-radiofrequency-induced-heating-magnetic-resonance-mr-environment-multi-configuration,https://www.fda.gov/media/92447/download,2016-03-22,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Premarket Approval (PMA)','Investigational Device Exemption (IDE)','Anesthesiology','Physical Medicine','Orthopedic','Ophthalmic','Obstetrical & Gynecological','Neurological','Cardiovascular','General Hospital & Personal Use','General & Plastic Surgery','Gastroenterology-Urology','Ear','Nose & Throat','Dental','Radiology','Labeling','Safety - Issues, Errors, and Problems']",Final,FDA-2015-D-2104,No,2015-08-28
CVM GFI #158 Use of Material from Deer and Elk in Animal Feed,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-158-use-material-deer-and-elk-animal-feed,https://www.fda.gov/media/69936/download,2016-03-16,['Center for Veterinary Medicine'],"['Bovine Spongiform Encephalopathy (BSE)','Animal Feed']",Final,FDA-2003-D-0432,No,
Guidance for Industry: Acrylamide in Foods,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-acrylamide-foods,https://www.fda.gov/media/87150/download,2016-03-11,['Human Foods Program'],,Final,FDA-2013-D-0715,No,
CVM GFI #203 Ensuring Safety of Animal Feed Maintained and Fed On-Farm,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-203-ensuring-safety-animal-feed-maintained-and-fed-farm,https://www.fda.gov/media/91080/download,2016-03-09,['Center for Veterinary Medicine'],['Animal Feed'],Final,FDA-2014-D-1180,No,2015-06-03
"Investigating and Reporting Adverse Reactions Related to Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) Regulated Solely under Section 361 of the Public Health Service Act and 21 CFR Part 1271:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigating-and-reporting-adverse-reactions-related-human-cells-tissues-and-cellular-and-tissue,https://www.fda.gov/media/91082/download,2016-03-08,['Center for Biologics Evaluation and Research'],['Tissue'],Final,FDA-2015-D-0309,No,
Medical Devices and Clinical Trial Design for the Treatment or Improvement in the Appearance of Fungally-Infected Nails:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-devices-and-clinical-trial-design-treatment-or-improvement-appearance-fungally-infected,https://www.fda.gov/media/90831/download,2016-03-07,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Premarket Approval (PMA)','Investigational Device Exemption (IDE)','HUD/HDE','General & Plastic Surgery','Good Clinical Practice (GCP)','Labeling']",Final,FDA-2014-D-1849,No,
"Environmental Assessment: Questions and Answers Regarding Drugs With Estrogenic, Androgenic, or Thyroid Activity",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/environmental-assessment-questions-and-answers-regarding-drugs-estrogenic-androgenic-or-thyroid,https://www.fda.gov/media/91941/download,2016-03-04,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,,No,
"Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease, a Patient-Reported Outcome Instrument for the Measurement of Severity of Respiratory Symptoms in Stable Chronic Obstructive Pulmonary Disease: Qualification for Exploratory Use",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluating-respiratory-symptoms-chronic-obstructive-pulmonary-disease-patient-reported-outcome,https://www.fda.gov/media/96271/download,2016-03-01,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,,No,
"Requirements for Transactions with First Responders under Section 582 of the Federal Food, Drug, and Cosmetic Act— Compliance Policy Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requirements-transactions-first-responders-under-section-582-federal-food-drug-and-cosmetic-act,https://www.fda.gov/media/96584/download,2016-02-29,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2016-D-0631,No,
"Small Entity Compliance Guide: Alpha-Linolenic Acid, Eicosapentaenoic Acid, and Docosahexaenoic Acid Omega-3 Fatty Acids Nutrient Content Claims",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-alpha-linolenic-acid-eicosapentaenoic-acid-and-docosahexaenoic-acid,https://www.fda.gov/media/95996/download,2016-02-23,['Human Foods Program'],['Labeling'],Final,FDA-2016-N-0585,No,
Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/determining-extent-safety-data-collection-needed-late-stage-premarket-and-postapproval-clinical,https://www.fda.gov/media/82664/download,2016-02-19,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Final,FDA-2012-D-0096,No,
Immunogenicity-Related Considerations for Low Molecular Weight Heparin Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-related-considerations-low-molecular-weight-heparin-guidance-industry,https://www.fda.gov/media/88253/download,2016-02-18,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,,No,
Recommendations for Premarket Notifications for Lamotrigine and Zonisamide Assays:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-premarket-notifications-lamotrigine-and-zonisamide-assays,https://www.fda.gov/media/78784/download,2016-02-09,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2010-D-0395,No,
Applying Human Factors and Usability Engineering to Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applying-human-factors-and-usability-engineering-medical-devices,https://www.fda.gov/media/80481/download,2016-02-03,['Center for Devices and Radiological Health'],"['Postmarket','Premarket','510(k)','Premarket Approval (PMA)','Anesthesiology','Laboratory Tests','IVDs (In Vitro Diagnostic Devices)','Physical Medicine','Orthopedic','Ophthalmic','Obstetrical & Gynecological','Neurological','Molecular and Clinical Genetics','Immunology & Microbiology','Cardiovascular','Hematology & Pathology','General Hospital & Personal Use','General & Plastic Surgery','Gastroenterology-Urology','Ear','Nose & Throat','Digital Health','Dental','Clinical Chemistry & Clinical Toxicology','Radiology','Labeling','Safety - Issues, Errors, and Problems']",Final,FDA-2011-D-0469,No,2016-04-03
List of Highest Priority Devices for Human Factors Review: Draft Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/list-highest-priority-devices-human-factors-review,https://www.fda.gov/media/95804/download,2016-02-03,['Center for Devices and Radiological Health'],"['Postmarket','Premarket','Labeling','Safety - Issues, Errors, and Problems','Premarket Approval (PMA)','Investigational Device Exemption (IDE)']",Draft,FDA-2015-D-4599,No,2016-04-03
CVM GFI #226 Target Animal Safety Data Presentation and Statistical Analysis,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-226-target-animal-safety-data-presentation-and-statistical-analysis,https://www.fda.gov/media/91376/download,2016-01-21,['Center for Veterinary Medicine'],"['Target Animal – Safety','Investigational New Animal Drug (INAD)']",Final,FDA-2015-D-0839,No,2015-06-01
Implanted Blood Access Devices for Hemodialysis:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/implanted-blood-access-devices-hemodialysis,https://www.fda.gov/media/83696/download,2016-01-21,['Center for Devices and Radiological Health'],,Final,FDA-2013-D-0749,No,
Premarket Studies of Implantable Minimally Invasive Glaucoma Surgical (MIGS) Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-studies-implantable-minimally-invasive-glaucoma-surgical-migs-devices,https://www.fda.gov/media/90950/download,2015-12-15,['Center for Devices and Radiological Health'],"['Premarket','Ophthalmic','Premarket Approval (PMA)']",Final,FDA-2015-D-0288,No,2015-05-12
Premarket Notification Requirements Concerning Gowns Intended for Use in Health Care Settings:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-notification-requirements-concerning-gowns-intended-use-health-care-settings,https://www.fda.gov/media/92146/download,2015-12-09,['Center for Devices and Radiological Health'],['Ebola'],Final,FDA-2015-D-2261,No,2015-08-29
CVM GFI #204 Active Controls in Studies to Demonstrate Effectiveness of a New Animal Drug for use in Companion Animals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-204-active-controls-studies-demonstrate-effectiveness-new-animal-drug-use-companion-animals,https://www.fda.gov/media/83724/download,2015-12-01,['Center for Veterinary Medicine'],['Target Animal – Effectiveness'],Final,FDA-2012-D-0419,No,
Certification Process of Designated Medical Gases,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/certification-process-designated-medical-gases,https://www.fda.gov/media/85013/download,2015-11-25,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Draft,FDA-2012-D-1197,No,
"Organ-Specific Warnings: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use —:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/organ-specific-warnings-internal-analgesic-antipyretic-and-antirheumatic-drug-products-over-counter-0,https://www.fda.gov/media/83588/download,2015-11-17,['Center for Drug Evaluation and Research'],"['Compliance','Current Good Manufacturing Practice (CGMP)','Over-the-Counter Drugs','Pharmaceutical Quality']",Final,FDA-2012-D-0529,No,
Qualification of Biomarker — Galactomannan in studies of treatments of invasive,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/qualification-biomarker-galactomannan-studies-treatments-invasive,https://www.fda.gov/media/89512/download,2015-11-13,['Center for Drug Evaluation and Research'],['Drug Development Tools'],Draft,FDA-2013-D-1630,No,
Guidance for Industry: Questions and Answers on FDA’s Fortification Policy,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-fdas-fortification-policy,https://www.fda.gov/media/94563/download,2015-11-05,['Human Foods Program'],['Nutrition'],Final,,No,
DSCSA Implementation: Product Tracing Requirements for Dispensers — Compliance Policy (Revised) Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dscsa-implementation-product-tracing-requirements-dispensers-compliance-policy-revised-guidance,https://www.fda.gov/media/92650/download,2015-11-02,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2015-D-2270,No,
Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-immunodeficiency-virus-1-infection-developing-antiretroviral-drugs-treatment,https://www.fda.gov/media/86284/download,2015-11-02,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,,No,
Nonclinical Safety Evaluation of Reformulated Drug Products and Products Intended for Administration by an Alternate Route,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-safety-evaluation-reformulated-drug-products-and-products-intended-administration,https://www.fda.gov/media/72246/download,2015-10-28,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Final,FDA-2008-D-0142,No,
National Environmental Policy Act; Environmental Assessments for Tobacco Products; Categorical Exclusions – Small Entity Compliance Guide:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/national-environmental-policy-act-environmental-assessments-tobacco-products-categorical-exclusions,https://www.fda.gov/media/94445/download,2015-10-26,['Center for Tobacco Products'],['Environmental Safety'],Final,FDA-2013-N-1282,No,
CVM GFI #229 Evaluating the Effectiveness of New Animal Drugs for the Reduction of Pathogenic Shiga Toxin-Producing E. coli in Cattle,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-229-evaluating-effectiveness-new-animal-drugs-reduction-pathogenic-shiga-toxin-producing-e,https://www.fda.gov/media/91229/download,2015-10-19,['Center for Veterinary Medicine'],['Target Animal – Effectiveness'],Final,FDA-2015-D-0235,No,2015-04-27
"Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adverse-event-reporting-outsourcing-facilities-under-section-503b-federal-food-drug-and-cosmetic-act,https://www.fda.gov/media/90997/download,2015-10-08,['Center for Drug Evaluation and Research'],"['Compounding','Safety - Issues, Errors, and Problems']",Final,FDA-2014-D-2138,No,2015-05-17
Integrated Summary of Effectiveness,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/integrated-summary-effectiveness,https://www.fda.gov/media/72335/download,2015-10-08,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2008-D-0449,No,
Acceptability of Draft Labeling to Support Abbreviated New Drug Application Approval; Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acceptability-draft-labeling-support-abbreviated-new-drug-application-approval-guidance-industry,https://www.fda.gov/media/93971/download,2015-10-07,['Center for Drug Evaluation and Research'],['Generic Drugs'],Draft,FDA-2015-D-3378,No,
Product Development Under the Animal Rule,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-development-under-animal-rule,https://www.fda.gov/media/88625/download,2015-10-02,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Animal Rule'],Final,FDA-2009-D-0007,No,
CPG Sec 100.101 Crotalaria spp. Seeds in Grains,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-100101-crotalaria-spp-seeds-grains,https://www.fda.gov/media/94048/download,2015-09-21,"['Center for Veterinary Medicine','Office of Inspections and Investigations','Human Foods Program']",['Investigation & Enforcement'],Draft,FDA-2015-D-2994,No,
Enforcement Policy for Certain (Provisional) Tobacco Products that FDA Finds Not Substantially Equivalent:  Guidance for Industry and Tobacco Retailers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-certain-provisional-tobacco-products-fda-finds-not-substantially-equivalent,https://www.fda.gov/media/87919/download,2015-09-14,['Center for Tobacco Products'],,Final,FDA-2013-D-1600,No,
Nonclinical Evaluation of Endocrine-Related Drug Toxicity,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-evaluation-endocrine-related-drug-toxicity,https://www.fda.gov/media/86996/download,2015-09-09,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Final,,No,
"Use of Donor Screening Tests to Test Donors of Human Cells, Tissues and Cellular and Tissue-Based Products for Infection with Treponema pallidum (Syphilis):  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-donor-screening-tests-test-donors-human-cells-tissues-and-cellular-and-tissue-based-products,https://www.fda.gov/media/87143/download,2015-09-09,['Center for Biologics Evaluation and Research'],['Tissue'],Final,FDA-2013-D-1213,No,
CVM GFI #225 (VICH GL53) Electronic Exchange of Documents: File Format Recommendations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-225-vich-gl53-electronic-exchange-documents-file-format-recommendations,https://www.fda.gov/media/89444/download,2015-09-01,['Center for Veterinary Medicine'],"['Electronic Submissions','New Animal Drug Application (NADA)','VICH']",Final,FDA-2014-D-1177,No,2014-10-27
Guidance for Industry: Colored Sea Salt,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-colored-sea-salt,https://www.fda.gov/media/94036/download,2015-09-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-and-analysis-shedding-studies-virus-or-bacteria-based-gene-therapy-and-oncolytic-products,https://www.fda.gov/media/89036/download,2015-08-27,['Center for Biologics Evaluation and Research'],"['Cellular & Gene Therapy','Gene Therapy']",Final,FDA-2014-D-0852,No,
Uncomplicated Gonorrhea: Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/uncomplicated-gonorrhea-developing-drugs-treatment,https://www.fda.gov/media/88904/download,2015-08-18,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2014-D-0640,No,
Providing Submissions in Electronic Format — Postmarketing Safety Reports for Vaccines:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-submissions-electronic-format-postmarketing-safety-reports-vaccines,https://www.fda.gov/media/93233/download,2015-08-18,['Center for Biologics Evaluation and Research'],"['Postmarket','Electronic Submissions','Safety - Issues, Errors, and Problems','Vaccines']",Final,FDA-2014-D-0903,No,
Select Updates for Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/select-updates-non-clinical-engineering-tests-and-recommended-labeling-intravascular-stents-and,https://www.fda.gov/media/93134/download,2015-08-18,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2013-D-0920,No,
Endotoxin Testing Recommendations for Single-Use Intraocular Ophthalmic Devices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/endotoxin-testing-recommendations-single-use-intraocular-ophthalmic-devices,https://www.fda.gov/media/88615/download,2015-08-17,['Center for Devices and Radiological Health'],"['Premarket','Ophthalmic']",Final,FDA-2014-D-0332,No,
"Guidance For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-entities-considering-whether-register-outsourcing-facilities-under-section-503b-federal,https://www.fda.gov/media/90971/download,2015-08-11,['Center for Drug Evaluation and Research'],"['Administrative / Procedural','Compounding']",Final,,No,2015-05-17
Brief Summary and Adequate Directions for Use: Disclosing Risk Information in Consumer-Directed Print Advertisements and Promotional Labeling for Prescription Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/brief-summary-and-adequate-directions-use-disclosing-risk-information-consumer-directed-print,https://www.fda.gov/media/70768/download,2015-08-06,"['Center for Veterinary Medicine','Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Advertising'],Draft,FDA-2004-D-0500,No,2015-10-05
CVM GFI #220 Use of Nanomaterials in Food for Animals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-220-use-nanomaterials-food-animals,https://www.fda.gov/media/88828/download,2015-08-05,['Center for Veterinary Medicine'],"['Nanotechnology','Animal Food Additives']",Final,FDA-2013-D-1009,No,2014-09-10
Over-the-Counter Pediatric Oral Liquid Drug Products Containing Acetaminophen,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/over-counter-pediatric-oral-liquid-drug-products-containing-acetaminophen,https://www.fda.gov/media/89475/download,2015-08-05,['Center for Drug Evaluation and Research'],"['Over-the-Counter Drugs','Safety - Issues, Errors, and Problems','Administrative / Procedural','Combination Products']",Final,FDA-2014-D-1473,No,
CVM GFI #198 (VICH GL45) Bracketing and Matrixing Designs For Stability Testing of New Veterinary Drug Substances and Medicinal Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-198-vich-gl45-bracketing-and-matrixing-designs-stability-testing-new-veterinary-drug,https://www.fda.gov/media/77128/download,2015-07-31,['Center for Veterinary Medicine'],['VICH'],Final,FDA-2009-D-0309,No,
Recommendations for Premarket Notification (510(k)) Submissions for Nucleic Acid-Based Human Leukocyte Antigen (HLA) Test Kits Used for Matching of Donors and Recipients in Transfusion and Transplantation:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-premarket-notification-510k-submissions-nucleic-acid-based-human-leukocyte-antigen,https://www.fda.gov/media/87197/download,2015-07-31,['Center for Biologics Evaluation and Research'],"['Premarket','Blood','Blood Products']",Final,FDA-2013-D-1358,No,
Analytical Procedures and Methods Validation for Drugs and Biologics,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/analytical-procedures-and-methods-validation-drugs-and-biologics,https://www.fda.gov/media/87801/download,2015-07-27,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2015-N-0007,No,
"Meetings with the Office of Orphan Products Development:  Guidance for Industry, Researchers, Patient Groups, and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/meetings-office-orphan-products-development,https://www.fda.gov/media/111946/download,2015-07-09,['Office of the Commissioner'],"['Administrative / Procedural','Pediatric Product Development']",Final,FDA-2014-D-0313,No,
"Guidance for Industry: Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-regarding-final-rule-prevention-salmonella-enteritidis-shell,https://www.fda.gov/media/83513/download,2015-07-01,['Human Foods Program'],"['Egg/Egg Product','Transportation','Salmonella']",Final,FDA-2011-D-0398,No,
Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-design-early-phase-clinical-trials-cellular-and-gene-therapy-products,https://www.fda.gov/media/106369/download,2015-06-27,['Center for Biologics Evaluation and Research'],['Gene Therapy'],Final,FDA-2013-D-0576,No,
Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/allowable-excess-volume-and-labeled-vial-fill-size-injectable-drug-and-biological-products,https://www.fda.gov/media/88138/download,2015-06-25,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2014-D-0248,No,
Guidance for Industry: Food Allergen Labeling Exemption Petitions and Notifications,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-food-allergen-labeling-exemption-petitions-and-notifications,https://www.fda.gov/media/88332/download,2015-06-19,['Human Foods Program'],"['Allergens','Labeling']",Final,FDA-2014-D-0052,No,
Naming of Drug Products Containing Salt Drug Substances,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/naming-drug-products-containing-salt-drug-substances,https://www.fda.gov/media/87247/download,2015-06-17,['Center for Drug Evaluation and Research'],['Labeling'],Final,FDA-2013-D-1566,No,
Content and Format for Abbreviated 510(k)s for Early Growth Response 1 (EGR1) Gene Fluorescence In-Situ Hybridization (FISH) Test System for Specimen Characterization Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-format-abbreviated-510ks-early-growth-response-1-egr1-gene-fluorescence-situ,https://www.fda.gov/media/89551/download,2015-06-17,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Labeling','Laboratory Tests','IVDs (In Vitro Diagnostic Devices)','Molecular and Clinical Genetics','Immunology & Microbiology']",Final,FDA-2014-D-1242,No,
CVM GFI #218 Cell-Based Products for Animal Use,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-218-cell-based-products-animal-use,https://www.fda.gov/media/88925/download,2015-06-12,['Center for Veterinary Medicine'],"['Cellular & Gene Therapy','Investigational New Animal Drug (INAD)']",Final,FDA-2014-D-0634,No,2014-09-30
CVM GFI #221 Recommendations for Preparation and Submission of Animal Food Additive Petitions,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-221-recommendations-preparation-and-submission-animal-food-additive-petitions,https://www.fda.gov/media/86905/download,2015-06-12,['Center for Veterinary Medicine'],['Animal Food Additives'],Final,FDA-2013-D-0928,No,
"Pregnancy, Lactation, and Reproductive Potential:  Labeling for Human Prescription Drug and Biological Products — Content and Format Guidance for Industry  (Small Entity Compliance Guide)",,,2015-06-10,[],['Labeling'],Final,,No,
Investigational New Drug Applications Prepared and Submitted by Sponsor-Investigators,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-new-drug-applications-prepared-and-submitted-sponsor-investigators,https://www.fda.gov/media/92604/download,2015-05-15,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Administrative / Procedural'],Draft,FDA-2015-D-1484,No,
Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-considerations-demonstrating-biosimilarity-therapeutic-protein-product-reference-product,https://www.fda.gov/media/135612/download,2015-04-30,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Biosimilars'],Final,FDA-2011-D-0602,No,
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scientific-considerations-demonstrating-biosimilarity-reference-product,https://www.fda.gov/media/82647/download,2015-04-28,['Center for Drug Evaluation and Research'],['Biosimilars'],Final,FDA-2011-D-0605,No,
Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-non-small-cell-lung-cancer-drugs-and-biologics,https://www.fda.gov/media/116860/download,2015-04-22,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Final,FDA-2011-D-0432,No,
Balancing Premarket and Postmarket Data Collection for Devices Subject to Premarket Approval:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/balancing-premarket-and-postmarket-data-collection-devices-subject-premarket-approval,https://www.fda.gov/media/88381/download,2015-04-13,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Postmarket','Premarket','Premarket Approval (PMA)']",Final,FDA-2014-D-0090,No,
CVM GFI #211 Residual Solvents in Animal Drug Products Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-211-residual-solvents-animal-drug-products-questions-and-answers,https://www.fda.gov/media/79782/download,2015-04-03,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)']",Final,FDA-2010-D-0566,No,
Abuse-Deterrent Opioids-Evaluation and Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/abuse-deterrent-opioids-evaluation-and-labeling,https://www.fda.gov/media/84819/download,2015-04-02,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-2013-D-0045,No,
Critical Path Innovation Meetings,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/critical-path-innovation-meetings,https://www.fda.gov/media/89497/download,2015-03-30,[],['Administrative / Procedural'],Final,,No,
Electronic Submission of Lot Distribution Reports:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-submission-lot-distribution-reports,https://www.fda.gov/media/89610/download,2015-03-23,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Electronic Submissions'],Final,FDA-2014-D-1288,No,
Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling :  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reprocessing-medical-devices-health-care-settings-validation-methods-and-labeling,https://www.fda.gov/media/80265/download,2015-03-17,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Premarket Approval (PMA)','Investigational Device Exemption (IDE)']",Final,FDA-2011-D-0293,No,
Small Entity Compliance Guide: Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-nutrition-labeling-standard-menu-items-restaurants-and-similar-retail,https://www.fda.gov/media/91148/download,2015-03-13,['Human Foods Program'],"['Labeling','Nutrition']",Final,FDA-2011-F-0172,No,
CVM GFI #207 (VICH GL48) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs In Food-Producing Animals: Marker Residue Depletion Studies to Establish Product Withdrawal Periods,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-207-vich-gl48-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food,https://www.fda.gov/media/78351/download,2015-03-09,['Center for Veterinary Medicine'],"['Human Food Safety','VICH']",Final,FDA-2010-D-0166,No,
CVM GFI #208 (VICH GL49) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Validation of Analytical Methods Used in Residue Depletion Studies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-208-vich-gl49-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food,https://www.fda.gov/media/78356/download,2015-03-09,['Center for Veterinary Medicine'],"['Human Food Safety','VICH']",Final,FDA-2010-D-0165,No,
"Determining the Need for and Content of Environmental Assessments for Gene Therapies, Vectored Vaccines, and Related Recombinant Viral or Microbial Products:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/determining-need-and-content-environmental-assessments-gene-therapies-vectored-vaccines-and-related,https://www.fda.gov/media/91425/download,2015-03-01,['Center for Biologics Evaluation and Research'],['Gene Therapy'],Final,FDA-2014-D-0663,No,
Alcoholism:  Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/alcoholism-developing-drugs-treatment,https://www.fda.gov/media/91222/download,2015-02-12,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2015-D-0152,No,
Safety Considerations to Mitigate the Risks of Misconnections with Small-bore Connectors Intended for Enteral Applications:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-considerations-mitigate-risks-misconnections-small-bore-connectors-intended-enteral,https://www.fda.gov/media/83412/download,2015-02-11,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2012-D-0630,No,
S10 Photosafety Evaluation of Pharmaceuticals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s10-photosafety-evaluation-pharmaceuticals,https://www.fda.gov/media/85076/download,2015-01-27,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Safety'],Final,FDA-2013-D-0068,No,
DSCSA Implementation: Product Tracing Requirements — Compliance Policy,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dscsa-implementation-product-tracing-requirements-compliance-policy,https://www.fda.gov/media/90397/download,2014-12-31,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2014-D-2254,No,
Minimizing Risk for Children's Toy Laser Products:   Guidance for Industry and Food and Drug Administration Staff,,,2014-12-19,[],['Radiological Health'],Final,FDA-2012-D-1092,No,
"Providing Regulatory Submissions in Electronic Format — Submissions Under Section 745A(a) of the Federal Food, Drug, and Cosmetic Act",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-submissions-under-section-745aa-federal-food-drug,https://www.fda.gov/media/88120/download,2014-12-18,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Electronic Submissions'],Final,FDA-2014-D-1953,No,
"CPG Sec 540.275 (Draft) Crabmeat - Fresh and Frozen - Adulteration with Filth, Involving the Presence of Escherichia coli",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540275-draft-crabmeat-fresh-and-frozen-adulteration-filth-involving-presence-escherichia,https://www.fda.gov/media/90349/download,2014-12-16,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Seafood/Seafood Product']",Draft,FDA-2014-D-1842,No,
Patient Counseling Information Section of Labeling for Human Prescription Drug and Biological Products — Content and Format,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-counseling-information-section-labeling-human-prescription-drug-and-biological-products,https://www.fda.gov/media/86734/download,2014-12-10,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Labeling'],Final,FDA-2013-D-1067,No,
DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dscsa-implementation-annual-reporting-prescription-drug-wholesale-distributors-and-third-party,https://www.fda.gov/media/90442/download,2014-12-09,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Draft,FDA-2014-D-2083,No,
SUPAC: Manufacturing Equipment Addendum,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supac-manufacturing-equipment-addendum,https://www.fda.gov/media/85681/download,2014-12-02,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Draft,FDA-2013-D-0295,No,
Infusion Pumps Total Product Life Cycle:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/infusion-pumps-total-product-life-cycle,https://www.fda.gov/media/78369/download,2014-12-02,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2010-D-0194,No,
Recommendations for Labeling Medical Products to Inform Users that the Product or Product Container is not Made with Natural Rubber Latex:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-labeling-medical-products-inform-users-product-or-product-container-not-made-natural,https://www.fda.gov/media/85473/download,2014-12-02,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2013-D-0168,No,
CPG Sec 540.700 Labeling of Processed and Blended Seafood Products Made Primarily with Fish Protein,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540700-labeling-processed-and-blended-seafood-products-made-primarily-fish-protein,https://www.fda.gov/media/90259/download,2014-12-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Seafood/Seafood Product']",Final,,No,
Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture:  Final Guidance,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-approved-application-biological-products-human-blood-and-blood-components-intended,https://www.fda.gov/media/86137/download,2014-12-01,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-1999-D-3528,No,
"Registration for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/registration-human-drug-compounding-outsourcing-facilities-under-section-503b-federal-food-drug-and,https://www.fda.gov/media/87570/download,2014-11-24,['Center for Drug Evaluation and Research'],"['Administrative / Procedural','Compounding']",Final,FDA-2013-N-1429,No,
Design Considerations for Devices Intended for Home Use:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-considerations-devices-intended-home-use,https://www.fda.gov/media/84830/download,2014-11-24,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2012-D-1161,No,
Vaginal Microbicides:Development for the Prevention of HIV Infection PDF,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/vaginal-microbicidesdevelopment-prevention-hiv-infection-pdf,https://www.fda.gov/media/85288/download,2014-11-19,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2012-D-1120,No,
Molecular Diagnostic Instruments with Combined Functions:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/molecular-diagnostic-instruments-combined-functions,https://www.fda.gov/media/85513/download,2014-11-12,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Premarket'],Final,FDA-2013-D-0258,No,
Specification of the Unique Facility Identifier (UFI) System for Drug Establishment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/specification-unique-facility-identifier-ufi-system-drug-establishment,https://www.fda.gov/media/89926/download,2014-11-06,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2013-D-0984,No,
New Chemical Entity Exclusivity Determinations for Certain Fixed-Combination Drug Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/new-chemical-entity-exclusivity-determinations-certain-fixed-combination-drug-products,https://www.fda.gov/media/87932/download,2014-10-16,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2013-D-1675,No,
Distinguishing Medical Device Recalls from Medical Device Enhancements:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/distinguishing-medical-device-recalls-medical-device-enhancements,https://www.fda.gov/media/89909/download,2014-10-15,['Center for Devices and Radiological Health'],['Postmarket'],Final,FDA-2013-D-0114,No,
CVM GFI #143 (VICH GL30) Pharmacovigilance of Veterinary Medicinal Products: Controlled List of Terms,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-143-vich-gl30-pharmacovigilance-veterinary-medicinal-products-controlled-list-terms,https://www.fda.gov/media/69988/download,2014-10-09,['Center for Veterinary Medicine'],"['Adverse Event Reporting','VICH']",Final,FDA-2002-D-0268,No,
CVM GFI #224 (Supplement to VICH GL52) Supplemental Examples For Illustrating Statistical Concepts Described in the VICH In Vivo Bioequivalence Guidance GL52,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-224-supplement-vich-gl52-supplemental-examples-illustrating-statistical-concepts-described,https://www.fda.gov/media/89845/download,2014-09-24,['Center for Veterinary Medicine'],"['Generic Animal Drugs','Generic Drugs','New Animal Drug Application (NADA)','VICH']",Final,FDA-2014-D-1352,No,2014-11-24
Custom Device Exemption:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/custom-device-exemption,https://www.fda.gov/media/89897/download,2014-09-24,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2013-D-1601,No,
Highly Multiplexed Microbiological/Medical Countermeasure In Vitro Nucleic Acid Based Diagnostic Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/highly-multiplexed-microbiologicalmedical-countermeasure-in-vitro-nucleic-acid-based-diagnostic-devices,https://www.fda.gov/media/84491/download,2014-08-27,['Center for Devices and Radiological Health'],"['Laboratory Tests','IVDs (In Vitro Diagnostic Devices)']",Final,FDA-2012-D-1057,No,
Evaluation of Sex-Specific Data in Medical Device Clinical Studies - Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-sex-specific-data-medical-device-clinical-studies-guidance-industry-and-food-and-drug,https://www.fda.gov/media/82005/download,2014-08-22,['Center for Devices and Radiological Health'],"['Premarket','Good Clinical Practice (GCP)']",Final,FDA-2011-D-0817,No,
"Unique Device Identifier System: Frequently Asked Questions, Vol. 1 :  Guidance for Industry and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/unique-device-identifier-system-frequently-asked-questions-vol-1,https://www.fda.gov/media/89275/download,2014-08-20,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Labeling','UDI']",Final,FDA-2020-D-0957,No,
"FDA Decisions for Investigational Device Exemption Clinical Investigations:  Guidance for Sponsors, Clinical Investigators, Institutional Review Boards, and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-decisions-investigational-device-exemption-clinical-investigations,https://www.fda.gov/media/81792/download,2014-08-19,['Center for Devices and Radiological Health'],"['Premarket','Investigational Device Exemption (IDE)']",Final,FDA-2011-D-0790,No,
Immunogenicity Assessment for Therapeutic Protein Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-assessment-therapeutic-protein-products,https://www.fda.gov/media/85017/download,2014-08-14,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Chemistry, Manufacturing, and Controls (CMC)','Clinical - Medical','Pharmaceutical Quality']",Final,FDA-2013-D-0092,No,
Unique Device Identification System: Small Entity Compliance Guide:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/unique-device-identification-system-small-entity-compliance-guide,https://www.fda.gov/media/89222/download,2014-08-13,['Center for Devices and Radiological Health'],['Labeling'],Final,FDA-2011-D-0790,No,
Upper Facial Lines:  Developing Botulinum Toxin Drug Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/upper-facial-lines-developing-botulinum-toxin-drug-products,https://www.fda.gov/media/89195/download,2014-08-06,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2014-D-0968,No,
In Vitro Companion Diagnostic Devices:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/in-vitro-companion-diagnostic-devices,https://www.fda.gov/media/81309/download,2014-08-06,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2011-D-0215,No,
Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reference-product-exclusivity-biological-products-filed-under-section-351a-phs-act,https://www.fda.gov/media/89049/download,2014-08-04,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Administrative / Procedural','Biosimilars']",Draft,FDA-2013-D-1165,No,
CVM GFI #200 SECG for Designation of New Animal Drugs for Minor Uses or Minor Species,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-200-secg-designation-new-animal-drugs-minor-uses-or-minor-species,https://www.fda.gov/media/79363/download,2014-07-29,['Center for Veterinary Medicine'],['Minor Use/ Minor Species (MUMS)'],Final,FDA-2010-D-0432,No,
CVM GFI #201 SECG for The Index of Legally Marketed Unapproved New Animal Drugs for Minor Species,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-201-secg-index-legally-marketed-unapproved-new-animal-drugs-minor-species,https://www.fda.gov/media/79365/download,2014-07-29,['Center for Veterinary Medicine'],['Minor Use/ Minor Species (MUMS)'],Final,FDA-2010-D-0435,No,
The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/510k-program-evaluating-substantial-equivalence-premarket-notifications-510k,https://www.fda.gov/media/82395/download,2014-07-28,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Administrative / Procedural']",Final,FDA-2011-D-0652,No,
Reporting Drug Sample Information Under Section 6004 of the Affordable Care Act,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reporting-drug-sample-information-under-section-6004-affordable-care-act,https://www.fda.gov/media/88910/download,2014-07-11,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Electronic Submissions'],Draft,FDA-2014-D-0829,No,
Neglected Tropical Diseases of the Developing World: Developing Drugs for Treatment or Prevention,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/neglected-tropical-diseases-developing-world-developing-drugs-treatment-or-prevention,https://www.fda.gov/media/81312/download,2014-07-07,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2011-D-0587,No,
"Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacy-compounding-human-drug-products-under-section-503a-federal-food-drug-and-cosmetic-act,https://www.fda.gov/media/94393/download,2014-07-02,['Center for Drug Evaluation and Research'],"['Administrative / Procedural','Compounding']",Final,FDA-2013-D-1444,No,
"Guidance for Industry: Assessing the Effects of Significant Manufacturing Process Changes, Including Emerging Technologies, on the Safety and Regulatory Status of Food Ingredients and Food Contact Substances, Including Food Ingredients that Are Color Additives",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-assessing-effects-significant-manufacturing-process-changes-including-emerging,https://www.fda.gov/media/115075/download,2014-06-27,['Human Foods Program'],"['Food & Color Additives','Ingredients','Food Contact Substances (FCS)']",Final,FDA-2011-D-0490,No,
Global Unique Device Identification Database (GUDID):  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/global-unique-device-identification-database-gudid,https://www.fda.gov/media/86569/download,2014-06-27,['Center for Devices and Radiological Health'],"['GUDID','Labeling','UDI']",Final,FDA-2013-D-0636,No,
Small Entity Compliance Guide: Gluten-Free Labeling of Foods,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-gluten-free-labeling-foods,https://www.fda.gov/media/88857/download,2014-06-26,['Human Foods Program'],"['Allergens','Labeling']",Final,FDA-2005-N-0404,No,
Guidance for Industry: Safety of Nanomaterials in Cosmetic Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-safety-nanomaterials-cosmetic-products,https://www.fda.gov/media/83957/download,2014-06-24,['Office of the Commissioner'],,Final,FDA-2011-D-0489,No,
Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considering-whether-fda-regulated-product-involves-application-nanotechnology,https://www.fda.gov/media/88423/download,2014-06-23,['Office of the Commissioner'],"['Premarket','Food & Color Additives','Records']",Final,FDA-2010-D-0530,No,
Criteria for Significant Risk Investigations of Magnetic Resonance Diagnostic Devices - Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/criteria-significant-risk-investigations-magnetic-resonance-diagnostic-devices-guidance-industry-and,https://www.fda.gov/media/71385/download,2014-06-19,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Drug Master Files: Guidelines,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-master-files-guidelines,,2014-06-18,['Center for Drug Evaluation and Research'],['Pharmaceutical Quality'],Final,FDA-2014-D-0397,No,
Internet/Social Media Platforms with Character Space Limitations— Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/internetsocial-media-platforms-character-space-limitations-presenting-risk-and-benefit-information,https://www.fda.gov/media/88551/download,2014-06-18,"['Center for Veterinary Medicine','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Advertising'],Draft,FDA-2014-D-0397,No,
Internet/Social Media Platforms with Character Space Limitations— Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/internetsocial-media-platforms-character-space-limitations-presenting-risk-and-benefit-information,https://www.fda.gov/media/88551/download,2014-06-18,"['Center for Veterinary Medicine','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Advertising'],Draft,FDA-2014-D-0397,No,
Q4B Annex 6: Uniformity of Dosage Units General Chapter,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-6-uniformity-dosage-units-general-chapter,https://www.fda.gov/media/73112/download,2014-06-16,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['ICH-Quality'],Final,FDA-2009-D-0011,No,
Distributing Scientific and Medical Publications on Risk Information for Approved Prescription Drugs and Biological Products—Recommended Practices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/distributing-scientific-and-medical-publications-risk-information-approved-prescription-drugs-and,https://www.fda.gov/media/88674/download,2014-06-11,"['Center for Veterinary Medicine','Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Administrative / Procedural'],Draft,FDA-2014-D-0758,No,
"Guidance for Industry: Demonstration of the Quality Factor Requirements Under 21 CFR 106.96(i) for ""Eligible"" Infant Formulas",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-demonstration-quality-factor-requirements-under-21-cfr-10696i-eligible-infant,https://www.fda.gov/media/88686/download,2014-06-10,['Human Foods Program'],['Infant Formula & Foods'],Final,FDA-2014-D-0033,No,
CPG Sec 100.250 Food Facility Registration (Human and Animal Food),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-100250-food-facility-registration-human-and-animal-food,https://www.fda.gov/media/88691/download,2014-06-01,"['Center for Veterinary Medicine','Office of Inspections and Investigations','Human Foods Program']",['Investigation & Enforcement'],Final,FDA-2013-D-0126,No,
Expedited Programs for Serious Conditions | Drugs and Biologics,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics,https://www.fda.gov/media/86377/download,2014-05-30,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2013-D-0575,No,
CVM GFI #79 Dispute Resolution Procedures for Science-Based Decisions on Products Regulated by CVM,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-79-dispute-resolution-procedures-science-based-decisions-products-regulated-cvm,https://www.fda.gov/media/70279/download,2014-05-29,['Center for Veterinary Medicine'],['Administrative / Procedural'],Final,FDA-2003-D-0307,No,
"Considerations When Transferring Clinical Investigation Oversight to Another IRB:  Guidance for IRBs, Clinical Investigators, and Sponsors",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-when-transferring-clinical-investigation-oversight-another-irb,https://www.fda.gov/media/83801/download,2014-05-23,"['Office of the Commissioner','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Good Clinical Practice (GCP)'],Final,FDA-2011-D-0835,No,
"ANDAs: Stability Testing of Drug Substances and Products, Questions and Answers",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-stability-testing-drug-substances-and-products-questions-and-answers,https://www.fda.gov/media/87051/download,2014-05-15,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2014-D-0547,No,
CVM GFI #219 (VICH GL51) Statistical Evaluation of Stability Data,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-219-vich-gl51-statistical-evaluation-stability-data,https://www.fda.gov/media/83554/download,2014-05-13,['Center for Veterinary Medicine'],['VICH'],Final,FDA-2012-D-0288,No,
Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia:  Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia-developing-drugs,https://www.fda.gov/media/79516/download,2014-05-06,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2010-D-0589,No,
Providing Information about Pediatric Uses of Medical Devices:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-information-about-pediatric-uses-medical-devices,https://www.fda.gov/media/85233/download,2014-05-01,['Center for Devices and Radiological Health'],"['Premarket','Pediatric Product Development']",Final,FDA-2013-D-0117,No,
"Guidance for Industry: FDA Records Access Authority Under Sections 414 and 704 of the Federal Food, Drug, & Cosmetic Act",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-fda-records-access-authority-under-sections-414-and-704-federal-food-drug-cosmetic,https://www.fda.gov/media/83083/download,2014-04-04,"['Center for Veterinary Medicine','Office of Inspections and Investigations','Human Foods Program']",['Records'],Final,FDA-2011-D-0674,No,
Small Entity Compliance Guide: What You Need to Know About Establishment and Maintenance of Records,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-what-you-need-know-about-establishment-and-maintenance-records,https://www.fda.gov/media/88292/download,2014-04-04,"['Center for Veterinary Medicine','Office of Inspections and Investigations','Human Foods Program']",['Records'],Final,FDA-2013-N-1421,No,
Types of Communication During the Review of Medical Device Submissions:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/types-communication-during-review-medical-device-submissions,https://www.fda.gov/media/85200/download,2014-04-04,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2013-D-0147,No,
"CPG Sec 550.050 Canned Ackee, Frozen Ackee, and Other Ackee Products- Hypoglycin A Toxin",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550050-canned-ackee-frozen-ackee-and-other-ackee-products-hypoglycin-toxin,https://www.fda.gov/media/88521/download,2014-04-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
Interpreting Sameness of Monoclonal Antibody Products Under the Orphan Drug Regulations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interpreting-sameness-monoclonal-antibody-products-under-orphan-drug-regulations,https://www.fda.gov/media/77256/download,2014-04-01,['Center for Biologics Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-1999-D-0178,No,
"The Meaning of ""Spouse"" and ""Family"" in FDA's Regulations after the Supreme Court's Ruling in United States v. Windsor: Questions and Answers:  Guidance for Industry, Consumers, and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/meaning-spouse-and-family-fdas-regulations-after-supreme-courts-ruling-united-states-v-windsor,https://www.fda.gov/media/88114/download,2014-03-31,['Office of the Commissioner'],"['Administrative / Procedural','Food & Color Additives']",Final,FDA-2014-D-0261,No,
Medical Device Tracking :  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-device-tracking,https://www.fda.gov/media/71205/download,2014-03-27,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Premarket Assessment of Pediatric Medical Devices:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-assessment-pediatric-medical-devices,https://www.fda.gov/media/73510/download,2014-03-24,['Center for Devices and Radiological Health'],"['Premarket','Pediatric Product Development']",Final,FDA-2003-D-0367,No,
Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioavailability-and-bioequivalence-studies-submitted-ndas-or-inds-general-considerations,https://www.fda.gov/media/88254/download,2014-03-18,['Center for Drug Evaluation and Research'],['Biopharmaceutics'],Draft,FDA-2014-D-0204,No,
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis:  Developing Drug Products for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chronic-fatigue-syndromemyalgic-encephalomyelitis-developing-drug-products-treatment,https://www.fda.gov/media/87875/download,2014-03-11,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2014-D-0264,No,
CMC Postapproval Manufacturing Changes To Be Documented in Annual Reports,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cmc-postapproval-manufacturing-changes-be-documented-annual-reports,https://www.fda.gov/media/79182/download,2014-03-05,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2010-D-0283,No,
"BLA for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bla-minimally-manipulated-unrelated-allogeneic-placentalumbilical-cord-blood-intended-hematopoietic,https://www.fda.gov/media/86387/download,2014-03-01,['Center for Biologics Evaluation and Research'],"['Cellular & Gene Therapy','Gene Therapy']",Final,FDA-2006-D-0157,No,
"IND Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System:  Guidance for Industry and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-applications-minimally-manipulated-unrelated-allogeneic-placentalumbilical-cord-blood-intended,https://www.fda.gov/media/89441/download,2014-03-01,['Center for Biologics Evaluation and Research'],"['Cellular & Gene Therapy','Gene Therapy']",Final,FDA-2009-D-0490,No,
Antiviral Product Development — Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV-1 Resistance Data: Attachment to the Guidance: Draft Draft Guidance: This draft guidance updates the final guidance posted 6/2/06,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antiviral-product-development-conducting-and-submitting-virology-studies-agency-guidance-submitting-4,https://www.fda.gov/media/88255/download,2014-02-28,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Draft,FDA-2014-D-0180,No,
"Public Availability of Advisory Committee Members'Financial Interest Information and Waivers:  Guidance for the Public, FDA Advisory Committee Members, and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/public-availability-advisory-committee-members-financial-interest-information-and-waivers,https://www.fda.gov/media/83188/download,2014-02-28,['Office of the Commissioner'],"['Advisory Committees','Food & Color Additives']",Final,,No,
The Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-transmission-individual-case-safety-reports-implementation-guide-data-elements-and,https://www.fda.gov/media/81904/download,2014-02-27,['Center for Drug Evaluation and Research'],['ICH-Safety'],Final,,No,
"Questions and Answers about eMDR - Electronic Medical Device Reporting - Guidance for Industry, User Facilities and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/questions-and-answers-about-emdr-electronic-medical-device-reporting-guidance-industry-user,https://www.fda.gov/media/76993/download,2014-02-13,['Center for Devices and Radiological Health'],"['Adverse Event Reporting System (FAERS)','Adverse Event Reporting']",Final,FDA-2008-N-0393,No,
Providing Regulatory Submissions in Electronic Format--Receipt Date:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-receipt-date,https://www.fda.gov/media/71190/download,2014-02-10,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Electronic Submissions'],Final,FDA-2007-D-0077,No,
"Guidance for Industry: Considerations Regarding Substances Added to Foods, Including Beverages and Dietary Supplements",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-considerations-regarding-substances-added-foods-including-beverages-and-dietary,https://www.fda.gov/media/87680/download,2014-01-14,['Human Foods Program'],['Ingredients'],Final,FDA-2009-D-0542,No,
Guidance for Industry: Distinguishing Liquid Dietary Supplements from Beverages,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-distinguishing-liquid-dietary-supplements-beverages,https://www.fda.gov/media/87567/download,2014-01-14,['Human Foods Program'],,Final,FDA-2009-D-0542,No,
Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fulfilling-regulatory-requirements-postmarketing-submissions-interactive-promotional-media,https://www.fda.gov/media/87685/download,2014-01-14,"['Center for Veterinary Medicine','Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Antimicrobial Resistance'],Draft,FDA-2013-N-1430,No,
Community-Acquired Bacterial Pneumonia:  Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/community-acquired-bacterial-pneumonia-developing-drugs-treatment,https://www.fda.gov/media/75149/download,2014-01-10,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2009-D-0136,No,
Attachement - Qualification Process for Drug Development Tools: Qualification of Exacerbations of Chronic Pulmonary Disease Tool for Measurement of Symptoms of Acute Bacterial Exacerbation of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/attachement-qualification-process-drug-development-tools-qualification-exacerbations-chronic,https://www.fda.gov/media/87409/download,2014-01-10,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2013-D-1630,No,
Dear Health Care Provider Letters: Improving Communication of Important Safety Information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dear-health-care-provider-letters-improving-communication-important-safety-information,https://www.fda.gov/media/79793/download,2014-01-02,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2010-D-0319,No,
Guidance for Industry: Dear Manufacturer Letter Regarding Changes to FDA's Administration of Process Filings (Forms FDA 2541a and FDA 2541c) for Acidified Foods and Low-Acid Canned Foods,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-dear-manufacturer-letter-regarding-changes-fdas-administration-process-filings,https://www.fda.gov/media/87625/download,2013-12-31,['Human Foods Program'],['Canned Foods'],Final,,No,
CVM GFI #213 New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions with GFI #209,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-213-new-animal-drugs-and-new-animal-drug-combination-products-administered-or-medicated-feed,https://www.fda.gov/media/83488/download,2013-12-12,['Center for Veterinary Medicine'],"['Antimicrobial Resistance','New Animal Drug Application (NADA)']",Final,FDA-2011-D-0889,No,
FDA's Strategy on Antimicrobial Resistance - Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fdas-strategy-antimicrobial-resistance-questions-and-answers,,2013-12-10,['Center for Veterinary Medicine'],['Antimicrobial Resistance'],Final,FDA-2010-D-0094,No,
"CPG Sec. 460.200 Pharmacy Compounding (Withdrawn December 4, 2013)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-460200-pharmacy-compounding-withdrawn-december-4-2013,,2013-12-03,[],['Investigation & Enforcement'],Final,,No,
Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/distribution-in-vitro-diagnostic-products-labeled-research-use-only-or-investigational-use-only,https://www.fda.gov/media/87374/download,2013-11-25,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','Good Clinical Practice (GCP)','Investigational Device Exemption (IDE)','Laboratory Tests','IVDs (In Vitro Diagnostic Devices)']",Final,FDA-2011-D-0305,No,
"Design Considerations for Pivotal Clinical Investigations for Medical Devices:  Guidance for Industry, Clinical Investigators, Institutional Review Boards and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-considerations-pivotal-clinical-investigations-medical-devices,https://www.fda.gov/media/87363/download,2013-11-07,['Center for Devices and Radiological Health'],"['Premarket','Good Clinical Practice (GCP)','Investigational Device Exemption (IDE)']",Final,FDA-2011-D-0567,No,
Preclinical Assessment of Investigational Cellular and Gene Therapy Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/preclinical-assessment-investigational-cellular-and-gene-therapy-products,https://www.fda.gov/media/87564/download,2013-11-01,['Center for Biologics Evaluation and Research'],"['Cellular & Gene Therapy','Gene Therapy']",Final,FDA-2012-D-1038,No,
Acute Bacterial Skin and Skin Structure Infections:  Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acute-bacterial-skin-and-skin-structure-infections-developing-drugs-treatment,https://www.fda.gov/media/71052/download,2013-10-23,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2013-D-1181,No,
Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions: Annex 14: Bacterial Endotoxins Test General Chapter,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-annex-14-bacterial-endotoxins,https://www.fda.gov/media/79183/download,2013-10-23,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-2010-D-0343,No,
"Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies, Including Certain First in Human (FIH) Studies:  Guidance for Industry and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-device-exemptions-ides-early-feasibility-medical-device-clinical-studies-including,https://www.fda.gov/media/81784/download,2013-10-01,['Center for Devices and Radiological Health'],"['Premarket','Good Clinical Practice (GCP)','Investigational Device Exemption (IDE)']",Final,FDA-2011-D-0787,No,
CVM GFI #223 Small Entity Compliance Guide Declaring Color Additives in Animal Foods,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-223-small-entity-compliance-guide-declaring-color-additives-animal-foods,https://www.fda.gov/media/86896/download,2013-09-27,['Center for Veterinary Medicine'],['Animal Feed'],Final,FDA-2013-D-1088,No,
Electronic Source Data in Clinical Investigations:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-source-data-clinical-investigations,https://www.fda.gov/media/85183/download,2013-09-18,"['Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Administrative / Procedural','Good Clinical Practice (GCP)']",Final,FDA-2010-D-0643,No,
"Investigational New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted Without an IND:  Guidance for Clinical Investigators, Sponsors, and IRBs",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-new-drug-applications-inds-determining-whether-human-research-studies-can-be,https://www.fda.gov/media/79386/download,2013-09-10,"['Human Foods Program','Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Clinical - Medical','Good Clinical Practice (GCP)']",Final,FDA-2010-D-0503,No,
Guidance for Industry: Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-regarding-adverse-event-reporting-and-recordkeeping-dietary,https://www.fda.gov/media/87434/download,2013-09-01,['Human Foods Program'],['Adverse Event Reporting'],Final,FDA-2007-D-0372,No,
"IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed:  Guidance for IRBs, Clinical Investigators, and Sponsors",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/irb-responsibilities-reviewing-qualifications-investigators-adequacy-research-sites-and,https://www.fda.gov/media/85294/download,2013-08-27,"['Office of the Commissioner','Center for Drug Evaluation and Research']","['Administrative / Procedural','Good Clinical Practice (GCP)']",Final,FDA-2012-D-0847,No,
Compliance with Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco To Protect Children and Adolescents:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-regulations-restricting-sale-and-distribution-cigarettes-and-smokeless-tobacco-protect,https://www.fda.gov/media/80572/download,2013-08-22,['Center for Tobacco Products'],"['Cigarettes','Smokeless','Snuff','Chewing']",Final,FDA-2010-D-0277,No,2013-08-22
Radio Frequency Wireless Technology in Medical Devices - Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/radio-frequency-wireless-technology-medical-devices-guidance-industry-and-fda-staff,https://www.fda.gov/media/71975/download,2013-08-14,['Center for Devices and Radiological Health'],"['Premarket','Digital Health']",Final,FDA-2006-D-0300,No,
Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/oversight-clinical-investigations-risk-based-approach-monitoring,https://www.fda.gov/media/116754/download,2013-08-07,"['Office of Inspections and Investigations','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research','Office of the Commissioner']","['Investigation & Enforcement','Administrative / Procedural','Good Clinical Practice (GCP)']",Final,FDA-2011-D-0597,No,
"Safety Labeling Changes -- Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-labeling-changes-implementation-section-505o4-federal-food-drug-and-cosmetic-act,https://www.fda.gov/media/116594/download,2013-07-30,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Device & Drug Safety'],Final,FDA-2011-D-0164,No,
Providing Submissions in Electronic Format – Postmarket Non-Expedited ICSRs Technical Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-submissions-electronic-format-postmarket-non-expedited-icsrs-technical-questions-and,https://www.fda.gov/media/86236/download,2013-07-24,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Electronic Submissions'],Final,FDA-2013-D-0755,No,
CPG Sec  690.800 Compliance Policy Guide Salmonella in Food for Animals,,,2013-07-01,[],"['Investigation & Enforcement','Animal Feed']",Final,FDA-2010-D-0378,No,
Heparin for Drug and Medical Device Use:  Monitoring Crude Heparin for Quality:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/heparin-drug-and-medical-device-use-monitoring-crude-heparin-quality,https://www.fda.gov/media/82924/download,2013-06-25,"['Center for Veterinary Medicine','Center for Drug Evaluation and Research','Center for Devices and Radiological Health']","['Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,FDA-2012-D-0083,No,
ANDAs: Stability Testing of Drug Substances and Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-stability-testing-drug-substances-and-products-questions-and-answers,https://www.fda.gov/media/87051/download,2013-06-20,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2012-D-0938,No,
Codevelopment of Two or More New Investigational Drugs for Use in Combination,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/codevelopment-two-or-more-new-investigational-drugs-use-combination,https://www.fda.gov/media/80100/download,2013-06-14,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-2010-D-0616,No,
"Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products:  Guidance for Industry and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-considerations-pen-jet-and-related-injectors-intended-use-drugs-and-biological-products,https://www.fda.gov/media/76403/download,2013-06-07,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research','Office of the Commissioner']","['Administrative / Procedural','Combination Products']",Final,FDA-2009-D-0179,No,
Draft Guidance for Industry: Cosmetic Good Manufacturing Practices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-cosmetic-good-manufacturing-practices,https://www.fda.gov/media/86366/download,2013-06-01,['Office of the Commissioner'],['Current Good Manufacturing Practice (CGMP)'],Draft,,No,
Rheumatoid Arthritis: Developing Drug Products for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rheumatoid-arthritis-developing-drug-products-treatment,https://www.fda.gov/media/86066/download,2013-05-31,"['Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Draft,FDA-2013-D-0571,No,
Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Annex 13: Bulk Density and Tapped Density of Powders General Chapter,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-annex-13-bulk-density-and-tapped,https://www.fda.gov/media/78958/download,2013-05-28,['Center for Drug Evaluation and Research'],['ICH-Quality'],Final,,No,
Annex 13 Bulk Density and Tapped Density of Powders General Chapter,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/annex-13-bulk-density-and-tapped-density-powders-general-chapter,https://www.fda.gov/media/78958/download,2013-05-23,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",,Final,,No,
"The Open Public Hearing at FDA Advisory Committee Meetings:  Guidance for the Public, FDA Advisory Committee Members, and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/open-public-hearing-fda-advisory-committee-meetings,https://www.fda.gov/media/79874/download,2013-05-15,['Office of the Commissioner'],"['Advisory Committees','Food & Color Additives']",Final,,No,
Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-conducting-and-reporting-pharmacoepidemiologic-safety-studies-using-electronic,https://www.fda.gov/media/79922/download,2013-05-14,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Safety - Issues, Errors, and Problems']",Final,FDA-2011-D-0057,No,
Assay Migration Studies for In Vitro Diagnostic Devices:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assay-migration-studies-in-vitro-diagnostic-devices,https://www.fda.gov/media/73669/download,2013-04-25,['Center for Devices and Radiological Health'],"['Premarket','Laboratory Tests','IVDs (In Vitro Diagnostic Devices)']",Final,FDA-2008-D-0642,No,
Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-penicillin-beta-lactam-drugs-cgmp-framework-preventing-cross-contamination,https://www.fda.gov/media/79971/download,2013-04-17,['Center for Drug Evaluation and Research'],"['Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,FDA-2011-D-0104,No,
Self-Selection Studies for Nonprescription Drug Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/self-selection-studies-nonprescription-drug-products,https://www.fda.gov/media/81141/download,2013-04-11,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Final,FDA-2011-D-0620,No,
Medical Device Classification Product Codes - Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-device-classification-product-codes-guidance-industry-and-food-and-drug-administration-staff,https://www.fda.gov/media/82781/download,2013-04-10,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']",['Premarket'],Final,FDA-2011-D-0916,No,
Blood Establishment Computer System Validation in the User's Facility:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/blood-establishment-computer-system-validation-users-facility,https://www.fda.gov/media/72533/download,2013-04-01,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-2007-D-0069,No,
"Exception from Informed Consent Requirements for Emergency Research:  Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exception-informed-consent-requirements-emergency-research,https://www.fda.gov/media/80554/download,2013-04-01,"['Office of the Commissioner','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Good Clinical Practice (GCP)'],Final,FDA-2006-D-0464,No,
Glass Syringes for Delivering Drug and Biological Products: Technical Information to Supplement International Organization for Standardization (ISO) Standard 11040-4: Draft Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/glass-syringes-delivering-drug-and-biological-products-technical-information-supplement,https://www.fda.gov/media/85748/download,2013-03-31,['Office of the Commissioner'],['Combination Products'],Draft,FDA-2013-D-0362,No,2013-07-01
Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection of Antibodies to Borrelia burgdorferi - Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/establishing-performance-characteristics-in-vitro-diagnostic-devices-detection-antibodies-borrelia,https://www.fda.gov/media/85572/download,2013-03-27,['Center for Devices and Radiological Health'],"['Premarket','Laboratory Tests']",Final,FDA-2008-D-0095,No,
M3(R2)Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals: Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m3r2nonclinical-safety-studies-conduct-human-clinical-trials-and-marketing-authorization,https://www.fda.gov/media/82725/download,2013-03-13,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Multidisciplinary'],Final,FDA-2008-D-0470,No,
"Tablet Scoring:Nomenclature, Labeling, and Data for Evaluation",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/tablet-scoringnomenclature-labeling-and-data-evaluation,https://www.fda.gov/media/81626/download,2013-03-13,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2011-D-0595,No,
Small Entity Compliance Guide: What You Need To Know About Administrative Detention of Foods,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-what-you-need-know-about-administrative-detention-foods,https://www.fda.gov/media/85381/download,2013-03-08,"['Center for Veterinary Medicine','Office of Inspections and Investigations','Human Foods Program']",,Final,FDA-2011-D-0643,No,
Investigational Device Exemption (IDE) Guidance for Retinal Prostheses:  Guidance for Industry and FDA  Staff,,,2013-03-06,[],"['Investigational Device Exemption (IDE)','Ophthalmic']",Final,FDA-2009-D-0010,No,
Pulse Oximeters - Premarket Notification Submissions [510(k)s]: Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pulse-oximeters-premarket-notification-submissions-510ks-guidance-industry-and-food-and-drug,https://www.fda.gov/media/72470/download,2013-03-03,['Center for Devices and Radiological Health'],"['Premarket','Pediatric Product Development']",Final,FDA-2007-D-0205,No,
Labeling for Human Prescription Drug and Biological Products - Implementing the PLR Content and Format Requirements,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-human-prescription-drug-and-biological-products-implementing-plr-content-and-format,https://www.fda.gov/media/71836/download,2013-02-25,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Labeling'],Final,FDA-2005-D-0153,No,
Antiviral Product Development — Conducting and Submitting Virology Studies to the Agency Guidance for Submitting HCV Resistance Data -Attachment to Guidance,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antiviral-product-development-conducting-and-submitting-virology-studies-agency-guidance-submitting-3,https://www.fda.gov/media/85149/download,2013-02-25,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Draft,FDA-2005-D-0282,No,
Clinical Study Designs for Surgical Ablation Devices for Treatment of Atrial Fibrillation - Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-study-designs-surgical-ablation-devices-treatment-atrial-fibrillation-guidance-industry-and,https://www.fda.gov/media/77365/download,2013-02-14,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2009-D-0395,No,
CPG Sec. 390.225 Early Defects or Noncompliance - 21 CFR 1004.6,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-390225-early-defects-or-noncompliance-21-cfr-10046,,2013-02-03,['Center for Devices and Radiological Health'],['Investigation & Enforcement'],Final,FDA-2020-D-0957,No,
"Financial Disclosure by Clinical Investigators:  Guidance for Clinical Investigators, Industry,and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/financial-disclosure-clinical-investigators,https://www.fda.gov/media/85293/download,2013-02-01,"['Office of the Commissioner','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Good Clinical Practice (GCP)','Investigational Device Exemption (IDE)']",Final,FDA-1999-D-0742,No,
E3 Structure and Content of Clinical Study Reports - Questions and Answers (R1),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e3-structure-and-content-clinical-study-reports-questions-and-answers-r1,https://www.fda.gov/media/84857/download,2013-01-29,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Efficacy'],Final,,No,
Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacogenomics-premarket-evaluation-early-phase-clinical-studies-and-recommendations,https://www.fda.gov/media/84923/download,2013-01-28,"['Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Clinical - Medical','Clinical - Pharmacology']",Final,FDA-2011-D-0082,No,
"Submissions for Postapproval Modifications to a Combination Product Approved Under a BLA, NDA, or PMA: Draft Guidance for Industry and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submissions-postapproval-modifications-combination-product-approved-under-bla-nda-or-pma,https://www.fda.gov/media/85267/download,2013-01-18,['Office of the Commissioner'],['Combination Products'],Draft,FDA-2012-D-1240,No,2013-04-01
Guidance for Industry: Food Labeling Guide,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-food-labeling-guide,https://www.fda.gov/media/81606/download,2013-01-01,['Human Foods Program'],"['Labeling','Nutrition Label']",Final,,No,
Safety Reporting Requirements for INDs (Investigational New Drug Applications) and BA/BE (Bioavailability/Bioequivalence) Studies:  Guidance for Industry and Investigators,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-reporting-requirements-inds-investigational-new-drug-applications-and-babe,https://www.fda.gov/media/79394/download,2012-12-20,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Generic Drugs','Good Clinical Practice (GCP)','Safety - Issues, Errors, and Problems']",Final,FDA-2010-D-0482,No,
Safety Reporting Requirements for INDs and BA/BE Studies:  Guidance for Industry and Investigators,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-reporting-requirements-inds-and-babe-studies,https://www.fda.gov/media/85124/download,2012-12-20,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Generic Drugs','Good Clinical Practice (GCP)','Safety - Issues, Errors, and Problems']",Final,FDA-2010-D-0482,No,
Labeling and Effectiveness Testing: Sunscreen Drug Products for Over-The-Counter Human Use — Small Entity Compliance Guide:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-and-effectiveness-testing-sunscreen-drug-products-over-counter-human-use-small-entity,,2012-12-06,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Final,,No,
Limiting the Use of Certain Phthalates as Excipients in CDER-Regulated Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/limiting-use-certain-phthalates-excipients-cder-regulated-products,,2012-12-06,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2012-D-1135,No,
FDA Oversight of PET Drug Products -- Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-oversight-pet-drug-products-questions-and-answers,https://www.fda.gov/media/82911/download,2012-12-03,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,,No,
Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-new-drug-applications-positron-emission-tomography-pet-drugs,https://www.fda.gov/media/83077/download,2012-12-03,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-2012-D-0081,No,
CVM GFI #217 Evaluating the Effectiveness of Anticoccidial Drugs in Food-Producing Animals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-217-evaluating-effectiveness-anticoccidial-drugs-food-producing-animals,https://www.fda.gov/media/81837/download,2012-11-20,['Center for Veterinary Medicine'],['Target Animal – Effectiveness'],Final,FDA-2011-D-0784,No,
Q11 Development and Manufacture of Drug Substances,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q11-development-and-manufacture-drug-substances-questions-and-answers-chemical-entities-and,https://www.fda.gov/media/103162/download,2012-11-20,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,,No,
"Labeling for Bronchodilators: Cold, Cough, Allergy, Bronchodilator, And Antiasthmatic Drug Products for Over-the-Counter Human Use (Small Entity Compliance Guide):  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-bronchodilators-cold-cough-allergy-bronchodilator-and-antiasthmatic-drug-products-over,,2012-11-15,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Final,,No,
The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Artificial Pancreas Device Systems:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-investigational-device-exemption-ide-and-premarket-approval-pma-applications-artificial,https://www.fda.gov/media/80644/download,2012-11-09,['Center for Devices and Radiological Health'],"['Premarket','Premarket Approval (PMA)','Investigational Device Exemption (IDE)']",Final,FDA-2011-D-0464,No,
Compliance Policy Guide Sec. 390.200 Determination by Secretary that Product Fails to Comply or has Defect - 21 CFR 1003.11,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-policy-guide-sec-390200-determination-secretary-product-fails-comply-or-has-defect-21-cfr,https://www.fda.gov/media/85319/download,2012-11-01,['Center for Devices and Radiological Health'],['Investigation & Enforcement'],Final,FDA-2020-D-0957,No,
CPG Sec. 420.500 *Interference with Compendial Tests* (revised 11/14/2012),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-420500-interference-compendial-tests-revised-11142012,https://www.fda.gov/media/84697/download,2012-11-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
"CPG Sec 550.050 (Draft) Canned Ackee, Frozen Ackee, and Other Ackee Products – Hypoglycin A Toxin",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550050-draft-canned-ackee-frozen-ackee-and-other-ackee-products-hypoglycin-toxin,https://www.fda.gov/media/84578/download,2012-11-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Draft,,No,
E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs  - Questions and Answers (R1),,,2012-10-11,[],['ICH-Efficacy'],Final,,No,
Acute Bacterial Sinusitis — Developing Antimicrobial Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acute-bacterial-sinusitis-developing-antimicrobial-drugs-treatment,https://www.fda.gov/media/71161/download,2012-10-05,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,,No,
Guidance for Industry Acute Bacterial Sinusitis: Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-acute-bacterial-sinusitis-developing-drugs-treatment,https://www.fda.gov/media/71161/download,2012-10-04,['Center for Drug Evaluation and Research'],['Pediatric Product Development'],Final,,No,
Acute Bacterial Exacerbations of Chronic Bronchitis in Patients with Chronic Obstructive Pulmonary Disease: Developing Antimicrobial Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acute-bacterial-exacerbations-chronic-bronchitis-patients-chronic-obstructive-pulmonary-disease-0,https://www.fda.gov/media/71151/download,2012-10-01,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2008-D-0419,No,
"Use of Nucleic Acid Tests on Pooled and Individual Samples From Donors of Whole Blood and Blood Components, Including Source Plasma, to Reduce the Risk of Transmission of Hepatitis B Virus:  Final Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-nucleic-acid-tests-pooled-and-individual-samples-donors-whole-blood-and-blood-components,https://www.fda.gov/media/124225/download,2012-10-01,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-2011-D-0799,No,
Guidance for Industry: Acute Bacterial Otitis Media: Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-acute-bacterial-otitis-media-developing-drugs-treatment,https://www.fda.gov/media/71197/download,2012-09-30,['Center for Drug Evaluation and Research'],,Final,,No,
Acute Bacterial Exacerbations of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease:  Acute Bacterial Exacerbations of Chronic Bronchitis in Patients,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acute-bacterial-exacerbations-chronic-bronchitis-patients-chronic-obstructive-pulmonary-disease,,2012-09-27,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2008-D-0419,No,
Pre-Storage Leukocyte Reduction of Whole Blood and Blood Components Intended for Transfusion:  Final Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pre-storage-leukocyte-reduction-whole-blood-and-blood-components-intended-transfusion,https://www.fda.gov/media/84460/download,2012-09-01,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-2001-D-0254,No,
"Q8, Q9, & Q10 Questions and Answers -- Appendix:  Q&As from Training Sessions (Q8, Q9, & Q10 Points to Consider)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q8-q9-q10-questions-and-answers-appendix-qas-training-sessions-q8-q9-q10-points-consider,https://www.fda.gov/media/83904/download,2012-08-13,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,,No,
Guidance for Industry:  Suicidal Ideation and Behavior:  Prospective Assessment of Occurrence in Clinical Trials,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-suicidal-ideation-and-behavior-prospective-assessment-occurrence-clinical-trials,https://www.fda.gov/media/79482/download,2012-08-13,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,,No,
CPG Sec. 490.200 Parametric Release of Parenteral Drug Products Terminally Sterilized by Moist Heat,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-490200-parametric-release-parenteral-drug-products-terminally-sterilized-moist-heat,,2012-07-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
Pyrogen and Endotoxins Testing: Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pyrogen-and-endotoxins-testing-questions-and-answers,https://www.fda.gov/media/83477/download,2012-06-28,"['Center for Veterinary Medicine','Human Foods Program','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Investigation & Enforcement','Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,,No,
Guidance for Industry:  Pyrogen and Endotoxins Testing: Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-pyrogen-and-endotoxins-testing-questions-and-answers,,2012-06-27,['Center for Drug Evaluation and Research'],['Pharmaceutical Quality'],Final,,No,
"""Toll-Free Number Labeling and Related Requirements for Over-the-Counter and Prescription Drugs Marketed With Approved Applications""",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toll-free-number-labeling-and-related-requirements-over-counter-and-prescription-drugs-marketed,https://www.fda.gov/media/131807/download,2012-06-15,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2012-D-0544,No,
Irritable Bowel Syndrome -- Clinical Evaluation of Products for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/irritable-bowel-syndrome-clinical-evaluation-products-treatment,https://www.fda.gov/media/78622/download,2012-06-14,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-2010-D-0146,No,
S2(R1) Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s2r1-genotoxicity-testing-and-data-interpretation-pharmaceuticals-intended-human-use,https://www.fda.gov/media/71980/download,2012-06-07,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Safety'],Final,FDA-2008-D-0178,No,
S6(R1) Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s6r1-preclinical-safety-evaluation-biotechnology-derived-pharmaceuticals,,2012-05-18,['Center for Drug Evaluation and Research'],['ICH-Safety'],Final,FDA-2009-D-0573,No,
Size of Beads in Drug Products Labeled for Sprinkle Rev.1:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/size-beads-drug-products-labeled-sprinkle-rev1,https://www.fda.gov/media/79676/download,2012-05-16,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2011-D-0021,No,
Small Entity Compliance Guide: Establishing an Allowable Level for di (2-ethylhexyl)phthalate in Bottled Water,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-establishing-allowable-level-di-2-ethylhexylphthalate-bottled-water,https://www.fda.gov/media/84475/download,2012-05-01,['Human Foods Program'],['Bottled Water'],Final,FDA-2012-D-0316,No,
CVM GFI #209 The Judicious Use of Medically Important Antimicrobial Drugs in Food-Producing Animals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-209-judicious-use-medically-important-antimicrobial-drugs-food-producing-animals,https://www.fda.gov/media/79140/download,2012-04-13,['Center for Veterinary Medicine'],['Antimicrobial Resistance'],Final,FDA-2010-D-0094,No,
Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/media-fills-validation-aseptic-preparations-positron-emission-tomography,https://www.fda.gov/media/81974/download,2012-04-11,['Center for Drug Evaluation and Research'],"['Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,FDA-2011-D-0691,No,
Modified Risk Tobacco Product Applications: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/modified-risk-tobacco-product-applications,https://www.fda.gov/media/83300/download,2012-04-03,['Center for Tobacco Products'],['Modified Risk Tobacco Product (MRTP)'],Draft,FDA-2012-D-0071,No,2012-06-04
"Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reporting-harmful-and-potentially-harmful-constituents-tobacco-products-and-tobacco-smoke-under,https://www.fda.gov/media/83375/download,2012-04-03,['Center for Tobacco Products'],,Draft,FDA-2012-D-0049,No,2012-04-03
"CVM GFI #216 Chemistry, Manufacturing, and Controls (CMC) Information - Fermentation-Derived Intermediates, Drug Substances, and Related Drug Products for Veterinary Medicinal Use",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-216-chemistry-manufacturing-and-controls-cmc-information-fermentation-derived-intermediates,https://www.fda.gov/media/79873/download,2012-03-08,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)']",Final,FDA-2011-D-0112,No,
Guidance for Industry: Testing for Salmonella Species in Human Foods and Direct-Human-Contact Animal Foods,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-testing-salmonella-species-human-foods-and-direct-human-contact-animal-foods,https://www.fda.gov/media/83177/download,2012-03-08,"['Center for Veterinary Medicine','Human Foods Program']",['Salmonella'],Final,FDA-2011-D-0091,No,
E7 Studies in Support of Special Populations; Geriatrics; Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e7-studies-support-special-populations-geriatrics-questions-and-answers,https://www.fda.gov/media/78220/download,2012-03-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Efficacy'],Final,FDA-2009-D-0528,No,
FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND: Frequently Asked Questions:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-acceptance-foreign-clinical-studies-not-conducted-under-ind-frequently-asked-questions,https://www.fda.gov/media/83209/download,2012-03-01,"['Office of the Commissioner','Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Clinical - Medical','Good Clinical Practice (GCP)']",Final,,No,
"IRB Continuing Review After Clinical Investigation Approval:  Guidance for IRBs, Clinical Investigators, and Sponsors",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/irb-continuing-review-after-clinical-investigation-approval,https://www.fda.gov/media/83121/download,2012-02-27,"['Office of the Commissioner','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Administrative / Procedural','Good Clinical Practice (GCP)']",Final,FDA-2009-D-0605,No,
"Questions and Answers on Informed Consent Elements, 21 CFR § 50.25(c):  Guidance for Sponsors, Investigators, and Institutional Review Boards",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/questions-and-answers-informed-consent-elements-21-cfr-ss-5025c,https://www.fda.gov/media/82634/download,2012-02-01,"['Office of the Commissioner','Office of the Commissioner']",['Good Clinical Practice (GCP)'],Final,,No,
"CPG Sec. 400.210, Radiofrequency Identification Feasibility Studies and Pilot Programs for Drugs",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-400210-radiofrequency-identification-feasibility-studies-and-pilot-programs-drugs,,2012-01-31,['Office of Inspections and Investigations'],['Investigation & Enforcement'],Final,,No,
"Guidance for Industry: Questions and Answers Regarding Establishment and Maintenance of Records By Persons Who Manufacture, Process, Pack, Transport, Distribute, Receive, Hold, or Import Food (Edition 5)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-regarding-establishment-and-maintenance-records-persons-who,https://www.fda.gov/media/83073/download,2012-01-31,['Human Foods Program'],"['Import','Packaging','Records','Transportation']",Final,FDA-2011-D-0598,No,
Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/responding-unsolicited-requests-label-information-about-prescription-drugs-and-medical-devices,https://www.fda.gov/media/82660/download,2011-12-30,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Veterinary Medicine']",['Administrative / Procedural'],Draft,FDA-2011-D-0868,No,
"Guidance for Industry: Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-prevention-salmonella-enteritidis-shell-eggs-during-production-storage-and,https://www.fda.gov/media/82653/download,2011-12-28,['Human Foods Program'],"['Egg/Egg Product','Salmonella','Transportation']",Final,FDA-2010-D-0313,No,
General Principles for the Development of Vaccines to Protect Against Global Infectious Diseases:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-development-vaccines-protect-against-global-infectious-diseases,https://www.fda.gov/media/82306/download,2011-12-01,['Center for Biologics Evaluation and Research'],['Vaccines'],Final,FDA-2011-D-0855,No,
"Current Good Tissue Practice (CGTP) and Additional Requirements for Manufacturers of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps):  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-tissue-practice-cgtp-and-additional-requirements-manufacturers-human-cells-tissues-and,https://www.fda.gov/media/82724/download,2011-12-01,['Center for Biologics Evaluation and Research'],['Tissue'],Final,FDA–2008–D–0659,No,
Preparation of IDEs and INDs for Products Intended to Repair or Replace Knee Cartilage:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/preparation-ides-and-inds-products-intended-repair-or-replace-knee-cartilage,https://www.fda.gov/media/82562/download,2011-12-01,['Center for Biologics Evaluation and Research'],"['Cellular & Gene Therapy','Gene Therapy']",Final,FDA-2007-D-0020,No,
Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic Radiopharmaceuticals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-evaluation-late-radiation-toxicity-therapeutic-radiopharmaceuticals,https://www.fda.gov/media/72237/download,2011-11-28,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Final,,No,
Medication Guides — Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medication-guides-distribution-requirements-and-inclusion-risk-evaluation-and-mitigation-strategies,https://www.fda.gov/media/79776/download,2011-11-18,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Safety - Issues, Errors, and Problems']",Final,,No,
"Q8, Q9, and Q10 Questions and Answers",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q8-q9-and-q10-questions-and-answers,https://www.fda.gov/media/78668/download,2011-11-17,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,,No,
Requalification Method for Reentry of Donors Who Test Hepatitis B Surface Antigen (HBsAg) Positive Following a Recent Vaccination against Hepatitis B Virus Infection:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requalification-method-reentry-donors-who-test-hepatitis-b-surface-antigen-hbsag-positive-following,https://www.fda.gov/media/124253/download,2011-11-01,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-2008-D-0263,No,
"Guidance for Industry: Letter to Firms that Grow, Harvest, Sort, Pack, Process, or Ship Fresh Cantaloupe",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-letter-firms-grow-harvest-sort-pack-process-or-ship-fresh-cantaloupe,https://www.fda.gov/media/82249/download,2011-10-31,['Human Foods Program'],['Fruit/Fruit Product'],Final,,No,
Guidance for Industry: Evaluating the Safety of Flood-affected Food Crops for Human Consumption,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-evaluating-safety-flood-affected-food-crops-human-consumption,,2011-10-24,['Human Foods Program'],['Emergencies'],Final,FDA-2011-D-0733,No,
"Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products — Content and Format",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/warnings-and-precautions-contraindications-and-boxed-warning-sections-labeling-human-prescription,https://www.fda.gov/media/71866/download,2011-10-12,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Labeling'],Final,FDA-2011-D-0694,No,
Incorporation of  Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting:  Guidance for Industry,,,2011-10-11,[],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2009-D-0212,No,
Guidance for Industry: Implementation of the Fee Provisions of Section 107 of the FDA Food Safety Modernization Act,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-implementation-fee-provisions-section-107-fda-food-safety-modernization-act,,2011-10-06,['Office of Inspections and Investigations'],['User Fees'],Final,FDA-2011-D-0721,No,
Clinical Considerations for Therapeutic Cancer Vaccines:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-considerations-therapeutic-cancer-vaccines,https://www.fda.gov/media/82312/download,2011-10-01,['Center for Biologics Evaluation and Research'],"['Cellular & Gene Therapy','Gene Therapy','Vaccines','Good Clinical Practice (GCP)']",Final,FDA-2009-D-0427,No,
CVM GFI #215 Target Animal Safety & Effectiveness Protocol Development & Submission,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-215-target-animal-safety-effectiveness-protocol-development-submission,https://www.fda.gov/media/79732/download,2011-09-29,['Center for Veterinary Medicine'],"['Target Animal – Effectiveness','Target Animal – Safety']",Final,FDA-2011-D-0023,No,
Time and Extent Applications for Nonprescription Drug Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/time-and-extent-applications-nonprescription-drug-products,https://www.fda.gov/media/72219/download,2011-09-29,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Final,FDA-2004-D-0438,No,
Applications for Premarket Review of New Tobacco Products: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applications-premarket-review-new-tobacco-products,https://www.fda.gov/media/81821/download,2011-09-28,['Center for Tobacco Products'],['PreMarket'],Draft,FDA-2011-D-0212,No,2011-09-27
"User Fee Waivers, Reductions, and Refunds for Drug and Biological Products",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/user-fee-waivers-reductions-and-refunds-drug-and-biological-products,https://www.fda.gov/media/72340/download,2011-09-27,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['User Fees'],Final,FDA-2011-D-0108,No,
Reproductive and Developmental Toxicities -- Integrating Study Results to Assess Concerns,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reproductive-and-developmental-toxicities-integrating-study-results-assess-concerns,https://www.fda.gov/media/72231/download,2011-09-23,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Final,FDA-1999-N-0082,No,
CVM GFI #205 (VICH GL46) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals:  Metabolism Study to Determine the Quantity and Identify the Nature of Residues (MRK),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-205-vich-gl46-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food,https://www.fda.gov/media/78339/download,2011-09-15,['Center for Veterinary Medicine'],"['Human Food Safety','VICH']",Final,FDA-2010-D-8228,No,
CVM GFI #206 (VICH GL47) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Comparative Metabolism Studies in Laboratory Animals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-206-vich-gl47-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food,https://www.fda.gov/media/78347/download,2011-09-15,['Center for Veterinary Medicine'],"['Human Food Safety','VICH']",Final,FDA-2010-D-8229,No,
Submission of Warning Plans for Cigarettes and Smokeless Tobacco Products: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-warning-plans-cigarettes-and-smokeless-tobacco-products,https://www.fda.gov/media/81594/download,2011-09-09,['Center for Tobacco Products'],['Warning plans'],Draft,FDA-2011-D-0480,No,2011-11-08
"PET Drug Applications - Content and Format for NDAs and ANDAs:  Attachment I: Sample formats for chemistry, manufacturing, and controls (CMC) sections_2011",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pet-drug-applications-content-and-format-ndas-and-andas-attachment-i-sample-formats-chemistry,https://www.fda.gov/media/72278/download,2011-09-01,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2000-D-1542,No,
Guidance for Industry:  Measures to Address the Risk for Contamination by Salmonella Species in Food Containing a Pistachio-Derived Product as an Ingredient,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-measures-address-risk-contamination-salmonella-species-food-containing-pistachio,https://www.fda.gov/media/81864/download,2011-08-31,['Human Foods Program'],"['Nuts & Nut Products','Salmonella']",Final,FDA-2009-D-0271,No,
PET Drug Applications - Content and Format for NDAs and ANDAs_2011,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pet-drug-applications-content-and-format-ndas-and-andas_2011,https://www.fda.gov/media/72271/download,2011-08-31,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,,No,
E2F Development Safety Update Report,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2f-development-safety-update-report,https://www.fda.gov/media/71255/download,2011-08-23,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Efficacy'],Final,FDA-2008-D-0386,No,
Exculpatory Language in Informed Consent,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exculpatory-language-informed-consent,https://www.fda.gov/media/81521/download,2011-08-19,['Office of the Commissioner'],['Good Clinical Practice (GCP)'],Draft,HHS-OPHS-2011-0014,No,2011-11-01
Residual Drug in Transdermal and Related Drug Delivery Systems:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/residual-drug-transdermal-and-related-drug-delivery-systems,https://www.fda.gov/media/79401/download,2011-08-17,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2010-D-0246,No,
Guidance for Industry: What You Need to Know About Prior Notice of Imported Food Shipments,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-what-you-need-know-about-prior-notice-imported-food-shipments,,2011-08-15,"['Office of Inspections and Investigations','Human Foods Program']",['Import'],Final,FDA-2011-N-0179,No,
"E16 Biomarkers Related to Drug or Biotechnology Product Development:  Context, Structure, and Format of Qualification Submissions",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e16-biomarkers-related-drug-or-biotechnology-product-development-context-structure-and-format,https://www.fda.gov/media/81311/download,2011-08-11,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Efficacy'],Final,FDA-2009-D-0324,No,
PET Drugs--Current Good Manufacturing Practice (CGMP); Small Entity Compliance Guide,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pet-drugs-current-good-manufacturing-practice-cgmp-small-entity-compliance-guide,https://www.fda.gov/media/81038/download,2011-08-05,['Center for Drug Evaluation and Research'],"['Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,FDA-2011-D-0541,No,
Availability of FDA’s eSubmitter Program for Regulatory Submissions from Licensed Blood Establishments:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/availability-fdas-esubmitter-program-regulatory-submissions-licensed-blood-establishments,https://www.fda.gov/media/81207/download,2011-08-01,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-2011-D-0579,No,
Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Influenza Viruses - Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/establishing-performance-characteristics-in-vitro-diagnostic-devices-detection-or-detection-and,https://www.fda.gov/media/71519/download,2011-07-14,['Center for Devices and Radiological Health'],['Pediatric Product Development'],Final,FDA-2008-D-0095,No,
Q4B Annex 7 (R2): Dissolution Test General Chapter,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-7-r2-dissolution-test-general-chapter,https://www.fda.gov/media/73122/download,2011-06-24,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['ICH-Quality'],Final,FDA-2009-D-0012,No,
Topical Acne Drug Products for Over-the-Counter Human Use--Revision of Labeling and Classification of Benzoyl Peroxide as Safe and Effective:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/topical-acne-drug-products-over-counter-human-use-revision-labeling-and-classification-benzoyl,https://www.fda.gov/media/80442/download,2011-06-21,['Center for Drug Evaluation and Research'],"['Labeling','Over-the-Counter Drugs']",Final,FDA-2011-D-0404,No,
"Donors of Blood and Blood Components: Notification of Donor Deferral, Small Entity Compliance Guide:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/donors-blood-and-blood-components-notification-donor-deferral-small-entity-compliance-guide,https://www.fda.gov/media/80682/download,2011-06-01,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-1998-N-1016,No,
Submission of Summary Bioequivalence Data for Abbreviated New Drug Applications,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-summary-bioequivalence-data-abbreviated-new-drug-applications,https://www.fda.gov/media/75535/download,2011-05-06,['Center for Drug Evaluation and Research'],['Generic Drugs'],Final,FDA-2009-D-0126,No,
Dosage Delivery Devices for Orally Ingested OTC Liquid Drug Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dosage-delivery-devices-orally-ingested-otc-liquid-drug-products,https://www.fda.gov/media/78087/download,2011-05-05,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Final,FDA-2009-D-0322,No,
How to Write a Request for Designation (RFD):  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/how-write-request-designation-rfd,https://www.fda.gov/media/80495/download,2011-04-14,['Office of the Commissioner'],['Combination Products'],Final,FDA-2011-D-0214,No,
Influenza: Developing Drugs for Treatment and/or Prophylaxis,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/influenza-developing-drugs-treatment-andor-prophylaxis,https://www.fda.gov/media/73339/download,2011-04-13,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2009-D-0044,No,
"Postmarketing Studies and  Clinical Trials—Implementation  of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry",,,2011-04-12,[],['Device & Drug Safety'],Final,FDA-2009-D-0283,No,
"""Computer Crossmatch"" (Computerized Analysis of the Compatibility between the Donor's Cell Type and the Recipient's Serum or Plasma Type); :  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/computer-crossmatch-computerized-analysis-compatibility-between-donors-cell-type-and-recipients,https://www.fda.gov/media/80857/download,2011-04-01,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-2007-D-0019,No,
Guidance for Industry: Questions and Answers About the Food Additive or Color Additive Petition Process,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-about-food-additive-or-color-additive-petition-process,,2011-03-31,['Human Foods Program'],['Food & Color Additives'],Final,FDA-2020-D-1917,No,
Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hypertension-indication-drug-labeling-cardiovascular-outcome-claims,https://www.fda.gov/media/134777/download,2011-03-15,['Center for Drug Evaluation and Research'],['Labeling'],Final,FDA-2008-D-0150,No,
Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/planning-effects-high-absenteeism-ensure-availability-medically-necessary-drug-products-0,https://www.fda.gov/media/120092/download,2011-03-15,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2009-D-0568,No,2020-05-31
Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/planning-effects-high-absenteeism-ensure-availability-medically-necessary-drug-products-0,https://www.fda.gov/media/120092/download,2011-03-14,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,,No,
Clinical Investigations of Devices Indicated for the Treatment of Urinary Incontinence - Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-investigations-devices-indicated-treatment-urinary-incontinence-guidance-industry-and-fda,https://www.fda.gov/media/71054/download,2011-03-07,['Center for Devices and Radiological Health'],"['Premarket','Pediatric Product Development']",Final,FDA-2008-D-0457,No,
"Guidance for Industry: Letter to Firms that Grow, Harvest, Sort, Pack, or Ship Fresh Cilantro",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-letter-firms-grow-harvest-sort-pack-or-ship-fresh-cilantro,,2011-03-01,['Human Foods Program'],"['Vegetable Products','Produce']",Final,,No,
CPG Sec. 335.700 Surgeons'Gloves and Patient Examination Gloves; Defects - Criteria for Direct Reference Seizure,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-335700-surgeons-gloves-and-patient-examination-gloves-defects-criteria-direct-reference,https://www.fda.gov/media/80870/download,2011-03-01,['Center for Devices and Radiological Health'],['Investigation & Enforcement'],Final,FDA-2020-D-0957,No,
Sample formats for Form FDA 356h_2011,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sample-formats-form-fda-356h_2011,https://www.fda.gov/media/72293/download,2011-02-02,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Draft,FDA-2000-D-1542,No,
Process Validation: General Principles and Practices:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/process-validation-general-principles-and-practices,https://www.fda.gov/media/71021/download,2011-01-25,"['Center for Veterinary Medicine','Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,FDA-2008-D-0559,No,
Potency Tests for Cellular and Gene Therapy Products:  Final Guidance for Industry:,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/potency-tests-cellular-and-gene-therapy-products,https://www.fda.gov/media/79856/download,2011-01-01,['Center for Biologics Evaluation and Research'],"['Cellular & Gene Therapy','Gene Therapy']",Final,FDA-2008-D-0520,No,
CPG Sec 527.300 Microbial Contaminants & Alkaline Phosphatase Activity,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527300-microbial-contaminants-alkaline-phosphatase-activity,https://www.fda.gov/media/80074/download,2010-12-23,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Dairy']",Final,FDA-2009-D-0466,No,2010-02-21
"Small Entity Compliance Guide: Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-current-good-manufacturing-practice-manufacturing-packaging-labeling,,2010-12-16,['Human Foods Program'],"['Labeling','Packaging']",Final,FDA-2010-D-0605,No,
CPG Sec 510.800 Beverages-Serving Size Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-510800-beverages-serving-size-labeling,,2010-12-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Beverage Bases/Conc/Nectar']",Final,,No,
CPG Sec 527.300 Dairy Products - Microbial Contaminants & Alkaline Phosphatase Activity,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527300-dairy-products-microbial-contaminants-alkaline-phosphatase-activity,https://www.fda.gov/media/80058/download,2010-12-01,['Office of Inspections and Investigations'],['Investigation & Enforcement'],Final,,No,
"“Lookback” for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test Results Indicating Infection with HCV:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/lookback-hepatitis-c-virus-hcv-product-quarantine-consignee-notification-further-testing-product,https://www.fda.gov/media/124265/download,2010-12-01,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-1999-D-0002,No,
Antibacterial Drug Products: Use of Noninferiority Studies to Support Approval,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antibacterial-drug-products-use-noninferiority-studies-support-approval,https://www.fda.gov/media/71215/download,2010-11-29,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2007-D-0150,No,
ANDAs: Impurities in Drug Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-impurities-drug-products,https://www.fda.gov/media/71351/download,2010-11-29,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2010-D-0584,No,
Blood Lancet Labeling - Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/blood-lancet-labeling-guidance-industry-and-food-and-drug-administration-staff,https://www.fda.gov/media/80085/download,2010-11-28,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2010-D-0590,No,
"Guidance for Industry: Safety of Imported Traditional Pottery Intended for Use with Food and the Use of the Term ""Lead Free"" in the Labeling of Pottery/Proper Identification of Ornamental and Decorative Ceramicware",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-safety-imported-traditional-pottery-intended-use-food-and-use-term-lead-free,,2010-11-22,['Human Foods Program'],"['Import','Labeling','Lead']",Final,FDA-2010-D-0571,No,
"Recommendations for Blood Establishments: Training of Back-Up Personnel, Assessment of Blood Donor Suitability and Reporting Certain Changes to an Approved Application:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-blood-establishments-training-back-personnel-assessment-blood-donor-suitability-and,https://www.fda.gov/media/124266/download,2010-11-01,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-2009-D-0533,No,
Cellular Therapy for Cardiac Disease:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cellular-therapy-cardiac-disease,https://www.fda.gov/media/76587/download,2010-10-01,['Center for Biologics Evaluation and Research'],"['Cellular & Gene Therapy','Gene Therapy']",Final,FDA-2009-D-0132,No,
Guidance for Industry: Food Additive Petition Expedited Review,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-food-additive-petition-expedited-review,,2010-09-30,['Human Foods Program'],['Food & Color Additives'],Final,FDA-2020-D-1918,No,
Addition of URLs to Electronic Product Labeling:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/addition-urls-electronic-product-labeling,https://www.fda.gov/media/79209/download,2010-09-29,['Center for Devices and Radiological Health'],"['Postmarket','Labeling']",Final,FDA-2020-D-0957,No,
Q4B Annex 10: Polyacrylamide Gel Electrophoresis General Chapter,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-10-polyacrylamide-gel-electrophoresis-general-chapter,https://www.fda.gov/media/77011/download,2010-09-12,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['ICH-Quality'],Final,FDA-2009-D-0342,No,
Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions Annex 11: Capillary Electrophoresis General Chapter,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-annex-11-capillary,https://www.fda.gov/media/78043/download,2010-09-03,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-2009-D-0579,No,
Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions Annex 12: Analytical Sieving General Chapter,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-annex-12-analytical-sieving,https://www.fda.gov/media/78048/download,2010-09-02,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-2009-D-0579,No,
Impact-Resistant Lenses: Questions and Answers:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/impact-resistant-lenses-questions-and-answers,https://www.fda.gov/media/71020/download,2010-09-02,['Center for Devices and Radiological Health'],,Final,FDA-2007-D-0367,No,
"Organ-Specific Warnings:  Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use — Small Entity Compliance Guide",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/organ-specific-warnings-internal-analgesic-antipyretic-and-antirheumatic-drug-products-over-counter,https://www.fda.gov/media/79064/download,2010-08-17,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Final,,No,
Contact Lens Care Products Labeling:  Guidance for Industry and Food and Drug Administration Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/contact-lens-care-products-labeling,https://www.fda.gov/media/79409/download,2010-08-15,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Ophthalmic']",Final,FDA-2020-D-0957,No,
"CVM GFI #169 Drug Substance Chemistry, Manufacturing, and Controls Information",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-169-drug-substance-chemistry-manufacturing-and-controls-information,https://www.fda.gov/media/69923/download,2010-08-06,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)']",Final,FDA-2003-D-0243,No,
Label Comprehension Studies for Nonprescription Drug Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/label-comprehension-studies-nonprescription-drug-products,https://www.fda.gov/media/75626/download,2010-08-03,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Final,FDA-2009-D-0181,No,
Radioactive Drug Research Committee: Human Research Without An Investigational New Drug Application,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/radioactive-drug-research-committee-human-research-without-investigational-new-drug-application,https://www.fda.gov/media/76286/download,2010-08-02,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Clinical - Medical'],Final,FDA-2009-D-0125,No,
Guidance for Industry and FDA: Advisory Levels for Deoxynivalenol (DON) in Finished Wheat Products for Human Consumption and Grains and Grain By-Products used for Animal Feed,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-advisory-levels-deoxynivalenol-don-finished-wheat-products-human,,2010-07-07,"['Center for Veterinary Medicine','Human Foods Program']","['Animal Feed','Grain/Grain Product']",Final,,No,
Guidance for Industry: Recommendations for Submission of Chemical and Technological Data for Food Additive Petitions and GRAS Notices for Enzyme Preparations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-recommendations-submission-chemical-and-technological-data-food-additive-petitions,https://www.fda.gov/media/79379/download,2010-06-30,['Human Foods Program'],"['Food & Color Additives','GRAS']",Final,,No,
In Vitro Diagnostic (IVD) Device Studies - Frequently Asked Questions:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/in-vitro-diagnostic-ivd-device-studies-frequently-asked-questions,https://www.fda.gov/media/71075/download,2010-06-25,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','Good Clinical Practice (GCP)','Laboratory Tests','IVDs (In Vitro Diagnostic Devices)']",Final,FDA-2007-D-0076,No,
Systemic Lupus Erythematosus --Developing Medical Products for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/systemic-lupus-erythematosus-developing-medical-products-treatment,https://www.fda.gov/media/71150/download,2010-06-22,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research']",['Clinical - Medical'],Final,FDA-2010-D-0249,No,
Individual Product Bioequivalence Recommendations for Specific Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/individual-product-bioequivalence-recommendations-specific-products,https://www.fda.gov/media/71401/download,2010-06-10,['Center for Drug Evaluation and Research'],['Generic Drugs'],Final,FDA-2007-D-0433,No,
"Use of “Light,” “Mild,” “Low,” or Similar Descriptors in the Label, Labeling, or Advertising of Tobacco Products:  Guidance for Industry and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-light-mild-low-or-similar-descriptors-label-labeling-or-advertising-tobacco-products,https://www.fda.gov/media/78927/download,2010-06-10,['Center for Tobacco Products'],['Labeling'],Final,FDA-2010-D-0282,No,2010-06-10
"Frequently Asked Questions – Statement of Investigator (Form FDA 1572):  Guidance for Sponsors, Clinical Investigators, and IRBs",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/frequently-asked-questions-statement-investigator-form-fda-1572,https://www.fda.gov/media/78830/download,2010-06-04,"['Office of the Commissioner','Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Administrative / Procedural','Good Clinical Practice (GCP)']",Final,FDA-2008-D-0406,No,
"FDA Inspections of Clinical Investigators:  Guidance For IRBs, Clinical Investigators, and Sponsors",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-inspections-clinical-investigators,https://www.fda.gov/media/75185/download,2010-06-01,['Office of the Commissioner'],"['Administrative / Procedural','Good Clinical Practice (GCP)']",Final,,No,
Draft Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry as Established by the Food and Drug Administration Amendments Act of 2007 (Edition 2),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-questions-and-answers-regarding-reportable-food-registry-established-food,https://www.fda.gov/media/79130/download,2010-05-25,"['Center for Veterinary Medicine','Human Foods Program']",['Reportable Food Registry'],Draft,FDA-2009-D-0260,No,2010-07-26
"Orientación preliminar de la industria: Preguntas y respuestas sobre el Registro de productos sanitarios en productos agroalimentarios, según establecido por la Ley de Enmiendas a la Alimentación y Medicamentos (FDA), 2007 (Edición 2)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orientacion-preliminar-de-la-industria-preguntas-y-respuestas-sobre-el-registro-de-productos,,2010-05-23,['Human Foods Program'],['Reportable Food Registry'],Draft,FDA-2009-D-0260,No,2010-07-26
Chinese Translation of Draft Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry Edition 2 (关于美国食品药品管理局2007年修正法案规定的应通报食品注册的问答 2010年5月),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chinese-translation-draft-guidance-industry-questions-and-answers-regarding-reportable-food-registry,https://www.fda.gov/media/172976/download,2010-05-23,['Human Foods Program'],['Reportable Food Registry'],Draft,FDA-2009-D-0260,No,2010-07-26
Guide pour l’industrie: Questions et réponses concernant le Registre de denrées alimentaires à signaler Reportable Food Registry (RFR) tel qu’établi par le Food and Drug Administration Amendments Act de 2007 (FDAAA) (2ème édition),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guide-pour-lindustrie-questions-et-reponses-concernant-le-registre-de-denrees-alimentaires-signaler,https://www.fda.gov/media/79279/download,2010-05-23,['Human Foods Program'],['Reportable Food Registry'],Draft,FDA-2009-D-0260,No,2010-07-26
Guidance for Industry: Use of Water by Food Manufacturers in Areas Subject to a Boil-Water Advisory,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-use-water-food-manufacturers-areas-subject-boil-water-advisory,,2010-05-13,['Human Foods Program'],['Emergencies'],Final,FDA-2010-D-0236,No,
Enforcement Policy Concerning Certain Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-concerning-certain-regulations-restricting-sale-and-distribution-cigarettes-and,https://www.fda.gov/media/78660/download,2010-05-07,['Center for Tobacco Products'],"['Cigarettes','Smokeless','Snuff','Chewing']",Final,FDA-2010-D-0189,No,2011-05-07
Requalification Method for Reentry of Blood Donors Deferred Because of Reactive Test Results for Antibody to Hepatitis B Core Antigen (Anti-HBc):  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requalification-method-reentry-blood-donors-deferred-because-reactive-test-results-antibody,https://www.fda.gov/media/78533/download,2010-05-01,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-2008-D-0263,No,
Guidance for Industry: Sanitary Transportation of Food,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-sanitary-transportation-food,,2010-04-29,['Human Foods Program'],"['Sanitation','Transportation']",Final,FDA-2020-D-1920,No,
Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems - Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-clinical-engineering-tests-and-recommended-labeling-intravascular-stents-and-associated-delivery,https://www.fda.gov/media/71639/download,2010-04-17,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
"Small Entity Compliance Guide: Prevention of Salmonella Enteritidis in Shell Eggs During Production, Transportation, and Storage",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-prevention-salmonella-enteritidis-shell-eggs-during-production,,2010-04-13,['Human Foods Program'],"['Egg/Egg Product','Transportation','Salmonella']",Final,FDA-2010-D-0183,No,
Q4B Annex 9: Tablet Friability General Chapter,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-9-tablet-friability-general-chapter,https://www.fda.gov/media/77008/download,2010-04-05,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['ICH-Quality'],Final,FDA-2009-D-0343,No,
Small Entity Compliance Guide: Bottled Water and Total Coliform and E. coli,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-bottled-water-and-total-coliform-and-e-coli,,2010-03-26,['Human Foods Program'],"['Bottled Water','E. coli']",Final,FDA-2010-D-0141,No,
French Translation of Guidance for Industry: Submitting a Report for Multiple Facilities to the Reportable Food Electronic Portal (Soumission d’un rapport concernant plusieurs usines auprès du portail électronique d’enregistrement des denrées alimentaires),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/french-translation-guidance-industry-submitting-report-multiple-facilities-reportable-food,,2010-03-25,"['Center for Veterinary Medicine','Human Foods Program']",['Reportable Food Registry'],Final,FDA-2009-D-0260,No,
Guidance for Industry: Submitting a Report for Multiple Facilities to the Reportable Food Electronic Portal as Established by the Food and Drug Administration Amendments Act of 2007,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-submitting-report-multiple-facilities-reportable-food-electronic-portal,,2010-03-25,['Human Foods Program'],['Reportable Food Registry'],Final,FDA-2009-D-0260,No,
Orientación preliminar para la industria: Presentación de Informe para múltiples instalaciones al Portal electrónico de incidentes,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orientacion-preliminar-para-la-industria-presentacion-de-informe-para-multiples-instalaciones-al,,2010-03-25,"['Center for Veterinary Medicine','Human Foods Program']",['Reportable Food Registry'],Final,FDA-2009-D-0260,No,
CVM GFI #192 Anesthetics for Companion Animals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-192-anesthetics-companion-animals,https://www.fda.gov/media/73814/download,2010-03-25,['Center for Veterinary Medicine'],['Target Animal – Safety'],Final,FDA-2008-D-0623,No,
CPG Sec 540.375 Canned Salmon - Adulteration Involving Decomposition (Withdrawn 3/22/2010),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540375-canned-salmon-adulteration-involving-decomposition-withdrawn-3222010,,2010-03-21,['Office of Inspections and Investigations'],['Investigation & Enforcement'],Final,,No,
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s9-nonclinical-evaluation-anticancer-pharmaceuticals,https://www.fda.gov/media/73161/download,2010-03-08,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Safety'],Final,FDA-2009-D-0006,No,
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s9-nonclinical-evaluation-anticancer-pharmaceuticals-questions-and-answers,https://www.fda.gov/media/100344/download,2010-03-08,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Safety'],Final,FDA-2009-D-0006,No,2016-11-16
Draft Guidance for Industry: Providing Regulatory Submissions in Electronic or Paper Format to the Office of Food Additive Safety,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-providing-regulatory-submissions-electronic-or-paper-format-office-food,https://www.fda.gov/media/78268/download,2010-03-01,['Human Foods Program'],['Food & Color Additives'],Draft,,No,
Chinese Translation of Guidance for Industry: Submitting a Report for Multiple Facilities to the Reportable Food Electronic Portal (行业指南：向美国食规定的应通报食品门户网提交多个机构的报告),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chinese-translation-guidance-industry-submitting-report-multiple-facilities-reportable-food,,2010-02-28,"['Center for Veterinary Medicine','Human Foods Program']",['Reportable Food Registry'],Final,FDA-2009-D-0260,No,
Standards for Securing the Drug Supply Chain - Standardized Numerical Identification for Prescription Drug Packages:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/standards-securing-drug-supply-chain-standardized-numerical-identification-prescription-drug,https://www.fda.gov/media/78317/download,2010-02-28,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Office of the Commissioner']",['Labeling'],Final,,No,
Submission of Documentation in Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-documentation-applications-parametric-release-human-and-veterinary-drug-products,https://www.fda.gov/media/71461/download,2010-02-26,"['Center for Veterinary Medicine','Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Microbiology','Pharmaceutical Quality']",Final,FDA-2008-D-0391,No,
Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials (PDF Version),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-use-bayesian-statistics-medical-device-clinical-trials-pdf-version,https://www.fda.gov/media/71512/download,2010-02-05,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2006-D-0410,No,
Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-use-bayesian-statistics-medical-device-clinical-trials-pdf-version,https://www.fda.gov/media/71512/download,2010-02-04,['Center for Devices and Radiological Health'],['Biostatistics'],Final,,No,
Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/characterization-and-qualification-cell-substrates-and-other-biological-materials-used-production,https://www.fda.gov/media/78428/download,2010-02-01,['Center for Biologics Evaluation and Research'],['Vaccines'],Final,FDA-2006-D-0223,No,
The Use of Mechanical Calibration of Dissolution Apparatus 1 and 2 – Current Good Manufacturing Practice (CGMP):  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-mechanical-calibration-dissolution-apparatus-1-and-2-current-good-manufacturing-practice-cgmp,https://www.fda.gov/media/77799/download,2010-01-27,['Center for Drug Evaluation and Research'],['Current Good Manufacturing Practice (CGMP)'],Final,FDA-2007-D-0420,No,
M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m3r2-nonclinical-safety-studies-conduct-human-clinical-trials-and-marketing-authorization,https://www.fda.gov/media/71542/download,2010-01-21,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Multidisciplinary'],Final,FDA-2008-D-0470,No,
New Contrast Imaging Indication Considerations for Devices and Approved Drug and Biological Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/new-contrast-imaging-indication-considerations-devices-and-approved-drug-and-biological-products,https://www.fda.gov/media/77679/download,2010-01-06,"['Office of the Commissioner','Center for Drug Evaluation and Research','Center for Devices and Radiological Health']",['Combination Products'],Final,FDA-2008-D-0525,No,
Q4B Annex 5: Disintegration Test General Chapter,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-5-disintegration-test-general-chapter,https://www.fda.gov/media/71306/download,2009-12-23,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-2008-D-0399,No,
General Questions and Answers on the Ban of Cigarettes that Contain Certain Characterizing Flavors (Edition 2):  Guidance to Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-questions-and-answers-ban-cigarettes-contain-certain-characterizing-flavors-edition-2,https://www.fda.gov/media/116681/download,2009-12-23,['Center for Tobacco Products'],"['Cigarettes','Flavored']",Final,FDA-2009-N-0449,No,
Q4B Annex 8: Sterility Test General Chapter,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-8-sterility-test-general-chapter,https://www.fda.gov/media/73134/download,2009-12-22,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['ICH-Quality'],Final,FDA-2009-D-0013,No,
S6(R1) Addendum: Preclinical Safety Evaluation of Biotechnology:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s6r1-addendum-preclinical-safety-evaluation-biotechnology,https://www.fda.gov/media/78034/download,2009-12-17,['Center for Drug Evaluation and Research'],['ICH-Safety'],Final,FDA-2009-D-0573,No,
S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s6-r1-addendum-preclinical-safety-evaluation-biotechnology-derived-pharmaceuticals,https://www.fda.gov/media/78034/download,2009-12-16,[],['ICH-Safety'],Final,,No,
PET Drug Products - Current Good Manufacturing Practice (CGMP),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pet-drug-products-current-good-manufacturing-practice-cgmp,https://www.fda.gov/media/71013/download,2009-12-10,['Center for Drug Evaluation and Research'],"['Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,FDA-1998-D-0025,No,
Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims,https://www.fda.gov/media/77832/download,2009-12-09,"['Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Clinical - Medical','Good Clinical Practice (GCP)']",Final,FDA-2006-D-0362,No,
Residual Solvents in Drug Products Marketed in the United States:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/residual-solvents-drug-products-marketed-united-states,https://www.fda.gov/media/70928/download,2009-11-25,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2008-D-0413,No,
Q8(R2) Pharmaceutical Development,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q8r2-pharmaceutical-development,https://www.fda.gov/media/71535/download,2009-11-20,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-2005-D-0154,No,
Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Donors of Whole Blood and Blood Components Intended for Transfusion:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-nucleic-acid-tests-reduce-risk-transmission-west-nile-virus-donors-whole-blood-and-blood,https://www.fda.gov/media/124300/download,2009-11-06,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-2008-D-0263,No,
SPL Standard for Content of Labeling Technical Qs & As,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/spl-standard-content-labeling-technical-qs,https://www.fda.gov/media/71211/download,2009-10-28,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Electronic Submissions'],Draft,FDA-2009-D-0355,No,
"Investigator Responsibilities — Protecting the Rights, Safety, and Welfare of Study Subjects:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigator-responsibilities-protecting-rights-safety-and-welfare-study-subjects,https://www.fda.gov/media/77765/download,2009-10-23,"['Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Administrative / Procedural','Good Clinical Practice (GCP)']",Final,,No,
Guidance for Industry: Letter Regarding Point of Purchase Food Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-letter-regarding-point-purchase-food-labeling,,2009-10-21,['Human Foods Program'],"['Labeling','Nutrition']",Final,FDA-2020-D-1921,No,
Labeling for Human Prescription Drug and Biological Products — Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-human-prescription-drug-and-biological-products-determining-established-pharmacologic-class,https://www.fda.gov/media/77834/download,2009-10-19,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Labeling'],Final,FDA-2007-D-0302,No,
Helicobacter pylori-Associated Duodenal Ulcer Disease in Adults:  Developing Drugs for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/helicobacter-pylori-associated-duodenal-ulcer-disease-adults-developing-drugs-treatment,https://www.fda.gov/media/78115/download,2009-10-05,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Draft,FDA-2009-D-0447,No,
"The Scope of the Prohibition Against Marketing a Tobacco Product in Combination with Another Article or Product Regulated under the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Manufacturers, Retailers, Importers and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scope-prohibition-against-marketing-tobacco-product-combination-another-article-or-product-regulated,https://www.fda.gov/media/80592/download,2009-09-29,['Center for Tobacco Products'],,Draft,FDA-2009-D-0470,No,2009-09-30
End-of-Phase 2A Meetings,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/end-phase-2a-meetings,https://www.fda.gov/media/72211/download,2009-09-18,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2008-D-0514,No,
Chinese Translation of the Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry (关于美国食品药品管理局2007年修正法案规定的应通报食品注册的问答),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chinese-translation-guidance-industry-questions-and-answers-regarding-reportable-food-registry,,2009-09-09,['Human Foods Program'],['Reportable Food Registry'],Final,FDA-2009-D-0260,No,
French Translation of Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry (Questions et Réponses relatives au Registre des aliments à signaler),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/french-translation-guidance-industry-questions-and-answers-regarding-reportable-food-registry,,2009-09-09,['Human Foods Program'],['Reportable Food Registry'],Final,FDA-2009-D-0260,No,
Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry as Established by the Food and Drug Administration Amendments Act of 2007,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-questions-and-answers-regarding-reportable-food-registry-established-food,https://www.fda.gov/media/79130/download,2009-09-09,"['Center for Veterinary Medicine','Human Foods Program']",['Reportable Food Registry'],Final,FDA-2009-D-0260,No,
Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry as Established by the Food and Drug Adminstration Amendments Act of 2007 - Appendix,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-regarding-reportable-food-registry-established-food-and-drug-0,,2009-09-09,['Human Foods Program'],['Reportable Food Registry'],Final,FDA-2009-D-0260,No,
"Preguntas y respuestas sobre el Registro de incidentes sanitarios en productos agroalimentarios, según lo establecido por la Ley de Enmiendas de la Administración de Medicamentos y Alimentos de 2007",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/preguntas-y-respuestas-sobre-el-registro-de-incidentes-sanitarios-en-productos-agroalimentarios,,2009-09-09,['Human Foods Program'],['Reportable Food Registry'],Final,FDA-2009-D-0260,No,
Guidance for Industry: Questions and Answers Regarding the Labeling of Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-regarding-labeling-dietary-supplements-required-dietary,,2009-09-01,['Human Foods Program'],,Final,FDA-2007-D-0209,No,
Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act:  Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-nonprescription-human-drug-products-marketed-without-approved-application-required-dietary,https://www.fda.gov/media/77411/download,2009-09-01,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Final,FDA-2007-D-0429,No,
Considerations for Allogeneic Pancreatic Islet Cell Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-allogeneic-pancreatic-islet-cell-products,https://www.fda.gov/media/77497/download,2009-09-01,['Center for Biologics Evaluation and Research'],"['Cellular & Gene Therapy','Gene Therapy']",Final,FDA-2008-D-0293,No,
Pharmaceutical Components at Risk for Melamine Contamination:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmaceutical-components-risk-melamine-contamination,https://www.fda.gov/media/77196/download,2009-08-06,"['Center for Veterinary Medicine','Center for Drug Evaluation and Research']","['Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,FDA-2009-D-0354,No,
Drug-Induced Liver Injury: Premarketing Clinical Evaluation,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-induced-liver-injury-premarketing-clinical-evaluation,https://www.fda.gov/media/116737/download,2009-07-29,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Safety - Issues, Errors, and Problems']",Final,FDA-2008-D-0128,No,
Nucleic Acid Testing  to Reduce the Possible Risk of Parvovirus B19 Transmission by Plasma-Derived Products:  Guidance for Industry,,,2009-07-28,[],['Blood Products'],Final,FDA-2008-D-0379,No,
ANDAs: Impurities in Drug Substances:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-impurities-drug-substances,https://www.fda.gov/media/77324/download,2009-07-15,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-1998-D-0021,No,
Postmarketing Adverse Event Reporting for Nonprescription Human Drug Products Marketed Without an Approved Application,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-adverse-event-reporting-nonprescription-human-drug-products-marketed-without-approved,https://www.fda.gov/media/77193/download,2009-07-14,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Final,FDA-2007-D-0434,No,
CVM GFI #70 Small Entities Compliance Guide for Feeders of Ruminant Animals Without On-Farm Feed Mixing Operations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-70-small-entities-compliance-guide-feeders-ruminant-animals-without-farm-feed-mixing,https://www.fda.gov/media/70227/download,2009-07-13,['Center for Veterinary Medicine'],"['Bovine Spongiform Encephalopathy (BSE)','Animal Feed','Current Good Manufacturing Practice (CGMP)']",Final,,No,
Frequently Asked Questions - IRB Registration:  Guidance for Institutional Review Boards (IRBs),PDF (48.34 KB)PDF (48.34 KB) of Frequently Asked Questions - IRB Registration: Guidance for Institutional Review Boards (IRBs),https://www.fda.gov/media/77059/download,2009-07-09,['Office of the Commissioner'],['Good Clinical Practice (GCP)'],Final,FDA-2009-D-0312,No,
"Guidance for Industry: Color Additive Petitions - FDA Recommendations for Submission of Chemical and Technological Data on Color Additives for Food, Drugs, Cosmetics, or Medical Devices",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-color-additive-petitions-fda-recommendations-submission-chemical-and-technological,,2009-07-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Medication Guides — Adding a Toll-Free Number for Reporting Adverse Events,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medication-guides-adding-toll-free-number-reporting-adverse-events,https://www.fda.gov/media/76667/download,2009-06-08,['Center for Drug Evaluation and Research'],"['Administrative / Procedural','Safety - Issues, Errors, and Problems']",Final,FDA-2009-D-0217,No,
Small Entity Compliance Guide: Bottled Water and Residual Disinfectants and Disinfection Byproducts,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-bottled-water-and-residual-disinfectants-and-disinfection-byproducts,,2009-06-01,['Human Foods Program'],['Bottled Water'],Final,FDA-2009-D-0224,No,
Providing Regulatory Submissions in Electronic Format – Drug Establishment Registration and Drug Listing,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-drug-establishment-registration-and-drug-listing,https://www.fda.gov/media/71146/download,2009-06-01,"['Center for Drug Evaluation and Research','Center for Veterinary Medicine']",['Electronic Submissions'],Final,FDA-2005-N-0464,No,
Presenting Risk Information in Prescription Drug and Medical Device Promotion,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/presenting-risk-information-prescription-drug-and-medical-device-promotion,https://www.fda.gov/media/76269/download,2009-05-27,"['Center for Veterinary Medicine','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Advertising'],Draft,FDA-2008-D-0253,No,
"Small Entity Compliance Guide: Health Claims on Calcium and Osteoporosis; and Calcium, Vitamin D, and Osteoporosis",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-health-claims-calcium-and-osteoporosis-and-calcium-vitamin-d-and,,2009-05-15,['Human Foods Program'],['Labeling'],Final,FDA-2009-D-0209,No,
Labeling OTC Human Drug Products; Small Entity Compliance Guide:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-otc-human-drug-products-small-entity-compliance-guide,https://www.fda.gov/media/76481/download,2009-05-13,['Center for Drug Evaluation and Research'],"['Compliance','Over-the-Counter Drugs']",Final,FDA-2004-D-0122,No,
CPG Sec 110.310 Prior Notice of Imported Food Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-110310-prior-notice-imported-food-under-public-health-security-and-bioterrorism-preparedness,,2009-05-06,"['Center for Veterinary Medicine','Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Import']",Final,FDA-2007-D-0487,No,
CVM GFI #195 Small Entities Compliance Guide For Renderers—Substances Prohibited From Use In Animal Food Or Feed,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-195-small-entities-compliance-guide-renderers-substances-prohibited-use-animal-food-or-feed,https://www.fda.gov/media/70417/download,2009-05-06,['Center for Veterinary Medicine'],['Bovine Spongiform Encephalopathy (BSE)'],Final,FDA-2008-D-0597,No,
Questions and Answers on Current Good Manufacturing Practice Questions and Answers on Current Good Manufacturing Practice Requirements | General Provisions,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/questions-and-answers-current-good-manufacturing-practice-questions-and-answers-current-good,,2009-04-30,['Center for Drug Evaluation and Research'],,Final,FDA-2017-D-6821,No,
Small Entity Compliance Guide: Declaration by Name on the Label of All Foods and Cosmetic Products that Contain Cochineal Extract and Carmine,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-declaration-name-label-all-foods-and-cosmetic-products-contain,,2009-04-30,['Human Foods Program'],"['Food & Color Additives','Labeling']",Final,FDA-2009-D-0198,No,
Small Entity Compliance Guide: Bottled Water and Arsenic,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-bottled-water-and-arsenic,,2009-04-29,['Human Foods Program'],"['Arsenic','Bottled Water']",Final,FDA-2009-D-0196,No,
Small Entity Compliance Guide: Bottled Water and Uranium,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-bottled-water-and-uranium,,2009-04-29,['Human Foods Program'],['Bottled Water'],Final,FDA-2009-D-0195,No,
CVM GFI #185 (VICH GL43) Target Animal Safety for Veterinary Pharmaceutical Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-185-vich-gl43-target-animal-safety-veterinary-pharmaceutical-products,https://www.fda.gov/media/70438/download,2009-04-24,['Center for Veterinary Medicine'],"['Target Animal – Safety','VICH']",Final,FDA-2007-D-0430,No,
Integrated Summaries of Effectiveness and Safety: Location Within the Common Technical Document,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/integrated-summaries-effectiveness-and-safety-location-within-common-technical-document,https://www.fda.gov/media/75783/download,2009-04-21,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2007-D-0031,No,
Q10 Pharmaceutical Quality System,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q10-pharmaceutical-quality-system,https://www.fda.gov/media/71553/download,2009-04-08,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-2007-D-0370,No,
Q4B Annex 4A: Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests General Chapter,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-4a-microbiological-examination-non-sterile-products-microbial-enumeration-tests-general,https://www.fda.gov/media/71241/download,2009-04-08,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['ICH-Quality'],Final,FDA-2008-D-0396,No,
Q4B Annex 4B: Microbiological Examination of Non-Sterile Products: Tests for Specified Micro-organisms General Chapter,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-4b-microbiological-examination-non-sterile-products-tests-specified-micro-organisms,https://www.fda.gov/media/71267/download,2009-04-08,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['ICH-Quality'],Final,FDA-2008-D-0398,No,
Q4B Annex 4C: Microbiological Examination of Non-Sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use General Chapter,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-4c-microbiological-examination-non-sterile-products-acceptance-criteria-pharmaceutical,https://www.fda.gov/media/71291/download,2009-04-08,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['ICH-Quality'],Final,FDA-2008-D-0400,No,
Guidance for Industry: Recommendations for Submission of Chemical and Technological Data for Direct Food Additive Petitions,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-recommendations-submission-chemical-and-technological-data-direct-food-additive,,2009-03-22,['Human Foods Program'],['Food & Color Additives'],Final,FDA-2020-D-1922,No,
CVM GFI #149 (VICH GL33) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Testing,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-149-vich-gl33-studies-evaluate-safety-residues-veterinary-drugs-human-food-general-approach,https://www.fda.gov/media/69960/download,2009-03-17,['Center for Veterinary Medicine'],"['Human Food Safety','VICH']",Final,FDA-2002-D-0186,No,
Guidance for Industry: Measures to Address the Risk for Contamination by Salmonella Species in Food Containing a Peanut-Derived Product as an Ingredient,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-measures-address-risk-contamination-salmonella-species-food-containing-peanut,,2009-03-11,['Human Foods Program'],"['Nuts & Nut Products','Salmonella']",Final,FDA-2009-D-0060,No,
Guidance for Industry: 1991 Letter to Seafood Manufacturers Regarding the Fraudulent Practice of Including Glaze (ice) as Part of the Weight of Frozen Seafood,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-1991-letter-seafood-manufacturers-regarding-fraudulent-practice-including-glaze,,2009-02-18,['Human Foods Program'],['Seafood/Seafood Product'],Final,FDA-2020-D-1923,No,
Guidance for Industry: Referral Program from the Food and Drug Administration to the National Oceanic and Atmospheric Administration Seafood Inspection Program for the Certification of Fish and Fishery Products for Export to the European Union and the European Free Trade Association,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-referral-program-food-and-drug-administration-national-oceanic-and-atmospheric,,2009-02-11,['Human Foods Program'],"['Export','Seafood/Seafood Product']",Final,FDA-2004-D-0043,No,
Animal Models — Essential Elements to Address Efficacy Under the Animal Rule_09,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/animal-models-essential-elements-address-efficacy-under-animal-rule_09,https://www.fda.gov/media/72265/download,2009-02-05,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Final,None found,No,
Guidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-evidence-based-review-system-scientific-evaluation-health-claims,,2009-01-16,['Human Foods Program'],['Labeling'],Final,FDA-2007-D-0371,No,
"Adverse Event Reporting to IRBs — Improving Human Subject Protection:  Guidance for Clinical Investigators, Sponsors, and IRBs",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adverse-event-reporting-irbs-improving-human-subject-protection,https://www.fda.gov/media/72267/download,2009-01-14,"['Office of the Commissioner','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Administrative / Procedural','Good Clinical Practice (GCP)']",Final,FDA-2007-D-0202,No,
Q4B Annex 3: Test for Particulate Contamination: Subvisible Particles General Chapter,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-3-test-particulate-contamination-subvisible-particles-general-chapter,https://www.fda.gov/media/71231/download,2009-01-09,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['ICH-Quality'],Final,FDA-2007-D-0306,No,
"Guidance for Industry: Substantiation for Dietary Supplement Claims Made Under Section 403(r) (6) of the Federal Food, Drug, and Cosmetic Act",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-substantiation-dietary-supplement-claims-made-under-section-403r-6-federal-food,,2009-01-05,['Human Foods Program'],['Labeling'],Final,FDA-2004-D-0303,No,
Labeling OTC Human Drug Products -- Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-otc-human-drug-products-questions-and-answers,https://www.fda.gov/media/72441/download,2009-01-05,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Final,FDA-2004-D-0437,No,
CPG Sec 540.370 Fish and Fishery Products - Decomposition,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540370-fish-and-fishery-products-decomposition,https://www.fda.gov/media/75141/download,2009-01-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Seafood/Seafood Product']",Final,,No,
Radiation Safety Considerations for X-Ray Equipment Designed for Hand-Held Use,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/radiation-safety-considerations-x-ray-equipment-designed-hand-held-use,https://www.fda.gov/media/73890/download,2008-12-23,['Center for Devices and Radiological Health'],['Postmarket'],Final,FDA-2020-D-0957,No,
Orally Disintegrating Tablets:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orally-disintegrating-tablets,https://www.fda.gov/media/70877/download,2008-12-16,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2007-D-0365,No,
Modifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making Process:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/modifications-devices-subject-premarket-approval-pma-pma-supplement-decision-making-process,https://www.fda.gov/media/81431/download,2008-12-11,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health']","['Premarket','Premarket Approval (PMA)']",Final,FDA-2007-D-0025,No,
CVM GFI #5 Drug Stability Guidelines,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-5-drug-stability-guidelines,https://www.fda.gov/media/69957/download,2008-12-09,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)']",Final,FDA-2020-D-1385,No,
Guidance for Industry: Dear Manufacturer Letter Regarding Front-of-Package Symbols,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-dear-manufacturer-letter-regarding-front-package-symbols,,2008-12-01,['Human Foods Program'],['Labeling'],Final,FDA-2020-D-1924,No,
Cooperative Manufacturing Arrangements for Licensed Biologics:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cooperative-manufacturing-arrangements-licensed-biologics,https://www.fda.gov/media/70712/download,2008-11-28,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Administrative / Procedural'],Final,FDA-1999-D-0128,No,
PDUFA Pilot Project: Proprietary Name Review - Concept Paper,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pdufa-pilot-project-proprietary-name-review-concept-paper,https://www.fda.gov/media/71630/download,2008-10-07,['Center for Drug Evaluation and Research'],,Final,FDA-2008-N-0281,No,
"Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials:  Guidance for Sponsors, Clinical Investigators, and IRBs",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-retention-when-subjects-withdraw-fda-regulated-clinical-trials,https://www.fda.gov/media/75138/download,2008-10-01,['Office of the Commissioner'],['Good Clinical Practice (GCP)'],Final,FDA-2008-D-0576,No,
S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s1cr2-dose-selection-carcinogenicity-studies-pharmaceuticals,https://www.fda.gov/media/71944/download,2008-09-17,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Safety'],Final,,No,
Animal Models — Essential Elements to Address Efficacy Under the Animal Rule - Concept Paper,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/animal-models-essential-elements-address-efficacy-under-animal-rule-concept-paper,https://www.fda.gov/media/71592/download,2008-09-09,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Final,None found,No,
Clinical Study Designs for Catheter Ablation Devices for Treatment of Atrial Flutter:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-study-designs-catheter-ablation-devices-treatment-atrial-flutter,https://www.fda.gov/media/71116/download,2008-08-05,['Center for Devices and Radiological Health'],"['Premarket','Good Clinical Practice (GCP)']",Final,FDA-2020-D-0957,No,
Voting Procedures for Advisory Committee Meetings:  Guidance for FDA Advisory Committee Members and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/voting-procedures-advisory-committee-meetings,https://www.fda.gov/media/75426/download,2008-08-01,['Office of the Commissioner'],"['Advisory Committees','Food & Color Additives']",Final,,No,
Preparation and Public Availability  of Information Given to Advisory Committee Members:  Guidance for Industry,,,2008-08-01,[],"['Advisory Committees','Food & Color Additives']",Final,,No,
CPG Sec 540.575 Fish - Fresh and Frozen - Adulteration Involving Decomposition (Withdrawn 7/18/2008),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540575-fish-fresh-and-frozen-adulteration-involving-decomposition-withdrawn-7182008,,2008-07-18,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Seafood/Seafood Product']",Final,,No,
Small Entity Compliance Guide: Nutrient Content Claims Definition for “High Potency” and Definition for “Antioxidant” for Use in Nutrient Content Claims for Dietary Supplements and Conventional Foods,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-nutrient-content-claims-definition-high-potency-and-definition,,2008-07-18,['Human Foods Program'],['Labeling'],Final,FDA-1995-N-0400,No,
Small Entity Compliance Guide: Final Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated Because They Present an Unreasonable Risk,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-final-rule-declaring-dietary-supplements-containing-ephedrine,,2008-07-17,['Human Foods Program'],,Final,FDA-1995-N-0054,No,
Small Entity Compliance Guide: Standard of Identity for White Chocolate,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-standard-identity-white-chocolate,,2008-07-16,['Human Foods Program'],['Chocolate/Cocoa Product'],Final,FDA-2008-N-0361,No,
Current Good Manufacturing Practice for Phase 1 Investigational Drugs:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-manufacturing-practice-phase-1-investigational-drugs,https://www.fda.gov/media/70975/download,2008-07-14,"['Office of Regulatory Affairs','Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Investigation & Enforcement','Current Good Manufacturing Practice (CGMP)','Good Clinical Practice (GCP)','Pharmaceutical Quality']",Final,FDA-2005-D-0157,No,
Intravascular Administration Sets Premarket Notification Submissions [510(k)]:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/intravascular-administration-sets-premarket-notification-submissions-510k,https://www.fda.gov/media/71046/download,2008-07-11,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2020-D-0957,No,
Surveillance and Detention Without Physical Examination of Condoms:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/surveillance-and-detention-without-physical-examination-condoms,https://www.fda.gov/media/71018/download,2008-07-11,['Center for Devices and Radiological Health'],['Postmarket'],Final,FDA-2000-D-0137,No,
Surveillance and Detention Without Physical Examination of Surgeons'and/or Patient Examination Gloves:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/surveillance-and-detention-without-physical-examination-surgeons-andor-patient-examination-gloves,https://www.fda.gov/media/71086/download,2008-07-11,['Center for Devices and Radiological Health'],['Postmarket'],Final,FDA-2000-D-0186,No,
"CPG Sec 560.700 - Processing of Imported Frozen Products of Multiple Sizes (e.g., Shrimp, Prawns, Etc.) (Withdrawn 6/6/2008)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-560700-processing-imported-frozen-products-multiple-sizes-eg-shrimp-prawns-etc-withdrawn,,2008-06-06,['Human Foods Program'],"['Investigation & Enforcement','Import']",Final,,No,
Q3A(R) Impurities in New Drug Substances,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q3ar-impurities-new-drug-substances,https://www.fda.gov/media/71727/download,2008-06-06,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,,No,
Indexing Structured Product Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/indexing-structured-product-labeling,https://www.fda.gov/media/71110/download,2008-06-02,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Electronic Submissions'],Final,FDA-2007-D-0364,No,
"Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-efficacy-and-pharmacokinetic-studies-support-marketing-immune-globulin-intravenous-human,https://www.fda.gov/media/124333/download,2008-06-01,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-2005-D-0208,No,
Hemodialysis Blood Tubing Sets - Premarket Notification [510(k)] Submissions:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hemodialysis-blood-tubing-sets-premarket-notification-510k-submissions,https://www.fda.gov/media/71429/download,2008-04-23,['Center for Devices and Radiological Health'],['510(k)'],Final,FDA-2020-D-0957,No,
"Certain Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) Recovered from Donors Who Were Tested for Communicable Diseases Using Pooled Specimens or Diagnostic Tests:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/certain-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-recovered-donors-who-were,https://www.fda.gov/media/70696/download,2008-04-16,['Center for Biologics Evaluation and Research'],['Tissue'],Final,FDA-2007-D-0070,No,
Investigational Device Exemptions (IDEs) for Devices Indicated for Nocturnal Home Hemodialysis:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-device-exemptions-ides-devices-indicated-nocturnal-home-hemodialysis,https://www.fda.gov/media/71554/download,2008-04-15,['Center for Devices and Radiological Health'],"['Premarket','Investigational Device Exemption (IDE)']",Final,FDA-2020-D-0957,No,
Preparation and Review of Investigational Device Exemption Applications (IDEs) for Total Artificial Discs:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/preparation-and-review-investigational-device-exemption-applications-ides-total-artificial-discs,https://www.fda.gov/media/71039/download,2008-04-11,['Center for Devices and Radiological Health'],"['Premarket','Investigational Device Exemption (IDE)','Orthopedic']",Final,FDA-2020-D-0957,No,
E15 Pharmacogenomics Definitions and Sample Coding,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e15-pharmacogenomics-definitions-and-sample-coding,https://www.fda.gov/media/71389/download,2008-04-08,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Efficacy'],Final,FDA-2008-D-0199,No,
"Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs):  Guidance for FDA Reviewers and Sponsors",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-review-chemistry-manufacturing-and-control-cmc-information-human-somatic-cell-therapy,https://www.fda.gov/media/73624/download,2008-04-01,['Center for Biologics Evaluation and Research'],"['Cellular & Gene Therapy','Gene Therapy']",Final,FDA-2008-D-0206,No,
Guidance for Industry: A Labeling Guide for Restaurants and Retail Establishments Selling Away-From-Home Foods - Part I,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-labeling-guide-restaurants-and-retail-establishments-selling-away-home-foods-part-0,https://www.fda.gov/media/93414/download,2008-03-31,['Human Foods Program'],"['Labeling','Retail Food Protection']",Final,,No,
"CPG Sec 500.500 Guidance Levels for 3-MCPD (3-chloro-1,2-propanediol) in Acid-Hydrolyzed Protein and Asian-Style Sauces",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-500500-guidance-levels-3-mcpd-3-chloro-12-propanediol-acid-hydrolyzed-protein-and-asian,https://www.fda.gov/media/71760/download,2008-03-14,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Ingredients']",Final,,No,
Guidance for Industry: Guide to Minimize Microbial Food Safety Hazards of Fresh-cut Fruits and Vegetables,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-guide-minimize-microbial-food-safety-hazards-fresh-cut-fruits-and-vegetables,,2008-02-25,['Human Foods Program'],"['Fruit/Fruit Product','Vegetable Products','Produce','Sanitation']",Final,FDA-2008-D-0108,No,
Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/container-and-closure-system-integrity-testing-lieu-sterility-testing-component-stability-protocol,https://www.fda.gov/media/76338/download,2008-02-25,"['Center for Veterinary Medicine','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Postmarket','Administrative / Procedural']",Final,FDA-2008-D-0060,No,
Q4B Annex I: Residue on Ignition/Sulphated Ash General Chapter,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-i-residue-ignitionsulphated-ash-general-chapter,https://www.fda.gov/media/71214/download,2008-02-21,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['ICH-Quality'],Final,FDA-2008-D-0083,No,
Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the International Conference on Harmonisation Regions,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-evaluation-and-recommendation-pharmacopoeial-texts-use-international-conference-harmonisation,https://www.fda.gov/media/71204/download,2008-02-20,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-2008-D-0081,No,
Coronary and Carotid Embolic Protection Devices - Premarket Notification [510(k)] Submissions :  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/coronary-and-carotid-embolic-protection-devices-premarket-notification-510k-submissions,https://www.fda.gov/media/71061/download,2008-02-15,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2020-D-0957,No,
CPG Sec 555.320 Listeria monocytogenes,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555320-listeria-monocytogenes,,2008-02-01,"['Office of Inspections and Investigations','Human Foods Program']",['Investigation & Enforcement'],Draft,,No,
Medical Glove Guidance Manual:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-glove-guidance-manual,https://www.fda.gov/media/90612/download,2008-01-22,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2020-D-0957,No,
CVM GFI #179 Use of Animal Clones and Clone Progeny for Human Food and Animal Feed,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-179-use-animal-clones-and-clone-progeny-human-food-and-animal-feed,https://www.fda.gov/media/69900/download,2008-01-15,['Center for Veterinary Medicine'],['Biotechnology'],Final,FDA-2008-N-0033,No,
The Review and Inspection of Premarket Approval Application Manufacturing Information and Operations:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/review-and-inspection-premarket-approval-application-manufacturing-information-and-operations,https://www.fda.gov/media/72153/download,2008-01-08,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
CPG Sec 575.100 Draft Revision - Pesticide Chemical Residues in Food - Enforcement Criteria,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-575100-draft-revision-pesticide-chemical-residues-food-enforcement-criteria,https://www.fda.gov/media/77986/download,2008-01-01,"['Office of Inspections and Investigations','Human Foods Program']",['Investigation & Enforcement'],Draft,,No,
Guidance for Industry: Preparation of Premarket Submissions for Food Contact Substances (Chemistry Recommendations),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-preparation-premarket-submissions-food-contact-substances-chemistry,,2007-12-01,['Human Foods Program'],"['Food & Color Additives','Ingredients']",Final,FDA-2020-D-1925,No,
Collection of Platelets by Automated Methods:  Guidance for Industry and FDA Review Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/collection-platelets-automated-methods,https://www.fda.gov/media/70720/download,2007-12-01,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-2005-D-0013,No,
CVM GFI #92 (VICH GL10(R)) Impurities In New Veterinary Drug Substances,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-92-vich-gl10r-impurities-new-veterinary-drug-substances,https://www.fda.gov/media/70365/download,2007-11-26,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)','VICH']",Final,FDA-1999-D-0064,No,
CVM GFI #73 (VICH GL3(R)) Stability Testing of New Veterinary Drug Substances and Medicinal Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-73-vich-gl3r-stability-testing-new-veterinary-drug-substances-and-medicinal-products,https://www.fda.gov/media/70241/download,2007-11-21,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)','VICH']",Final,FDA-2006-D-0299,No,
CVM GFI #93 (VICH GL11(R)) Impurities in New Veterinary Medicinal Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-93-vich-gl11r-impurities-new-veterinary-medicinal-products,https://www.fda.gov/media/70368/download,2007-11-21,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)','VICH']",Final,FDA-1999-D-0048,No,
"Adequate and Appropriate Donor Screening Tests for Hepatitis B; Hepatitis B Surface Antigen (HBsAg) Assays Used to Test Donors of Whole Blood and Blood Components, Including Source Plasma and Source Leukocytes:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adequate-and-appropriate-donor-screening-tests-hepatitis-b-hepatitis-b-surface-antigen-hbsag-assays,https://www.fda.gov/media/124336/download,2007-11-21,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-2002-D-0175,No,
Considerations for Plasmid DNA Vaccines for Infectious Disease Indications:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-plasmid-dna-vaccines-infectious-disease-indications,https://www.fda.gov/media/73667/download,2007-11-01,['Center for Biologics Evaluation and Research'],['Vaccines'],Final,FDA-2005-D-0211,No,
Role of HIV Drug Resistance Testing in Antiretroviral Drug Development,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/role-hiv-drug-resistance-testing-antiretroviral-drug-development,https://www.fda.gov/media/71044/download,2007-10-31,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2004-D-0242,No,
Inspection and Field Testing of Radiation-Emitting Electronic Products: Attachment A,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/inspection-and-field-testing-radiation-emitting-electronic-products-attachment,,2007-10-30,['Center for Devices and Radiological Health'],['Postmarket'],Final,FDA-2020-D-0957,No,
Inspection and Field Testing of Radiation-Emitting Electronic Products: Attachment C: Specific Instructions for Sunlamp Product Inspections and Tests,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/inspection-and-field-testing-radiation-emitting-electronic-products-attachment-c-specific,,2007-10-30,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Biological Indicator (BI) Premarket Notification [510(k)] Submissions :  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biological-indicator-bi-premarket-notification-510k-submissions,https://www.fda.gov/media/71134/download,2007-10-04,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2020-D-0957,No,
Guidance for Industry: Food Security Preventive Measures for Importers and Filers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-food-security-preventive-measures-importers-and-filers,,2007-10-01,['Human Foods Program'],"['Import','Defense & Security']",Final,FDA-2020-D-1926,No,
Guidance for Industry: Food Security Preventive Measures Guidance for  Retail Food Stores and Food Service Establishments,,,2007-10-01,[],"['Defense & Security','Retail Food Protection']",Final,FDA-2020-D-1927,No,
"Guidance for Industry: Food Security Preventive Measures Guidance for Dairy Farms, Bulk Milk Transporters, Bulk Milk Transfer Stations and Fluid Milk Processors",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-food-security-preventive-measures-guidance-dairy-farms-bulk-milk-transporters-bulk,,2007-10-01,['Human Foods Program'],['Milk/Milk Product'],Final,FDA-2020-D-1928,No,
CVM GFI #178 Recommended Design and Evaluation of Effectiveness Studies for Swine Respiratory Disease Claims,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-178-recommended-design-and-evaluation-effectiveness-studies-swine-respiratory-disease-claims,https://www.fda.gov/media/69903/download,2007-10-01,['Center for Veterinary Medicine'],['Animal Feed'],Final,FDA-2006-D-0479,No,
"Guidance for Industry: Food Security Preventive Measures Guidance for Food Producers, Processors, and Transporters",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-food-security-preventive-measures-guidance-food-producers-processors-and,,2007-09-30,['Human Foods Program'],['Transportation'],Final,FDA-2020-D-1929,No,
Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical,https://www.fda.gov/media/73679/download,2007-09-27,['Center for Biologics Evaluation and Research'],['Vaccines'],Final,FDA-2005-D-0272,No,
Procedures for Renewal and Amendment of Certain Laser Light Show Variances (Laser Notice 55),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/procedures-renewal-and-amendment-certain-laser-light-show-variances-laser-notice-55,https://www.fda.gov/media/73900/download,2007-09-24,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Compliance Guide for Cabinet X-Ray Systems,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-guide-cabinet-x-ray-systems,https://www.fda.gov/media/73918/download,2007-09-18,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Non-clinical Information for Femoral Stem Prostheses:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-clinical-information-femoral-stem-prostheses,https://www.fda.gov/media/71998/download,2007-09-17,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Commercially Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/commercially-distributed-analyte-specific-reagents-asrs-frequently-asked-questions,https://www.fda.gov/media/71127/download,2007-09-13,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','Good Clinical Practice (GCP)']",Final,FDA-2006-D-0357,No,
Guidance for Industry and FDA: Dear Manufacturer Letter Regarding Sugar Free Claims,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-dear-manufacturer-letter-regarding-sugar-free-claims,,2007-09-03,['Human Foods Program'],['Labeling'],Final,FDA-2020-D-1930,No,
Manufacturing Biological Intermediates and Biological Drug Substances Using Spore-Forming Microorganisms:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacturing-biological-intermediates-and-biological-drug-substances-using-spore-forming,https://www.fda.gov/media/77849/download,2007-09-01,['Center for Biologics Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2003-N-0096,No,
Pharmacogenomic Data Submissions — Companion Guidance,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacogenomic-data-submissions-companion-guidance,https://www.fda.gov/media/72431/download,2007-08-28,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Draft,FDA-2007-D-0136,No,
"Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/eligibility-determination-donors-human-cells-tissues-and-cellular-and-tissue-based-products,https://www.fda.gov/media/73072/download,2007-08-08,['Center for Biologics Evaluation and Research'],"['Cellular & Gene Therapy','Gene Therapy']",Final,FDA-2004-D-0225,No,
Writing Dear Doctor Letters for Recalls of Implantable Cardioverter Defibrillators (ICDs):  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/writing-dear-doctor-letters-recalls-implantable-cardioverter-defibrillators-icds,https://www.fda.gov/media/71206/download,2007-07-19,['Center for Devices and Radiological Health'],"['Postmarket','Radiological Health']",Final,FDA-2020-D-0957,No,
"ANDAs:Pharmaceutical Solid Polymorphism: Chemistry, Manufacturing, and Controls Information:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andaspharmaceutical-solid-polymorphism-chemistry-manufacturing-and-controls-information,https://www.fda.gov/media/71375/download,2007-07-09,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Generic Drugs','Pharmaceutical Quality']",Final,FDA-2004-D-0182,No,
Guidance for Industry and Other Stakeholders: Redbook 2000 :  Toxicological Principles for the Safety Assessment of Food Ingredients,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-other-stakeholders-redbook-2000,,2007-07-02,['Human Foods Program'],"['Food & Color Additives','Ingredients']",Final,,No,
Redbook 2000: I Introduction,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-i-introduction,,2007-07-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Redbook 2000: III Recommended Toxicity Studies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-iii-recommended-toxicity-studies,,2007-07-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Redbook 2000: IV.C.1. Short-Term Tests for Genetic Toxicity,#ERROR!,,2007-07-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Redbook 2000: IV.C.5.a. Chronic Toxicity Studies with Rodents,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc5a-chronic-toxicity-studies-rodents,,2007-07-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Redbook 2000: IV.C.7. Combined Chronic Toxicity/Carcinogenicity Studies with Rodents,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc7-combined-chronic-toxicitycarcinogenicity-studies-rodents,,2007-07-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Redbook 2000: IV.C.8. In-Utero Exposure Phase for Addition to Carcinogenicity Studies or Chronic Toxicity Studies with Rodents,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc8-utero-exposure-phase-addition-carcinogenicity-studies-or-chronic-toxicity-studies,,2007-07-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
"Devices Used to Process Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps):  Guidance for Industry and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/devices-used-process-human-cells-tissues-and-cellular-and-tissue-based-products-hctps,https://www.fda.gov/media/148619/download,2007-07-01,['Office of the Commissioner'],['Combination Products'],Final,FDA-2020-D-1407,No,
Laser Products - Conformance with IEC 60825-1 and IEC 60601-2-22; (Laser Notice No. 50),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/laser-products-conformance-iec-60825-1-and-iec-60601-2-22-laser-notice-no-50,https://www.fda.gov/media/73929/download,2007-06-24,['Center for Devices and Radiological Health'],"['Postmarket','Laser Notice','Laser Notice']",Final,FDA-2020-D-0957,No,
Bundling Multiple Devices or Multiple Indications in a Single Submission:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bundling-multiple-devices-or-multiple-indications-single-submission,https://www.fda.gov/media/73500/download,2007-06-22,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Premarket'],Final,FDA-2003-D-0376,No,
Pre-Clinical and Clinical Studies for Neurothrombectomy Devices:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pre-clinical-and-clinical-studies-neurothrombectomy-devices,https://www.fda.gov/media/71411/download,2007-06-18,['Center for Devices and Radiological Health'],"['Premarket','Good Clinical Practice (GCP)']",Final,FDA-2020-D-0957,No,
Guidance for Industry: Refrigerated Carrot Juice and Other Refrigerated Low-Acid Juices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-refrigerated-carrot-juice-and-other-refrigerated-low-acid-juices,,2007-06-05,['Human Foods Program'],['Juice'],Final,FDA-2007-D-0030,No,
CPG Sec. 130.300  FDA Access to Results of Quality Assurance Program Audits and Inspections,,,2007-06-01,[],['Investigation & Enforcement'],Final,,No,
Redbook 2000: IV.B.4. Statistical Considerations in Toxicity Studies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivb4-statistical-considerations-toxicity-studies,,2007-06-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Informed Consent Recommendations for Source Plasma Donors Participating in Plasmapheresis and Immunization Programs:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/informed-consent-recommendations-source-plasma-donors-participating-plasmapheresis-and-immunization,https://www.fda.gov/media/70685/download,2007-06-01,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2006-D-0350,No,
Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-data-needed-support-licensure-pandemic-influenza-vaccines,https://www.fda.gov/media/73691/download,2007-05-31,['Center for Biologics Evaluation and Research'],['Vaccines'],Final,FDA-2006-D-0351,No,
Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-data-needed-support-licensure-seasonal-inactivated-influenza-vaccines,https://www.fda.gov/media/73706/download,2007-05-31,['Center for Biologics Evaluation and Research'],['Vaccines'],Final,FDA-2006-D-0222,No,
"CVM GFI #83 Chemistry, Manufacturing and Controls Changes to Approved NADA/ANADA",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-83-chemistry-manufacturing-and-controls-changes-approved-nadaanada,https://www.fda.gov/media/70323/download,2007-05-30,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)','New Animal Drug Application (NADA)']",Final,FDA-1999-D-0011,No,
CVM GFI #137 Analytical Methods Description for Type C Medicated Feeds,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-137-analytical-methods-description-type-c-medicated-feeds,https://www.fda.gov/media/70003/download,2007-05-08,['Center for Veterinary Medicine'],"['Animal Feed','Chemistry, Manufacturing, and Controls (CMC)']",Final,FDA-2006-D-0231,No,
Small Business Nutrition Labeling Exemption Guidance,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-business-nutrition-labeling-exemption-guidance,,2007-05-07,['Human Foods Program'],['Labeling'],Final,,No,
Dental Handpieces - Premarket Notification [510(k)] Submissions:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dental-handpieces-premarket-notification-510k-submissions,https://www.fda.gov/media/71432/download,2007-05-02,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
CVM GFI #136 Protocols for the Conduct of Method Transfer Studies for Type C Medicated Feed Assay Methods,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-136-protocols-conduct-method-transfer-studies-type-c-medicated-feed-assay-methods,https://www.fda.gov/media/70012/download,2007-04-26,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)']",Final,FDA-2006-D-0230,No,
CVM GFI #150 Concerns Related to the use of Clove Oil as an Anesthetic for Fish,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-150-concerns-related-use-clove-oil-anesthetic-fish,https://www.fda.gov/media/69954/download,2007-04-24,['Center for Veterinary Medicine'],['Aquaculture'],Final,FDA-2020-D-1442,No,
Approval of Alternate Means of Labeling for Laser Products (Laser Notice 53),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/approval-alternate-means-labeling-laser-products-laser-notice-53,https://www.fda.gov/media/73953/download,2007-03-22,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests - Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-guidance-reporting-results-studies-evaluating-diagnostic-tests-guidance-industry-and-fda,https://www.fda.gov/media/71147/download,2007-03-12,['Center for Devices and Radiological Health'],['Biostatistics'],Final,FDA-2020-D-0957,No,
CVM GFI #183 Animal Drug User Fees: Fees Exceed Costs Waiver/Reduction,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-183-animal-drug-user-fees-fees-exceed-costs-waiverreduction,https://www.fda.gov/media/70445/download,2007-03-09,['Center for Veterinary Medicine'],['User Fees'],Final,FDA-2006-D-0361,No,
Orally Inhaled and Intranasal Corticosteroids: Evaluation of the Effects on Growth in Children,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orally-inhaled-and-intranasal-corticosteroids-evaluation-effects-growth-children,https://www.fda.gov/media/71624/download,2007-03-06,['Center for Drug Evaluation and Research'],"['Clinical - Medical','Pediatric Product Development']",Final,FDA-2001-D-0137,No,
Complementary and Alternative Medicine Products and their Regulation by the Food and Drug Administration: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/complementary-and-alternative-medicine-products-and-their-regulation-food-and-drug-administration,https://www.fda.gov/media/76323/download,2007-02-27,"['Human Foods Program','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research']","['Premarket','Administrative / Procedural','Food & Color Additives']",Draft,FDA-2006-D-0102,No,2006-03-01
"Guidance for Industry and FDA: Letter to Industry, State and Local Food Regulators and Inspectors Regarding  Web-based ALERT Training",,,2007-02-22,[],,Final,,No,
Developing Products for Weight Management Revision 1,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-products-weight-management-revision-1,https://www.fda.gov/media/71252/download,2007-02-15,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,FDA-2007-D-0435,No,
User Fee Waivers for FDC and Co-Packaged HIV Drugs for PEPFAR,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/user-fee-waivers-fdc-and-co-packaged-hiv-drugs-pepfar,https://www.fda.gov/media/72406/download,2007-02-08,['Center for Drug Evaluation and Research'],['User Fees'],Final,FDA-2005-D-0083,No,
"CPG Sec 540.600 Fish, Shellfish, Crustaceans and other Aquatic Animals - Fresh, Frozen or Processed - Methyl Mercury",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540600-fish-shellfish-crustaceans-and-other-aquatic-animals-fresh-frozen-or-processed-methyl,,2007-02-06,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Seafood/Seafood Product']",Final,,No,
Guidance for Industry and FDA: Dear Manufacturer Letter Regarding Food Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-dear-manufacturer-letter-regarding-food-labeling,,2007-01-01,['Human Foods Program'],['Labeling'],Final,FDA-1998-N-0050,No,
"Process for Handling Referrals to FDA Under 21 CFR 50.54 - Additional Safeguards for Children in Clinical Investigations:  Guidance for Clinical Investigators, Institutional Review Boards and Sponsors",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/process-handling-referrals-fda-under-21-cfr-5054-additional-safeguards-children-clinical,https://www.fda.gov/media/75222/download,2006-12-01,['Office of the Commissioner'],"['Good Clinical Practice (GCP)','Pediatric Product Development']",Final,,No,
Guidance for Industry: Lead in Candy Likely To Be Consumed Frequently by Small Children:  Recommended Maximum Level and Enforcement Policy,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-lead-candy-likely-be-consumed-frequently-small-children,,2006-11-24,['Human Foods Program'],"['Candy/Gum (without chocolate)','Lead']",Final,FDA-2005-D-0084,No,
"Decorative, Non-corrective Contact Lenses:  Guidance for Industry, FDA Staff, Eye Care Professionals, and Consumers",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/decorative-non-corrective-contact-lenses,https://www.fda.gov/media/71138/download,2006-11-24,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Prescription Drug Marketing Act (PDMA) Requirements- Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prescription-drug-marketing-act-pdma-requirements-questions-and-answers,https://www.fda.gov/media/75595/download,2006-11-15,['Center for Drug Evaluation and Research'],['Compliance'],Final,FDA-1992-N-0056,No,
CVM GFI #35 Bioequivalence Guidance,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-35-bioequivalence-guidance,https://www.fda.gov/media/70115/download,2006-11-08,['Center for Veterinary Medicine'],"['Generic Animal Drugs','Generic Drugs']",Final,FDA-1994-D-0317,No,
Biological Product Deviation Reporting for Licensed Manufacturers of Biological Products Other than Blood and Blood Components,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biological-product-deviation-reporting-licensed-manufacturers-biological-products-other-blood-and,https://www.fda.gov/media/76309/download,2006-10-19,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)']",Final,FDA-2001-D-0008,No,
CPG Sec. 100.550 Status and Responsibilities of Contract Sterilizers Engaged in the Sterilization of Drugs and Devices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-100550-status-and-responsibilities-contract-sterilizers-engaged-sterilization-drugs-and,,2006-10-02,"['Center for Devices and Radiological Health','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,FDA-2020-D-0957,No,
Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations,https://www.fda.gov/media/71023/download,2006-10-02,"['Center for Veterinary Medicine','Office of Regulatory Affairs','Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Investigation & Enforcement','Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,FDA-2004-D-0300,No,
"Public Availability of Labeling Changes in ""Changes Being Effected"" Supplements",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/public-availability-labeling-changes-changes-being-effected-supplements,https://www.fda.gov/media/71848/download,2006-09-20,['Center for Drug Evaluation and Research'],['Labeling'],Draft,FDA-2006-D-0038,No,
Keratome and Replacement Keratome Blades Premarket Notification [510(k)] Submissions:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/keratome-and-replacement-keratome-blades-premarket-notification-510k-submissions,https://www.fda.gov/media/71574/download,2006-09-18,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2020-D-0957,No,
Compliance with 21 CFR Part 1271.150(c)(1) – Manufacturing Arrangements:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-21-cfr-part-1271150c1-manufacturing-arrangements,https://www.fda.gov/media/73522/download,2006-09-08,['Center for Biologics Evaluation and Research'],"['Compliance','Tissue']",Final,,No,
Early Development Considerations for Innovative Combination Products:  Guidance for Industry  and FDA Staff,,,2006-09-01,[],['Combination Products'],Final,FDA-2020-D-1455,No,
Implementing a Collection Program for Source Plasma Containing Disease-Associated and Other Immunoglobulin (IgG) Antibodies:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/implementing-collection-program-source-plasma-containing-disease-associated-and-other-immunoglobulin,https://www.fda.gov/media/72196/download,2006-08-08,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-2005-D-0014,No,
Q3B(R) Impurities in New Drug Products (Revision 3),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q3br-impurities-new-drug-products-revision-3,https://www.fda.gov/media/71733/download,2006-08-04,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-1996-D-0048 (Revision 1),No,
Guidance for Industry: Estimating Dietary Intake of Substances in Food,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-estimating-dietary-intake-substances-food,,2006-08-01,['Human Foods Program'],"['Food & Color Additives','Ingredients']",Final,,No,
CVM GFI #141 (VICH GL28) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Carcinogenicity Testing,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-141-vich-gl28-studies-evaluate-safety-residues-veterinary-drugs-human-food-carcinogenicity,https://www.fda.gov/media/69996/download,2006-07-27,['Center for Veterinary Medicine'],"['Human Food Safety','VICH']",Final,FDA-2001-D-0101,No,
CVM GFI #147 (VICH GL31) Studies to Evaluate the Safety of Residues of  Veterinary Drugs in Human Food: Repeat-Dose (90 Day) Toxicity Testing,,,2006-07-27,[],"['Human Food Safety','VICH']",Final,FDA-2002-D-0091,No,
CVM GFI #148 (VICH GL32) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Developmental Toxicity Testing,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-148-vich-gl32-studies-evaluate-safety-residues-veterinary-drugs-human-food-developmental,https://www.fda.gov/media/69968/download,2006-07-27,['Center for Veterinary Medicine'],"['Human Food Safety','VICH']",Final,FDA-2002-D-0090,No,
CVM GFI #160 (VICH GL37) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Repeat-Dose (Chronic) Toxicity Testing,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-160-vich-gl37-studies-evaluate-safety-residues-veterinary-drugs-human-food-repeat-dose,https://www.fda.gov/media/69931/download,2006-07-27,['Center for Veterinary Medicine'],"['Human Food Safety','VICH']",Final,FDA-2003-D-0372,No,
Useful Written Consumer Medication Information (CMI),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/useful-written-consumer-medication-information-cmi,https://www.fda.gov/media/72574/download,2006-07-18,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Administrative / Procedural'],Final,FDA-2005-D-0397,No,
CPG Sec. 608.100  Human-Labeled Drugs Distributed and Used in Animal  Medicine (Withdrawn 7/7/2006),,,2006-07-07,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 616.100  Streptomycin Residues in Cattle Tissues (Withdrawn 7/7/2006),,,2006-07-06,[],"['Investigation & Enforcement','Animal Drugs','Human Food Safety']",Final,,No,
Guidance for Industry: Recommendations for the Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties Intended for Food Use,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-recommendations-early-food-safety-evaluation-new-non-pesticidal-proteins-produced,,2006-06-19,['Human Foods Program'],['Bioengineering / GMOs'],Final,FDA-2004-D-0044,No,
CVM GFI #176 (VICH GL39) Specifications: Test Procedures and Acceptance Criteria for New Veterinary Drug Substances and New Medicinal Products: Chemical Substances,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-176-vich-gl39-specifications-test-procedures-and-acceptance-criteria-new-veterinary-drug,https://www.fda.gov/media/69909/download,2006-06-14,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)','VICH']",Final,FDA-2005-D-0336,No,
CVM GFI #177 (VICH GL40) Test Procedures/Acceptance Criteria for New Biotechnological/Biological Veterinary Medicinal Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-177-vich-gl40-test-proceduresacceptance-criteria-new-biotechnologicalbiological-veterinary,https://www.fda.gov/media/69907/download,2006-06-14,['Center for Veterinary Medicine'],['VICH'],Final,FDA-2005-D-0028,No,
Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antiviral-product-development-conducting-and-submitting-virology-studies-agency,https://www.fda.gov/media/71223/download,2006-06-05,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2005-D-0282,No,
Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency : Guidance for Submitting Influenza Resistance Data,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antiviral-product-development-conducting-and-submitting-virology-studies-agency-guidance-submitting-0,https://www.fda.gov/media/71250/download,2006-06-02,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2005-D-0282,No,
Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency:  Guidance for Submitting HCV Resistance Data,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antiviral-product-development-conducting-and-submitting-virology-studies-agency-guidance-submitting-1,https://www.fda.gov/media/71269/download,2006-06-02,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,,No,
Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HBV Resistance Data,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antiviral-product-development-conducting-and-submitting-virology-studies-agency-guidance-submitting-2,https://www.fda.gov/media/71283/download,2006-06-02,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,FDA-2005-D-0183,No,
Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV Resistance Data,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antiviral-product-development-conducting-and-submitting-virology-studies-agency-guidance-submitting,https://www.fda.gov/media/71233/download,2006-06-02,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,None found,No,
Chronic Cutaneous Ulcer and Burn Wounds -- Developing Products for Treatment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chronic-cutaneous-ulcer-and-burn-wounds-developing-products-treatment,https://www.fda.gov/media/71278/download,2006-06-02,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-2000-D-0037,No,
Guidance for Industry: Summary Table of Recommended Toxicological Testing for Additives Used in Food,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-summary-table-recommended-toxicological-testing-additives-used-food,,2006-06-01,['Human Foods Program'],['Food & Color Additives'],Final,FDA-2020-D-1936,No,
"CVM GFI #126 BACPAC I-Intermediates in Drug Substance Synthesis Bulk Actives Postapproval Changes: Chemistry, Manufacturing, and Controls Documentation",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-126-bacpac-i-intermediates-drug-substance-synthesis-bulk-actives-postapproval-changes,https://www.fda.gov/media/70037/download,2006-06-01,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)']",Final,FDA-2021-D-0610,No,
Guidance for Industry: Appendix C of Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-appendix-c-preparing-claim-categorical-exclusion-or-environmental-assessment,,2006-05-16,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Guidance for Industry: Appendix D of Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-appendix-d-preparing-claim-categorical-exclusion-or-environmental-assessment,,2006-05-16,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Guidance for Industry: Appendix E of Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN (40 CFR 1508.27),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-appendix-e-preparing-claim-categorical-exclusion-or-environmental-assessment,,2006-05-16,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Guidance for Industry: Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-preparing-claim-categorical-exclusion-or-environmental-assessment-submission-cfsan,,2006-05-16,['Human Foods Program'],['Food & Color Additives'],Final,FDA-2003-D-0087,No,
Guidance for Industry: Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN - Attachment 1,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-preparing-claim-categorical-exclusion-or-environmental-assessment-submission-cfsan-1,,2006-05-16,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Guidance for Industry: Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN - Attachment 2,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-preparing-claim-categorical-exclusion-or-environmental-assessment-submission-cfsan-0,,2006-05-16,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Guidance for Industry: FDA's Implementation of Qualified Health Claims,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-fdas-implementation-qualified-health-claims,,2006-05-12,['Human Foods Program'],['Labeling'],Final,,No,
Guidance for Industry: Appendix A of Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-appendix-preparing-claim-categorical-exclusion-or-environmental-assessment,,2006-05-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Guidance for Industry: Appendix B for Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-appendix-b-preparing-claim-categorical-exclusion-or-environmental-assessment,,2006-05-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Guidance for Industry: Preparing a Color Additive Petition for Submission to the Center for Food Safety and Applied Nutrition for Color Additives Used in or on Contact Lenses,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-preparing-color-additive-petition-submission-center-food-safety-and-applied,,2006-05-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
CVM GFI #117 (VICH GL24) Management of Adverse Event Reports (AER's),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-117-vich-gl24-management-adverse-event-reports-aers,https://www.fda.gov/media/70144/download,2006-05-01,['Center for Veterinary Medicine'],"['Adverse Event Reporting','VICH']",Draft,FDA-2000-D-0136,No,
"Compliance with Section 301 of the Medical Device User Fee and Modernization Act of 2002, as amended – Prominent and Conspicuous Mark of Manufacturers on Single-Use Devices:  Guidance for Industry and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-section-301-medical-device-user-fee-and-modernization-act-2002-amended-prominent-and,https://www.fda.gov/media/71187/download,2006-05-01,['Center for Devices and Radiological Health'],"['Postmarket','User Fees','Labeling']",Final,FDA-2005-D-0156,No,
"Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable :  Guidance for Sponsors, Institutional Review Boards, and Food and Drug Administration Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-informed-consent-in-vitro-diagnostic-device-studies-using-leftover-human-specimens-are-not,https://www.fda.gov/media/122648/download,2006-04-25,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','Good Clinical Practice (GCP)']",Final,FDA-2006-D-0095,No,
S8 Immunotoxicity Studies for Human Pharmaceuticals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s8-immunotoxicity-studies-human-pharmaceuticals,https://www.fda.gov/media/72047/download,2006-04-12,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Safety'],Final,FDA-2005-D-0398,No,
Redbook 2000: IV.C.1.c Mouse Lymphoma Thymidine Kinase Gene Mutation Assay,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc1c-mouse-lymphoma-thymidine-kinase-gene-mutation-assay,,2006-04-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Establishment and Operation of Clinical Trial Data Monitoring Committees:  Guidance for Clinical Trial Sponsors,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/establishment-and-operation-clinical-trial-data-monitoring-committees,https://www.fda.gov/media/75398/download,2006-03-28,"['Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research']","['Clinical - Medical','Good Clinical Practice (GCP)']",Final,FDA-2001-D-0219,No,
Dental Curing Lights - Premarket Notification [510(k)]:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dental-curing-lights-premarket-notification-510k,https://www.fda.gov/media/74206/download,2006-03-27,['Center for Devices and Radiological Health'],"['Premarket','510(k)','Dental']",Final,FDA-2020-D-0957,No,
Tonometers - Premarket Notification [510(k)] Submissions :  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/tonometers-premarket-notification-510k-submissions,https://www.fda.gov/media/71593/download,2006-03-27,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2020-D-0957,No,
Using a Centralized IRB Review Process in Multicenter Clinical Trials:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/using-centralized-irb-review-process-multicenter-clinical-trials,https://www.fda.gov/media/75329/download,2006-03-16,"['Office of Regulatory Affairs','Office of the Commissioner','Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Investigation & Enforcement','Administrative / Procedural','Good Clinical Practice (GCP)']",Final,FDA-2005-D-0443,No,
Nonclinical Safety Evaluation of Drug or Biologic Combinations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-safety-evaluation-drug-or-biologic-combinations,https://www.fda.gov/media/119657/download,2006-03-15,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Final,2005D-0004,No,
Prescription Drug Marketing Act — Donation of Prescription Drug Samples to Free Clinics,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prescription-drug-marketing-act-donation-prescription-drug-samples-free-clinics,https://www.fda.gov/media/71019/download,2006-03-14,['Center for Drug Evaluation and Research'],['Compliance'],Final,FDA-2002-D-0092,No,
Hospital Bed System Dimensional and Assessment Guidance to Reduce Entrapment:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hospital-bed-system-dimensional-and-assessment-guidance-reduce-entrapment,https://www.fda.gov/media/71460/download,2006-03-10,['Center for Devices and Radiological Health'],['Postmarket'],Final,FDA-2004-D-0499,No,
Internal Radioactive Contamination —Development of Decorporation Agents,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/internal-radioactive-contamination-development-decorporation-agents,https://www.fda.gov/media/71589/download,2006-03-02,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-2005-D-0025,No,
Guidance for Industry: Frequently Asked Questions about FDA's Regulation of Infant Formula,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-frequently-asked-questions-about-fdas-regulation-infant-formula,,2006-03-01,['Human Foods Program'],['Infant Formula & Foods'],Final,FDA-2020-D-1937,No,
Using Electronic Means to Distribute Certain Product Information:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/using-electronic-means-distribute-certain-product-information,,2006-02-28,['Office of the Commissioner'],"['Administrative / Procedural','Food & Color Additives']",Final,,No,
Draft Guidance for Industry and FDA Staff: Whole Grain Label Statements,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-and-fda-staff-whole-grain-label-statements,,2006-02-17,['Human Foods Program'],['Labeling'],Draft,FDA-2006-D-0298,No,2006-04-18
Reports on the Status of Postmarketing Study Commitments — Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reports-status-postmarketing-study-commitments-implementation-section-130-food-and-drug,https://www.fda.gov/media/72535/download,2006-02-16,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Administrative / Procedural'],Final,FDA-1999-N-0098,No,
Nonclinical Safety Evaluation of Pediatric Drug Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-safety-evaluation-pediatric-drug-products,https://www.fda.gov/media/119658/download,2006-02-15,['Center for Drug Evaluation and Research'],"['Pediatric Product Development','Pharmacology/Toxicology']",Final,2003D-0001,No,
Pharmacogenetic Tests and Genetic Tests for Heritable Markers:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacogenetic-tests-and-genetic-tests-heritable-markers,https://www.fda.gov/media/71422/download,2006-02-09,"['Center for Devices and Radiological Health','Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Premarket'],Final,FDA-2006-D-0232,No,
Providing Regulatory Submissions in Electronic Format Orphan-Drug and Humanitarian Use Device Designation Requests and Related Submissions: Draft Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-orphan-drug-and-humanitarian-use-device,https://www.fda.gov/media/111920/download,2006-02-01,['Office of the Commissioner'],['Administrative / Procedural'],Draft,FDA-2006-D-0159,No,
Considerations for Developmental Toxicity Studies for Preventive and Therapeutic Vaccines for Infectious Disease Indications:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-developmental-toxicity-studies-preventive-and-therapeutic-vaccines-infectious-disease,https://www.fda.gov/media/73986/download,2006-02-01,['Center for Biologics Evaluation and Research'],"['Pediatric Product Development','Vaccines']",Final,FDA-2000-D-0029,No,
Adverse Reactions Section of Labeling for Human Prescription Drug and Biological Products — Content and Format,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adverse-reactions-section-labeling-human-prescription-drug-and-biological-products-content-and,https://www.fda.gov/media/72139/download,2006-01-24,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Labeling'],Final,FDA-2005-D-0153,No,
Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products — Content and Format:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-studies-section-labeling-human-prescription-drug-and-biological-products-content-and-format,https://www.fda.gov/media/72140/download,2006-01-24,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Good Clinical Practice (GCP)','Labeling']",Final,FDA-2000-D-0074,No,
"Exploratory IND Studies:  Guidance for Industry, Investigators, and Reviewers",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exploratory-ind-studies,https://www.fda.gov/media/72325/download,2006-01-12,['Center for Drug Evaluation and Research'],"['Good Clinical Practice (GCP)','Pharmacology/Toxicology']",Final,,No,
Formal Dispute Resolution:  Scientific and Technical Issues Related to Pharmaceutical CGMP,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formal-dispute-resolution-scientific-and-technical-issues-related-pharmaceutical-cgmp,https://www.fda.gov/media/171562/download,2006-01-11,"['Center for Veterinary Medicine','Office of Regulatory Affairs','Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Investigation & Enforcement','Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,FDA-2003-D-0369,No,
CVM GFI #166 (VICH GL38) Environmental Impact Assessments (EIA's) for Veterinary Medicinal Products (VMP’s) - Phase II,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-166-vich-gl38-environmental-impact-assessments-eias-veterinary-medicinal-products-vmps-phase,https://www.fda.gov/media/69927/download,2006-01-09,['Center for Veterinary Medicine'],"['Environmental Safety','VICH']",Final,FDA-2004-D-0273,No,
CVM GFI #123 Development of Data Supporting Approval of NSAIDS for Use in Animals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-123-development-data-supporting-approval-nsaids-use-animals,https://www.fda.gov/media/70191/download,2006-01-05,['Center for Veterinary Medicine'],"['Target Animal – Effectiveness','Target Animal – Safety']",Final,FDA-2004-D-0372,No,
Exemption from Reporting and Recordkeeping Requirements for Low Power Laser Products (Laser Notice 54):  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exemption-reporting-and-recordkeeping-requirements-low-power-laser-products-laser-notice-54,https://www.fda.gov/media/74001/download,2006-01-05,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Recommended Approaches to Integration of Genetic Toxicology Study Results,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommended-approaches-integration-genetic-toxicology-study-results,https://www.fda.gov/media/72266/download,2006-01-04,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Final,FDA-2004-D-0374,No,
Redbook 2000: IV.C.6. Carcinogenicity Studies with Rodents,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc6-carcinogenicity-studies-rodents,,2006-01-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
"FDA Institutional Review Board Inspections:  Guidance For IRBs, Clinical Investigators, and Sponsors",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-institutional-review-board-inspections,https://www.fda.gov/media/75192/download,2006-01-01,['Office of the Commissioner'],"['Administrative / Procedural','Good Clinical Practice (GCP)']",Final,,No,
"Frequently Asked Questions About Medical Devices:  Guidance For IRBs, Clinical Investigators, and Sponsors",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/frequently-asked-questions-about-medical-devices,https://www.fda.gov/media/75381/download,2006-01-01,"['Office of the Commissioner','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Good Clinical Practice (GCP)'],Final,FDA-2006-D-0031,No,
"Significant Risk and Nonsignificant Risk Medical Device Studies:  Guidance For IRBs, Clinical Investigators, and Sponsors",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/significant-risk-and-nonsignificant-risk-medical-device-studies,https://www.fda.gov/media/75459/download,2006-01-01,"['Office of the Commissioner','Center for Devices and Radiological Health']","['Good Clinical Practice (GCP)','Investigational Device Exemption (IDE)']",Final,FDA-2006-D-0031,No,
"CPG Sec 500.200 Food Additives -""GRAS""",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-500200-food-additives-gras,,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Ingredients']",Final,,No,
CPG Sec 500.425 Use of Color Additives in Paper and Paperboard Intended for Use with Food,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-500425-use-color-additives-paper-and-paperboard-intended-use-food,,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Ingredients']",Final,,No,
CPG Sec 500.450 Volatile N-Nitrosamines in Rubber Baby Bottle Nipples,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-500450-volatile-n-nitrosamines-rubber-baby-bottle-nipples,,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Ingredients']",Final,,No,
"CPG Sec 505.100 Bakery Products, Candy - ""Catch-All"" or ""Shotgun"" Ingredients Declaration",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-505100-bakery-products-candy-catch-all-or-shotgun-ingredients-declaration,,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Bakery Product/Mix']",Final,,No,
"CPG Sec 510.150 Apple Juice, Apple Juice Concentrates, and Apple Juice Products - Adulteration with Patulin",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-510150-apple-juice-apple-juice-concentrates-and-apple-juice-products-adulteration-patulin,,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Beverage Bases/Conc/Nectar']",Final,,No,
CPG Sec 510.400 Dealcoholized Wine and Malt Beverages - Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-510400-dealcoholized-wine-and-malt-beverages-labeling,,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Beverage Bases/Conc/Nectar']",Final,,No,
CPG Sec 510.600 Dimethylnitrosamine in Malt Beverages,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-510600-dimethylnitrosamine-malt-beverages,,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Beverage Bases/Conc/Nectar']",Final,,No,
"CPG Sec 515.775 Cocoa Powder, Press Cake - Adulteration with Insect and Rodent Filth",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515775-cocoa-powder-press-cake-adulteration-insect-and-rodent-filth,,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Chocolate/Cocoa Product']",Final,,No,
CPG Sec 540.420 Raw Breaded Shrimp - Microbiological Criteria for Evaluating Compliance with Current Good Manufacturing Practice Regulations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540420-raw-breaded-shrimp-microbiological-criteria-evaluating-compliance-current-good,,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Seafood/Seafood Product']",Final,,No,
"CPG Sec 540.500 Tuna, Sable, Salmon, Shad-Smoked Cured, Adulteration Involving Food Additives, Sodium Nitrite",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540500-tuna-sable-salmon-shad-smoked-cured-adulteration-involving-food-additives-sodium,,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Seafood/Seafood Product']",Final,,No,
"CPG Sec 540.650 Uneviscerated Fish Products that are Salt-cured, Dried, or Smoked (Revised)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540650-uneviscerated-fish-products-are-salt-cured-dried-or-smoked-revised,,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Seeds']",Final,,No,
"CPG Sec 560.600 Clams, Mussels, Oysters; Fresh or Frozen - Adulteration by Bacteriological Contamination",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-560600-clams-mussels-oysters-fresh-or-frozen-adulteration-bacteriological-contamination,,2005-11-29,['Office of Inspections and Investigations'],"['Investigation & Enforcement','Import']",Final,,No,
CPG Sec 562.200 Foods - FPLA Compliance,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562200-foods-fpla-compliance,,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Labeling']",Final,,No,
CPG Sec 562.300 Foods - Net Weight,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562300-foods-net-weight,,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Labeling']",Final,,No,
CPG Sec 562.550 Safety and Labeling of Waxed (Coated) Fruits and Vegetables,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562550-safety-and-labeling-waxed-coated-fruits-and-vegetables,,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Labeling']",Final,,No,
CPG Sec 565.100 FDA Jurisdiction Over Meat and Poultry Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-565100-fda-jurisdiction-over-meat-and-poultry-products,,2005-11-29,['Office of Inspections and Investigations'],"['Investigation & Enforcement','Meat/Meat Products & Poultry']",Final,,No,
CPG Sec 570.700 Mixed Nuts - Misbranding Involving Food Standards,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-570700-mixed-nuts-misbranding-involving-food-standards,,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Nuts & Nut Products']",Final,,No,
CPG Sec 587.100 Label Declaration of Certification-Exempt Color Additives,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-587100-label-declaration-certification-exempt-color-additives,,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Food & Color Additives']",Final,,No,
CPG Sec 590.500 Packaging Technologies and Tamper-Resistant Packaging Requirements for Cosmetic Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-590500-packaging-technologies-and-tamper-resistant-packaging-requirements-cosmetic-products,,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
"Guidance for Industry and FDA Staff: Guidance for Records Access Authority Provided in Title III, Subtitle A, of the Public Health Security and Bioterrorism Preparedness and Response Act of 2002",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-staff-guidance-records-access-authority-provided-title-iii-subtitle-public,,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']",['Records'],Final,FDA-2004-G-0002,No,
CPG Sec 510.500 Green Coffee Beans - Adulteration with Insects; Mold,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-510500-green-coffee-beans-adulteration-insects-mold,https://www.fda.gov/media/71780/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Beverage Bases/Conc/Nectar']",Final,,No,
"CPG Sec 515.750 Cocoa Beans - Adulteration by Mold, Insect Infestation, and Mammalian Excreta",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515750-cocoa-beans-adulteration-mold-insect-infestation-and-mammalian-excreta,https://www.fda.gov/media/71815/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Chocolate/Cocoa Product']",Final,,No,
CPG Sec 525.150 Bay (Laurel) Leaves - Adulteration by Insect Filth; Mold; Mammalian Excreta,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525150-bay-laurel-leaves-adulteration-insect-filth-mold-mammalian-excreta,https://www.fda.gov/media/71839/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
"CPG Sec 525.200 Capsicum Pods, Ground Capsicums Excluding Paprika, Ground Paprika - Adulteration with Insect and Rodent Filth, Mold, Mammalian Excreta",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525200-capsicum-pods-ground-capsicums-excluding-paprika-ground-paprika-adulteration-insect,https://www.fda.gov/media/71842/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
CPG Sec 525.250 Cloves - Adulteration with Stems,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525250-cloves-adulteration-stems,https://www.fda.gov/media/71852/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
CPG Sec 525.300 Condimental Seeds Other than Fennel Seeds and Sesame Seeds - Adulteration by Mammalian Excreta,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525300-condimental-seeds-other-fennel-seeds-and-sesame-seeds-adulteration-mammalian-excreta,https://www.fda.gov/media/71857/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
CPG Sec 525.325 Cumin Seed - Adulteration with Sand and Grit,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525325-cumin-seed-adulteration-sand-and-grit,https://www.fda.gov/media/71863/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
CPG Sec 525.330 Curry Powder - Adulteration by Insect and Rodent Filth,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525330-curry-powder-adulteration-insect-and-rodent-filth,https://www.fda.gov/media/71870/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
CPG Sec 525.350 Fennel Seed - Adulteration by Mammalian Excreta; Insects,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525350-fennel-seed-adulteration-mammalian-excreta-insects,https://www.fda.gov/media/71875/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
CPG Sec 525.375 Whole Ginger - Adulteration with Insect Filth; Mold; Mammalian Excreta,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525375-whole-ginger-adulteration-insect-filth-mold-mammalian-excreta,https://www.fda.gov/media/71882/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
"CPG Sec 525.500 Leafy Spices, Other than Bay Leaves - Whole Oregano Leaves, Whole Marjoram, Whole Sage Leaves and Whole Thyme Leaves - Adulteration with Insect Filth; Mold; Mammalian Excreta",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525500-leafy-spices-other-bay-leaves-whole-oregano-leaves-whole-marjoram-whole-sage-leaves,https://www.fda.gov/media/71893/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
CPG Sec 525.550 Mace - Adulteration with Insect Filth; Mold; Foreign Matter; Mammalian Excreta,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525550-mace-adulteration-insect-filth-mold-foreign-matter-mammalian-excreta,https://www.fda.gov/media/71900/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
CPG Sec 525.600 Whole and Ground Nutmeg - Adulteration with Insect Filth; Mold; Rodent Filth,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525600-whole-and-ground-nutmeg-adulteration-insect-filth-mold-rodent-filth,https://www.fda.gov/media/71907/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
CPG Sec 525.625 Whole and Ground Pepper - Adulteration with Insect & Rodent Filth; Mold; Mammalian Excreta; Foreign Matter,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525625-whole-and-ground-pepper-adulteration-insect-rodent-filth-mold-mammalian-excreta,https://www.fda.gov/media/71915/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
CPG Sec 525.700 Sesame Seeds - Adulteration with Insect Filth; Decomposition; Mammalian Excreta; Foreign Matter,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525700-sesame-seeds-adulteration-insect-filth-decomposition-mammalian-excreta-foreign-matter,https://www.fda.gov/media/71926/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
"CPG Sec 525.850 Whole Plant (Unprocessed) Oregano, Crushed Oregano & Ground Oregano - Adulteration by Insect & Rodent Filth; Mold; Mammalian Excreta",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525850-whole-plant-unprocessed-oregano-crushed-oregano-ground-oregano-adulteration-insect,https://www.fda.gov/media/71942/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
"CPG Sec 525.900 Whole Plant (Unprocessed) Marjoram, Unground (Processed) Marjoram & Ground Marjoram - Adulteration by Insect & Rodent Filth; Mold; Mammalian Excreta",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525900-whole-plant-unprocessed-marjoram-unground-processed-marjoram-ground-marjoram,https://www.fda.gov/media/71948/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
"CPG Sec 525.925 Whole Plant (Unprocessed) Thyme, Unground (Processed) Thyme & Ground Thyme - Adulteration by Insect & Rodent Filth; Mold; Mammalian Excreta",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525925-whole-plant-unprocessed-thyme-unground-processed-thyme-ground-thyme-adulteration,https://www.fda.gov/media/71956/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
"CPG Sec 525.950 Whole Plant (Unprocessed) Sage, and Ground Sage - Adulteration by Insect and Rodent Filth; Mold; Mammalian Excreta",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525950-whole-plant-unprocessed-sage-and-ground-sage-adulteration-insect-and-rodent-filth,https://www.fda.gov/media/71962/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
CPG Sec 527.100 Butter - Adulteration Involving Insufficient Fat Content,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527100-butter-adulteration-involving-insufficient-fat-content,https://www.fda.gov/media/71967/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dairy']",Final,,No,
CPG Sec 527.225 Cheese - Misbranding Due to Moisture and Fat,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527225-cheese-misbranding-due-moisture-and-fat,https://www.fda.gov/media/71978/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Dairy']",Final,,No,
CPG Sec 535.100 Oleomargarine - Misbranding Due to Insufficient Fat,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-535100-oleomargarine-misbranding-due-insufficient-fat,https://www.fda.gov/media/71996/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Oils']",Final,,No,
CPG Sec 537.100 Eggs and Egg Products - Frozen - Adulteration Involving Decomposition,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-537100-eggs-and-egg-products-frozen-adulteration-involving-decomposition,https://www.fda.gov/media/72002/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Egg/Egg Product']",Final,,No,
"CPG Sec 540.590 Fish - Fresh and Frozen, as Listed - Adulteration by Parasites",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540590-fish-fresh-and-frozen-listed-adulteration-parasites,https://www.fda.gov/media/72041/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Seafood/Seafood Product']",Final,,No,
"CPG Sec 545.300 Foods, Rail Car Sanitation - Adulteration",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-545300-foods-rail-car-sanitation-adulteration,https://www.fda.gov/media/72054/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
CPG Sec 545.400 Pottery (Ceramics); Import and Domestic - Cadmium Contamination,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-545400-pottery-ceramics-import-and-domestic-cadmium-contamination,https://www.fda.gov/media/71762/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
CPG Sec 545.450 Pottery (Ceramics); Import and Domestic - Lead Contamination,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-545450-pottery-ceramics-import-and-domestic-lead-contamination,https://www.fda.gov/media/71764/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
CPG Sec 545.500 Silver-Plated Hollowware - Lead Contamination,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-545500-silver-plated-hollowware-lead-contamination,https://www.fda.gov/media/71767/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
CPG Sec 545.600 Cinnamon-Flavored Toothpicks,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-545600-cinnamon-flavored-toothpicks,https://www.fda.gov/media/71771/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']",['Investigation & Enforcement'],Final,,No,
"CPG Sec 550.100 Apple Butter - Adulteration with Mold; Rodent Filth, Insect",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550100-apple-butter-adulteration-mold-rodent-filth-insect,https://www.fda.gov/media/71774/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
CPG Sec 550.150 Apricots - Canned - Adulteration with Insects,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550150-apricots-canned-adulteration-insects,https://www.fda.gov/media/71775/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
"CPG Sec 550.155 Apricot, Peach and Pear Nectars and Purees - Adulteration with Mold",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550155-apricot-peach-and-pear-nectars-and-purees-adulteration-mold,https://www.fda.gov/media/71779/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']",['Investigation & Enforcement'],Final,,No,
"CPG Sec 550.200 Drupelet Berries (Blackberries, Raspberries, Etc.) - Common or Usual Names of Varieties; Canned and Frozen - Adulteration with Rot and Insects",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550200-drupelet-berries-blackberries-raspberries-etc-common-or-usual-names-varieties-canned,https://www.fda.gov/media/71784/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
"CPG Sec 550.225 Cherries Brined, Fresh, Canned and Frozen - Adulteration Involving Rot and Insect",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550225-cherries-brined-fresh-canned-and-frozen-adulteration-involving-rot-and-insect,https://www.fda.gov/media/71788/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
"CPG Sec 550.230 Cherries, Canned - Misbranding Involving Food Standards",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550230-cherries-canned-misbranding-involving-food-standards,https://www.fda.gov/media/71792/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
"CPG Sec 550.300 Dates and Date Material; Imported and Domestic - Adulteration Involving Mold, Insect Excreta, Sour, Dirty, Worthless and Pits",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550300-dates-and-date-material-imported-and-domestic-adulteration-involving-mold-insect,https://www.fda.gov/media/71813/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
"CPG Sec 550.350 Figs; Fig Paste - Adulteration Involving Insect Infestation; Mold, Dirt",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550350-figs-fig-paste-adulteration-involving-insect-infestation-mold-dirt,https://www.fda.gov/media/71818/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
"CPG Sec 550.500 Lingon Berries, Canned - Adulteration by Insects",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550500-lingon-berries-canned-adulteration-insects,https://www.fda.gov/media/71834/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
CPG Sec 550.600 Olives - Adulteration Involving Pits; Rot; Insect Infestation,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550600-olives-adulteration-involving-pits-rot-insect-infestation,https://www.fda.gov/media/71862/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
"CPG Sec 550.655 Peaches, Canned - Misbranding Involving Food Standards",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550655-peaches-canned-misbranding-involving-food-standards,https://www.fda.gov/media/71880/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
"CPG Sec 550.685 Pineapple, Canned; Imported and Domestic - Misbranding Involving Food Standards",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550685-pineapple-canned-imported-and-domestic-misbranding-involving-food-standards,https://www.fda.gov/media/71895/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
"CPG Sec 550.690 Plums, Canned - Adulteration with Rot",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550690-plums-canned-adulteration-rot,https://www.fda.gov/media/71903/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
"CPG Sec 550.700 Dried Prunes, Dehydrated Low Moisture Prunes, and Pitted Prunes - Adulteration Involving Insects; Decomposition; Dirt; Pits; and Pit Fragments",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550700-dried-prunes-dehydrated-low-moisture-prunes-and-pitted-prunes-adulteration-involving,https://www.fda.gov/media/71909/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
"CPG Sec 550.750 Raisins - Adulteration Involving Mold, Sand, Grit, & Insects",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550750-raisins-adulteration-involving-mold-sand-grit-insects,https://www.fda.gov/media/71918/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
CPG Sec 550.800 Standardized Canned Fruit - Misbranding Involving Improper Declaration of Packing Medium,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550800-standardized-canned-fruit-misbranding-involving-improper-declaration-packing-medium,https://www.fda.gov/media/71924/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
"CPG Sec 550.850 Strawberries; Frozen, Whole, or Sliced - Adulteration with Sand, Mold",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550850-strawberries-frozen-whole-or-sliced-adulteration-sand-mold,https://www.fda.gov/media/71930/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
CPG Sec 555.250 Statement of Policy for Labeling and Preventing Cross-contact of Common Food Allergens,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555250-statement-policy-labeling-and-preventing-cross-contact-common-food-allergens,https://www.fda.gov/media/71940/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']",['Investigation & Enforcement'],Final,,No,
CPG Sec 555.880 Guidance Levels for Radionuclides in Domestic and Imported Foods,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555880-guidance-levels-radionuclides-domestic-and-imported-foods,https://www.fda.gov/media/72014/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Import']",Final,,No,
CPG Sec 560.200 Country of Origin Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-560200-country-origin-labeling,https://www.fda.gov/media/71994/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Import']",Final,,No,
CPG Sec 570.300 Peanut Butter - Adulteration with Filth; Grit,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-570300-peanut-butter-adulteration-filth-grit,https://www.fda.gov/media/72060/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Nuts & Nut Products']",Final,,No,
"CPG Sec 570.350 Peanuts, Shelled and Unshelled - Adulteration with Filth and Reject Nuts",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-570350-peanuts-shelled-and-unshelled-adulteration-filth-and-reject-nuts,https://www.fda.gov/media/72068/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Nuts & Nut Products']",Final,,No,
"CPG Sec 570.425 Tree Nuts - Adulteration Involving Rejects (Insect Infestation, Moldy, Rancid, Otherwise Decomposed, Blanks, and Shriveled)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-570425-tree-nuts-adulteration-involving-rejects-insect-infestation-moldy-rancid-otherwise,https://www.fda.gov/media/72078/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Nuts & Nut Products']",Final,,No,
"CPG Sec 570.450 Tree Nuts - Adulteration with Filth, Involving the Presence of the Organism Escherichia coli",#ERROR!,https://www.fda.gov/media/72081/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Nuts & Nut Products']",Final,,No,
CPG Sec 580.100 Food Storage and Warehousing-Adulteration-Filth (Domestic and Import),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-580100-food-storage-and-warehousing-adulteration-filth-domestic-and-import,https://www.fda.gov/media/72108/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']",['Investigation & Enforcement'],Final,,No,
"CPG Sec 585.200 Beets, Canned - Adulteration with Rot",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585200-beets-canned-adulteration-rot,https://www.fda.gov/media/71782/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
"CPG Sec 585.275 Brussels Sprouts, Frozen - Adulteration by Insects",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585275-brussels-sprouts-frozen-adulteration-insects,https://www.fda.gov/media/71797/download,2005-11-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
"CPG Sec 585.300 Corn, Sweet; Canned - Adulteration by Corn Ear Worms, Corn Borers",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585300-corn-sweet-canned-adulteration-corn-ear-worms-corn-borers,https://www.fda.gov/media/71801/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
CPG Sec 585.400 Cowpeas (Black-Eyed Peas); Canned (Succulent Peas) - Adulteration by Insects,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585400-cowpeas-black-eyed-peas-canned-succulent-peas-adulteration-insects,https://www.fda.gov/media/71817/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
CPG Sec 585.475 Canned Green Beans and Canned Wax Beans - Misbranding Involving Food Standards,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585475-canned-green-beans-and-canned-wax-beans-misbranding-involving-food-standards,https://www.fda.gov/media/71830/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
"CPG Sec 585.575 Peas and Beans; Dried - Adulteration Involving Storage, Insect Damage, Rocks",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585575-peas-and-beans-dried-adulteration-involving-storage-insect-damage-rocks,https://www.fda.gov/media/71838/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
"CPG Sec 585.775 Spinach, Canned or Frozen - Adulteration Involving Insects, Decomposition",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585775-spinach-canned-or-frozen-adulteration-involving-insects-decomposition,https://www.fda.gov/media/71867/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
CPG Sec 585.825 Sweet Potatoes - Dyeing of Yellow and Red Varieties,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585825-sweet-potatoes-dyeing-yellow-and-red-varieties,https://www.fda.gov/media/71874/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
CPG Sec 587.300 Color Additives,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-587300-color-additives,https://www.fda.gov/media/71911/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Food & Color Additives']",Final,,No,
CPG Sec 590.300 Direct Reference Authority for Pseudomonas Contamination of Cosmetics Used in the Eye Area,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-590300-direct-reference-authority-pseudomonas-contamination-cosmetics-used-eye-area,https://www.fda.gov/media/71920/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
"CPG Sec 590.400 Natural Bristle Brushes (i.e., Hair Brushes, Shaving Brushes) - Nit Contamination",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-590400-natural-bristle-brushes-ie-hair-brushes-shaving-brushes-nit-contamination,https://www.fda.gov/media/71925/download,2005-11-29,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
CPG Sec 520.300 Acidified Low-Acid Canned Foods - Adulteration Due to High pH,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-520300-acidified-low-acid-canned-foods-adulteration-due-high-ph,,2005-11-28,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Canned Foods']",Final,,No,
CPG Sec 525.100 Whole & Ground Allspice - Adulteration by Mold; Insect & Rodent Filth,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525100-whole-ground-allspice-adulteration-mold-insect-rodent-filth,,2005-11-28,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
CPG Sec 525.575 Prepared Mustard - Composition,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525575-prepared-mustard-composition,,2005-11-28,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
CPG Sec 525.800 Tomato Sauce or Tomato Hot Sauce Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525800-tomato-sauce-or-tomato-hot-sauce-labeling,,2005-11-28,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
CPG Sec 527.250 Cheese & Cheese Products - Misbranding Involving Net Contents,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527250-cheese-cheese-products-misbranding-involving-net-contents,,2005-11-28,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dairy']",Final,,No,
CPG Sec 527.350 Eggnog; Egg Nog Flavored Milk - Common or Usual Names,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527350-eggnog-egg-nog-flavored-milk-common-or-usual-names,,2005-11-28,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dairy']",Final,,No,
"CPG Sec 527.400 Whole Milk, Lowfat Milk, Skim Milk - Aflatoxin M1",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527400-whole-milk-lowfat-milk-skim-milk-aflatoxin-m1,,2005-11-28,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dairy']",Final,,No,
CPG Sec 530.500 Wheat Germ Containing Non-Wheat Germ Tissue,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-530500-wheat-germ-containing-non-wheat-germ-tissue,,2005-11-28,"['Office of Inspections and Investigations','Human Foods Program']",['Investigation & Enforcement'],Final,,No,
"CPG Sec 540.200 Chubs, Hot Process Smoked with Added Nitrite - Adulteration Involving Food Additives, Sodium Nitrite",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540200-chubs-hot-process-smoked-added-nitrite-adulteration-involving-food-additives-sodium,,2005-11-28,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Seafood/Seafood Product']",Final,,No,
"CPG Sec 540.250 Clams, Mussels, Oysters, Fresh, Frozen or Canned - Paralytic Shellfish Poison",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540250-clams-mussels-oysters-fresh-frozen-or-canned-paralytic-shellfish-poison,,2005-11-28,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Seafood/Seafood Product']",Final,,No,
"CPG Sec 540.410 Shrimp - Frozen, Raw, Breaded or Lightly Breaded, Misbranding Involving Non-Compliance with Standards",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540410-shrimp-frozen-raw-breaded-or-lightly-breaded-misbranding-involving-non-compliance,,2005-11-28,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Seafood/Seafood Product']",Final,,No,
"CPG Sec 550.475 Jellies, Nonstandardized",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550475-jellies-nonstandardized,,2005-11-28,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
CPG Sec 550.605 Olives Stuffed with Minced Pimentos - Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550605-olives-stuffed-minced-pimentos-labeling,,2005-11-28,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
"CPG Sec 550.650 Peaches, Canned, Frozen - Adulteration Due to Insects and Mold",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550650-peaches-canned-frozen-adulteration-due-insects-and-mold,,2005-11-28,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
CPG Sec 578.500 Dimethylnitrosamine (DMNA) in Barley Malt,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-578500-dimethylnitrosamine-dmna-barley-malt,,2005-11-28,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Grain/Grain Product']",Final,,No,
"CPG Sec 585.325 Corn on the Cob, Canned - Quantity of Contents Declaration",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585325-corn-cob-canned-quantity-contents-declaration,,2005-11-28,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
"CPG Sec 585.500 Mushrooms, Canned or Dried (Freeze-Dried or Dehydrated) - Adulteration Involving Maggots, Mites, Decomposition",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585500-mushrooms-canned-or-dried-freeze-dried-or-dehydrated-adulteration-involving-maggots,,2005-11-28,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
CPG Sec 585.750 Sauerkraut - Definition; Adulteration by Thrips,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585750-sauerkraut-definition-adulteration-thrips,,2005-11-28,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
CPG Sec. 160.100 Regulatory Actions and Small Business,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-160100-regulatory-actions-and-small-business,,2005-11-28,['Office of Inspections and Investigations'],['Investigation & Enforcement'],Final,,No,
CPG Sec 585.875 Tomatoes - Canned - Misbranding Involving Food Standards (Peel),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585875-tomatoes-canned-misbranding-involving-food-standards-peel,https://www.fda.gov/media/71886/download,2005-11-25,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
CPG Sec 585.890 Tomato Products - Adulteration with Drosophila Fly Eggs and Maggots,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585890-tomato-products-adulteration-drosophila-fly-eggs-and-maggots,https://www.fda.gov/media/71892/download,2005-11-25,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
CPG Sec 585.900 Tomato Products - Adulteration with Mold,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585900-tomato-products-adulteration-mold,https://www.fda.gov/media/71898/download,2005-11-25,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
CVM GFI #135 Validation of Analytical Procedures for Type C Medicated Feeds,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-135-validation-analytical-procedures-type-c-medicated-feeds,https://www.fda.gov/media/70019/download,2005-11-07,['Center for Veterinary Medicine'],"['Animal Feed','Chemistry, Manufacturing, and Controls (CMC)']",Final,FDA-2004-D-0370,No,
Applicability of the Performance Standard for High-Intensity Mercury Vapor Discharge Lamps (21 CFR 1040.30),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applicability-performance-standard-high-intensity-mercury-vapor-discharge-lamps-21-cfr-104030,https://www.fda.gov/media/74008/download,2005-11-05,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
"Guidance for Industry: Notice to Growers, Food Manufacturers, Food Warehouse Managers, and Transporters of Food Products on Decontamination of Transport Vehicles",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-notice-growers-food-manufacturers-food-warehouse-managers-and-transporters-food,,2005-11-01,['Human Foods Program'],['Transportation'],Final,FDA-2005-D-0337,No,
Dental Composite Resin Devices - Premarket Notification [510(k)] Submissions -  Guidance for Industry and FDA Staff,,,2005-10-25,[],['Premarket'],Final,FDA-2020-D-0957,No,
S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s7b-nonclinical-evaluation-potential-delayed-ventricular-repolarization-qt-interval-prolongation,https://www.fda.gov/media/72043/download,2005-10-20,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['ICH-Safety'],Final,FDA-2004-D-0366,No,
E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e14-clinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic-potential-non-antiarrhythmic-1,https://www.fda.gov/media/71379/download,2005-10-11,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Efficacy'],Final,FDA-2004-D-0241,No,
Letter to State Regulatory Agencies and Firms That Produce Treated (but not Pasteurized) and Untreated Juice and Cider,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/letter-state-regulatory-agencies-and-firms-produce-treated-not-pasteurized-and-untreated-juice-and,,2005-09-22,['Human Foods Program'],['Juice'],Final,FDA-2020-D-1938,No,
"Review Criteria for Assessment of C-Reactive Protein (CRP), High Sensitivity C-Reactive Protein (hsCRP) and Cardiac C-Reactive Assays:  Guidance for Industry and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/review-criteria-assessment-c-reactive-protein-crp-high-sensitivity-c-reactive-protein-hscrp-and,https://www.fda.gov/media/71337/download,2005-09-22,['Center for Devices and Radiological Health'],"['Postmarket','Cardiovascular']",Final,FDA-2020-D-0957,No,
How to Comply with the Pediatric Research Equity Act,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/how-comply-pediatric-research-equity-act,https://www.fda.gov/media/72274/download,2005-09-07,['Center for Drug Evaluation and Research'],"['Administrative / Procedural','Pediatric Product Development']",Draft,,No,
M5International Conference on Harmonisation; Draft Guidance on M5 Data Elements and Standards for Drug Dictionaries,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m5international-conference-harmonisation-draft-guidance-m5-data-elements-and-standards-drug,https://www.fda.gov/media/71663/download,2005-09-06,['Center for Drug Evaluation and Research'],['ICH-Multidisciplinary'],Draft,FDA-2005-D-0459,No,
Medical Devices with Sharps Injury Prevention Features -  Guidance for Industry and FDA Staff,,,2005-08-08,[],['Premarket'],Final,FDA-2020-D-0957,No,
Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers,https://www.fda.gov/media/72309/download,2005-07-28,[],['Pharmacology/Toxicology'],Final,,No,
Menstrual Tampons and Pads: Information for Premarket Notification Submissions (510(k)s) -  Guidance for Industry and FDA Staff,,,2005-07-26,[],"['Premarket','510(k)']",Final,FDA-2020-D-0957,No,
Nonclinical Pharmacology/Toxicology Development of Topical Drugs Intended to Prevent the Transmission of Sexually Transmitted Diseases (STD) and/or for the Development of Drugs Intended to Act as Vaginal Contraceptives,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-pharmacologytoxicology-development-topical-drugs-intended-prevent-transmission-sexually,,2005-06-30,[],['Pharmacology/Toxicology'],Final,,No,
Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q5e-comparability-biotechnologicalbiological-products-subject-changes-their-manufacturing-process,https://www.fda.gov/media/71489/download,2005-06-30,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-2004-D-0440,No,
Assessing Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-donor-suitability-and-blood-and-blood-product-safety-cases-known-or-suspected-west-nile,https://www.fda.gov/media/72269/download,2005-06-23,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-2005-D-0139,No,
CPG Sec. 315.100 Illegal Interstate Commercial Shipment of Dentures (CPG retitled and revised 5/19/2005),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-315100-illegal-interstate-commercial-shipment-dentures-cpg-retitled-and-revised-5192005,https://www.fda.gov/media/71787/download,2005-05-19,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']","['Investigation & Enforcement','Dental']",Final,FDA-2020-D-0957,No,
Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-studies-safety-evaluation-pharmaceutical-excipients,https://www.fda.gov/media/72260/download,2005-05-19,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Final,FDA-2002-D-0188,No,
"Guidance for Industry: Channels of Trade Policy for Commodities With Residues of Pesticide Chemicals, for Which Tolerances Have Been Revoked, Suspended, or Modified by the Environmental Protection Agency Pursuant to Dietary Risk Considerations",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-channels-trade-policy-commodities-residues-pesticide-chemicals-which-tolerances,,2005-05-18,['Human Foods Program'],['Pesticide'],Final,FDA-2003-D-0430,No,
CPG Sec 560.400 Imported Milk and Cream - Federal Import Milk Act,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-560400-imported-milk-and-cream-federal-import-milk-act,https://www.fda.gov/media/72004/download,2005-05-12,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Import']",Final,,No,
"CPG Sec 525.225 - Whole Cassia or Whole Cinnamon, Ground Cinnamon - Adulteration by Insect and Rodent Filth; Mold; Mammalian Excreta",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525225-whole-cassia-or-whole-cinnamon-ground-cinnamon-adulteration-insect-and-rodent-filth,https://www.fda.gov/media/71847/download,2005-05-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
"CPG Sec 555.425  Foods, Adulteration Involving hard or Sharp Foreign Objects",,,2005-05-01,[],['Investigation & Enforcement'],Final,,No,
Evaluating the Risks of Drug Exposure in Human Pregnancies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluating-risks-drug-exposure-human-pregnancies,https://www.fda.gov/media/71368/download,2005-04-27,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,,No,
CPG Sec. 100.700  GWQAP Pre-Award Evaluation - Inadequate Information to Evaluate Prospective Supplier,,,2005-04-24,[],['Investigation & Enforcement'],Final,,No,
Providing Regulatory Submissions in Electronic Format — Content of Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-content-labeling,https://www.fda.gov/media/71129/download,2005-04-21,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Electronic Submissions'],Final,,No,
Guidance for Industry: Templates for Reporting Toxicology Data,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-templates-reporting-toxicology-data,,2005-04-11,['Human Foods Program'],['Food & Color Additives'],Final,FDA-2020-D-1941,No,
CPG Sec. 390.300 Assessment of Civil Penalties Against Manufacturers and Importers of Electronic Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-390300-assessment-civil-penalties-against-manufacturers-and-importers-electronic-products,,2005-04-01,[],"['Investigation & Enforcement','Administrative / Procedural']",Final,,No,
Guidance for Industry: Pre-Petition Consultations for Food Additives and Color Additives,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-pre-petition-consultations-food-additives-and-color-additives,,2005-04-01,['Human Foods Program'],"['Food & Color Additives','Ingredients']",Final,FDA-2020-D-1944,No,
Guidance for Industry: Submitting Requests under 21 CFR 170.39 Threshold of Regulation for Substances Used in Food-Contact Articles,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-submitting-requests-under-21-cfr-17039-threshold-regulation-substances-used-food,,2005-04-01,['Human Foods Program'],"['Food & Color Additives','Ingredients']",Final,FDA-2013-N-0730,No,
E2E Pharmacovigilance Planning,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2e-pharmacovigilance-planning,https://www.fda.gov/media/71238/download,2005-04-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Efficacy'],Final,FDA-2004-D-0245,No,
Guidance for Review Staff and Industry Good Review Management Principles and Practices for PDUFA Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-review-staff-and-industry-good-review-management-principles-and-practices-pdufa-products,https://www.fda.gov/media/132157/download,2005-04-01,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Draft,,No,
Guidance for Industry: Dietary Supplement Labeling Guide,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-dietary-supplement-labeling-guide,,2005-03-31,['Human Foods Program'],['Labeling'],Final,FDA-2004-D-0544,No,
Development and Use of Risk Minimization Action Plans:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-use-risk-minimization-action-plans,https://www.fda.gov/media/71268/download,2005-03-29,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Clinical - Medical','Good Clinical Practice (GCP)']",Final,FDA-2004-D-0441,No,
Premarketing Risk Assessment:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarketing-risk-assessment,https://www.fda.gov/media/71650/download,2005-03-29,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Clinical - Medical','Good Clinical Practice (GCP)']",Final,FDA-2004-D-0121,No,
Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-pharmacovigilance-practices-and-pharmacoepidemiologic-assessment,https://www.fda.gov/media/71546/download,2005-03-24,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Clinical - Medical','Good Clinical Practice (GCP)']",Final,FDA-2004-D-0041,No,
E2B(M) Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2bm-questions-and-answers,https://www.fda.gov/media/71218/download,2005-03-09,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Efficacy'],Final,FDA-1996-D-0168,No,
CPG Sec. 390.400 Examples of Electronic Products Subject to the Reporting Requirements Under 21 CFR 1000.15(a),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-390400-examples-electronic-products-subject-reporting-requirements-under-21-cfr-100015a,,2005-03-01,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']","['Investigation & Enforcement','Administrative / Procedural']",Final,FDA-2020-D-0957,No,
"Pharmacogenomic Data Submissions; Examples of Voluntary Submissions or Submissions Required Under 21 CFR 312, 314, or 601",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacogenomic-data-submissions-examples-voluntary-submissions-or-submissions-required-under-21-cfr,https://www.fda.gov/media/72428/download,2005-03-01,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,,No,
Pharmacogenomic Data Submissions:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacogenomic-data-submissions,https://www.fda.gov/media/122944/download,2005-03-01,"['Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Administrative / Procedural','Good Clinical Practice (GCP)']",Final,FDA-2003-D-0031,No,
CPG Sec. 396.300 Defective Suntanning Booths and Bed,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-396300-defective-suntanning-booths-and-bed,,2005-02-28,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 398.100 Definition of General Purpose Radiographic X-Ray System - 21 CFR 1020.30(b),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-398100-definition-general-purpose-radiographic-x-ray-system-21-cfr-102030b,,2005-02-28,"['Office of Regulatory Affairs','Center for Devices and Radiological Health']","['Investigation & Enforcement','Radiology']",Final,FDA-2020-D-0957,No,
CPG Sec. 398.325 Regulatory Actions Against Assemblers Noncompliant Diagnostic X-Ray Equipment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-398325-regulatory-actions-against-assemblers-noncompliant-diagnostic-x-ray-equipment,,2005-02-28,[],['Investigation & Enforcement'],Final,,No,
"CPG Sec. 398.700 Reloaders of X-ray Tube Housing Assemblies; Applicability of Medical Device Establishment Registration, Device Listing and Biennial Inspection",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-398700-reloaders-x-ray-tube-housing-assemblies-applicability-medical-device-establishment,,2005-02-28,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 310.210 Blood Pressure Measurement Devices (Sphygmomanometers) - Accuracy,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-310210-blood-pressure-measurement-devices-sphygmomanometers-accuracy,https://www.fda.gov/media/71783/download,2005-02-18,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']",['Investigation & Enforcement'],Final,FDA-2005-D-0029,No,
"Information for Healthcare Organizations about FDA's ""Guidance for Industry: Cybersecurity for Networked Medical Devices Containing Off-The-Shelf (OTS) Software""",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/information-healthcare-organizations-about-fdas-guidance-industry-cybersecurity-networked-medical,,2005-02-08,['Center for Devices and Radiological Health'],['Digital Health'],Final,FDA-2020-D-0957,No,
CVM GFI #173 Animal Drug Sponsor Fees Under the Animal Drug User Fee Act (ADUFA),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-173-animal-drug-sponsor-fees-under-animal-drug-user-fee-act-adufa,https://www.fda.gov/media/69912/download,2005-02-07,['Center for Veterinary Medicine'],['User Fees'],Final,FDA-2004-D-0181,No,
CVM GFI #173 Appendix for the Animal Drug Sponsor Fees Under ADUFA,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-173-appendix-animal-drug-sponsor-fees-under-adufa,https://www.fda.gov/media/69915/download,2005-02-07,['Center for Veterinary Medicine'],['User Fees'],Final,FDA-2004-D-0181,No,
Gingivitis: Development and Evaluation of Drugs for Treatment or Prevention,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/gingivitis-development-and-evaluation-drugs-treatment-or-prevention,https://www.fda.gov/media/71536/download,2005-01-28,['Center for Drug Evaluation and Research'],"['Clinical - Medical','Pediatric Product Development']",Draft,,No,
Cybersecurity for Networked Medical Devices Containing Off-the-Shelf (OTS) Software:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-networked-medical-devices-containing-shelf-ots-software,https://www.fda.gov/media/72154/download,2005-01-14,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Guidance for Industry: Labeling for Cosmetics Containing Alpha Hydroxy Acids,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-labeling-cosmetics-containing-alpha-hydroxy-acids,,2005-01-10,['Office of the Commissioner'],"['Ingredients','Labeling']",Final,FDA-2000-P-0063,No,
Submitting Separate Marketing Applications and Clinical Data for Purposes of Assessing User Fees:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-separate-marketing-applications-and-clinical-data-purposes-assessing-user-fees,https://www.fda.gov/media/72397/download,2005-01-03,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['User Fees'],Final,FDA-2001-D-0134,No,
M4:  The CTD -- General Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m4-ctd-general-questions-and-answers,https://www.fda.gov/media/71559/download,2004-12-22,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Multidisciplinary'],Final,,No,
Clinical Data Presentations for Orthopedic Device Applications -  Guidance for Industry and FDA Staff,,,2004-12-01,[],['Premarket'],Final,FDA-2020-D-0957,No,
M4: The CTD -- Efficacy Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m4-ctd-efficacy-questions-and-answers,https://www.fda.gov/media/71616/download,2004-12-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Multidisciplinary'],Final,,No,
Changes to an Approved NDA or ANDA; Specifications – Use of Enforcement Discretion for Compendial Changes:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-approved-nda-or-anda-specifications-use-enforcement-discretion-compendial-changes,https://www.fda.gov/media/70772/download,2004-11-22,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-2004-D-0179,No,
CVM GFI #122 Manufacture and Labeling of Raw Meat Foods for Companion and Captive Noncompanion Carnivores and Omnivores,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-122-manufacture-and-labeling-raw-meat-foods-companion-and-captive-noncompanion-carnivores,https://www.fda.gov/media/70183/download,2004-11-09,['Center for Veterinary Medicine'],['Animal Feed'],Final,FDA-2002-D-0148,No,
CPG Sec. 130.400  Use of Microfiche and/or Microfilm for Method of Records Retention,,,2004-11-07,[],"['Investigation & Enforcement','Records']",Final,,No,
"Pharmacokinetics in Pregnancy — Study Design, Data Analysis, and Impact on Dosing and Labeling",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacokinetics-pregnancy-study-design-data-analysis-and-impact-dosing-and-labeling,https://www.fda.gov/media/71353/download,2004-11-01,['Center for Drug Evaluation and Research'],['Clinical - Pharmacology'],Draft,FDA-2004-D-0459,No,
"Recommendations for Obtaining a Labeling Claim for Communicable Disease Donor Screening Tests Using Cadaveric Blood Specimens from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps):  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-obtaining-labeling-claim-communicable-disease-donor-screening-tests-using-cadaveric,https://www.fda.gov/media/73121/download,2004-11-01,['Center for Biologics Evaluation and Research'],"['Labeling','Tissue']",Final,FDA-2005-D-0273,No,
Clinical Trial Considerations: Vertebral Augmentation Devices to Treat Spinal Insufficiency Fractures -  Guidance for Industry and FDA Staff,,,2004-10-23,[],['Premarket'],Final,FDA-2020-D-0957,No,
Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components (including Source Plasma and Source Leukocytes) to Adequately and Appropriately Reduce the Risk of Transmission of  of HIV-1 and HCV:  Guidance for Industry,,,2004-10-21,[],"['Blood','Blood Products']",Final,FDA-2001-D-0095,No,
"PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pat-framework-innovative-pharmaceutical-development-manufacturing-and-quality-assurance,https://www.fda.gov/media/71012/download,2004-10-04,"['Center for Veterinary Medicine','Office of Regulatory Affairs','Center for Drug Evaluation and Research']","['Investigation & Enforcement','Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,FDA-2003-D-0032,No,
Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice,https://www.fda.gov/media/71026/download,2004-10-04,"['Office of Regulatory Affairs','Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Investigation & Enforcement','Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,FDA-2003-D-0145,No,
Guidance for Industry: Recommendations to Processors of Apple Juice or Cider on the Use of Ozone for Pathogen Reduction Purposes,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-recommendations-processors-apple-juice-or-cider-use-ozone-pathogen-reduction,,2004-10-01,['Human Foods Program'],['Juice'],Final,FDA-2004-D-0531,No,
"FDA Review of Vaccine Labeling Requirements for Warnings, Use Instructions, and Precautionary Information:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-review-vaccine-labeling-requirements-warnings-use-instructions-and-precautionary-information,https://www.fda.gov/media/73544/download,2004-10-01,['Center for Biologics Evaluation and Research'],"['Pediatric Product Development','Vaccines']",Final,FDA-2004-D-0286,No,
Class II Special Controls Guidance Document: Serological Assays for the Detection of Beta-Glucan (PDF version),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/class-ii-special-controls-guidance-document-serological-assays-detection-beta-glucan-pdf-version,https://www.fda.gov/media/71529/download,2004-09-23,[],['Premarket'],Final,,No,
The Use of Clinical Holds Following Clinical Investigator Misconduct:  Guidance for Industry and Clinical Investigators,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-clinical-holds-following-clinical-investigator-misconduct,https://www.fda.gov/media/75301/download,2004-09-02,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Administrative / Procedural','Good Clinical Practice (GCP)']",Final,FDA-2002-D-0053,No,
Independent Consultants for Biotechnology Clinical Trial Protocols:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/independent-consultants-biotechnology-clinical-trial-protocols,https://www.fda.gov/media/75135/download,2004-08-19,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Administrative / Procedural','Good Clinical Practice (GCP)']",Final,FDA-2003-D-0288,No,
Calcium DTPA and Zinc DTPA Drug Products-Submitting a New Drug Application,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/calcium-dtpa-and-zinc-dtpa-drug-products-submitting-new-drug-application,https://www.fda.gov/media/71258/download,2004-08-13,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,None found,No,
Developing Medical Imaging Drug and Biological Products Part 1: Conducting Safety Assessments,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-medical-imaging-drug-and-biological-products-part-1-conducting-safety-assessments,https://www.fda.gov/media/71212/download,2004-06-22,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Final,FDA-1998-D-0035,No,
Developing Medical Imaging Drug and Biological Products Part 2: Clinical Indications,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-medical-imaging-drug-and-biological-products-part-2-clinical-indications,https://www.fda.gov/media/71226/download,2004-06-22,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Final,FDA-1998-D-0035,No,
"Developing Medical Imaging Drug and Biological Products Part 3: Design, Analysis, and Interpretation of Clinical Studies",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-medical-imaging-drug-and-biological-products-part-3-design-analysis-and-interpretation,https://www.fda.gov/media/71237/download,2004-06-22,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Final,FDA-1998-D-0035,No,
CPG Sec. 690.300  Canned Pet Food (Withdrawn 4/30/2019),,,2004-06-10,[],"['Investigation & Enforcement','Pet Food']",Final,,No,
M4: The CTD -- Quality Questions and Answers /Location Issues,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m4-ctd-quality-questions-and-answers-location-issues,https://www.fda.gov/media/71599/download,2004-06-09,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Multidisciplinary'],Final,FDA-2002-D-0261,No,
Q1E Evaluation of Stability Data,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1e-evaluation-stability-data,https://www.fda.gov/media/71722/download,2004-06-08,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-2002-D-0180,No,
"Medical Device User Fee and Modernization Act of 2002, Validation Data in Premarket Notification Submissions (510(k)s) for Reprocessed Single-Use Medical Devices:  Guidance for Industry and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-device-user-fee-and-modernization-act-2002-validation-data-premarket-notification,https://www.fda.gov/media/71482/download,2004-06-02,['Center for Devices and Radiological Health'],"['User Fees','510(k)']",Final,FDA-2003-D-0309,No,
Class II Special Controls Guidance Document: Immunomagnetic Circulating Cancer Cell Selection and Enumeration System (PDF version),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/class-ii-special-controls-guidance-document-immunomagnetic-circulating-cancer-cell-selection-and,https://www.fda.gov/media/71378/download,2004-05-11,[],['Premarket'],Final,,No,
Submission and Resolution of Formal Disputes Regarding the Timeliness of Premarket Review of a Combination Product:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-and-resolution-formal-disputes-regarding-timeliness-premarket-review-combination-product,https://www.fda.gov/media/76420/download,2004-05-03,['Office of the Commissioner'],['Combination Products'],Final,FDA-2004-D-0502,No,
Guidance for Industry and FDA Staff: Spinal System 510(k)s,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-staff-spinal-system-510ks,https://www.fda.gov/media/71604/download,2004-05-02,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
CVM GFI #144 (VICH GL27) Pre-Approval Information for Registration of New Veterinary Medicinal Products for Food-Producing Animals with Respect to Antimicrobial Resistance,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-144-vich-gl27-pre-approval-information-registration-new-veterinary-medicinal-products-food,https://www.fda.gov/media/69981/download,2004-04-27,['Center for Veterinary Medicine'],"['Antimicrobial Resistance','VICH']",Final,FDA-2003-D-0152,No,
"Redbook 2000: VII Glossary, Acronyms and Definitions",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-vii-glossary-acronyms-and-definitions,,2004-04-25,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Changes to an Approved NDA or ANDA:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-approved-nda-or-anda,https://www.fda.gov/media/71846/download,2004-04-08,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-1999-D-0049,No,
CPG Sec.  490.100 Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval,,,2004-03-12,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 490.100 Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-490100-process-validation-requirements-drug-products-and-active-pharmaceutical-ingredients,https://www.fda.gov/media/71756/download,2004-03-12,[],,Final,,No,
Potassium Iodide Tablets - Shelf Life Extension,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/potassium-iodide-tablets-shelf-life-extension,https://www.fda.gov/media/72521/download,2004-03-08,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2003-D-0029,No,
Surgical Masks - Premarket Notification [510(k)] Submissions:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/surgical-masks-premarket-notification-510k-submissions,https://www.fda.gov/media/71660/download,2004-03-04,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2003-D-0305,No,
"Guidance for Industry: Juice Hazard Analysis Critical Control Point Hazards and Controls Guidance, First Edition",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-juice-hazard-analysis-critical-control-point-hazards-and-controls-guidance-first,,2004-03-03,['Human Foods Program'],"['HACCP','Juice']",Final,FDA-2002-D-0298,No,
Guidance for Industry and FDA Staff: Vocal Fold Medialization Devices - Premarket Notification [510(k)] Submissions,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-staff-vocal-fold-medialization-devices-premarket-notification-510k,https://www.fda.gov/media/71688/download,2004-02-12,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-exemptions-studies-lawfully-marketed-drug-or-biological-products-treatment-cancer,https://www.fda.gov/media/71627/download,2004-01-15,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Clinical - Medical','Good Clinical Practice (GCP)']",Final,,No,
Premarket Notification [510(k)] Submissions for Chemical Indicators - Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-notification-510k-submissions-chemical-indicators-guidance-industry-and-fda-staff,https://www.fda.gov/media/72010/download,2003-12-18,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Q1A(R2) Stability Testing of New Drug Substances and Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1ar2-stability-testing-new-drug-substances-and-products,https://www.fda.gov/media/71707/download,2003-11-21,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-2002-D-0222,No,
Premarket Approval Application Modular Review:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-approval-application-modular-review,https://www.fda.gov/media/73513/download,2003-11-03,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Redbook 2000: IV. A. Introduction to Guidelines for Toxicity Studies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-iv-introduction-guidelines-toxicity-studies,,2003-11-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Redbook 2000: IV.B.1. General Guidelines for Designing and Conducting Toxicity Studies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivb1-general-guidelines-designing-and-conducting-toxicity-studies,,2003-11-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Redbook 2000: IV.B.2 Guidelines for Reporting the Results of Toxicity Studies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivb2-guidelines-reporting-results-toxicity-studies,,2003-11-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Redbook 2000: IV.C.1.b. In vitro Mammalian Chromosomal Aberration Test,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc1b-in-vitro-mammalian-chromosomal-aberration-test,,2003-11-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Redbook 2000: IV.C.3.a. Short-Term Toxicity Studies with Rodents,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc3a-short-term-toxicity-studies-rodents,,2003-11-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Redbook 2000: IV.C.3.b. Short-Term Toxicity Studies with Non-Rodents,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc3b-short-term-toxicity-studies-non-rodents,,2003-11-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Redbook 2000: IV.C.4.a. Subchronic Toxicity Studies with Rodents,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc4a-subchronic-toxicity-studies-rodents,,2003-11-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Redbook 2000: IV.C.4.b. Subchronic Toxicity Studies with Non-Rodents,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc4b-subchronic-toxicity-studies-non-rodents,,2003-11-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Redbook 2000: IV.C.5.b. One-Year Toxicity Studies with Non-Rodents,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc5b-one-year-toxicity-studies-non-rodents,,2003-11-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Small Entity Compliance Guide: Label Warning Statements for Iron-Containing Supplements and Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-label-warning-statements-iron-containing-supplements-and-drugs,,2003-10-17,['Human Foods Program'],['Labeling'],Final,FDA-1997-D-0056,No,
E2D Postapproval Safety Data Management: Definitions and Standards for Expedited Reporting,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2d-postapproval-safety-data-management-definitions-and-standards-expedited-reporting,https://www.fda.gov/media/71228/download,2003-09-12,['Center for Drug Evaluation and Research'],['ICH-Efficacy'],Final,FDA-2003-D-0371,No,
"Part 11, Electronic Records; Electronic Signatures - Scope and Application:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application,https://www.fda.gov/media/75414/download,2003-09-05,"['Human Foods Program','Center for Veterinary Medicine','Office of Inspections and Investigations','Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Postmarket','Compliance','Electronic Submissions','Investigation & Enforcement','Administrative / Procedural','Current Good Manufacturing Practice (CGMP)','Good Clinical Practice (GCP)','Food & Color Additives']",Final,FDA-2003-D-0143,No,
Information Disclosure by Manufacturers to Assemblers for Diagnostic X-ray Systems - Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/information-disclosure-manufacturers-assemblers-diagnostic-x-ray-systems-guidance-industry-and-fda,https://www.fda.gov/media/76019/download,2003-09-04,['Center for Devices and Radiological Health'],['Postmarket'],Final,FDA-2020-D-0957,No,
Guidance for Industry: Questions and Answers on Juice HACCP Regulation (2003),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-juice-haccp-regulation-2003,,2003-09-03,['Human Foods Program'],"['HACCP','Juice']",Final,FDA-2020-D-1951,No,
"Small Entity Compliance Guide: Trans Fatty Acids in Nutrition Labeling, Nutrient Content Claims, and Health Claims",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-trans-fatty-acids-nutrition-labeling-nutrient-content-claims-and,,2003-08-20,['Human Foods Program'],['Labeling'],Final,FDA-2003-D-0035,No,
IRB Review of Stand-Alone HIPAA Authorizations Under FDA Regulations:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/irb-review-stand-alone-hipaa-authorizations-under-fda-regulations,https://www.fda.gov/media/75279/download,2003-08-16,['Office of the Commissioner'],,Final,FDA-2003-D-0037,No,
"Frequently-Asked-Questions about the Reprocessing and Reuse of Single-Use Devices by Third-Party and Hospital Reprocessors - Three Additional Questions:  Guidance for Industry, FDA Staff, Third-Party and Hospital Reprocessors",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/frequently-asked-questions-about-reprocessing-and-reuse-single-use-devices-third-party-and-hospital-0,https://www.fda.gov/media/71124/download,2003-07-16,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Guidance for Industry: Interim Procedures for Qualified Health Claims in the Labeling of Conventional Human Food and Human Dietary Supplements,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-interim-procedures-qualified-health-claims-labeling-conventional-human-food-and,,2003-07-11,['Human Foods Program'],['Labeling'],Final,FDA-2003-N-0103,No,
Streamlining the Donor Interview Process: Recommendations for Self-Administered Questionnaires:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/streamlining-donor-interview-process-recommendations-self-administered-questionnaires,https://www.fda.gov/media/70688/download,2003-07-03,['Center for Biologics Evaluation and Research'],"['Application & Approvals','Blood Products']",Final,FDA-2002-D-0524,No,
180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/180-day-exclusivity-when-multiple-andas-are-submitted-same-day,https://www.fda.gov/media/71304/download,2003-07-01,['Center for Drug Evaluation and Research'],['Generic Drugs'],Final,2003D-0325,No,
Guidance for Industry: Standardized Training Curriculum for Application of HACCP Principles to Juice Processing,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-standardized-training-curriculum-application-haccp-principles-juice-processing,,2003-06-13,['Human Foods Program'],"['HACCP','Juice']",Final,FDA-2002-D-0227,No,
"Drug Products Containing Ensulizole, Hypromellose, Meradimate, Octinoxate, and Octisalate — Labeling Enforcement Policy",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-products-containing-ensulizole-hypromellose-meradimate-octinoxate-and-octisalate-labeling,https://www.fda.gov/media/72206/download,2003-06-03,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2003-D-0090,No,
Pediatric Expertise for Advisory Panels - Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-expertise-advisory-panels-guidance-industry-and-fda-staff,https://www.fda.gov/media/72451/download,2003-06-02,['Center for Devices and Radiological Health'],"['Advisory Committees','Pediatric Product Development']",Final,FDA-2003-D-0147,No,
"Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacokinetics-patients-impaired-hepatic-function-study-design-data-analysis-and-impact-dosing-and,https://www.fda.gov/media/71311/download,2003-05-30,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Pharmacology'],Final,FDA-1999-D-0063,No,
"INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/inds-phase-2-and-phase-3-studies-chemistry-manufacturing-and-controls-information,https://www.fda.gov/media/70822/download,2003-05-20,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Good Clinical Practice (GCP)','Pharmaceutical Quality']",Final,FDA-1999-D-0030,No,
"Exposure-Response Relationships — Study Design, Data Analysis, and Regulatory Applications",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exposure-response-relationships-study-design-data-analysis-and-regulatory-applications,https://www.fda.gov/media/71277/download,2003-05-05,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Pharmacology'],Final,FDA-2002-D-0177,No,
CVM GFI #118 Mass Spectrometry for Confirmation of Identity of Animal Drug Residues,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-118-mass-spectrometry-confirmation-identity-animal-drug-residues,https://www.fda.gov/media/70154/download,2003-05-01,['Center for Veterinary Medicine'],['Human Food Safety'],Final,FDA-2001-D-0102,No,
Guidance for Industry: Bulk Transport of Juice Concentrates and Certain Shelf-Stable Juices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-bulk-transport-juice-concentrates-and-certain-shelf-stable-juices,,2003-04-24,['Human Foods Program'],"['Juice','Transportation']",Final,FDA-2002-P-0302,No,
Guidance for Industry: Recommendations for the Assessment of Donor Suitability and Blood Product Safety in Cases of Suspected Severe Acute Respiratory Syndrome (SARS) or Exposure to SARS,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-recommendations-assessment-donor-suitability-and-blood-product-safety-cases,https://www.fda.gov/media/72313/download,2003-04-17,[],['Blood Products'],Final,,No,
"Statistical Information from the June 1999 Draft Guidance and Statistical Information for In Vitro Bioequivalence Data Posted on August 18, 1999",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-information-june-1999-draft-guidance-and-statistical-information-in-vitro-bioequivalence,https://www.fda.gov/media/70878/download,2003-04-11,['Center for Drug Evaluation and Research'],"['Biopharmaceutics','Generic Drugs']",Draft,,No,
Small Entity Compliance Guide: Juice HACCP,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-juice-haccp,,2003-04-04,['Human Foods Program'],"['HACCP','Juice']",Final,FDA-2003-D-0283,No,
Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioavailability-and-bioequivalence-studies-nasal-aerosols-and-nasal-sprays-local-action,https://www.fda.gov/media/70867/download,2003-04-03,['Center for Drug Evaluation and Research'],"['Biopharmaceutics','Generic Drugs']",Draft,FDA-1999-D-0050,No,
User Labeling for Devices that Contain Natural Rubber (21 CFR 801.437); Small Entity Compliance Guide - Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/user-labeling-devices-contain-natural-rubber-21-cfr-801437-small-entity-compliance-guide-guidance,https://www.fda.gov/media/71135/download,2003-04-01,['Center for Devices and Radiological Health'],['Radiological Health'],Final,FDA-2020-D-0957,No,
Integration of Dose-Counting Mechanisms into MDI Drug Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/integration-dose-counting-mechanisms-mdi-drug-products,https://www.fda.gov/media/71073/download,2003-03-13,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-2003-D-0285,No,
M4: The CTD -- Safety Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m4-ctd-safety-questions-and-answers,https://www.fda.gov/media/71658/download,2003-02-04,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Multidisciplinary'],Final,,No,
Prussian Blue Drug Products — Submitting a New Drug Application,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prussian-blue-drug-products-submitting-new-drug-application,https://www.fda.gov/media/71071/download,2003-02-04,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-2003-D-0727,No,
Quality System Information for Certain Premarket Application Reviews :  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-system-information-certain-premarket-application-reviews,https://www.fda.gov/media/71083/download,2003-02-03,['Center for Devices and Radiological Health'],"['Premarket','Premarket Approval (PMA)']",Final,FDA-2020-D-0957,No,
Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms — Recommendations for Clinical Evaluation,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/estrogen-and-estrogenprogestin-drug-products-treat-vasomotor-symptoms-and-vulvar-and-vaginal-atrophy,https://www.fda.gov/media/71359/download,2003-01-31,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Draft,,No,
Q1D Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1d-bracketing-and-matrixing-designs-stability-testing-new-drug-substances-and-products,https://www.fda.gov/media/71720/download,2003-01-16,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-2001-D-0164,No,
Recommendations for Deferral of Donors and Quarantine and Retrieval of Blood and Blood Products in Recent Recipients of Smallpox Vaccine (Vaccinia Virus) and Certain Contacts of Smallpox Vaccine Recipients:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-deferral-donors-and-quarantine-and-retrieval-blood-and-blood-products-recent,https://www.fda.gov/media/124362/download,2002-12-30,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-2002-D-0013,No,
(Potassium Iodide) KI in Radiation Emergencies-Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/potassium-iodide-ki-radiation-emergencies-questions-and-answers,https://www.fda.gov/media/72515/download,2002-12-23,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,None found,No,
"Guidance for Industry: Implementation of Section 403(t) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 343(t)) Regarding the Use of the Term ""Catfish""",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-implementation-section-403t-federal-food-drug-and-cosmetic-act-21-usc-343t,,2002-12-06,['Human Foods Program'],['Seafood/Seafood Product'],Final,FDA-2002-D-0174,No,
Determination of Intended Use for 510(k) Devices - Guidance for CDRH Staff (Update to K98-1),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/determination-intended-use-510k-devices-guidance-cdrh-staff-update-k98-1,https://www.fda.gov/media/72446/download,2002-12-02,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Food-Effect Bioavailability and Fed Bioequivalence Studies:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/food-effect-bioavailability-and-fed-bioequivalence-studies,https://www.fda.gov/media/70945/download,2002-12-01,['Center for Drug Evaluation and Research'],"['Biopharmaceutics','Good Clinical Practice (GCP)']",Final,FDA-2001-D-0040,No,
CVM GFI #80 Evaluation the Utility of Anti-Salmonella Chemical Food Additives,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-80-evaluation-utility-anti-salmonella-chemical-food-additives,https://www.fda.gov/media/70304/download,2002-11-21,['Center for Veterinary Medicine'],['Animal Food Additives'],Final,FDA-1994-D-0007,No,
"CPG Sec 555.600 Filth from Insects, Rodents, and Other Pests in Foods",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555600-filth-insects-rodents-and-other-pests-foods,,2002-11-13,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
"Needlesticks -  Medical Device Reporting Guidance for User Facilities, Manufacturers, and Importers",,,2002-11-11,[],['Adverse Event Reporting System (FAERS)'],Final,FDA-2020-D-0957,No,
Draft Guidance for Industry: Regulatory Procedures Manual Chapter 9 Subchapter on Recommending Customs'Seizure and Destruction of Imported Human and Animal Food That Has Not Been Reconditioned,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-regulatory-procedures-manual-chapter-9-subchapter-recommending-customs,,2002-11-05,"['Center for Veterinary Medicine','Human Foods Program']",['Import'],Draft,FDA-2002-D309,No,2003-01-06
CVM GFI #82 Development of Supplemental Applications for Approved New Animal Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-82-development-supplemental-applications-approved-new-animal-drugs,https://www.fda.gov/media/70308/download,2002-10-28,['Center for Veterinary Medicine'],['New Animal Drug Application (NADA)'],Final,FDA-1999-N-1881,No,
Guidance for Small Businesses: Submission of Comments for CFSAN Rulemaking,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-small-businesses-submission-comments-cfsan-rulemaking,,2002-10-20,['Human Foods Program'],['Rulemaking'],Final,,No,
Labeling OTC Human Drug Products Updating Labeling in RLDs and ANDAs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-otc-human-drug-products-updating-labeling-rlds-and-andas,https://www.fda.gov/media/72594/download,2002-10-18,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Final,FDA-2001-D-0135,No,
Guidance for Industry:  Implementation of Section 10809 of the Farm Security and Investment Act of 2002 Regarding the Petition Process to Request Approval of Labeling for Foods that Have Been Treated with Irradiation,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-implementation-section-10809-farm-security-and-investment-act-2002-regarding,,2002-10-07,['Human Foods Program'],['Labeling'],Final,FDA-2002-D-0189,No,
Guidance for Industry: Exemptions from the Warning Label Requirement for Juice,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-exemptions-warning-label-requirement-juice,,2002-10-07,['Human Foods Program'],"['HACCP','Juice','Labeling']",Final,FDA-2001-D-0138,No,
CVM GFI #119 How CVM Intends to Handle Deficient Submissions Filed During the Investigation of a New Animal Drug,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-119-how-cvm-intends-handle-deficient-submissions-filed-during-investigation-new-animal-drug,https://www.fda.gov/media/70164/download,2002-08-29,['Center for Veterinary Medicine'],['Investigational New Animal Drug (INAD)'],Final,FDA-2001-D-0011,No,
Guidance on the Department of Defense Exemption from the FDA Performance Standard for Laser Products:  Guidance for Industry and FDA,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-department-defense-exemption-fda-performance-standard-laser-products,https://www.fda.gov/media/71322/download,2002-07-12,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
"Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products--Chemistry, Manufacturing, and Controls Documentation:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nasal-spray-and-inhalation-solution-suspension-and-spray-drug-products-chemistry-manufacturing-and,https://www.fda.gov/media/70857/download,2002-07-05,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-1999-D-0060,No,
Guidance for Resorbable Adhesion Barrier Devices for Use in Abdominal and/or Pelvic Surgery - Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-resorbable-adhesion-barrier-devices-use-abdominal-andor-pelvic-surgery-guidance-industry,https://www.fda.gov/media/71607/download,2002-06-17,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Guidance for Industry: Channels of Trade Policy for Commodities with Vinclozolin Residues,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-channels-trade-policy-commodities-vinclozolin-residues,,2002-06-12,['Human Foods Program'],['Pesticide'],Final,FDA-2001-D-0094,No,
Carcinogenicity Study Protocol Submissions,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/carcinogenicity-study-protocol-submissions,https://www.fda.gov/media/72270/download,2002-05-23,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Final,FDA-2000-D-1405,No,
Container Closure Systems for Packaging Human Drugs and Biologics -- Questions and Answers:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/container-closure-systems-packaging-human-drugs-and-biologics-questions-and-answers,https://www.fda.gov/media/70794/download,2002-05-01,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']","['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,None found,No,
E2BM Data Elements for Transmission Of Individual Case Safety Reports,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2bm-data-elements-transmission-individual-case-safety-reports,https://www.fda.gov/media/71208/download,2002-04-04,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Efficacy'],Final,FDA-1996-D-0168,No,
Validation of Procedures for Processing of Human Tissues Intended for Transplantation:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/validation-procedures-processing-human-tissues-intended-transplantation,https://www.fda.gov/media/73242/download,2002-03-08,['Center for Biologics Evaluation and Research'],['Tissue'],Final,FDA-2002-D-0181,No,
Guidance for Industry: Providing Regulatory Submissions to CBER in Electronic Format -- Investigational New Drug Applications (INDs) (PDF),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-providing-regulatory-submissions-cber-electronic-format-investigational-new-drug,https://www.fda.gov/media/76466/download,2002-03-01,[],['Administrative / Procedural'],Final,,No,
General Principles of Software Validation:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-software-validation,https://www.fda.gov/media/73141/download,2002-01-11,"['Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']","['Premarket','Digital Health','Good Clinical Practice (GCP)']",Final,FDA-1997-D-0029,No,
Small Entity Compliance Guide on Structure/Function Claims,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-structurefunction-claims,,2002-01-09,['Human Foods Program'],['Labeling'],Final,FDA-1998-N-0071,No,
Sterilized Convenience Kits for Clinical and Surgical Use:  Final Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sterilized-convenience-kits-clinical-and-surgical-use,https://www.fda.gov/media/71358/download,2002-01-07,['Center for Devices and Radiological Health'],['Postmarket'],Final,FDA-2020-D-0957,No,
Potassium Iodide as a Thyroid Blocking Agent in Radiation Emergencies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/potassium-iodide-thyroid-blocking-agent-radiation-emergencies,https://www.fda.gov/media/72510/download,2001-12-11,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-2000-D-1403,No,
CVM GFI #142 (VICH GL29) Pharmacovigilance of Veterinary Medicinal Products: Management of Periodic Summary Update Reports (PSUs),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-142-vich-gl29-pharmacovigilance-veterinary-medicinal-products-management-periodic-summary,https://www.fda.gov/media/70371/download,2001-12-06,['Center for Veterinary Medicine'],"['Adverse Event Reporting','VICH']",Draft,FDA-2001-D-0398,No,
Information Request and Discipline Review Letters Under the Prescription Drug User Fee Act:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/information-request-and-discipline-review-letters-under-prescription-drug-user-fee-act,https://www.fda.gov/media/77409/download,2001-11-21,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['User Fees'],Final,FDA-1999-D-1301,No,
Guidance for Industry: Fumonisin Levels in Human Foods and Animal Feeds,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-fumonisin-levels-human-foods-and-animal-feeds,,2001-11-09,"['Center for Veterinary Medicine','Human Foods Program']",,Final,,No,
Sterility Requirement for Aqueous-Based Drug Products for Oral Inhalation — Small Entity Compliance Guide:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sterility-requirement-aqueous-based-drug-products-oral-inhalation-small-entity-compliance-guide,https://www.fda.gov/media/72306/download,2001-11-07,['Center for Drug Evaluation and Research'],,Final,,No,
Recommendations for Assessment of Donor Suitability and Blood and Blood Product Safety in Cases of Possible Exposure to Anthrax:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-assessment-donor-suitability-and-blood-and-blood-product-safety-cases-possible,https://www.fda.gov/media/70766/download,2001-10-17,['Center for Biologics Evaluation and Research'],"['Application & Approvals','Blood Products']",Final,FDA-2001-D-0488,No,
Cancer Drug and Biological Products - Clinical Data in Marketing Applications,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-drug-and-biological-products-clinical-data-marketing-applications,https://www.fda.gov/media/71270/download,2001-10-11,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Final,FDA-2000-D-0100,No,
Redbook 2000: VI.B Epidemiology,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-vib-epidemiology,,2001-10-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Submitting Marketing Applications According to the ICH/CTD Format: General Considerations 2001,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-marketing-applications-according-ichctd-format-general-considerations-2001,,2001-09-05,['Center for Drug Evaluation and Research'],"['Administrative / Procedural','ICH-Multidisciplinary']",Draft,FDA-2001-D-0061,No,
Submitting Marketing Applications According to the ICH/CTD Format: General Considerations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-marketing-applications-according-ichctd-format-general-considerations-2001,,2001-09-01,['Center for Drug Evaluation and Research'],"['Administrative / Procedural','ICH-Multidisciplinary']",Draft,,No,
Guidance for Industry: Questions and Answers on Juice HACCP Regulation,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-juice-haccp-regulation-2003,,2001-08-31,['Human Foods Program'],"['HACCP','Juice']",Final,,No,
Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q7a-good-manufacturing-practice-guidance-active-pharmaceutical-ingredients,,2001-08-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
M4: The CTD -- Quality,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m4-ctd-quality-questions-and-answers-location-issues,https://www.fda.gov/media/71599/download,2001-08-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Multidisciplinary'],Final,,No,
M4S: The CTD -- Safety,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m4s-ctd-safety,https://www.fda.gov/media/71628/download,2001-08-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Multidisciplinary'],Final,,No,
M4S: The CTD -- Safety Appendices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m4s-ctd-safety-appendices,https://www.fda.gov/media/71642/download,2001-08-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Multidisciplinary'],Final,,No,
Labeling Recommendations for Single-Use Devices Reprocessed by Third Parties and Hospitals:  Final Guidance for Industry and FDA,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-recommendations-single-use-devices-reprocessed-third-parties-and-hospitals,https://www.fda.gov/media/71405/download,2001-07-30,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Premarket Notification Submissions for Empty Containers for the Collection and Processing of Blood and Blood Components:  Guidance for FDA Reviewers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-notification-submissions-empty-containers-collection-and-processing-blood-and-blood,https://www.fda.gov/media/70716/download,2001-07-19,['Center for Biologics Evaluation and Research'],"['Application & Approvals','Blood Products']",Final,FDA-2007-D-0251,No,
Premarket Notification Submissions for Blood and Plasma Warmers:  Guidance for FDA Reviewers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-notification-submissions-blood-and-plasma-warmers,https://www.fda.gov/media/70728/download,2001-07-19,['Center for Biologics Evaluation and Research'],"['Application & Approvals','Blood Products']",Final,FDA-2022-D-0484,No,
Premarket Notification Submissions for Transfer Sets (Excluding Sterile Connecting Devices):  Guidance for FDA Reviewers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-notification-submissions-transfer-sets-excluding-sterile-connecting-devices,https://www.fda.gov/media/70734/download,2001-07-19,['Center for Biologics Evaluation and Research'],"['Application & Approvals','Blood Products']",Final,FDA-2022-D-0485,No,
"Levothyroxine Sodium Products Enforcement of August 14, 2001 Compliance Date and Submission of New Applications",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/levothyroxine-sodium-products-enforcement-august-14-2001-compliance-date-and-submission-new,https://www.fda.gov/media/72341/download,2001-07-13,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,,No,
S7A Safety Pharmacology Studies for Human Pharmaceuticals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s7a-safety-pharmacology-studies-human-pharmaceuticals,https://www.fda.gov/media/72033/download,2001-07-13,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Safety'],Final,FDA-2000-D-0274,No,
Revised Recommendations Regarding Invalidation of Test Results of Licensed and 510(k) Cleared Bloodborne Pathogen Assays Used to Test Donors:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/revised-recommendations-regarding-invalidation-test-results-licensed-and-510k-cleared-bloodborne,https://www.fda.gov/media/70633/download,2001-07-11,['Center for Biologics Evaluation and Research'],"['Application & Approvals','Blood Products']",Final,FDA-1999-D-0743,No,
CVM GFI #104 Content and Format of Effectiveness and Target Animal Safety Technical Sections and Final Study Reports For Submission,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-104-content-and-format-effectiveness-and-target-animal-safety-technical-sections-and-final,https://www.fda.gov/media/70050/download,2001-07-10,['Center for Veterinary Medicine'],"['New Animal Drug Application (NADA)','Target Animal – Effectiveness','Target Animal – Safety','Investigational New Animal Drug (INAD)']",Final,FDA-2021-D-0619,No,
CVM GFI #56 Protocol Development Guideline for Clinical Effectiveness and Target Animal Safety Trials,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-56-protocol-development-guideline-clinical-effectiveness-and-target-animal-safety-trials,https://www.fda.gov/media/70137/download,2001-07-10,['Center for Veterinary Medicine'],"['Environmental Safety','Target Animal – Effectiveness','Target Animal – Safety']",Final,FDA-2021-D-0611,No,
Frequently-Asked-Questions about the Reprocessing and Reuse of Single-Use Devices by Third-Party and Hospital Reprocessors:  Final Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/frequently-asked-questions-about-reprocessing-and-reuse-single-use-devices-third-party-and-hospital,https://www.fda.gov/media/71057/download,2001-07-06,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Guidance for Industry: Refusal of Inspection or Access to HACCP Records Pertaining to the Safe and Sanitary Processing of Fish and Fishery Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-refusal-inspection-or-access-haccp-records-pertaining-safe-and-sanitary-processing,,2001-07-01,['Human Foods Program'],"['HACCP','Records','Seafood/Seafood Product']",Final,FDA-2000-D-0278,No,
Small Entity Compliance Guide: Safe Handling Statements on Labeling of Shell Eggs and the Refrigeration of Shell Eggs Held for Retail Distribution,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-safe-handling-statements-labeling-shell-eggs-and-refrigeration-shell,,2001-07-01,['Human Foods Program'],"['Egg/Egg Product','Retail Food Protection']",Final,FDA-2020-D-1954,No,
"Small Entity Compliance Guide: Serving Sizes Reference Amount for Baking Powder, Baking Soda, and Pectin",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-serving-sizes-reference-amount-baking-powder-baking-soda-and-pectin,,2001-07-01,['Human Foods Program'],"['Bakery Product/Mix','Labeling','Nutrition Label']",Final,FDA-2020-D-1955,No,
Information for Keratome Manufacturers Regarding LASIK - Final Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/information-keratome-manufacturers-regarding-lasik-final-guidance-industry,https://www.fda.gov/media/72327/download,2001-06-20,['Center for Devices and Radiological Health'],['Postmarket'],Final,FDA-2020-D-0957,No,
Changes or Modifications During the Conduct of a Clinical Investigation; Final Guidance for Industry and CDRH Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-or-modifications-during-conduct-clinical-investigation-final-guidance-industry-and-cdrh,https://www.fda.gov/media/72429/download,2001-05-28,['Center for Devices and Radiological Health'],"['Premarket','Investigational Device Exemption (IDE)']",Final,FDA-2020-D-0957,No,
"Responsibilities of Laser Light Show Projector Manufacturers, Dealers, and Distributors; (Laser Notice 51)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/responsibilities-laser-light-show-projector-manufacturers-dealers-and-distributors-laser-notice-51,https://www.fda.gov/media/74032/download,2001-05-26,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
E10 Choice of Control Group and Related Issues in Clinical Trials,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e10-choice-control-group-and-related-issues-clinical-trials,https://www.fda.gov/media/71349/download,2001-05-14,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Efficacy'],Final,FDA-1999-D-1874,No,
CVM GFI #85 (VICH GL9) Good Clinical Practice,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-85-vich-gl9-good-clinical-practice,https://www.fda.gov/media/70333/download,2001-05-09,['Center for Veterinary Medicine'],"['Target Animal – Effectiveness','Target Animal – Safety','VICH']",Final,FDA-1999-D-0754,No,
"Statistical Aspects of the Design, Analysis, and Interpretation of Chronic Rodent Carcinogenicity Studies of Pharmaceuticals",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-aspects-design-analysis-and-interpretation-chronic-rodent-carcinogenicity-studies,https://www.fda.gov/media/72296/download,2001-05-08,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Draft,FDA-2001-D-0043,No,
"IND Meetings for Human Drugs and Biologics Chemistry, Manufacturing, and Controls Information:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-meetings-human-drugs-and-biologics-chemistry-manufacturing-and-controls-information,https://www.fda.gov/media/70827/download,2001-05-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,,No,
Guidance on Medical Device Patient Labeling:  Final Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-medical-device-patient-labeling,https://www.fda.gov/media/71030/download,2001-04-19,['Center for Devices and Radiological Health'],['Labeling'],Final,FDA-2000-D-0067,No,
"Guidance for Hospitals, Nursing Homes, and Other Health Care Facilities - FDA Public Health Advisory:  Guidance for Hospitals, Nursing Homes, and Other Health Care Facilities",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-hospitals-nursing-homes-and-other-health-care-facilities-fda-public-health-advisory,https://www.fda.gov/media/70999/download,2001-04-05,['Center for Drug Evaluation and Research'],"['Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,,No,
CVM GFI #99 (VICH GL17) Testing of New Biotechnological/Biological Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-99-vich-gl17-testing-new-biotechnologicalbiological-products,https://www.fda.gov/media/70404/download,2001-03-26,['Center for Veterinary Medicine'],"['Biotechnology','Chemistry, Manufacturing, and Controls (CMC)','VICH']",Final,FDA-2021-D-0612,No,
Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines: Draft Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-safety-reporting-human-drug-and-biological-products-including-vaccines,https://www.fda.gov/media/73593/download,2001-03-12,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Safety - Issues, Errors, and Problems','Vaccines']",Draft,FDA-2001-D-0506,No,
Levothyroxine Sodium Tablets - In Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/levothyroxine-sodium-tablets-in-vivo-pharmacokinetic-and-bioavailability-studies-and-in-vitro-dissolution,https://www.fda.gov/media/71591/download,2001-03-08,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-1999-D-0010,No,
CVM GFI #89 (VICH GL6) EIAs for Veterinary Medicinal Products  - Phase I,,,2001-03-07,[],"['Environmental Safety','VICH']",Final,FDA-1999-D-3541,No,
Monoclonal Antibodies Used as Reagents in Drug Manufacturing,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/monoclonal-antibodies-used-reagents-drug-manufacturing,https://www.fda.gov/media/70845/download,2001-03-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,,No,
Early Collaboration Meetings Under the FDA Modernization Act (FDAMA); Final Guidance for Industry and for CDRH Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/early-collaboration-meetings-under-fda-modernization-act-fdama-final-guidance-industry-and-cdrh,https://www.fda.gov/media/71676/download,2001-02-27,['Center for Devices and Radiological Health'],"['Premarket','Investigational Device Exemption (IDE)']",Final,FDA-2020-D-0957,No,
Recommendations for Collecting Red Blood Cells by Automated Apheresis Methods - Technical Correction February 2001:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-collecting-red-blood-cells-automated-apheresis-methods-technical-correction-february,https://www.fda.gov/media/72714/download,2001-02-13,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-1998-D-0851,No,
Clinical Development and Labeling of Anti-Infective Drug Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-development-and-labeling-anti-infective-drug-products,https://www.fda.gov/media/71295/download,2001-02-12,['Center for Drug Evaluation and Research'],['Clinical - Antimicrobial'],Final,None found,No,
Statistical Approaches to Establishing Bioequivalence,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-approaches-establishing-bioequivalence-0,https://www.fda.gov/media/163638/download,2001-02-01,['Center for Drug Evaluation and Research'],"['Biopharmaceutics','Generic Drugs']",Final,01D-0027,No,
PHS Guideline on Infectious Disease Issues in Xenotransplantation:  PHS Guideline,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/phs-guideline-infectious-disease-issues-xenotransplantation,https://www.fda.gov/media/73803/download,2001-01-19,['Center for Biologics Evaluation and Research'],['Xenotransplantation'],Final,FDA-1996-M-0140,No,
"Content of Investigational Device Exemptions for Solutions for Hypothermic Flushing, Transport and Storage of Organs for Transplantation - Guidance for Industry and FDA Reviewers",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-investigational-device-exemptions-solutions-hypothermic-flushing-transport-and-storage,https://www.fda.gov/media/71703/download,2001-01-15,['Center for Devices and Radiological Health'],"['Premarket','Investigational Device Exemption (IDE)']",Final,FDA-2020-D-0957,No,
Changes to an Approved NDA or ANDA: Questions and Answers:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-approved-nda-or-anda-questions-and-answers,https://www.fda.gov/media/75058/download,2001-01-01,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)']",Final,FDA-1999-D-0049,No,
Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products:  Chemical Substances,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q6a-specifications-test-procedures-and-acceptance-criteria-new-drug-substances-and-new-drug-products,,2000-12-29,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-1997-D-0005,No,
Labeling OTC Human Drug Products Using a Column Format,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-otc-human-drug-products-using-column-format,https://www.fda.gov/media/72208/download,2000-12-19,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Final,FDA-1999-D-1300,No,
E11 Clinical Investigation of Medicinal Products in the Pediatric Population,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e11-clinical-investigation-medicinal-products-pediatric-population,https://www.fda.gov/media/71355/download,2000-12-15,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['ICH-Efficacy','Pediatric Product Development']",Final,FDA-2000-D-0942,No,
Alternate Source of the Active Pharmaceutical Ingredient in Pending ANDAs:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/alternate-source-active-pharmaceutical-ingredient-pending-andas,https://www.fda.gov/media/71321/download,2000-12-01,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Generic Drugs','Pharmaceutical Quality']",Final,None found,No,
Guidance for Industry: Channels of Trade Policy for Commodities with Methyl Parathion Residues,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-channels-trade-policy-commodities-methyl-parathion-residues,,2000-11-30,['Human Foods Program'],['Pesticide'],Final,FDA-2000-D-0028,No,
Use of Sterile Connecting Devices in Blood Bank Practices:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-sterile-connecting-devices-blood-bank-practices,https://www.fda.gov/media/70656/download,2000-11-22,['Center for Biologics Evaluation and Research'],"['Application & Approvals','Blood Products']",Final,FDA-2022-D-0486,No,
Guidance Document for Dura Substitute Devices - Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-dura-substitute-devices-guidance-industry,https://www.fda.gov/media/71729/download,2000-11-08,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Submitting and Reviewing Complete Responses to Clinical Holds (Revised),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-and-reviewing-complete-responses-clinical-holds-revised,https://www.fda.gov/media/72548/download,2000-10-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Administrative / Procedural','Good Clinical Practice (GCP)']",Final,FDA-1998-D-0279,No,
"Content and Format of INDs for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products.  Questions and Answers:  Guidance for Industry Q&A",,,2000-10-01,[],"['Clinical - Medical','Pharmacology/Toxicology','Investigational New Drug Application (INDA)']",Final,None found,No,
"CPG Sec. 230.110-  Registration of Blood Banks, Other Firms Collecting, Manufacturing, Preparing or Processing Human Blood or Blood Products",,,2000-08-16,[],['Investigation & Enforcement'],Final,,No,
Labeling for Electronic Anti-Theft Systems:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-electronic-anti-theft-systems,https://www.fda.gov/media/71106/download,2000-08-15,['Center for Devices and Radiological Health'],"['Premarket','Labeling']",Final,FDA-2020-D-0957,No,
E12A Principles for Clinical Evaluation of New Antihypertensive Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e12a-principles-clinical-evaluation-new-antihypertensive-drugs,https://www.fda.gov/media/71363/download,2000-08-09,['Center for Drug Evaluation and Research'],['ICH-Efficacy'],Draft,FDA-2000-D-0785,No,
Guidance on Section 216 of the Food and Drug Administration Modernization Act of 1997 - Guidance for Industry and for FDA Reviewers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-section-216-food-and-drug-administration-modernization-act-1997-guidance-industry-and-fda,https://www.fda.gov/media/71743/download,2000-08-08,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
CPG Sec 515.700 Chocolate & Chocolate Liquor - Adulteration with Insect and Rodent Filth,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515700-chocolate-chocolate-liquor-adulteration-insect-and-rodent-filth,https://www.fda.gov/media/71809/download,2000-08-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Chocolate/Cocoa Product']",Final,,No,
Guidance for the Submission of Premarket Notifications for Photon-Emitting Brachytherapy Sources - Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-submission-premarket-notifications-photon-emitting-brachytherapy-sources-guidance-industry,https://www.fda.gov/media/71747/download,2000-08-01,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
CPG Sec. 220.100 - IS Shipment Biologicals for Medical Emergency,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-220100-shipment-biologicals-medical-emergency,,2000-07-31,[],"['Investigation & Enforcement','Investigational New Drug Application (INDA)']",Final,,No,
CPG Sec. 270.100 Final Container Labels - Allergenic Extracts Containing Glycerin; Reporting Changes,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-270100-final-container-labels-allergenic-extracts-containing-glycerin-reporting-changes,,2000-07-31,['Office of Regulatory Affairs'],"['Investigation & Enforcement','Allergenics']",Final,,No,
Guidance for Industry: Action Levels for Poisonous or Deleterious Substances in Human Food and Animal Feed,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-action-levels-poisonous-or-deleterious-substances-human-food-and-animal-feed,,2000-07-31,['Human Foods Program'],"['Animal Feed','Sanitation']",Final,FDA-2020-D-1956,No,
Guidance for Over-the-Counter (OTC) Human Chorionic Gonadotropin (hCG) 510(k)s - Guidance for Industry and FDA Reviewers/Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-over-counter-otc-human-chorionic-gonadotropin-hcg-510ks-guidance-industry-and-fda,https://www.fda.gov/media/73757/download,2000-07-21,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
1-Consolidated Annual Report for a Device product line (1-CARD) - Guidance for Industry and CDRH Reviewers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/1-consolidated-annual-report-device-product-line-1-card-guidance-industry-and-cdrh-reviewers,https://www.fda.gov/media/71752/download,2000-07-05,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Redbook 2000: IV.B.3. Pathology Considerations in Toxicity Studies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivb3-pathology-considerations-toxicity-studies,,2000-07-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Redbook 2000: IV.C.1.a. Bacterial Reverse Mutation Test,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc1a-bacterial-reverse-mutation-test,,2000-07-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Redbook 2000: IV.C.1.d. Mammalian Erythrocyte Micronucleus Test,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc1d-mammalian-erythrocyte-micronucleus-test,,2000-07-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Redbook 2000: IV.C.10. Neurotoxicity Studies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc10-neurotoxicity-studies,,2000-07-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Redbook 2000: IV.C.9.a.Guidelines for Reproduction Studies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc9aguidelines-reproduction-studies,,2000-07-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
Redbook 2000: IV.C.9.b. Guidelines for Developmental Toxicity Studies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc9b-guidelines-developmental-toxicity-studies,,2000-07-01,['Human Foods Program'],['Food & Color Additives'],Final,,No,
CPG Sec. 100.950  International Partnership Agreements for Compliance Activities,,,2000-06-28,[],['Investigation & Enforcement'],Final,,No,
CVM GFI #98  Dioxin In Anti-Caking Agents In Animal Feed And Feed Ingredients,,,2000-04-12,[],['Animal Feed'],Final,FDA-1999-D-2441,No,
Guidance for Premarket Submissions of Orthokeratology Rigid Gas Permeable Contact Lenses - Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-premarket-submissions-orthokeratology-rigid-gas-permeable-contact-lenses-guidance-industry,https://www.fda.gov/media/72074/download,2000-04-09,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Street Drug Alternatives,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/street-drug-alternatives,https://www.fda.gov/media/71027/download,2000-04-03,['Center for Drug Evaluation and Research'],['Compliance'],Final,FDA-2000-D-0783,No,
"CPG Sec. 215.100 IND Filings; Completion of Applicable Portions Prior to Final Action on License Applications or License Supplements, Deleted 03/28/2000, Outdated and Obsolete",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-215100-ind-filings-completion-applicable-portions-prior-final-action-license-applications-or,,2000-03-27,[],['Investigation & Enforcement'],Final,,No,
"Court Decisions, ANDA Approvals, and 180-Day Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/court-decisions-anda-approvals-and-180-day-exclusivity-under-hatch-waxman-amendments-federal-food,https://www.fda.gov/media/72194/download,2000-03-27,[],['Administrative / Procedural'],Final,,No,
"Guidance for Manufacturers Seeking Marketing Clearance of Ear, Nose, and Throat Endoscope Sheaths Used as Protective Barriers: Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-manufacturers-seeking-marketing-clearance-ear-nose-and-throat-endoscope-sheaths-used,https://www.fda.gov/media/71758/download,2000-03-11,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
"CPG Sec. 252.110 Volume Limits for Automated Collection of Source Plasma (Obsolete, Withdrawn on 11/28/2017)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-252110-volume-limits-automated-collection-source-plasma-obsolete-withdrawn-11282017,,2000-03-05,[],"['Investigation & Enforcement','Blood Products']",Final,,No,
CVM GFI #91 (VICH GL8) Stability Testing for Medicated Premixes,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-91-vich-gl8-stability-testing-medicated-premixes,https://www.fda.gov/media/70356/download,2000-03-01,['Center for Veterinary Medicine'],"['Animal Feed','Chemistry, Manufacturing, and Controls (CMC)','VICH']",Final,FDA-2021-D-0613,No,
Guidance for Industry on the Testing of Metallic Plasma Sprayed Coatings on Orthopedic Implants to Support Reconsideration of Postmarket Surveillance Requirements - Guidance for Industry and for FDA Reviewers/Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-testing-metallic-plasma-sprayed-coatings-orthopedic-implants-support,https://www.fda.gov/media/74184/download,2000-02-01,['Center for Devices and Radiological Health'],['Postmarket'],Final,FDA-2020-D-0957,No,
NDAs: Impurities in Drug Substances,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-impurities-drug-substances,https://www.fda.gov/media/77324/download,2000-02-01,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)']",Final,FDA-1998-D-0277,No,
"Guidance Document for Premarket Notification Submissions for Nitric Oxide Delivery Apparatus, Nitric Oxide Analyzer and Nitrogen Dioxide Analyzer:  Guidance for Industry and for FDA Reviewers",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-premarket-notification-submissions-nitric-oxide-delivery-apparatus-nitric-oxide,https://www.fda.gov/media/71766/download,2000-01-24,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-1999-D-4090,No,
Guidance for the Content of Premarket Notifications for Penile Rigidity Implants - Guidance for Industry and for FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-premarket-notifications-penile-rigidity-implants-guidance-industry-and-fda-staff,https://www.fda.gov/media/71772/download,2000-01-15,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2020-D-0957,No,
Guidance Document for the Preparation of IDEs for Spinal Systems - Guidance for Industry and/or FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-preparation-ides-spinal-systems-guidance-industry-andor-fda-staff,https://www.fda.gov/media/71777/download,2000-01-12,['Center for Devices and Radiological Health'],"['Labeling','Pediatric Product Development']",Final,FDA-2020-D-0957,No,
Content and Format of Premarket Notification [510(k)] Submissions for Liquid Chemical Sterilants/High Level Disinfectants - Guidance for Industry and FDA Reviewers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-format-premarket-notification-510k-submissions-liquid-chemical-sterilantshigh-level,https://www.fda.gov/media/72097/download,2000-01-02,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2020-D-0957,No,
"Disclosure of Materials Provided to Advisory Committees in Connection with Open Advisory Committee Meetings Convened by the Center for Drug Evaluation and Research Beginning on January 1, 2000",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/disclosure-materials-provided-advisory-committees-connection-open-advisory-committee-meetings,https://www.fda.gov/media/72201/download,1999-12-22,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,,No,
Applications Covered by Section 505(b)(2),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applications-covered-section-505b2,https://www.fda.gov/media/72419/download,1999-12-08,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Draft,FDA-1999-D-0738,No,
Guidance for Industry: Seafood HACCP Transition Guidance,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-seafood-haccp-transition-guidance,,1999-12-01,['Human Foods Program'],"['HACCP','Seafood/Seafood Product']",Final,FDA-1999-D-3543,No,
Drug Master Files for Bulk Antibiotic Drug Substances:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-master-files-bulk-antibiotic-drug-substances,https://www.fda.gov/media/70803/download,1999-11-29,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-1999-D-1314,No,
Guidance for Cardiovascular Intravascular Filter 510(k) Submissions - Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-cardiovascular-intravascular-filter-510k-submissions-guidance-industry-and-fda-staff,,1999-11-25,['Center for Devices and Radiological Health'],"['Premarket','Cardiovascular']",Final,FDA-2020-D-0957,No,
Providing Regulatory Submissions to the Center for Biologics Evaluation and Research (CBER) in Electronic Format - Biologics Marketing Applications:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-center-biologics-evaluation-and-research-cber-electronic-format,https://www.fda.gov/media/77755/download,1999-11-01,['Center for Biologics Evaluation and Research'],['Administrative / Procedural'],Final,FDA-1998-D-0850,No,
Submission of Abbreviated Reports and Synopses in Support of Marketing Applications.,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-abbreviated-reports-and-synopses-support-marketing-applications,https://www.fda.gov/media/71125/download,1999-09-13,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Final,FDA-1998-D-0141,No,
CVM GFI #74 (VICH GL4 ) Stability Testing of New Veterinary Dosage Forms,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-74-vich-gl4-stability-testing-new-veterinary-dosage-forms,https://www.fda.gov/media/70255/download,1999-09-01,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)','VICH']",Final,FDA -2006-D-0299,No,
CVM GFI #75 (VICH GL5) Stability Testing-Photostability Testing of New Veterinary Drug Substances and Medicinal Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-75-vich-gl5-stability-testing-photostability-testing-new-veterinary-drug-substances-and,https://www.fda.gov/media/70262/download,1999-09-01,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)','VICH']",Final,FDA-1998-D-1165,No,
Possible Dioxin/PCB Contamination of Drug and Biological Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/possible-dioxinpcb-contamination-drug-and-biological-products,https://www.fda.gov/media/71015/download,1999-08-23,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Center for Veterinary Medicine']","['Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,,No,
Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q6b-specifications-test-procedures-and-acceptance-criteria-biotechnologicalbiological-products,https://www.fda.gov/media/71510/download,1999-08-18,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-1998-D-0003,No,
Consumer-Directed Broadcast Advertisements:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/consumer-directed-broadcast-advertisements,https://www.fda.gov/media/75406/download,1999-08-01,"['Center for Veterinary Medicine','Center for Drug Evaluation and Research']",['Advertising'],Final,FDA-1997-D-0048,No,
CPG Sec. 230.140 Evaluation and Processing Post Donation Information Reports is obsolete and was withdrawn on 7/16/2018.,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-230140-evaluation-and-processing-post-donation-information-reports-obsolete-and-was,https://www.fda.gov/media/71746/download,1999-07-09,[],"['Investigation & Enforcement','Blood Products']",Final,,No,
Container Closure Systems for Packaging Human Drugs and Biologics:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/container-closure-systems-packaging-human-drugs-and-biologics,https://www.fda.gov/media/70788/download,1999-07-07,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-1997-D-0145,No,
Guidance for Industry: Antimicrobial Food Additives,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-antimicrobial-food-additives,,1999-06-30,['Human Foods Program'],"['Food & Color Additives','Ingredients']",Final,FDA-1999-D-1298,No,
S4A Duration of Chronic Toxicity Testing in Animals (Rodent and Nonrodent Toxicity Testing),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s4a-duration-chronic-toxicity-testing-animals-rodent-and-nonrodent-toxicity-testing,https://www.fda.gov/media/72003/download,1999-06-25,['Center for Drug Evaluation and Research'],['ICH-Safety'],Final,FDA-1997-D-0153,No,
"Guidance Document for Powered Muscle Stimulator 510(k)s - Guidance for Industry, FDA Reviewers/Staff and Compliance",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-powered-muscle-stimulator-510ks-guidance-industry-fda-reviewersstaff-and,https://www.fda.gov/media/71804/download,1999-06-08,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Fees-Exceed-the-Costs Waivers Under the Prescription Drug User Fee Act,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fees-exceed-costs-waivers-under-prescription-drug-user-fee-act,https://www.fda.gov/media/72352/download,1999-06-01,['Center for Drug Evaluation and Research'],['User Fees'],Final,,No,
Efficacy Studies to Support Marketing of Fibrin Sealant Products Manufactured for Commercial Use:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/efficacy-studies-support-marketing-fibrin-sealant-products-manufactured-commercial-use,https://www.fda.gov/media/72283/download,1999-05-20,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-1997-D-0186,No,
"For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Blood and Blood Components Intended for Transfusion or for Further Manufacture and For the Completion of the Form FDA 356h:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-chemistry-manufacturing-and-controls-and-establishment-description-information-human,https://www.fda.gov/media/124371/download,1999-05-10,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-1998-D-0995,No,1999-05-10
Recommended Clinical Study Design for Ventricular Tachycardia Ablation,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommended-clinical-study-design-ventricular-tachycardia-ablation,https://www.fda.gov/media/72128/download,1999-05-07,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Immunotoxicity Testing Guidance,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunotoxicity-testing-guidance,,1999-05-05,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
"CPG Sec. 210.100 Deleted 4/26/99,  Outdated and Obsolete",,,1999-04-25,[],['Investigation & Enforcement'],Final,,No,
"On the Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for an Allergenic Extract or Allergen Patch Test:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-format-chemistry-manufacturing-and-controls-information-and-establishment-description,https://www.fda.gov/media/124400/download,1999-04-23,['Center for Biologics Evaluation and Research'],['Allergenics'],Final,FDA-1998-D-1277,No,
Preparing Notices of Availability of Investigational Medical Devices and for Recruiting Study Subjects:  Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/preparing-notices-availability-investigational-medical-devices-and-recruiting-study-subjects,https://www.fda.gov/media/71657/download,1999-03-19,['Center for Devices and Radiological Health'],"['Premarket','Investigational Device Exemption (IDE)']",Final,FDA-2020-D-0957,No,
"Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for a Biological In Vitro Diagnostic Product:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-format-chemistry-manufacturing-and-controls-information-and-establishment-description-0,https://www.fda.gov/media/124394/download,1999-03-08,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-1998-D-0689,No,
Guidance on 510(k) Submissions for Keratoprostheses - Guidance for Industry and for FDA Reviewers/Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-510k-submissions-keratoprostheses-guidance-industry-and-fda-reviewersstaff,https://www.fda.gov/media/71810/download,1999-03-02,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Guidance for Dermabrasion Devices - Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-dermabrasion-devices-guidance-industry,https://www.fda.gov/media/71819/download,1999-03-01,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Guidance for the Preparation of a Premarket Notification Application for a Surgical Mesh - Guidance for Industry and/or for FDA Reviewers/Staff and/or Compliance,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-preparation-premarket-notification-application-surgical-mesh-guidance-industry-andor-fda,https://www.fda.gov/media/71828/download,1999-03-01,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
"Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-development-programs-drugs-devices-and-biological-products-treatment-rheumatoid-arthritis,https://www.fda.gov/media/71145/download,1999-02-17,"['Center for Drug Evaluation and Research','Center for Devices and Radiological Health','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Final,FDA-1996-D-0004,No,
"For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Plasma-Derived Biological Products, Animal Plasma or Serum-Derived Products:  Guidance for Industry:",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-chemistry-manufacturing-and-controls-and-establishment-description-information-human-0,https://www.fda.gov/media/124397/download,1999-02-17,['Center for Biologics Evaluation and Research'],['Blood Products'],Final,FDA-1998-D-0405,No,
Providing Regulatory Submissions in Electronic Format; General Considerations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-general-considerations,https://www.fda.gov/media/71200/download,1999-01-28,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Electronic Submissions'],Final,,No,
Premarket Notification [510(k)] Submissions for Testing for Skin Sensitization To Chemicals In Natural Rubber Products - Guidance for Industry and FDA Reviewers/Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-notification-510k-submissions-testing-skin-sensitization-chemicals-natural-rubber-products,https://www.fda.gov/media/71835/download,1999-01-12,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
"Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for a Vaccine or Related Product:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-format-chemistry-manufacturing-and-controls-information-and-establishment-description-1,https://www.fda.gov/media/73614/download,1999-01-05,['Center for Biologics Evaluation and Research'],['Vaccines'],Final,FDA-1998-D-0854,No,
"Small Entity Compliance Guide: Statement of Identity, Nutrition Labeling and Ingredient Labeling of Dietary Supplements",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-statement-identity-nutrition-labeling-and-ingredient-labeling-dietary,,1999-01-03,['Human Foods Program'],['Labeling'],Final,FDA-2020-D-1959,No,
Guidance for Industry: Questions and Answers on HACCP Regulation for Fish and Fishery Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-haccp-regulation-fish-and-fishery-products,,1999-01-01,['Human Foods Program'],"['HACCP','Seafood/Seafood Product']",Final,FDA-2020-D-1960,No,
"CPG Sec. 205.100 Deleted 12/21/98, Obsolete",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-205100-deleted-122198-obsolete,,1998-12-20,[],['Investigation & Enforcement'],Final,,No,
Guidance for the Submission of Premarket Notifications for Emission Computed Tomography Devices and Accessories (SPECT and PET) and Nuclear Tomography Systems :  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-submission-premarket-notifications-emission-computed-tomography-devices-and-accessories,https://www.fda.gov/media/71845/download,1998-12-02,['Center for Devices and Radiological Health'],"['Premarket','Radiology']",Final,FDA-2020-D-0957,No,
FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-approval-new-cancer-treatment-uses-marketed-drug-and-biological-products,https://www.fda.gov/media/71396/download,1998-12-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Final,,No,
Variations in Drug Products that May Be Included in a Single ANDA,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/variations-drug-products-may-be-included-single-anda,https://www.fda.gov/media/71497/download,1998-12-01,['Center for Drug Evaluation and Research'],['Generic Drugs'],Final,FDA-2021-D-0385,No,
Guidance for the Submission of Premarket Notifications For Radionuclide Dose Calibrators - Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-submission-premarket-notifications-radionuclide-dose-calibrators-guidance-industry,https://www.fda.gov/media/71864/download,1998-11-19,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Non-Automated Sphygmomanometer (Blood Pressure Cuff) Guidance - Version 1 - Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-automated-sphygmomanometer-blood-pressure-cuff-guidance-version-1-guidance-industry,https://www.fda.gov/media/71873/download,1998-11-18,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Aqueous Shunts - 510(k) Submissions - Guidance for Industry and for FDA Reviewers/Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/aqueous-shunts-510k-submissions-guidance-industry-and-fda-reviewersstaff,https://www.fda.gov/media/71885/download,1998-11-15,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
CPG Sec. 675.400 Rendered Animal Feed Ingredients (Withdrawn 4/30/2019),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-675400-rendered-animal-feed-ingredients-withdrawn-4302019,,1998-11-12,"['Center for Veterinary Medicine','Office of Regulatory Affairs']","['Investigation & Enforcement','Animal Feed']",Final,,No,
Protection of Human Subjects: Categories of Research That May Be Reviewed by the Institutional Review Board (IRB) Through an Expedited Review Procedure:  Guidance for Institutional Review Boards and Clinical Investigators,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/protection-human-subjects-categories-research-may-be-reviewed-institutional-review-board-irb-through,https://www.fda.gov/media/144917/download,1998-11-09,['Office of the Commissioner'],"['Clinical Trials','Good Clinical Practice (GCP)']",Final,FDA-1997-N-0257,No,1998-03-10
FDA Animal Products Database Data Entry Form,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-animal-products-database-data-entry-form,https://www.fda.gov/media/71910/download,1998-11-06,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Cardiac Monitor Guidance (including Cardiotachometer and Rate Alarm) - Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cardiac-monitor-guidance-including-cardiotachometer-and-rate-alarm-guidance-industry,https://www.fda.gov/media/71947/download,1998-11-04,['Center for Devices and Radiological Health'],"['Premarket','Cardiovascular']",Final,FDA-2020-D-0957,No,
Diagnostic ECG Guidance (Including Non-Alarming ST Segment Measurement) - Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diagnostic-ecg-guidance-including-non-alarming-st-segment-measurement-guidance-industry,https://www.fda.gov/media/71957/download,1998-11-04,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
General/Specific Intended Use - Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/generalspecific-intended-use-guidance-industry,https://www.fda.gov/media/71966/download,1998-11-03,['Center for Devices and Radiological Health'],"['Premarket','Pediatric Product Development']",Final,FDA-2020-D-0957,No,
Guidance for Industry: Guide to Minimize Microbial Food Safety Hazards for Fresh Fruits and Vegetables,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-guide-minimize-microbial-food-safety-hazards-fresh-fruits-and-vegetables,https://www.fda.gov/media/117408/download,1998-10-25,['Human Foods Program'],"['Fruit/Fruit Product','Vegetable Products']",Final,FDA-1997-N-0152,No,
Noise Claims in Hearing Aid Labeling - Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/noise-claims-hearing-aid-labeling-guidance-industry,https://www.fda.gov/media/71982/download,1998-10-20,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Guidance Document For Nonprescription Sunglasses - Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-nonprescription-sunglasses-guidance-industry,https://www.fda.gov/media/71989/download,1998-10-08,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Submitting Debarment Certification Statements,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-debarment-certification-statements,https://www.fda.gov/media/72557/download,1998-10-02,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research','Center for Veterinary Medicine']",['Administrative / Procedural'],Draft,FDA-1998-D-0556,No,
Implementation of Section 120 of the Food and Drug Administration Modernization Act of 1997-Advisory Committees,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/implementation-section-120-food-and-drug-administration-modernization-act-1997-advisory-committees,https://www.fda.gov/media/72297/download,1998-10-01,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,,No,
Guidance Document for Powered Suction Pump 510(k)s - Guidance for Industry and FDA Reviewers/Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-powered-suction-pump-510ks-guidance-industry-and-fda-reviewersstaff,https://www.fda.gov/media/71745/download,1998-09-29,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
CPG Sec. 615.100  Extralabel Use of New Animal Drugs in Food Producing Animals - Revoked on 09/24/1998 (63 FR 51074),,,1998-09-24,[],"['Investigation & Enforcement','Animal Drugs']",Final,,No,
Q5D Quality of Biotechnological/Biological Products: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products; Availability,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q5d-quality-biotechnologicalbiological-products-derivation-and-characterization-cell-substrates-used,https://www.fda.gov/media/71463/download,1998-09-21,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-1997-D-0098,No,
E9 Statistical Principles for Clinical Trials,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e9-statistical-principles-clinical-trials,https://www.fda.gov/media/71336/download,1998-09-16,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Efficacy'],Final,FDA-1997-D-0508,No,
How to Complete the Vaccine Adverse Event Reporting System Form (VAERS-1):  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/how-complete-vaccine-adverse-event-reporting-system-form-vaers-1,https://www.fda.gov/media/76517/download,1998-09-09,['Center for Biologics Evaluation and Research'],['Vaccines'],Final,FDA-2022-D-0487,No,
"OTC Denture Cushions, Pads, Reliners, Repair Kits, and Partially Fabricated Denture Kits - Guidance for Industry and FDA Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/otc-denture-cushions-pads-reliners-repair-kits-and-partially-fabricated-denture-kits-guidance,https://www.fda.gov/media/72467/download,1998-08-17,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2017-P-5124,No,
Accidental Radioactive Contamination of Human Food and Animal Feeds:  Recommendations for State and Local Agencies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/accidental-radioactive-contamination-human-food-and-animal-feeds,https://www.fda.gov/media/74043/download,1998-08-13,['Center for Devices and Radiological Health'],['Radiological Health'],Final,FDA-2020-D-0957,No,
Revised Procedures for Adding Lens Finishing Laboratories to Approved Premarket Approval Applications for Class III Rigid Gas Permeable Contact Lenses for Extended Wear - Guidance for Industry and FDA Staff,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/revised-procedures-adding-lens-finishing-laboratories-approved-premarket-approval-applications-class,https://www.fda.gov/media/72479/download,1998-08-10,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Environmental Assessment of Human Drug and Biologics Applications:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/environmental-assessment-human-drug-and-biologics-applications,https://www.fda.gov/media/70809/download,1998-07-27,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-1998-D-0278,No,
Latex Condoms for Men - Information for 510(k) Premarket Notifications: Use of Consensus Standards for Abbreviated Submissions:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/latex-condoms-men-information-510k-premarket-notifications-use-consensus-standards-abbreviated,https://www.fda.gov/media/72943/download,1998-07-23,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2020-D-0957,No,
Uniform Contraceptive Labeling - Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/uniform-contraceptive-labeling-guidance-industry,https://www.fda.gov/media/72591/download,1998-07-22,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Women and Minorities Guidance Requirements,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/women-and-minorities-guidance-requirements,https://www.fda.gov/media/72599/download,1998-07-20,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,,No,
Slit Lamp Guidance - Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/slit-lamp-guidance-guidance-industry,https://www.fda.gov/media/72617/download,1998-07-07,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
CVM GFI #76 Questions and Answers BSE Feed Regulations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-76-questions-and-answers-bse-feed-regulations,https://www.fda.gov/media/70270/download,1998-07-01,['Center for Veterinary Medicine'],"['Bovine Spongiform Encephalopathy (BSE)','Current Good Manufacturing Practice (CGMP)']",Final,,No,
"Repeal of Section 507 of the Federal Food, Drug and Cosmetic Act _1",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/repeal-section-507-federal-food-drug-and-cosmetic-act-_1,https://www.fda.gov/media/72530/download,1998-06-15,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-1998-D-0864,No,
Guidance for Industry: Notification of a Health Claim or Nutrient Content Claim Based on an Authoritative Statement of a Scientific Body,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-notification-health-claim-or-nutrient-content-claim-based-authoritative-statement,,1998-06-11,['Human Foods Program'],['Labeling'],Final,FDA-1998-D-0102,No,
E5 Ethnic Factors in the Acceptability of Foreign Clinical Data,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e5-ethnic-factors-acceptability-foreign-clinical-data,https://www.fda.gov/media/71287/download,1998-06-10,['Center for Drug Evaluation and Research'],['ICH-Efficacy'],Final,FDA-1997-D-0360,No,
Guidance Document For Washers And Washer-Disinfectors Intended For Processing Reusable Medical Devices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-washers-and-washer-disinfectors-intended-processing-reusable-medical-devices,,1998-06-01,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
"180-Day Generic Drug Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/180-day-generic-drug-exclusivity-under-hatch-waxman-amendments-federal-food-drug-and-cosmetic-act,https://www.fda.gov/media/72414/download,1998-06-01,['Center for Drug Evaluation and Research'],"['Administrative / Procedural','Generic Drugs']",Final,FDA-1998-D-101c,No,
"Supplements to Approved Applications for Class III Medical Devices: Use of Published Literature, Use of Previously Submitted Materials, and Priority Review :  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supplements-approved-applications-class-iii-medical-devices-use-published-literature-use-previously,,1998-05-19,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products.,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-clinical-evidence-effectiveness-human-drug-and-biological-products,https://www.fda.gov/media/71655/download,1998-05-15,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Final,FDA-1997-D-0027,No,
CVM GFI #72 GMP'S For Medicated Feed Manufacturers Not Required to Register and be Licensed with FDA,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-72-gmps-medicated-feed-manufacturers-not-required-register-and-be-licensed-fda,https://www.fda.gov/media/70235/download,1998-05-01,['Center for Veterinary Medicine'],"['Animal Feed','Current Good Manufacturing Practice (CGMP)']",Final,,No,
"Standards for the Prompt Review of Efficacy Supplements, Including Priority Efficacy Supplements :  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/standards-prompt-review-efficacy-supplements-including-priority-efficacy-supplements,https://www.fda.gov/media/72048/download,1998-05-01,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Administrative / Procedural'],Final,98-0276,No,
PAC-ATLS: Postapproval Changes - Analytical Testing Laboratory Sites:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pac-atls-postapproval-changes-analytical-testing-laboratory-sites,https://www.fda.gov/media/70885/download,1998-04-28,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-1998-D-1157,No,
Guidance For The Content Of Premarket Notifications For Esophageal And Tracheal Prostheses - Guidance For Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-premarket-notifications-esophageal-and-tracheal-prostheses-guidance-industry,https://www.fda.gov/media/72632/download,1998-04-27,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
National Uniformity for Nonpresciption Drugs - Ingredient Listing for OTC Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/national-uniformity-nonpresciption-drugs-ingredient-listing-otc-drugs,https://www.fda.gov/media/72250/download,1998-04-09,['Center for Drug Evaluation and Research'],['Administrative / Procedural'],Final,FDA-1998-D-1007,No,
Q3C: Appendix 5,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q3c-appendix-5,https://www.fda.gov/media/71186/download,1998-03-18,['Center for Drug Evaluation and Research'],['ICH-Quality'],Final,None found,No,
Q3C: Appendix 4,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q3c-appendix-4,https://www.fda.gov/media/71738/download,1998-03-18,['Center for Drug Evaluation and Research'],['ICH-Quality'],Draft,,No,
Q3C: Appendix 6,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q3c-appendix-6,https://www.fda.gov/media/71194/download,1998-03-18,['Center for Drug Evaluation and Research'],['ICH-Quality'],Draft,,No,
Local Anesthetics--Clinical Evaluation,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/local-anesthetics-clinical-evaluation,,1998-03-02,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,,No,
FDA Requirements for Approval of Drugs to Treat Non-Small Cell Lung Cancer,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-requirements-approval-drugs-treat-non-small-cell-lung-cancer,https://www.fda.gov/media/71407/download,1998-03-02,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,,No,
Good Laboratory Practice Regulations Questions and Answers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-laboratory-practice-regulations-questions-and-answers,https://www.fda.gov/media/70993/download,1998-03-02,['Center for Drug Evaluation and Research'],"['Compliance','Current Good Manufacturing Practice (CGMP)']",Final,,No,
Guidance for the Development of Vaginal Contraceptive Drugs (NDA),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-development-vaginal-contraceptive-drugs-nda,https://www.fda.gov/media/71584/download,1998-03-02,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,,No,
Oncologic Drugs Advisory Committee Discussion on FDA Requirements or Approval of New Drugs for Treatment of Colon and Rectal Cancer,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/oncologic-drugs-advisory-committee-discussion-fda-requirements-or-approval-new-drugs-treatment-colon,https://www.fda.gov/media/71617/download,1998-03-02,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,,No,
Psychoactive Drugs in Infants and Children--Clinical Evaluation,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychoactive-drugs-infants-and-children-clinical-evaluation,https://www.fda.gov/media/71089/download,1998-03-02,['Center for Drug Evaluation and Research'],"['Clinical - Medical','Pediatric Product Development']",Final,,No,
Reference Guide for the Nonclinical Toxicity Studies of Antivial Drugs Indicated for the Treatment of N/A Non-Life Threatening Disease Evaluation of Drug Toxicity Prior to Phase I Clinical Studies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reference-guide-nonclinical-toxicity-studies-antivial-drugs-indicated-treatment-na-non-life,https://www.fda.gov/media/72272/download,1998-03-02,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Final,,No,
"Supplement to 10/11/1984 letter about policies, procedures and implementation of the Act (Q&A format)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supplement-10111984-letter-about-policies-procedures-and-implementation-act-qa-format,https://www.fda.gov/media/72106/download,1998-03-02,['Center for Drug Evaluation and Research'],['Generic Drugs'],Final,,No,
Third of a series of letters regarding the implementation of the Act,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/third-series-letters-regarding-implementation-act,https://www.fda.gov/media/116580/download,1998-03-02,['Center for Drug Evaluation and Research'],['Generic Drugs'],Final,FDA-2011-D-0595,No,
Guidance for Industry: Guide for Developing and Using Data Bases for Nutrition Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-guide-developing-and-using-data-bases-nutrition-labeling,,1998-03-01,['Human Foods Program'],"['Labeling','Nutrition Label']",Final,FDA-2020-D-1961,No,
Guidance for Human Somatic Cell Therapy and Gene Therapy:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-human-somatic-cell-therapy-and-gene-therapy,https://www.fda.gov/media/72402/download,1998-03-01,['Center for Biologics Evaluation and Research'],"['Cellular & Gene Therapy','Gene Therapy']",Final,FDA-2009-D-0132-0016,No,
S1B Testing for Carcinogenicity of Pharmaceuticals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s1br1-addendum-s1b-testing-carcinogenicity-pharmaceuticals,https://www.fda.gov/media/152777/download,1998-02-23,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Safety'],Final,FDA-1996-D-0010,No,
Guidance on PMA Interactive Procedures for Day-100 Meetings and Subsequent Deficiencies - for Use by CDRH and Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-pma-interactive-procedures-day-100-meetings-and-subsequent-deficiencies-use-cdrh-and,https://www.fda.gov/media/72655/download,1998-02-18,['Center for Devices and Radiological Health'],"['Premarket','Administrative / Procedural','Premarket Approval (PMA)']",Final,FDA-2020-D-0957,No,
"Procedures for Class II Device Exemptions from Premarket Notification, Guidance for Industry and CDRH Staff",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/procedures-class-ii-device-exemptions-premarket-notification-guidance-industry-and-cdrh-staff,https://www.fda.gov/media/72685/download,1998-02-18,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2017-N-1129,No,
CVM GFI #67 Small Entities Compliance Guide for Renderers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-67-small-entities-compliance-guide-renderers,https://www.fda.gov/media/70197/download,1998-02-01,['Center for Veterinary Medicine'],"['Bovine Spongiform Encephalopathy (BSE)','Current Good Manufacturing Practice (CGMP)']",Final,,No,
"CVM GFI #68  Small Entities Compliance Guide for Protein Blenders, Feed Manufacturers, and Distributors",,,1998-02-01,[],"['Bovine Spongiform Encephalopathy (BSE)','Current Good Manufacturing Practice (CGMP)']",Final,,No,
CVM GFI #69  Small Entities Compliance Guide for Feeders of Ruminant Animals with On-Farm Feed Mixing Operations,,,1998-02-01,[],"['Bovine Spongiform Encephalopathy (BSE)','Animal Feed']",Final,,No,
Cooperative Research:  Guidance for Institutional Review Boards and Clinical Investigators,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cooperative-research,,1998-01-01,['Office of the Commissioner'],['Good Clinical Practice (GCP)'],Final,,No,
Emergency Use of an Investigational Drug or Biologic:  Guidance for Institutional Review Boards and Clinical Investigators,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-investigational-drug-or-biologic,,1998-01-01,['Office of the Commissioner'],['Good Clinical Practice (GCP)'],Final,,No,
Evaluation of Gender Differences in Clinical Investigations:  Guidance for Institutional Review Boards and Clinical Investigators,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-gender-differences-clinical-investigations,,1998-01-01,['Office of the Commissioner'],['Good Clinical Practice (GCP)'],Final,,No,
Institutional Review Boards Frequently Asked Questions:  Guidance for Institutional Review Boards and Clinical Investigators,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/institutional-review-boards-frequently-asked-questions,,1998-01-01,['Office of the Commissioner'],"['Good Clinical Practice (GCP)','Pediatric Product Development']",Final,,No,
Non-local IRB Review :  Guidance for Institutional Review Boards and Clinical Investigators,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-local-irb-review,,1998-01-01,['Office of the Commissioner'],['Good Clinical Practice (GCP)'],Final,,No,
Recruiting Study Subjects:  Guidance for Institutional Review Boards and Clinical Investigators,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recruiting-study-subjects,,1998-01-01,['Office of the Commissioner'],['Good Clinical Practice (GCP)'],Final,,No,
Screening Tests Prior to Study Enrollment:  Guidance for Institutional Review Boards and Clinical Investigators,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/screening-tests-prior-study-enrollment,,1998-01-01,['Office of the Commissioner'],['Good Clinical Practice (GCP)'],Final,,No,
Sponsor - Investigator - IRB Interrelationship:  Guidance for Institutional Review Boards and Clinical Investigators,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sponsor-investigator-irb-interrelationship,,1998-01-01,['Office of the Commissioner'],['Good Clinical Practice (GCP)'],Final,,No,
Use of Investigational Products When Subjects Enter a Second Institution:  Guidance for Institutional Review Boards and Clinical Investigators,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-investigational-products-when-subjects-enter-second-institution,,1998-01-01,['Office of the Commissioner'],['Good Clinical Practice (GCP)'],Final,,No,
Q3C Impurities: Residual Solvents_2011,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q3c-impurities-residual-solvents_2011,https://www.fda.gov/media/71736/download,1997-12-24,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-1997-D-0381,No,
Industry-Supported Scientific and Educational Activites,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/industry-supported-scientific-and-educational-activites,https://www.fda.gov/media/70844/download,1997-12-03,['Office of the Commissioner'],"['Administrative / Procedural','Advertising']",Final,92N-0434,No,
S2B Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s2b-genotoxicity-standard-battery-genotoxicity-testing-pharmaceuticals,https://www.fda.gov/media/71971/download,1997-11-21,['Center for Drug Evaluation and Research'],['ICH-Safety'],Final,FDA-1997-D-0199,No,
Direct Final Rule Procedures:  Guidance for FDA and Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/direct-final-rule-procedures,,1997-11-20,['Office of the Commissioner'],['Administrative / Procedural'],Final,,No,
S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s6-preclinical-safety-evaluation-biotechnology-derived-pharmaceuticals,https://www.fda.gov/media/72028/download,1997-11-18,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['ICH-Safety'],Final,FDA-1997-D-0265,No,
Industry Supported Scientific and Educational Activities:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/industry-supported-scientific-and-educational-activities,https://www.fda.gov/media/75334/download,1997-11-01,"['Office of the Commissioner','Center for Veterinary Medicine']",['Administrative / Procedural'],Final,FDA-1992-N-0007,No,
"SUPAC-MR: Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supac-mr-modified-release-solid-oral-dosage-forms-scale-and-postapproval-changes-chemistry,https://www.fda.gov/media/70956/download,1997-10-06,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-1997-D-0507,No,
Guidance for Industry: Consultation Procedures under FDA's 1992 Statement of Policy for Foods Derived from New Plant Varieties,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-consultation-procedures-under-fdas-1992-statement-policy-foods-derived-new-plant,,1997-10-01,['Human Foods Program'],,Final,,No,
"Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/extended-release-oral-dosage-forms-development-evaluation-and-application-vitroin-in-vivo-correlations,https://www.fda.gov/media/70939/download,1997-09-01,['Center for Drug Evaluation and Research'],['Biopharmaceutics'],Final,,No,
Postmarketing Adverse Experience Reporting for Human Drug and Licensed Biological Products: Clarification of What to Report,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-adverse-experience-reporting-human-drug-and-licensed-biological-products-clarification,https://www.fda.gov/media/71635/download,1997-08-27,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['Clinical - Medical'],Final,FDA-1997-D-0445,No,
Dissolution Testing of Immediate Release Solid Oral Dosage Forms,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dissolution-testing-immediate-release-solid-oral-dosage-forms,https://www.fda.gov/media/70936/download,1997-08-25,['Center for Drug Evaluation and Research'],['Biopharmaceutics'],Final,FDA-1997-D-0187,No,
Expiration Dating and Stability Testing of Solid Oral Dosage Form Drugs Containing Iron:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expiration-dating-and-stability-testing-solid-oral-dosage-form-drugs-containing-iron,https://www.fda.gov/media/70979/download,1997-07-09,['Center for Drug Evaluation and Research'],"['Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,FDA-1997-D-0489,No,
Changes to an Approved Application for Specified Biotechnology and Specified Synthetic Biological Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-approved-application-specified-biotechnology-and-specified-synthetic-biological-products,https://www.fda.gov/media/75318/download,1997-07-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-1995-D-0101,No,
Kit Certification for 510(k)s,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/kit-certification-510ks,,1997-06-30,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Convenience Kits Interim Regulatory Guidance,#ERROR!,https://www.fda.gov/media/72720/download,1997-05-19,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Q2B Validation of Analytical Procedures: Methodology,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q2b-validation-analytical-procedures-methodology,https://www.fda.gov/media/71725/download,1997-05-19,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-1996-D-0169,No,
Q1C Stability Testing for New Dosage Forms,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1c-stability-testing-new-dosage-forms,https://www.fda.gov/media/71715/download,1997-05-09,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['ICH-Quality'],Final,FDA-2013-S-0610,No,
"SUPAC-SS: Nonsterile Semisolid Dosage Forms; Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supac-ss-nonsterile-semisolid-dosage-forms-scale-and-post-approval-changes-chemistry-manufacturing,https://www.fda.gov/media/71141/download,1997-05-01,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,FDA-1997-D-0380,No,
"Guidance for Industry for the Evaluation of Combination Vaccines for Preventable Diseases: Production, Testing and Clinical Studies:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-evaluation-combination-vaccines-preventable-diseases-production-testing-and,https://www.fda.gov/media/77191/download,1997-04-10,['Center for Biologics Evaluation and Research'],['Vaccines'],Final,FDA-1997-N-0454,No,
Design Control Guidance For Medical Device Manufacturers:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-control-guidance-medical-device-manufacturers,https://www.fda.gov/media/116573/download,1997-03-11,['Center for Devices and Radiological Health'],['Good Clinical Practice (GCP)'],Final,FDA-2020-D-0957,No,
Non-Invasive Blood Pressure (NIBP) Monitor Guidance,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-invasive-blood-pressure-nibp-monitor-guidance,,1997-03-09,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/points-consider-manufacture-and-testing-monoclonal-antibody-products-human-use,https://www.fda.gov/media/76798/download,1997-02-28,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",,Final,FDA-1994-D-0318,No,
Proposed Approach to Regulation of Cellular and Tissue-Based Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/proposed-approach-regulation-cellular-and-tissue-based-products,https://www.fda.gov/media/70704/download,1997-02-28,['Center for Biologics Evaluation and Research'],,Final,FDA-1997-N-0207,No,1997-04-17
Guidance on Labeling of Foods That Need Refrigeration by Consumers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-labeling-foods-need-refrigeration-consumers,https://www.fda.gov/media/134845/download,1997-02-24,['Human Foods Program'],['Labeling'],Final,FDA-1996-D-0012,No,
Reviewers Guidance Checklist For Orthopedic External Fixation Devices Version #5,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reviewers-guidance-checklist-orthopedic-external-fixation-devices-version-5,https://www.fda.gov/media/72733/download,1997-02-20,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
510(K) Information Needed for Hydroxyapatite Coated Orthopedic Implants,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/510k-information-needed-hydroxyapatite-coated-orthopedic-implants,,1997-02-19,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
SUPAC-IR Questions and Answers about SUPAC-IR Guidance,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supac-ir-questions-and-answers-about-supac-ir-guidance,,1997-02-18,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)']",Final,,No,
Third Party Review Guidance for Phacofragmentation System Device Premarket Notification (510(k)),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/third-party-review-guidance-phacofragmentation-system-device-premarket-notification-510k,https://www.fda.gov/media/72212/download,1997-01-31,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Third Party Review Guidance For Vitreous Aspiration and Cutting Device Premarket Notification (510(k)),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/third-party-review-guidance-vitreous-aspiration-and-cutting-device-premarket-notification-510k,,1997-01-30,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
General Considerations for the Clinical Evaluation of Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-considerations-clinical-evaluation-drugs,https://www.fda.gov/media/71495/download,1997-01-01,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,,No,
"CPG Sec 540.400 Shrimp - Fresh or Frozen, Raw, Headless, Peeled or Breaded (Revoked 12/24/96)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540400-shrimp-fresh-or-frozen-raw-headless-peeled-or-breaded-revoked-122496,,1996-12-23,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Seafood/Seafood Product']",Final,,No,
Guidance for Industry: Exports Under the FDA Export Reform and Enhancement Act of 1996 :  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-exports-under-fda-export-reform-and-enhancement-act-1996,https://www.fda.gov/media/138075/download,1996-12-01,"['Center for Veterinary Medicine','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research']",,Final,,No,
Prospective Manufacturers of Barrier Devices Used During Oral Sex for STD Protection,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prospective-manufacturers-barrier-devices-used-during-oral-sex-std-protection,https://www.fda.gov/media/74267/download,1996-10-30,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Checklist of Information Usually Submitted in an Investigational Device Exemptions (IDE) Application for Refractive Surgery Lasers [excimer],https://www.fda.gov/regulatory-information/search-fda-guidance-documents/checklist-information-usually-submitted-investigational-device-exemptions-ide-application-refractive,,1996-10-09,['Center for Devices and Radiological Health'],"['Premarket','Investigational Device Exemption (IDE)']",Final,FDA-2020-D-0957,No,
Emitted Laser Beam as Emission Indicator for Class II and Class IIIa Laser Products (Laser Notice 49),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emitted-laser-beam-emission-indicator-class-ii-and-class-iiia-laser-products-laser-notice-49,https://www.fda.gov/media/73925/download,1996-09-05,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Identification Labels for Certain Class I Laser Products (Laser Notice 48),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/identification-labels-certain-class-i-laser-products-laser-notice-48,https://www.fda.gov/media/73933/download,1996-09-05,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Single Dose Acute Toxicity Testing for Pharmaceuticals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/single-dose-acute-toxicity-testing-pharmaceuticals,https://www.fda.gov/media/72288/download,1996-08-26,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Final,FDA-1992-N-0026,No,
CPG Sec 540.100 Capelin - Prohibited from Being Labeled as Smelt (Revoked 8/23/96),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540100-capelin-prohibited-being-labeled-smelt-revoked-82396,,1996-08-22,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
CPG Sec 540.300 Crabmeat - Product Name (Revoked 8/23/96),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540300-crabmeat-product-name-revoked-82396,,1996-08-22,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
CPG Sec 540.350 Common or Usual Names for Crustaceans (Revoked 8/23/96),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540350-common-or-usual-names-crustaceans-revoked-82396,,1996-08-22,"['Office of Inspections and Investigations','Human Foods Program']",['Investigation & Enforcement'],Final,,No,
CPG Sec 110.900 Imported Products - Lack of English Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-110900-imported-products-lack-english-labeling,,1996-08-20,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Labeling']",Final,,No,
Variance from Manufacturer Report Number Format - No. 5,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/variance-manufacturer-report-number-format-no-5,,1996-08-11,['Center for Devices and Radiological Health'],['Postmarket'],Final,FDA-2020-D-0957,No,
"CPG Sec 500.300 ""Approved by FDA"" - Use of Phrase Objectionable in Marketing or Labeling of a Food Additive",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-500300-approved-fda-use-phrase-objectionable-marketing-or-labeling-food-additive,,1996-08-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Ingredients']",Final,,No,
"CPG Sec 505.400 Chow Mein Noodles, Chinese Noodles and Other Oriental Noodles (Labeling)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-505400-chow-mein-noodles-chinese-noodles-and-other-oriental-noodles-labeling,,1996-08-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Bakery Product/Mix']",Final,,No,
CPG Sec 510.450 Labeling - Diluted Wines and Cider with Less Than 7% Alcohol,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-510450-labeling-diluted-wines-and-cider-less-7-alcohol,,1996-08-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Beverage Bases/Conc/Nectar']",Final,,No,
CPG Sec 510.700 Fortification of Standardized Juices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-510700-fortification-standardized-juices,,1996-08-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Beverage Bases/Conc/Nectar']",Final,,No,
CPG Sec 515.200 Malt Extract; Malt Syrup; Malted Cereal Syrup; Liquid Malt; Dried Malt,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515200-malt-extract-malt-syrup-malted-cereal-syrup-liquid-malt-dried-malt,,1996-08-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Candy/Gum (without chocolate)']",Final,,No,
CPG Sec. 654.300  Chloramphenicol as an Unapproved New Animal Drug - Direct Reference Seizure Authority (Withdrawn 2/20/2020),,,1996-08-01,[],"['Investigation & Enforcement','Animal Drugs','Unapproved Animal Drugs']",Final,,No,
CPG Sec. 690.600  Rodent Contaminated Pet Foods - *Direct Reference  Seizure Authority* (Withdrawn 2/20/2020),,,1996-08-01,[],"['Investigation & Enforcement','Pet Food']",Final,,No,
CPG Sec 500.250 Food Additives - Labeling Directions Necessary for Safe Use:  CPG Sec 500.250 Food Additives,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-500250-food-additives-labeling-directions-necessary-safe-use,,1996-08-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Ingredients']",Final,,No,
CPG Sec 505.500 Macaroni and Noodle Products - Adulteration Involving Insect Fragments and Rodent Hairs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-505500-macaroni-and-noodle-products-adulteration-involving-insect-fragments-and-rodent-hairs,https://www.fda.gov/media/71768/download,1996-08-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Bakery Product/Mix']",Final,,No,
CPG Sec 527.200 Cheese & Cheese Products - Adulteration with Filth,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527200-cheese-cheese-products-adulteration-filth,https://www.fda.gov/media/71972/download,1996-08-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dairy']",Final,,No,
CPG Sec 585.675 Popcorn - Adulteration with Rodent Filth and Field Corn,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585675-popcorn-adulteration-rodent-filth-and-field-corn,https://www.fda.gov/media/71849/download,1996-08-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
"Guidance for Industry for the Submission of Chemistry, Manufacturing, and Controls Information for a Therapeutic Recombinant DNA-Derived Product or a Monoclonal Antibody Product for In Vivo Use",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-submission-chemistry-manufacturing-and-controls-information-therapeutic,https://www.fda.gov/media/77528/download,1996-08-01,"['Center for Biologics Evaluation and Research','Center for Drug Evaluation and Research']",['Administrative / Procedural'],Final,FDA-1996-D-0071,No,
CPG Sec 527.500 Malted Milk,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527500-malted-milk,,1996-07-31,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dairy']",Final,,No,
CPG Sec 527.600 Use of DDVP (dichlorvos) Strips in Milkhouses and Milkrooms,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527600-use-ddvp-dichlorvos-strips-milkhouses-and-milkrooms,,1996-07-31,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dairy']",Final,,No,
CPG Sec. 160.500  Answering Inquiries on Status of Criminal Referrals,,,1996-07-31,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 160.750  Drug and Device Products (Including Biologics and Animal Drugs) Found in Violation of GMPRs - Reconditioning,,,1996-07-31,[],['Investigation & Enforcement'],Final,,No,
"Recommendations for the Quarantine and Disposition of Units from Prior Collections from Donors with Repeatedly Reactive Screening Tests for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human T-Lymphotropic Virus Type I (HTLV-I)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-quarantine-and-disposition-units-prior-collections-donors-repeatedly-reactive,https://www.fda.gov/media/70701/download,1996-07-19,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2022-D-0497,No,
Variance from Manufacturer Report Number Format [MDR letter],https://www.fda.gov/regulatory-information/search-fda-guidance-documents/variance-manufacturer-report-number-format-mdr-letter,,1996-07-15,['Center for Devices and Radiological Health'],['Adverse Event Reporting System (FAERS)'],Final,FDA-2020-D-0957,No,
E3 Structure and Content of Clinical Study Reports,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e3-structure-and-content-clinical-study-reports-questions-and-answers-r1,https://www.fda.gov/media/84857/download,1996-07-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Efficacy'],Final,FDA-1995-D-0201,No,
E4 Dose-Response Information to Support Drug Registration,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e4-dose-response-information-support-drug-registration,https://www.fda.gov/media/71279/download,1996-07-01,['Center for Drug Evaluation and Research'],['ICH-Efficacy'],Final,FDA-1993-D-0183,No,
Q5C Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q5c-quality-biotechnological-products-stability-testing-biotechnologicalbiological-products,https://www.fda.gov/media/71441/download,1996-07-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,,No,
Effective Visual Control of Laser Projections (Laser Notice 47),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/effective-visual-control-laser-projections-laser-notice-47,https://www.fda.gov/media/73939/download,1996-06-06,['Center for Devices and Radiological Health'],['Radiological Health'],Final,FDA-2020-D-0957,No,
Suggested Format For IDE Progress Report,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/suggested-format-ide-progress-report,,1996-05-31,['Center for Devices and Radiological Health'],"['Premarket','Investigational Device Exemption (IDE)']",Final,FDA-2020-D-0957,No,
"Additional Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV):  Memorandum to Registered Blood and Plasma Establishments",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/additional-recommendations-testing-whole-blood-blood-components-source-plasma-and-source-leukocytes,https://www.fda.gov/media/70714/download,1996-05-16,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2022-D-0498,No,
S2A Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s2a-specific-aspects-regulatory-genotoxicity-tests-pharmaceuticals,https://www.fda.gov/media/71959/download,1996-04-24,['Center for Drug Evaluation and Research'],['ICH-Safety'],Final,FDA-1994-D-0134,No,
CVM GFI #49 Target Animal Safety And Drug Effectiveness Studies for Anti-Microbial Bovine Mastitis Products (Lactating and Non-Lactating Cow Products),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-49-target-animal-safety-and-drug-effectiveness-studies-anti-microbial-bovine-mastitis,,1996-04-03,['Center for Veterinary Medicine'],"['Target Animal – Effectiveness','Target Animal – Safety']",Final,FDA-1993-D-0285,No,
Medical Device Reporting for User Facilities,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-device-reporting-user-facilities,https://www.fda.gov/media/73972/download,1996-04-01,['Center for Devices and Radiological Health'],['Radiological Health'],Final,FDA-2020-D-0957,No,
"Demonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnology-derived Products",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/demonstration-comparability-human-biological-products-including-therapeutic-biotechnology-derived,,1996-03-31,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,,No,
Additional Recommendations for Donor Screening With a Licensed Test for HIV-1 Antigen:  Memorandum to Registered Blood and Plasma Establishments,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/additional-recommendations-donor-screening-licensed-test-hiv-1-antigen,https://www.fda.gov/media/70719/download,1996-03-14,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2022-D-0499,No,
Thermal Endometrial Ablation Devices (Submission Guidance for an IDE),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/thermal-endometrial-ablation-devices-submission-guidance-ide,,1996-03-13,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Hysteroscopes and Gynecology Laparoscopes - Submission Guidance for a 510(k),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hysteroscopes-and-gynecology-laparoscopes-submission-guidance-510k,https://www.fda.gov/media/72262/download,1996-03-07,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2020-D-0957,No,
Q1B Photostability Testing of New Drug Substances and Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1b-photostability-testing-new-drug-substances-and-products,https://www.fda.gov/media/71713/download,1996-03-07,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Draft,,No,
S1A The Need for Long-term Rodent Carcinogenicity Studies of Pharmaceuticals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s1a-need-long-term-rodent-carcinogenicity-studies-pharmaceuticals,https://www.fda.gov/media/71921/download,1996-03-01,['Center for Drug Evaluation and Research'],['ICH-Safety'],Final,FDA-1996-D-0010,No,
Q5B Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q5b-quality-biotechnological-products-analysis-expression-construct-cells-used-production-r-dna,https://www.fda.gov/media/71417/download,1996-02-23,['Center for Drug Evaluation and Research'],['ICH-Quality'],Final,FDA-1995-D-0245,No,
All Holders of Approved Variances For Laser Light Shows and Displays (Laser Notice 46),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/all-holders-approved-variances-laser-light-shows-and-displays-laser-notice-46,https://www.fda.gov/media/73998/download,1995-12-11,['Center for Devices and Radiological Health'],['Radiological Health'],Final,FDA-2020-D-0957,No,
Donor Deferral Due to Red Blood Cell Loss During Collection of Source Plasma by Automated Plasmapheresis,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/donor-deferral-due-red-blood-cell-loss-during-collection-source-plasma-automated-plasmapheresis,https://www.fda.gov/media/70729/download,1995-12-04,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2022-D-0500,No,
"SUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supac-ir-immediate-release-solid-oral-dosage-forms-scale-and-post-approval-changes-chemistry,https://www.fda.gov/media/70949/download,1995-11-01,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,,No,
"Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-format-investigational-new-drug-applications-inds-phase-1-studies-drugs-including-well,https://www.fda.gov/media/71203/download,1995-11-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Clinical - Medical','Pharmacology/Toxicology','Investigational New Drug Application (INDA)']",Final,FDA-1995-D-0251,No,
Addendum to: Guidance on Premarket Notification [510(k)] Submissions for Sterilizers Intended for Use in Health Care Facilities,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/addendum-guidance-premarket-notification-510k-submissions-sterilizers-intended-use-health-care,,1995-09-18,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
User Instruction for Medical Products (Laser Notice 44),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/user-instruction-medical-products-laser-notice-44,https://www.fda.gov/media/74002/download,1995-08-11,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Recommendations for Donor Screening with a Licensed Test for HIV-1 Antigen:  Memorandum to All Registered Blood Establishments,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-donor-screening-licensed-test-hiv-1-antigen,https://www.fda.gov/media/70745/download,1995-08-08,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2022-D-0501,No,
Hysteroscopic and Laparoscopic Insufflators: Submission Guidance for a 510(k),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hysteroscopic-and-laparoscopic-insufflators-submission-guidance-510k,,1995-07-31,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Guidance Document for the Preparation of Premarket Notification [510(K)] Applications for Exercise Equipment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-preparation-premarket-notification-510k-applications-exercise-equipment,https://www.fda.gov/media/72390/download,1995-07-25,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Guidance Document for the Preparation of Premarket Notification [510(k)] Applications for Heating and Cooling Devices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-preparation-premarket-notification-510k-applications-heating-and-cooling-devices,https://www.fda.gov/media/72413/download,1995-07-25,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
"Guidance Document for the Preparation of Premarket Notification [510(k)] Applications for Mechanical and Powered Wheelchairs, and Motorized Three-Wheeled Vehicles",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-preparation-premarket-notification-510k-applications-mechanical-and-powered,https://www.fda.gov/media/72525/download,1995-07-25,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
FDA Guidance Document Concerning Use of Pilot Manufacturing Facilities for the Development and Manufacture of Biological Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-document-concerning-use-pilot-manufacturing-facilities-development-and-manufacture,https://www.fda.gov/media/77030/download,1995-07-11,['Center for Biologics Evaluation and Research'],['Administrative / Procedural'],Final,FDA-1995-D-0149,No,
Testing Guidance for Male Condoms Made From New Material (Non-Latex),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/testing-guidance-male-condoms-made-new-material-non-latex,,1995-06-28,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
"Guidance for Industry: Letter to Manufacturers, Importers, and Distributors of Imported Candy and Candy Wrappers",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-letter-manufacturers-importers-and-distributors-imported-candy-and-candy-wrappers,,1995-06-13,['Human Foods Program'],"['Candy/Gum (without chocolate)','Import','Lead']",Final,FDA-2020-D-2006,No,
CPG Sec 100.900  International Memoranda of Understanding,,,1995-06-06,[],['Investigation & Enforcement'],Final,,No,
Topical Dermatologic Corticosteroids: in Vivo Bioequivalence,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/topical-dermatologic-corticosteroids-in-vivo-bioequivalence-0,https://www.fda.gov/media/162457/download,1995-06-02,['Center for Drug Evaluation and Research'],"['Biopharmaceutics','Generic Drugs']",Final,FDA-2021-D-0384,No,
Guidance on the Content and Organization of a Premarket Notification for a Medical Laser,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-and-organization-premarket-notification-medical-laser,https://www.fda.gov/media/72668/download,1995-05-31,['Center for Devices and Radiological Health'],"['Premarket','Radiology']",Final,FDA-2020-D-0957,No,
"Guidance Document for Testing Non-Articulating,'Mechanically Locked', Modular Implant Components",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-testing-non-articulating-mechanically-locked-modular-implant-components,https://www.fda.gov/media/72680/download,1995-04-30,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Revised Recommendations for Red Blood Cell Immunization Programs for Source Plasma Donors:  Memorandum to Licensed Establishments,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/revised-recommendations-red-blood-cell-immunization-programs-source-plasma-donors,https://www.fda.gov/media/70771/download,1995-03-14,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2013-S-0611,No,
"CPG 230.130- Adequate Space for Determination of Donor Suitability (Obsolete, Withdrawn on 7/16/2018)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-230130-adequate-space-determination-donor-suitability-obsolete-withdrawn-7162018,,1995-03-01,[],"['Investigation & Enforcement','Blood Products']",Final,,No,
CPG Sec 120.500 Health Fraud - Factors in Considering Regulatory Action,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-120500-health-fraud-factors-considering-regulatory-action,,1995-03-01,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,FDA-2012-E-0163,No,
CPG Sec 500.400 Use of Calcium Chloride as a Drying Agent in Such Products as Packaged Potato Chips and Peanuts,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-500400-use-calcium-chloride-drying-agent-such-products-packaged-potato-chips-and-peanuts,,1995-03-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Ingredients']",Final,,No,
CPG Sec 515.400 Raw Sugar,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515400-raw-sugar,,1995-03-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Candy/Gum (without chocolate)']",Final,,No,
CPG Sec 515.600 Candied Citron - Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515600-candied-citron-labeling,,1995-03-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Candy/Gum (without chocolate)']",Final,,No,
"CPG Sec 587.200 Uncertified or Delisted Colors in Foods for Export -  (e.g., FD&C Red #2)",,,1995-03-01,[],"['Investigation & Enforcement','Food & Color Additives']",Final,,No,
"CPG Sec. 231.100-  *Platelets, Pooled* is obsolete and was withdrawn on 7/16/2018.",,,1995-03-01,[],"['Investigation & Enforcement','Blood Products']",Final,,No,
CPG Sec. 231.120-  Time Period for Separation of Platelets from Platelet-Rich Plasma When Preparing *Platelets* and Fresh Frozen Plasma* is obsolete and was withdrawn on 7/16/2018.,,,1995-03-01,[],"['Investigation & Enforcement','Blood Products']",Final,,No,
CPG Sec. 231.130-  Storage of *Platelets* [ ] for up to five (5) Days is obsolete and was withdrawn on 7/16/2018.,,,1995-03-01,[],"['Investigation & Enforcement','Blood Products']",Final,,No,
CPG Sec. 345.300 Menstrual Sponges,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-345300-menstrual-sponges,,1995-03-01,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']","['Investigation & Enforcement','Physical Medicine']",Final,FDA-2020-D-0957,No,
CPG Sec. 355.300 Ion Generating Devices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-355300-ion-generating-devices,,1995-03-01,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']","['Investigation & Enforcement','Radiological Health']",Final,FDA-2020-D-0957,No,
CPG Sec. 370.100 Cytotoxic Testing for Allergic Diseases,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-370100-cytotoxic-testing-allergic-diseases,,1995-03-01,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']","['Investigation & Enforcement','Clinical Chemistry & Clinical Toxicology']",Final,FDA-2020-D-0957,No,
CPG Sec. 390.425 Records and Reports; Applicability - 21 CFR 1002.1,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-390425-records-and-reports-applicability-21-cfr-10021,,1995-03-01,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']","['Investigation & Enforcement','Records']",Final,FDA-2020-D-0957,No,
CPG Sec. 391.200 Warning Statement in Advertisements for High-Intensity Mercury Vapor Discharge Lamps that are not Self-Extinguishing (21 CFR 1040.30(e)(3)*),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-391200-warning-statement-advertisements-high-intensity-mercury-vapor-discharge-lamps-are-not,,1995-03-01,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']","['Investigation & Enforcement','Advertising']",Final,FDA-2020-D-0957,No,
"CPG Sec. 393.200 Laser(s) as Medical Devices for Facelift, Wrinkle Removal, Acupuncture, Auricular Stimulation, etc. (CPG 7133.21)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-393200-lasers-medical-devices-facelift-wrinkle-removal-acupuncture-auricular-stimulation-etc,,1995-03-01,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']",['Investigation & Enforcement'],Final,FDA-2020-D-0957,No,
CPG Sec. 400.200 Consistent Application of CGMP Determinations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-400200-consistent-application-cgmp-determinations,,1995-03-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,None found,No,
CPG Sec. 400.500 Identical or Similar Product Names,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-400500-identical-or-similar-product-names,,1995-03-01,['Center for Drug Evaluation and Research'],"['Investigation & Enforcement','Labeling']",Final,None found,No,
CPG Sec. 430.400 Urinary Preparations - Misbranding - Lack of Rx Legend and Claims,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-430400-urinary-preparations-misbranding-lack-rx-legend-and-claims,,1995-03-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,None found,No,
CPG Sec. 450.200 Drugs - General Provisions and Administrative Procedures for Recognition as Safe and Effective,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-450200-drugs-general-provisions-and-administrative-procedures-recognition-safe-and-effective,,1995-03-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
CPG Sec. 450.300 OTC Drugs - General Provisions and Administrative Procedures for Marketing Combination Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-450300-otc-drugs-general-provisions-and-administrative-procedures-marketing-combination,,1995-03-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,None found,No,
CPG Sec. 456.100 Non-Rx Drugs Anti-Obesity Preparations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-456100-non-rx-drugs-anti-obesity-preparations,,1995-03-01,['Center for Drug Evaluation and Research'],,Final,None found,No,
CPG Sec. 457.100 Pangamic Acid and Pangamic Acid Products Unsafe for Food and Drug Use,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-457100-pangamic-acid-and-pangamic-acid-products-unsafe-food-and-drug-use,,1995-03-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
CPG Sec. 608.500  Illegal Sales of Veterinary Prescription Drugs Direct Reference Authority for *Warning* Letter Issuance (Withdrawn 2/20/2020),,,1995-03-01,[],"['Investigation & Enforcement','Animal Drugs']",Final,,No,
CPG Sec. 625.300  Unapproved New Animal Drugs - Follow-up Action to Approved Warning Letter - Direct Reference Seizure Authority (Withdrawn 2/20/2020),,,1995-03-01,[],"['Investigation & Enforcement','Animal Drugs','Unapproved Animal Drugs']",Final,,No,
CPG Sec. 625.500  Failure to Register *and/or Drug List* (Withdrawn 2/20/2020),,,1995-03-01,[],"['Registration','Investigation & Enforcement','Animal Drugs']",Final,,No,
CPG Sec 515.100 Confectionery - Use of Non-Nutritive Substances as Ingredients,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515100-confectionery-use-non-nutritive-substances-ingredients,https://www.fda.gov/media/71790/download,1995-03-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Candy/Gum (without chocolate)']",Final,,No,
CPG Sec 525.425 Hops - Adulteration Involving Aphid Infestation,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525425-hops-adulteration-involving-aphid-infestation,https://www.fda.gov/media/75127/download,1995-03-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
"CPG Sec 525.825 Vinegar, Definitions - Adulteration with Vinegar Eels",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525825-vinegar-definitions-adulteration-vinegar-eels,https://www.fda.gov/media/71937/download,1995-03-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
CPG Sec 550.235 Cherry Jam - Adulteration with Mold,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550235-cherry-jam-adulteration-mold,https://www.fda.gov/media/71795/download,1995-03-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
"CPG Sec 550.250 Citrus Fruit Juices, Canned - Adulteration with Fly Filth and Mold",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550250-citrus-fruit-juices-canned-adulteration-fly-filth-and-mold,https://www.fda.gov/media/71799/download,1995-03-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
CPG Sec 550.260 Cranberry Sauce - Adulteration with Mold,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550260-cranberry-sauce-adulteration-mold,https://www.fda.gov/media/71803/download,1995-03-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
CPG Sec 550.270 Currants - Adulteration Involving Wormy Fruits,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550270-currants-adulteration-involving-wormy-fruits,https://www.fda.gov/media/71808/download,1995-03-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
"CPG Sec 550.450 Jam, Black Currant - Adulteration with Mold",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550450-jam-black-currant-adulteration-mold,https://www.fda.gov/media/71829/download,1995-03-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
"CPG Sec 550.590 Cloudberries (Multer Berries), Canned - Adulteration by Insects",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550590-cloudberries-multer-berries-canned-adulteration-insects,https://www.fda.gov/media/71843/download,1995-03-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
"CPG Sec 550.680 Pineapple, Canned; Pineapple Juice - Adulteration with Mold",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550680-pineapple-canned-pineapple-juice-adulteration-mold,https://www.fda.gov/media/71889/download,1995-03-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
"CPG Sec 555.300 Foods, Except Dairy Products - Adulteration with Salmonella",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555300-foods-except-dairy-products-adulteration-salmonella,https://www.fda.gov/media/71946/download,1995-03-01,"['Office of Inspections and Investigations','Human Foods Program']",['Investigation & Enforcement'],Final,,No,
CPG Sec 575.100 Pesticide Residues in Food and Feed - Enforcement Criteria,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-575100-pesticide-residues-food-and-feed-enforcement-criteria,https://www.fda.gov/media/75151/download,1995-03-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Pesticide']",Final,,No,
"CPG Sec 585.225 Black-Eyed Peas (Cow Peas, Field Peas); Dried-Adulteration with Lygus Bug Damage",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585225-black-eyed-peas-cow-peas-field-peas-dried-adulteration-lygus-bug-damage,https://www.fda.gov/media/71786/download,1995-03-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
CPG Sec. 250.500-  Plasma Brokers - Registration and Compliance with Good Manufacturing Practices is obsolete and was withdrawn on 7/16/2018.,,,1995-03-01,[],"['Investigation & Enforcement','Blood Products']",Final,,No,
CPG Sec. 300.400 Contamination of Devices Labeled as Sterile,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-300400-contamination-devices-labeled-sterile,https://www.fda.gov/media/75112/download,1995-03-01,"['Office of Regulatory Affairs','Center for Devices and Radiological Health']","['Investigation & Enforcement','Labeling']",Final,FDA-2020-D-0957,No,
CPG Sec. 345.100 Condoms; Defects - Criteria for Direct Reference Seizure,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-345100-condoms-defects-criteria-direct-reference-seizure,https://www.fda.gov/media/71812/download,1995-03-01,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']","['Investigation & Enforcement','Administrative / Procedural']",Final,FDA-2020-D-0957,No,
CPG Sec. 355.200 Electrical Muscle Stimulators,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-355200-electrical-muscle-stimulators,https://www.fda.gov/media/71827/download,1995-03-01,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']",['Investigation & Enforcement'],Final,FDA-2020-D-0957,No,
CPG Sec. 398.350 Regulatory Actions Against Assemblers of X-ray Equipment that Fail to File Reports of Assembly,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-398350-regulatory-actions-against-assemblers-x-ray-equipment-fail-file-reports-assembly,https://www.fda.gov/media/71917/download,1995-03-01,[],"['Investigation & Enforcement','Radiology']",Final,,No,
"CPG Sec. 400.100 Drugs, Human - Failure to Register",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-400100-drugs-human-failure-register,https://www.fda.gov/media/71939/download,1995-03-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,None found,No,
CPG Sec. 448.100 Reconditioning of New Drugs Which Do Not Have Approved NDAs/ANDAs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-448100-reconditioning-new-drugs-which-do-not-have-approved-ndasandas,https://www.fda.gov/media/72017/download,1995-03-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,None found,No,
CPG Sec. 480.300 Lack of Expiration Date of Stability Data,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-480300-lack-expiration-date-stability-data,https://www.fda.gov/media/72066/download,1995-03-01,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 480.300 Lack of Expiration Date of Stability Data,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-480300-lack-expiration-date-stability-data,https://www.fda.gov/media/72066/download,1995-03-01,[],,Final,,No,
E1A The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Long-term Treatment of Non-Life-Threatening Conditions,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e1a-extent-population-exposure-assess-clinical-safety-drugs-intended-long-term-treatment-non-life,https://www.fda.gov/media/71180/download,1995-03-01,['Center for Drug Evaluation and Research'],['ICH-Efficacy'],Final,FDA-1994-D-0267,No,
E2A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2a-clinical-safety-data-management-definitions-and-standards-expedited-reporting,https://www.fda.gov/media/71188/download,1995-03-01,['Center for Drug Evaluation and Research'],['ICH-Efficacy'],Final,FDA-1993-D-0128,No,
Q2A Text on Validation of Analytical Procedures,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q2a-text-validation-analytical-procedures,https://www.fda.gov/media/71724/download,1995-03-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Quality'],Final,FDA-1994-D-0401,No,
S3A Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s3a-toxicokinetics-assessment-systemic-exposure-toxicity-studies,https://www.fda.gov/media/71990/download,1995-03-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Safety'],Final,,No,
S3B Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s3b-pharmacokinetics-guidance-repeated-dose-tissue-distribution-studies,https://www.fda.gov/media/71993/download,1995-03-01,['Center for Drug Evaluation and Research'],['ICH-Safety'],Final,,No,
CPG Sec 515.425 Sugar - Water Damaged - Reconditioning,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515425-sugar-water-damaged-reconditioning,,1995-02-28,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Candy/Gum (without chocolate)']",Final,,No,
"CPG Sec 520.100 Canned Foods, Use of the Term ""Solid Pack""",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-520100-canned-foods-use-term-solid-pack,,1995-02-28,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Canned Foods','Fruit/Fruit Product']",Final,,No,
CPG Sec 525.400 Hollandaise Sauce - Common or Usual Name,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525400-hollandaise-sauce-common-or-usual-name,,1995-02-28,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
CPG Sec 550.400 Grenadine,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550400-grenadine,,1995-02-28,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
CPG Sec 555.650 Reconditioning Foods by Diversion for Animal Feed,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555650-reconditioning-foods-diversion-animal-feed,,1995-02-28,"['Office of Inspections and Investigations','Human Foods Program']",['Investigation & Enforcement'],Final,,No,
CPG Sec 562.400 Foreign Language Declarations on Food Labels,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562400-foreign-language-declarations-food-labels,,1995-02-28,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Labeling']",Final,,No,
CPG Sec 578.600 Unapproved Additives for Exported Grains,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-578600-unapproved-additives-exported-grains,,1995-02-28,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Grain/Grain Product']",Final,,No,
CPG Sec. 150.500 Analytical Methodology Used by FDA - Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-150500-analytical-methodology-used-fda-drugs,,1995-02-28,"['Human Foods Program','Office of Inspections and Investigations','Center for Drug Evaluation and Research']",['Investigation & Enforcement'],Final,,No,
CPG Sec. 231.110-  Quality Control Testing of *Platelets* [ ] and Cryoprecipitated Antihemophilic Factor [ ],,,1995-02-28,[],"['Investigation & Enforcement','Blood Products']",Final,,No,
"CPG Sec. 250.100 Source Plasma – Guidelines for Informed Consent Forms (Obsolete, Withdrawn on 11/28/2017)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-250100-source-plasma-guidelines-informed-consent-forms-obsolete-withdrawn-11282017,,1995-02-28,[],"['Investigation & Enforcement','Blood Products']",Final,,No,
"CPG Sec. 252.100 Source Plasma - Regulatory Action Based on Overbleeding (Obsolete, Withdrawn on 11/28/2017)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-252100-source-plasma-regulatory-action-based-overbleeding-obsolete-withdrawn-11282017,,1995-02-28,[],"['Investigation & Enforcement','Blood Products']",Final,,No,
CPG Sec. 253.100- Use of Units of *Plasma and Fresh Frozen Plasma* Which Have Been Thawed,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-253100-use-units-plasma-and-fresh-frozen-plasma-which-have-been-thawed,,1995-02-28,[],"['Investigation & Enforcement','Blood Products']",Final,,No,
"CPG Sec. 254.100 Source Plasma - Use of Units from Donors Subsequently Found to be Reactive to a Serologic Test for Syphilis (Obsolete, Withdrawn on 11/28/2017)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-254100-source-plasma-use-units-donors-subsequently-found-be-reactive-serologic-test-syphilis,,1995-02-28,[],"['Investigation & Enforcement','Blood Products']",Final,,No,
"CPG Sec. 255.100 Quantitative Testing for Serum Proteins in Plasmapheresis Donors (Obsolete, Withdrawn on 11/28/2017)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-255100-quantitative-testing-serum-proteins-plasmapheresis-donors-obsolete-withdrawn-11282017,,1995-02-28,[],"['Investigation & Enforcement','Blood Products']",Final,,No,
"CPG Sec. 256.100 Plasmapheresis - 48-hour Period Between Plasmapheresis Procedures (Obsolete, Withdrawn on 11/28/2017)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-256100-plasmapheresis-48-hour-period-between-plasmapheresis-procedures-obsolete-withdrawn,,1995-02-28,[],"['Investigation & Enforcement','Blood Products']",Final,,No,
CPG Sec. 300.300 Ineffective Devices - 502(f)(I) Labeling Requirements,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-300300-ineffective-devices-502fi-labeling-requirements,,1995-02-28,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']","['Investigation & Enforcement','Labeling']",Final,FDA-2020-D-0957,No,
CPG Sec. 310.100 Pacemaker Reuse,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-310100-pacemaker-reuse,,1995-02-28,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']","['Investigation & Enforcement','Cardiovascular']",Final,FDA-2020-D-0957,No,
CPG Sec. 394.100 Retention of Microwave Oven Test Records,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-394100-retention-microwave-oven-test-records,,1995-02-28,[],"['Investigation & Enforcement','Records']",Final,,No,
CPG Sec. 396.100 Applicability of the Sunlamp Performance Standard To UVA Tanning Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-396100-applicability-sunlamp-performance-standard-uva-tanning-products,,1995-02-28,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 396.200 Exemption for Certain Sunlamp Product Purchaser Records,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-396200-exemption-certain-sunlamp-product-purchaser-records,,1995-02-28,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 396.400 Policy on Warned on Sunlamp Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-396400-policy-warned-sunlamp-products,,1995-02-28,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']","['Investigation & Enforcement','Labeling']",Final,FDA-2020-D-0957,No,
CPG Sec. 398.200 Hazardous Diagnostic X-ray Systems,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-398200-hazardous-diagnostic-x-ray-systems,,1995-02-28,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']","['Investigation & Enforcement','Radiology']",Final,FDA-2020-D-0957,No,
CPG Sec. 398.300 Registration of Assemblers of  Diagnostic X-Ray Systems as Device Manufacturers,,,1995-02-28,[],"['Investigation & Enforcement','Radiology']",Final,FDA-2020-D-0957,No,
CPG Sec. 398.375 Obligations of Factory-based Manufacturers and Assemblers of Diagnostic X-ray Equipment Under the Performance Standard for Diagnostic X-ray Equipment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-398375-obligations-factory-based-manufacturers-and-assemblers-diagnostic-x-ray-equipment,,1995-02-28,[],"['Investigation & Enforcement','Radiology']",Final,,No,
CPG Sec. 398.600 Certification and Identification of X-ray Components - Sections 1010.2 and 1020.30(e),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-398600-certification-and-identification-x-ray-components-sections-10102-and-102030e,,1995-02-28,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 480.100 Requirements for Expiration Dating and Stability Testing,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-480100-requirements-expiration-dating-and-stability-testing,,1995-02-28,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
CPG Sec. 480.200 Expiration Dating of Unit Dose Repackaged Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-480200-expiration-dating-unit-dose-repackaged-drugs,,1995-02-28,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,2020-07-30
CPG Sec. 607.100 -  Adequate Directions for Use (Species Designation) - Animal Drugs and Veterinary Devices,,,1995-02-28,[],"['Investigation & Enforcement','Animal Devices','Animal Drugs','Labeling']",Final,FDA-2021-D-0629,No,
CPG Sec. 608.300  Lay Use of *Animal Capture and Euthanasia* Drugs (Withdrawn 2/20/2020),,,1995-02-28,[],"['Investigation & Enforcement','Animal Drugs']",Final,,No,
CPG Sec. 637.100  Plastic Containers for Injectable Animal Drugs (Withdrawn 2/20/2020),,,1995-02-28,[],"['Investigation & Enforcement','Animal Drugs']",Final,,No,
CPG Sec. 638.100  Process Validation Requirements for Drug Products Subject to Pre-Market Approval,,,1995-02-28,[],"['Investigation & Enforcement','Animal Drugs']",Final,,No,
CPG Sec. 640.100  Anthelmintics (Withdrawn 2/20/2020),,,1995-02-28,[],"['Investigation & Enforcement','Anthelmintics']",Final,,No,
CPG Sec. 641.100  *Products for Control of Fleas and Ticks* Containing a Pesticide (Withdrawn 2/20/2020),,,1995-02-28,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 642.100  *Drugs for Odor Control and Conception in Pet Animals*,,,1995-02-28,[],"['Investigation & Enforcement','Animal Drugs']",Final,FDA-2021-D-0630,No,
CPG Sec. 643.100  Oral Iron Products for Baby Pigs (Withdrawn 2/20/2020),,,1995-02-28,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 650.100  Animal Drugs for Euthanasia (Withdrawn 5/23/2024),,,1995-02-28,[],"['Investigation & Enforcement','Animal Drugs']",Final,FDA-2021-D-0631,No,
CPG Sec. 654.100  Dimethyl Sulfoxide (DMSO) for Animal Use (Withdrawn 2/20/2020),,,1995-02-28,[],"['Investigation & Enforcement','Animal Drugs']",Final,,No,
CPG Sec. 654.200  Teat Dips and Udder Washes for Dairy Cows and Goats,,,1995-02-28,[],['Investigation & Enforcement'],Final,FDA-2021-D-0632,No,
CPG Sec. 665.100  Common or Usual Names for Animal Feed Ingredients,,,1995-02-28,[],"['Investigation & Enforcement','Animal Feed','Labeling']",Final,FDA-2021-D-0633,No,
CPG Sec. 665.200  Checklist Labeling for Custom Mixed Medicated Feeds (Withdrawn 7/23/2019),,,1995-02-28,[],"['Investigation & Enforcement','Labeling','Medicated Feed']",Final,,No,
CPG Sec. 670.500  Ammoniated Cottonseed Meal - Interpretation of 21 CFR,,,1995-02-28,[],"['Investigation & Enforcement','Animal Feed']",Final,FDA-2021-D-0634,No,
CPG Sec. 675.100  Diversion of Contaminated Food for Animal Use,,,1995-02-28,[],"['Investigation & Enforcement','Animal Feed']",Final,FDA-2021-D-0635,No,
CPG Sec. 675.200  Diversion of Adulterated Food to Acceptable Animal Feed Use,,,1995-02-28,[],"['Investigation & Enforcement','Animal Feed']",Final,FDA-2021-D-0636,No,
CPG Sec. 675.300  Moisture Damaged Grain,,,1995-02-28,[],"['Investigation & Enforcement','Animal Feed']",Final,FDA-2021-D-0637,No,
CPG Sec. 680.500  Unsafe Contamination of Animal Feed from Drug Carryover (Withdrawn 1/30/2023),,,1995-02-28,[],"['Investigation & Enforcement','Animal Feed']",Final,FDA-2021-D-0638,No,
"CPG Sec. 680.600  Sequencing as a Means to Prevent Unsafe Drug   Contamination in the Production, Storage, and Distribution of Feeds (Withdrawn 1/30/2023)",,,1995-02-28,[],"['Investigation & Enforcement','Animal Feed']",Final,FDA-2021-D-0639,No,
CPG Sec. 685.100  Recycled Animal Waste,,,1995-02-28,[],"['Investigation & Enforcement','Animal Feed']",Final,FDA-2021-D-0640,No,
CPG Sec. 687.500  Silage Ingredients,,,1995-02-28,[],"['Investigation & Enforcement','Animal Feed']",Final,FDA-2021-D-0641,No,
CPG Sec. 689.100  Direct-Fed Microbial Products,,,1995-02-28,[],"['Investigation & Enforcement','Animal Feed']",Final,FDA-2021-D-0642,No,
CPG Sec. 690.100  Nutritional Supplements for Companion Animals (Withdrawn 2/20/2020),,,1995-02-28,[],"['Investigation & Enforcement','Animal Feed']",Final,,No,
CPG Sec.140.500 Metric Declarations of Quantity of Contents on Product Labels,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec140500-metric-declarations-quantity-contents-product-labels,,1995-02-28,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Labeling']",Final,,No,
CPG Sec.625.400 Reconditioning of New Animal Drugs Seized Under Section 501(a)(5) (Withdrawn 2/20/2020),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec625400-reconditioning-new-animal-drugs-seized-under-section-501a5-withdrawn-2202020,,1995-02-28,"['Center for Veterinary Medicine','Office of Regulatory Affairs']","['Investigation & Enforcement','Animal Drugs']",Final,,No,
CPG Sec 275.100 Immune Milk (Withdrawn 1/30/2020) :  CPG Sec 275.100 Immune Milk,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-275100-immune-milk-withdrawn-1302020,,1995-02-28,"['Office of Inspections and Investigations','Human Foods Program']",['Investigation & Enforcement'],Final,,No,
Guidance Document For The Preparation of Premarket Notification For Ceramic Ball Hip Systems,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-preparation-premarket-notification-ceramic-ball-hip-systems,https://www.fda.gov/media/72249/download,1995-01-09,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
CVM GFI #57 Preparation and Submission of Veterinary Master Files,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-57-preparation-and-submission-veterinary-master-files,https://www.fda.gov/media/70147/download,1995-01-01,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)']",Final,FDA-2021-D-0617,No,
Checklist for Mechanical Lithotripters and Stone Dislodgers used in Gastroenterology and Urology,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/checklist-mechanical-lithotripters-and-stone-dislodgers-used-gastroenterology-and-urology,https://www.fda.gov/media/72275/download,1994-11-01,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
"Reviewer Guidance, Validation of Chromatographic Methods",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reviewer-guidance-validation-chromatographic-methods,https://www.fda.gov/media/75643/download,1994-11-01,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,,No,
Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-documentation-sterilization-process-validation-applications-human-and-veterinary-drug,https://www.fda.gov/media/71442/download,1994-11-01,"['Center for Veterinary Medicine','Center for Drug Evaluation and Research']","['Microbiology','Pharmaceutical Quality']",Final,,No,
510(k) Checklist for Sterile Lubricating Jelly Used With Transurethral Surgical Instruments,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/510k-checklist-sterile-lubricating-jelly-used-transurethral-surgical-instruments,,1994-09-18,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Guidance for the Content of Premarket Notifications for Conventional and Antimicrobial Foley Catheters,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-premarket-notifications-conventional-and-antimicrobial-foley-catheters,,1994-09-11,['Center for Devices and Radiological Health'],"['Premarket','Antimicrobial Resistance']",Final,FDA-2020-D-0957,No,
Format and Content for the CMC Section of an Annual Report,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/format-and-content-cmc-section-annual-report,https://www.fda.gov/media/70816/download,1994-09-01,['Center for Drug Evaluation and Research'],"['Chemistry, Manufacturing, and Controls (CMC)','Pharmaceutical Quality']",Final,,No,
Guidance for the Preparation of a Premarket Notification for Extended Laparoscopy Devices (ELD),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-preparation-premarket-notification-extended-laparoscopy-devices-eld,https://www.fda.gov/media/72392/download,1994-08-29,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
CPG Sec. 634.100  Drugs Packaged for Infusion or Injection of Food-Producing Animals (Withdrawn 2/20/2020),,,1994-08-22,[],"['Investigation & Enforcement','Animal Drugs']",Final,,No,
E7 Studies in Support of Special Populations: Geriatrics,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e7-studies-support-special-populations-geriatrics,https://www.fda.gov/media/71317/download,1994-08-01,"['Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']",['ICH-Efficacy'],Final,,No,
Points to Consider for Cervical Cytology Devices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/points-consider-cervical-cytology-devices,https://www.fda.gov/media/73795/download,1994-07-25,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Guidance for the Content of Premarket Notifications for Urine Drainage Bags,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-premarket-notifications-urine-drainage-bags,https://www.fda.gov/media/72716/download,1994-06-07,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2020-D-0957,No,
"CVM GFI #55 Supportive Data for Cat Food Labels Bearing ""Reduces Urinary pH Claims:  Protocol Development",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-55-supportive-data-cat-food-labels-bearing-reduces-urinary-ph-claims-protocol-development,,1994-05-31,['Center for Veterinary Medicine'],['Animal Feed'],Final,FDA-1994-D-0230,No,
CVM GFI #53  Evaluation of the Utility of Food Additives in Diet Fed to Aquatic Animals,,,1994-04-30,[],"['Animal Food Additives','Aquaculture']",Final,FDA-2021-D-0618,No,
Guidance Document for Testing Orthopedic Implants with Modified Metallic Surfaces Apposing Bone Or Bone Cement,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-testing-orthopedic-implants-modified-metallic-surfaces-apposing-bone-or-bone,https://www.fda.gov/media/72781/download,1994-04-27,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
"Letter - Manufacturers, Distributors and Importers of Condom Products (included in Condom Packet 398) :  Letter - Manufacturers, Distributors and Importers of Condom Products",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/letter-manufacturers-distributors-and-importers-condom-products-included-condom-packet-398,https://www.fda.gov/media/72114/download,1994-02-23,['Center for Devices and Radiological Health'],"['Postmarket','Premarket']",Final,FDA-2020-D-0957,No,
Manufacturers/Assemblers of Diagnostic X-ray Systems: Enforcement Policy for Positive-Beam Limitation (PBL) Requirements in 21 CFR 1020.31(g) :,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacturersassemblers-diagnostic-x-ray-systems-enforcement-policy-positive-beam-limitation-pbl,https://www.fda.gov/media/74016/download,1993-10-13,['Center for Devices and Radiological Health'],"['Postmarket','Investigation & Enforcement']",Final,FDA-2020-D-0957,No,
Guidance on the Content and Format of Premarket Notification [510(k)] Submissions for Sharps Containers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-and-format-premarket-notification-510k-submissions-sharps-containers,https://www.fda.gov/media/72328/download,1993-10-01,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2020-D-0957,No,
Guidance for Industry: Guidelines for Determining Metric Equivalents of Household Measures,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-guidelines-determining-metric-equivalents-household-measures,,1993-09-30,['Human Foods Program'],"['Labeling','Nutrition Label']",Final,FDA-2020-D-1977-0001,No,
"Reviewer Guidance for Nebulizers, Metered Dose Inhalers, Spacers and Actuators",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reviewer-guidance-nebulizers-metered-dose-inhalers-spacers-and-actuators,,1993-09-30,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
"Revised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/revised-recommendations-testing-whole-blood-blood-components-source-plasma-and-source-leukocytes,https://www.fda.gov/media/70924/download,1993-08-05,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2013-S-0612,No,
1993 Draft Redbook II,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/1993-draft-redbook-ii,,1993-08-01,['Human Foods Program'],['Food & Color Additives'],Draft,,No,
"Guidance on Premarket Notification [510(k)] Submissions for Automated Endoscope Washers, Washer/Disinfectors, and Disinfectors Intended for Use in Health Care Facilities",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-premarket-notification-510k-submissions-automated-endoscope-washers-washerdisinfectors-and,https://www.fda.gov/media/72345/download,1993-08-01,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2020-D-0957,No,
Guidance on Premarket Notification [510(k)] Submissions for Surgical Gowns and Surgical Drapes,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-premarket-notification-510k-submissions-surgical-gowns-and-surgical-drapes,https://www.fda.gov/media/72369/download,1993-08-01,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2020-D-0957,No,
CVM GFI #45 Guideline for Uniform Labeling of Drugs for Dairy and Beef Cattle,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-45-guideline-uniform-labeling-drugs-dairy-and-beef-cattle,,1993-07-31,['Center for Veterinary Medicine'],['Labeling'],Final,FDA-2021-D-0620,No,
Recommendations Regarding License Amendments and Procedures for Gamma Irradiation of Blood Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-regarding-license-amendments-and-procedures-gamma-irradiation-blood-products,https://www.fda.gov/media/70934/download,1993-07-22,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2013-S-0613,No,
Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/study-and-evaluation-gender-differences-clinical-evaluation-drugs,https://www.fda.gov/media/71107/download,1993-07-22,['Center for Drug Evaluation and Research'],"['Clinical - Medical','Good Clinical Practice (GCP)']",Final,FDA-1993-D-0184,No,
CPG Sec. 615.200  Proper Drug Use and Residue Avoidance by Non-Veterinarians,,,1993-07-08,[],"['Investigation & Enforcement','Animal Drugs','Human Food Safety']",Final,FDA-2021-D-0643,No,
Beam Attenuators and Emission Indicators for Class II and IIIa Laser Systems (Laser Notice 43),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/beam-attenuators-and-emission-indicators-class-ii-and-iiia-laser-systems-laser-notice-43,https://www.fda.gov/media/74022/download,1993-06-07,['Center for Devices and Radiological Health'],['Radiological Health'],Final,FDA-2020-D-0957,No,
"Letter to Industry, Powered Wheelchair Manufacturers from RMJohnson",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/letter-industry-powered-wheelchair-manufacturers-rmjohnson,https://www.fda.gov/media/74242/download,1993-05-10,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
CPG Sec. 680.100  Tracers in Animal Feed (Withdrawn 10/19/2022),,,1993-04-04,[],"['Investigation & Enforcement','Animal Feed']",Final,,No,
Guidance on the Content of Premarket Notification [510(K)] Submissions for Hypodermic Single Lumen Needles,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-premarket-notification-510k-submissions-hypodermic-single-lumen-needles,,1993-03-31,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2020-D-0957,No,
Guidance on the Content of Premarket Notification [510(K)] Submissions for Piston Syringes,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-premarket-notification-510k-submissions-piston-syringes,,1993-03-31,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Guidance on Premarket Notification 510(k) for Sterilizers Intended for Use in Health Care Facilities,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-premarket-notification-510k-sterilizers-intended-use-health-care-facilities,https://www.fda.gov/media/72458/download,1993-03-01,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2020-D-0957,No,
Guidance on the Content of Premarket Notification [510(K)] Submissions for Clinical Electronic Thermometers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-premarket-notification-510k-submissions-clinical-electronic-thermometers,,1993-02-28,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Guidance for the Content of Premarket Notifications for Biopsy Devices Used in Gastroenterology and Urology,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-premarket-notifications-biopsy-devices-used-gastroenterology-and-urology,,1993-02-09,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Guidance for the Content of Premarket Notifications for Ureteral Stents,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-premarket-notifications-ureteral-stents,,1993-02-09,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Volume Limits for Automated Collection of Source Plasma,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-252110-volume-limits-automated-collection-source-plasma-obsolete-withdrawn-11282017,,1992-11-04,[],"['Blood','Blood Products','Device & Drug Safety']",Final,FDA-2013-S-0613,No,
Preparation of Investigational New Drug Products (Human and Animal):  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/preparation-investigational-new-drug-products-human-and-animal,https://www.fda.gov/media/71017/download,1992-11-01,['Center for Drug Evaluation and Research'],"['Current Good Manufacturing Practice (CGMP)','Pharmaceutical Quality']",Final,,No,
CPG Sec. 625.600  Orders for Post-Approval Record Reviews,,,1992-06-24,[],"['Investigation & Enforcement','Animal Drugs','Records']",Final,,No,
CPG Sec. 681.100  Order for Post-Approval Record Reviews (Withdrawn 2/20/2020),,,1992-06-24,[],"['Investigation & Enforcement','Animal Feed','Records']",Final,,No,
CPG Sec. 470.100 Orders for Post-Approval Record Reviews,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-470100-orders-post-approval-record-reviews,https://www.fda.gov/media/72058/download,1992-06-24,[],['Investigation & Enforcement'],Final,,No,
Compliance Guide for Laser Products (FDA 86-8260),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-guide-laser-products-fda-86-8260,https://www.fda.gov/media/74026/download,1992-06-01,['Center for Devices and Radiological Health'],['Radiological Health'],Final,FDA-2020-D-0957,No,
Statement of Policy - Foods Derived from New Plant Varieties,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statement-policy-foods-derived-new-plant-varieties,,1992-05-29,['Human Foods Program'],['Bioengineering / GMOs'],Final,,No,
CPG Sec. 450.500 Tamper-Resistant Packaging Requirements for Certain Over-the-Counter Human Drug Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-450500-tamper-resistant-packaging-requirements-certain-over-counter-human-drug-products,,1992-05-21,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
Review Criteria For Premarket Approval of In Vitro Diagnostic Devices for Detection of Antibodies to Parvovirus B19,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/review-criteria-premarket-approval-in-vitro-diagnostic-devices-detection-antibodies-parvovirus-b19,https://www.fda.gov/media/73831/download,1992-05-15,['Center for Devices and Radiological Health'],"['Premarket','Laboratory Tests','IVDs (In Vitro Diagnostic Devices)']",Final,FDA-2020-D-0957,No,
Development of New Stereoisomeric Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-new-stereoisomeric-drugs,,1992-05-01,['Center for Drug Evaluation and Research'],,Final,,No,
CPG Sec. 420.100 Adulteration of Drugs Under Section 501(b) and 501(c) of the Act. *Direct Reference Seizure Authority for Adulterated Drugs Under Section 501(b)*,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-420100-adulteration-drugs-under-section-501b-and-501c-act-direct-reference-seizure-authority,https://www.fda.gov/media/71979/download,1992-05-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,None found,No,
"Revised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/revised-recommendations-testing-whole-blood-blood-components-source-plasma-and-source-leukocytes,https://www.fda.gov/media/70924/download,1992-04-23,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2013-S-0613,No,
Guideline for Postmarketing Reporting of Adverse Drug Experiences,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guideline-postmarketing-reporting-adverse-drug-experiences,https://www.fda.gov/media/83280/download,1992-03-01,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,FDA-1985-D-0044,No,
FDA Recommendations Concerning Testing for Antibody to Hepatitis B Core Antigen (Anti-HBc),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-recommendations-concerning-testing-antibody-hepatitis-b-core-antigen-anti-hbc,https://www.fda.gov/media/70616/download,1991-09-10,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2013-S-0613,No,
"CPG Sec. 120.100  Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities",,,1991-06-30,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 335.800 Clinical Thermometer - Adulteration; Misbranding Defects,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-335800-clinical-thermometer-adulteration-misbranding-defects,https://www.fda.gov/media/71806/download,1991-05-31,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']","['Investigation & Enforcement','Administrative / Procedural']",Final,FDA-2020-D-0957,No,
Shelf Life of Medical Devices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/shelf-life-medical-devices,https://www.fda.gov/media/72487/download,1991-04-01,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Device Labeling Guidance #G91-1 (Blue Book Memo),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/device-labeling-guidance-g91-1-blue-book-memo,,1991-03-07,['Center for Devices and Radiological Health'],"['Premarket','Labeling']",Final,FDA-2020-D-0957,No,
Quality Assurance Guidelines for Hemodialysis Devices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-assurance-guidelines-hemodialysis-devices,https://www.fda.gov/media/71346/download,1991-02-01,['Center for Devices and Radiological Health'],['Gastroenterology-Urology'],Final,FDA-2020-D-0957,No,
CPG Sec. 446.100 Regulatory Action Regarding Approved New Drugs and Antibiotic Drug Products Subjected to Additional Processing or other Manipulations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-446100-regulatory-action-regarding-approved-new-drugs-and-antibiotic-drug-products-subjected,,1991-01-18,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,None found,No,
"Continuation of a series of letters communicating interim and informal generic drug policy and guidance. Availability of Policy and Procedure Guides, and further operational changes to the generic drug review program",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/continuation-series-letters-communicating-interim-and-informal-generic-drug-policy-and-guidance,,1990-06-01,['Center for Drug Evaluation and Research'],['Generic Drugs'],Final,,No,
Format and Content of the Microbiology Section of an Application*:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/format-and-content-microbiology-section-application,https://www.fda.gov/media/71876/download,1990-01-01,['Center for Drug Evaluation and Research'],"['Microbiology','Pharmaceutical Quality']",Final,,No,
Clarification of Compliance Requirements for Certain Manufacturers Who Incorporate Certified Class I Laser Products into Their Products (Laser Notice 42),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clarification-compliance-requirements-certain-manufacturers-who-incorporate-certified-class-i-laser,https://www.fda.gov/media/74030/download,1989-12-18,['Center for Devices and Radiological Health'],['Radiological Health'],Final,FDA-2020-D-0957,No,
Review of FDA's Implementation of the Drug Export Amendments of 1986,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/review-fdas-implementation-drug-export-amendments-1986,https://www.fda.gov/media/71025/download,1989-11-01,"['Center for Veterinary Medicine','Center for Drug Evaluation and Research','Center for Biologics Evaluation and Research']","['Compliance','Current Good Manufacturing Practice (CGMP)']",Final,,No,
Study of Drugs Likely to be used in the Elderly,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/study-drugs-likely-be-used-elderly,https://www.fda.gov/media/71114/download,1989-11-01,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,,No,
CPG Sec 540.450 *Imitation Breaded Shrimp*,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540450-imitation-breaded-shrimp,,1989-10-30,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Seafood/Seafood Product']",Final,,No,
CPG Sec 540.550 Kipper and Kipper Unsplit - Definitions,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540550-kipper-and-kipper-unsplit-definitions,,1989-10-30,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Seafood/Seafood Product']",Final,,No,
"CPG Sec 540.150 Caviar, Use of Term - Labeling",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540150-caviar-use-term-labeling,,1989-10-29,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Seafood/Seafood Product']",Final,,No,
"CPG Sec 540.390 Canned Shrimp - Labeling, Size Designations and Corresponding Counts",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540390-canned-shrimp-labeling-size-designations-and-corresponding-counts,,1989-10-29,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Seafood/Seafood Product']",Final,,No,
CPG Sec 560.250 Imports - Importer can be Required to Reveal Identity of Ingredients,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-560250-imports-importer-can-be-required-reveal-identity-ingredients,,1989-09-19,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Import']",Final,,No,
Labeling - Regulatory Requirements for Medical Devices (FDA 89-4203),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-regulatory-requirements-medical-devices-fda-89-4203,https://www.fda.gov/media/74034/download,1989-09-01,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
CPG Sec 100.200 FDA Jurisdiction Over Products Composed of Interstate Ingredients,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-100200-fda-jurisdiction-over-products-composed-interstate-ingredients,,1989-08-31,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Food & Color Additives']",Final,,No,
"CPG Sec 100.600 Status of Facial Tissues, Paper Napkins, Paper Towels and Similar Paper Products",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-100600-status-facial-tissues-paper-napkins-paper-towels-and-similar-paper-products,,1989-08-30,"['Human Foods Program','Office of Inspections and Investigations','Center for Devices and Radiological Health','Center for Drug Evaluation and Research']",['Investigation & Enforcement'],Final,,No,
"CPG Sec. 100.500 - Common Carrier as a Relabeler, Repacker, Reprocessor, etc.",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-100500-common-carrier-relabeler-repacker-reprocessor-etc,,1989-08-30,['Office of Regulatory Affairs'],['Investigation & Enforcement'],Final,,No,
CPG Sec. 100.800  Guaranties Over Printed Signatures,,,1989-08-30,[],"['Investigation & Enforcement','Records']",Final,,No,
CPG Sec. 110.200  Export of FDA Regulated Products from U.S. Foreign Trade Zones,,,1989-08-30,[],['Investigation & Enforcement'],Final,,No,
"CPG Sec. 110.600  FDA Authority Over Products of Foreign Origin Located in Foreign Trade Zones, Bonded Warehouses or on Bonded Carriers",,,1989-08-30,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 110.700  Seizures by the U.S. Customs Service of Prohibited Articles of Foreign Origin Not Intended for Entry into the United States,,,1989-08-30,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 130.200  Inspection of Firms when Legal Action is Pending,,,1989-08-30,[],"['Investigation & Enforcement','Food & Color Additives']",Final,,No,
CPG Sec. 140.100  Seizure of Books that Constitute Misleading Labeling,,,1989-08-30,[],"['Investigation & Enforcement','Labeling']",Final,,No,
CPG Sec. 160.300  Requests for Records Under Section 703,,,1989-08-30,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 160.400  *Section 305 Meeting* Before Report of Criminal Violation,,,1989-08-30,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 400.700 Drug Product Entries in Periodic Publications,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-400700-drug-product-entries-periodic-publications,,1989-08-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
CPG Sec. 160.700 Reconditioning of Foods Adulterated Under 402(a)(4),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-160700-reconditioning-foods-adulterated-under-402a4,,1989-07-20,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
"CPG Sec 560.300 Reconditioning of Imported, Insect Infested, Insect Damaged or Moldy Coffee Beans",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-560300-reconditioning-imported-insect-infested-insect-damaged-or-moldy-coffee-beans,,1989-07-19,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Import']",Final,,No,
CPG Sec 560.350 Coffee and Cocoa Bean Sweeps,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-560350-coffee-and-cocoa-bean-sweeps,,1989-07-19,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Import']",Final,,No,
CPG Sec 560.100 Importation of Unlabeled Foods - Exemption Under *21 CFR 101.100(d)*,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-560100-importation-unlabeled-foods-exemption-under-21-cfr-101100d,,1989-07-18,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Import']",Final,,No,
Metaproterenol Sulfate and Albuterol Metered Dose Inhalers In Vitro,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/metaproterenol-sulfate-and-albuterol-metered-dose-inhalers-vitro,https://www.fda.gov/media/70953/download,1989-06-27,['Center for Drug Evaluation and Research'],['Biopharmaceutics'],Final,,No,
CPG Sec. 690.500  Uncooked Meat for Animal Food (Withdrawn 4/30/2019),,,1989-05-23,[],"['Investigation & Enforcement','Animal Feed']",Final,,No,
Clarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (Part 1 ),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clarification-radiation-control-regulations-diagnostic-x-ray-equipment-part-1,https://www.fda.gov/media/74040/download,1989-03-01,['Center for Devices and Radiological Health'],['Radiology'],Final,FDA-2018-D-4115,No,
Clarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (Part 2),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clarification-radiation-control-regulations-diagnostic-x-ray-equipment-part-2,https://www.fda.gov/media/74044/download,1989-03-01,['Center for Devices and Radiological Health'],['Radiology'],Final,FDA-2018-D-4115,No,
Clarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (Part 3),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clarification-radiation-control-regulations-diagnostic-x-ray-equipment-part-3,https://www.fda.gov/media/74048/download,1989-03-01,['Center for Devices and Radiological Health'],,Final,FDA-2018-D-4115,No,
Clarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (FDA 89-8221),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clarification-radiation-control-regulations-diagnostic-x-ray-equipment-fda-89-8221,,1989-02-28,[],['Radiology'],Final,,No,
CPG Sec 562.100 Acetic Acid - Use in Foods - Labeling of Foods in Which Used,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562100-acetic-acid-use-foods-labeling-foods-which-used,,1989-02-01,['Human Foods Program'],"['Investigation & Enforcement','Labeling']",Final,,No,
CPG Sec 562.600 Preservatives; Use in Nonstandardized Foods; Label Declaration,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562600-preservatives-use-nonstandardized-foods-label-declaration,,1989-02-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Labeling']",Final,,No,
CPG Sec 562.700 Labeling of Food Bearing Residues of Pesticide Chemicals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562700-labeling-food-bearing-residues-pesticide-chemicals,,1989-02-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Labeling']",Final,,No,
CPG Sec 562.750 Labeling of Food Articles Distributed Solely in Puerto Rico,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562750-labeling-food-articles-distributed-solely-puerto-rico,,1989-02-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Labeling']",Final,,No,
CPG Sec 562.800 Vending Machine Food - Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562800-vending-machine-food-labeling,,1989-02-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Labeling']",Final,,No,
"CPG Sec 555.550 Foods, Standardized; Enriched or Fortified - Adulteration Involving Misbranding - Potency",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555550-foods-standardized-enriched-or-fortified-adulteration-involving-misbranding-potency,https://www.fda.gov/media/71969/download,1989-02-01,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
"CPG Sec 555.850 Water Damaged Food Products in Screw-Top, Crimped-Cap and Similar Containers",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555850-water-damaged-food-products-screw-top-crimped-cap-and-similar-containers,https://www.fda.gov/media/71986/download,1989-02-01,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
Guidance for Oxygen Conserving Device 510(k) Review 73 BZD 868.5905 Non-continuous Ventilator Class II,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-oxygen-conserving-device-510k-review-73-bzd-8685905-non-continuous-ventilator-class-ii,https://www.fda.gov/media/72527/download,1989-02-01,['Center for Devices and Radiological Health'],"['Premarket','510(k)']",Final,FDA-2020-D-0957,No,
CPG Sec 555.100 Alcohol; Use of Synthetic Alcohol in Foods,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555100-alcohol-use-synthetic-alcohol-foods,,1989-01-31,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
"CPG Sec 555.750 Seeds for Sprouting Prior to Food Use, i.e., Dried Mung Beans, Alfalfa Seeds, Etc.",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555750-seeds-sprouting-prior-food-use-ie-dried-mung-beans-alfalfa-seeds-etc,,1989-01-31,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
"CPG Sec 555.800 Polysorbates 20, 40, 60, 65, 80, 85 - Common or Usual Names",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555800-polysorbates-20-40-60-65-80-85-common-or-usual-names,,1989-01-31,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
CPG Sec 555.875 Water in Food Products (Ingredient or Adulterant),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555875-water-food-products-ingredient-or-adulterant,,1989-01-31,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
"CPG Sec 562.650 ""Processing"" - Use of Term in Section 405 of the FD&C Act",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562650-processing-use-term-section-405-fdc-act,,1989-01-31,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Labeling']",Final,,No,
CPG Sec 570.550 Reconditioning - Tree Nuts Contaminated with E. coli,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-570550-reconditioning-tree-nuts-contaminated-e-coli,,1988-12-09,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Nuts & Nut Products']",Final,,No,
CPG Sec 585.100 Artichoke; Jerusalem Artichoke - Common or Usual Name,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585100-artichoke-jerusalem-artichoke-common-or-usual-name,,1988-12-08,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
CPG Sec 585.525: Mushroom Mycelium - Fitness for Food; Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585525-mushroom-mycelium-fitness-food-labeling,,1988-12-08,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
"CPG Sec 585.600 Peas and Carrots, Labeling of Canned Mixture",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585600-peas-and-carrots-labeling-canned-mixture,,1988-12-08,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
CPG Sec 585.625 Canned Peas - Label Designation of Sizes,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585625-canned-peas-label-designation-sizes,,1988-12-08,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
CPG Sec 585.650 Canned Pimentos and Red Sweet Peppers - Seeds Should be Removed,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585650-canned-pimentos-and-red-sweet-peppers-seeds-should-be-removed,,1988-12-08,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
"CPG Sec 585.710 Potato Chips, Ingredients - Labeling",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585710-potato-chips-ingredients-labeling,,1988-12-08,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
"CPG Sec 585.725 ""Pumpkin"" - Labeling Articles Made from Certain Varieties of Squash",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585725-pumpkin-labeling-articles-made-certain-varieties-squash,,1988-12-08,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
CPG Sec 585.800 Squash Seeds - Labeling as Pumpkin Seeds,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585800-squash-seeds-labeling-pumpkin-seeds,,1988-12-08,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
CPG Sec 585.850 Sweet Potatoes - Sirup Pack,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585850-sweet-potatoes-sirup-pack,,1988-12-08,"['Office of Inspections and Investigations','Human Foods Program']",['Investigation & Enforcement'],Final,,No,
"CPG Sec 585.150 Asparagus, Canned or Frozen - Adulteration with Insect Filth",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585150-asparagus-canned-or-frozen-adulteration-insect-filth,https://www.fda.gov/media/71778/download,1988-12-08,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
"CPG Sec 585.260 Broccoli, Frozen - Adulteration with Insects",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585260-broccoli-frozen-adulteration-insects,https://www.fda.gov/media/71793/download,1988-12-08,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
CPG Sec 585.350 Corn Husks (for Tamales) - Adulteration with Filth,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585350-corn-husks-tamales-adulteration-filth,https://www.fda.gov/media/71811/download,1988-12-08,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
"CPG Sec 585.450 Greens, Canned - Adulteration by Mildew",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585450-greens-canned-adulteration-mildew,https://www.fda.gov/media/71823/download,1988-12-08,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Spices','Flavors\xa0& \xa0Salts']",Final,,No,
CPG Sec 585.700 Potato Chips - Adulteration with Rot,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585700-potato-chips-adulteration-rot,https://www.fda.gov/media/71854/download,1988-12-08,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Vegetable Products']",Final,,No,
CPG Sec 570.100 Jordan Almonds - Common or Usual Name,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-570100-jordan-almonds-common-or-usual-name,,1988-12-02,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Nuts & Nut Products']",Final,,No,
"CPG Sec 570.250 Cashews, Insect Infested - Reconditioning",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-570250-cashews-insect-infested-reconditioning,,1988-12-02,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Nuts & Nut Products']",Final,,No,
CPG Sec. 350.100 Packaging Technologies and Tamper-Resistant Packaging Requirements for Contact Lens Solutions and Tablets,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-350100-packaging-technologies-and-tamper-resistant-packaging-requirements-contact-lens,,1988-11-21,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']",['Investigation & Enforcement'],Final,FDA-2020-D-0957,No,
CPG Sec 510.100 Beverage Bases,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-510100-beverage-bases,,1988-11-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Beverage Bases/Conc/Nectar']",Final,,No,
"Seventh of a series of letters about the Act providing guidance on the ""130-day exclusivity"" provision of section 505(j)(4)(B)(iv) of the FD&C",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/seventh-series-letters-about-act-providing-guidance-130-day-exclusivity-provision-section-505j4biv,,1988-07-29,['Center for Drug Evaluation and Research'],['Generic Drugs'],Final,,No,
Format and Content of the Clinical and Statistical Sections of an Application,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/format-and-content-clinical-and-statistical-sections-application,https://www.fda.gov/media/71436/download,1988-07-01,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,,No,
CPG Sec 545.200 Confectionery Decorations (Nutritive and Non-Nutritive),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-545200-confectionery-decorations-nutritive-and-non-nutritive,,1988-06-27,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
CPG Sec 578.200 Corn Meal - Adulteration by Insect and Rodent Filth,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-578200-corn-meal-adulteration-insect-and-rodent-filth,https://www.fda.gov/media/72092/download,1988-06-06,['Human Foods Program'],"['Investigation & Enforcement','Grain/Grain Product']",Final,,No,
CPG Sec 578.300 Wheat - Adulteration by Insect and Rodent filth,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-578300-wheat-adulteration-insect-and-rodent-filth,https://www.fda.gov/media/72096/download,1988-06-06,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Grain/Grain Product']",Final,,No,
"CPG Sec 515.800 Labeling of Products Purporting to be ""Chocolate"" or ""Chocolate Flavored""",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515800-labeling-products-purporting-be-chocolate-or-chocolate-flavored,,1988-05-12,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Chocolate/Cocoa Product']",Final,,No,
CPG Sec. 160.200  FDA Use of Income Tax Information from IRS in Compliance Activity,,,1988-04-20,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 150.100  Requests for Portions of Intermediate or End Products Resulting from FDA Sample Analysis,,,1988-03-22,[],['Investigation & Enforcement'],Final,,No,
"CPG Sec 505.200 ""Butter"" Featured in Product Name",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-505200-butter-featured-product-name,,1988-03-08,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Bakery Product/Mix']",Final,,No,
"CPG Sec 505.300 ""Butter-Nut"" Bread",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-505300-butter-nut-bread,,1988-03-08,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Bakery Product/Mix']",Final,,No,
"CPG Sec 505.350 Honey Bread, Honey Buns",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-505350-honey-bread-honey-buns,,1988-03-08,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Bakery Product/Mix']",Final,,No,
Guide for Establishing and Maintaining a Calibration Constancy Intercomparison System for Microwave Oven Compliance Survey Instruments (FDA 88-8264)] (PDF Only),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guide-establishing-and-maintaining-calibration-constancy-intercomparison-system-microwave-oven,https://www.fda.gov/media/74066/download,1988-03-01,[],['Radiological Health'],Final,,No,
Quality Control Guide for Sunlamp Products (FDA 88-8234),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-control-guide-sunlamp-products-fda-88-8234,https://www.fda.gov/media/74980/download,1988-03-01,['Center for Devices and Radiological Health'],"['Tanning Lamps','Booths & Beds']",Final,FDA-2020-D-0957,No,
CPG Sec 578.450 Wheat Flour-Adulteration with Insect Fragments and Rodent Hairs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-578450-wheat-flour-adulteration-insect-fragments-and-rodent-hairs,https://www.fda.gov/media/72104/download,1987-12-31,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Grain/Grain Product']",Final,,No,
Recommendations for the Management of Donor and Units that are Initially Reactive for Hepatitis B Surface Antigen (HBsAg),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-management-donor-and-units-are-initially-reactive-hepatitis-b-surface-antigen-hbsag,https://www.fda.gov/media/70907/download,1987-12-02,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2013-S-0613,No,
CPG Sec 565.200 Red Meat Adulterated with PCBs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-565200-red-meat-adulterated-pcbs,,1987-11-10,['Office of Inspections and Investigations'],"['Investigation & Enforcement','Meat/Meat Products & Poultry']",Final,,No,
Class II and IIIA Laser Light Show Projectors and Shows (Laser Notice 40),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/class-ii-and-iiia-laser-light-show-projectors-and-shows-laser-notice-40,https://www.fda.gov/media/77188/download,1987-10-29,['Center for Devices and Radiological Health'],"['Laser Notice','Laser Notice']",Final,FDA-2020-D-0957,No,
CPG Sec. 160.600  Payment of Expert Witnesses,,,1987-10-15,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 460.600 Content Uniformity Testing of Tablets and Capsules,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-460600-content-uniformity-testing-tablets-and-capsules,,1987-10-02,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
CPG Sec 567.200 Pork and Beans and Similar Bean Products - Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-567200-pork-and-beans-and-similar-bean-products-labeling,,1987-10-01,['Office of Inspections and Investigations'],['Investigation & Enforcement'],Final,,No,
CPG Sec. 325.100 Karaya Gum Powder and Related Devices for Use by Ostomates,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-325100-karaya-gum-powder-and-related-devices-use-ostomates,,1987-09-24,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']","['Investigation & Enforcement','Safety - Issues, Errors, and Problems']",Final,FDA-2020-D-0957,No,
CPG Sec. 345.200 Diaphragms - Rx Devices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-345200-diaphragms-rx-devices,,1987-09-24,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']","['Investigation & Enforcement','Labeling']",Final,FDA-2020-D-0957,No,
CPG Sec. 300.100 Inspection of Manufacturers of Device Components,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-300100-inspection-manufacturers-device-components,,1987-09-23,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']",['Investigation & Enforcement'],Final,FDA-2020-D-0957,No,
CPG Sec. 300.600 Commercial Distribution with Regard to Premarket Notification (Section 510(k)),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-300600-commercial-distribution-regard-premarket-notification-section-510k,,1987-09-23,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']",['Investigation & Enforcement'],Final,FDA-2020-D-0957,No,
CPG Sec. 320.100 Ear Piercing Devices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-320100-ear-piercing-devices,,1987-09-23,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']",['Investigation & Enforcement'],Final,FDA-2020-D-0957,No,
CPG Sec. 410.100 *Finished Dosage Form Drug Products in Bulk Containers - Applications of Current Good Manufacturing Practice Regulations*,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-410100-finished-dosage-form-drug-products-bulk-containers-applications-current-good,,1987-09-04,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
CPG Sec. 425.100 Computerized Drug Processing; CGMP Applicability to Hardware and Software*,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-425100-computerized-drug-processing-cgmp-applicability-hardware-and-software,,1987-09-04,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
CPG Sec. 425.200 Computerized Drug Processing; Vendor Responsibility,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-425200-computerized-drug-processing-vendor-responsibility,,1987-09-04,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
CPG Sec. 425.400 Computerized Drug Processing; Input/Output Checking,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-425400-computerized-drug-processing-inputoutput-checking,,1987-09-04,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
"CPG Sec. 425.500 Computerized Drug Processing; Identification of ""Persons"" on Batch Production and Control Records",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-425500-computerized-drug-processing-identification-persons-batch-production-and-control,,1987-09-04,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
"CPG Sec 567.100 Antipasto, Common or Usual Name",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-567100-antipasto-common-or-usual-name,,1987-09-01,['Office of Inspections and Investigations'],['Investigation & Enforcement'],Final,,No,
"CPG Sec 567.300 *Bouillon, Bouillon Cubes, Granulated Bouillon*",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-567300-bouillon-bouillon-cubes-granulated-bouillon,,1987-09-01,['Human Foods Program'],['Investigation & Enforcement'],Final,,No,
"CPG Sec. 100.100  Responsibility for Reporting Possible or Potential Violations of Laws Administered by FDA, Regulations Issued by FDA, Other Possible or Potential Hazards to the Public Health",,,1987-09-01,[],"['Investigation & Enforcement','Administrative / Procedural','Food & Color Additives']",Final,,No,
CPG Sec. 100.300  *Non-FDA Regulated Products Involving Communicable Disease Hazards*,,,1987-09-01,[],"['Investigation & Enforcement','Food & Color Additives','Safety - Issues, Errors, and Problems']",Final,,No,
CPG Sec. 100.350  FDA Jurisdiction on Indian Reservations,,,1987-08-31,[],"['Investigation & Enforcement','Food & Color Additives']",Final,,No,
User Instructions - Multi Axis Workstations (Laser Notice 39),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/user-instructions-multi-axis-workstations-laser-notice-39,https://www.fda.gov/media/74071/download,1987-06-24,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
CPG Sec. 655.100  Devices for Use in Animals,,,1987-06-01,[],"['Investigation & Enforcement','Animal Devices']",Final,,No,
CPG Sec. 655.300  Barking Dog Collar (Withdrawn 2/20/2020),,,1987-06-01,[],"['Investigation & Enforcement','Animal Devices']",Final,,No,
CPG Sec. 655.400  The Status of Syringes and Needles for Animal Use (Withdrawn 2/20/2020),,,1987-06-01,[],"['Investigation & Enforcement','Animal Devices']",Final,,No,
Color Additive Petitions - Medical Devices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/color-additive-petitions-medical-devices,https://www.fda.gov/media/74234/download,1987-06-01,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Master Files Part III - Guidance on Scientific and Technical Information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-files-part-iii-guidance-scientific-and-technical-information,https://www.fda.gov/media/72543/download,1987-06-01,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
CPG Sec. 400.335 Fructose-Containing Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-400335-fructose-containing-drugs,,1987-05-22,['Office of Regulatory Affairs'],"['Investigation & Enforcement','Labeling']",Final,,No,
CPG Sec. 430.300 Labeling Shipping Containers of Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-430300-labeling-shipping-containers-drugs,,1987-05-22,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,None found,No,
CPG Sec. 450.400 Labeling and Distribution of OTC Drugs in Vending Machines,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-450400-labeling-and-distribution-otc-drugs-vending-machines,,1987-05-22,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,None found,No,
CPG Sec. 454.100 OTC Ear Drop Preparations,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-454100-otc-ear-drop-preparations,,1987-05-22,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,None found,No,
"CPG Sec. 455.100 Inert Glandular Preparations *(OTC)*, Inadequate Full Disclosure and Claims",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-455100-inert-glandular-preparations-otc-inadequate-full-disclosure-and-claims,,1987-05-22,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,None found,No,
CPG Sec. 460.450 Status of Mail-Order Filling of Prescriptions,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-460450-status-mail-order-filling-prescriptions,,1987-05-21,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
CPG Sec. 425.300 Computerized Drug Processing; Source Code for Process Control Application Programs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-425300-computerized-drug-processing-source-code-process-control-application-programs,,1987-04-15,[],['Investigation & Enforcement'],Final,,No,
"All U.S. Condom Manufacturers, Importers and Repackagers",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/all-us-condom-manufacturers-importers-and-repackagers,https://www.fda.gov/media/72176/download,1987-04-07,['Center for Devices and Radiological Health'],"['Postmarket','Premarket']",Final,FDA-2020-D-0957,No,
Format and Content of the Human Pharmacokinetics and Bioavailability Section of an Application,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/format-and-content-human-pharmacokinetics-and-bioavailability-section-application,https://www.fda.gov/media/71286/download,1987-02-01,['Center for Drug Evaluation and Research'],['Clinical - Pharmacology'],Final,,No,
"Formatting, Assembling and Submitting New Drug and Antibiotic Applications*",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formatting-assembling-and-submitting-new-drug-and-antibiotic-applications,https://www.fda.gov/media/71485/download,1987-02-01,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,,No,
GUIDELINE FOR SUBMITTING SUPPORTING DOCUMENTATION IN DRUG APPLICATIONS FOR THE MANUFACTURE OF DRUG PRODUCTS,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guideline-submitting-supporting-documentation-drug-applications-manufacture-drug-products,https://www.fda.gov/media/131685/download,1987-02-01,['Center for Drug Evaluation and Research'],,Final,FDA-1985-D-0033,No,
Summary for New Drug and Antibiotic Applications--Format and Content of the Summary for New Drug and Antibiotic Applications,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/summary-new-drug-and-antibiotic-applications-format-and-content-summary-new-drug-and-antibiotic,https://www.fda.gov/media/71139/download,1987-02-01,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,,No,
Format and Content of the Nonclinical Pharmacology/Toxicology Section of an Application*:  Guidance for Industry,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/format-and-content-nonclinical-pharmacologytoxicology-section-application,https://www.fda.gov/media/72223/download,1987-02-01,['Center for Drug Evaluation and Research'],['Pharmacology/Toxicology'],Final,,No,
Policy on Lamp Compatibility (sunlamps),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-lamp-compatibility-sunlamps,https://www.fda.gov/media/74075/download,1986-09-02,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
CPG Sec 590.600 Wigs Compliance Policy Guide 7128.05,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-590600-wigs-compliance-policy-guide-712805,,1986-09-01,['Office of Regulatory Affairs'],['Investigation & Enforcement'],Final,,No,
CPG Sec. 605.100 - Use of Statements Regarding NADA Approval by FDA in  Labeling and Advertising of New Animal Drugs (Withdrawn 2/20/2020),,,1986-08-31,[],"['Investigation & Enforcement','Animal Drugs','Labeling']",Final,,No,
CPG Sec. 680.200  CGMP Regulations for Medicated Feeds - Daily Inventory Requirements (Withdrawn 2/20/2020),,,1986-06-30,[],"['Investigation & Enforcement','Medicated Feed']",Final,,No,
CPG Sec. 670.100  Refusals of Formula Information During Inspection of Feed Mills Manufacturing Feeds Requiring Approved Medicated Feed Applications (Withdrawn 6/30/2020),,,1986-05-31,[],"['Investigation & Enforcement','Medicated Feed']",Final,,No,
CPG Sec. 670.200  Status of Vitamins and Minerals in Type B and C Medicated Feed and in Non-Medicated Feed (Withdrawn 2/20/2020),,,1986-05-31,[],['Medicated Feed'],Final,,No,
CPG Sec. 680.400  Medicated Feeds -- Combined Batches,,,1986-05-31,[],"['Investigation & Enforcement','Medicated Feed']",Final,FDA-2021-D-0644,No,
Walk-In Workstations (Laser Notice 37),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/walk-workstations-laser-notice-37,https://www.fda.gov/media/73615/download,1985-10-21,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Policy On Maximum Timer Interval and Exposure Schedule For Sunlamp Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-maximum-timer-interval-and-exposure-schedule-sunlamp-products,https://www.fda.gov/media/77779/download,1985-08-21,['Center for Devices and Radiological Health'],"['Tanning Lamps','Booths & Beds']",Final,FDA-2020-D-0957,No,
CVM GFI #23 Medicated Free Choice Feeds--Manufacturing Control,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-23-medicated-free-choice-feeds-manufacturing-control,,1985-06-30,['Center for Veterinary Medicine'],"['Chemistry, Manufacturing, and Controls (CMC)','Current Good Manufacturing Practice (CGMP)']",Final,FDA-2021-D-0623,No,
Policy on Warning Label Required on Sunlamp Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-warning-label-required-sunlamp-products,https://www.fda.gov/media/73620/download,1985-06-25,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
User Instruction Hazard Warnings (Laser Notice 35),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/user-instruction-hazard-warnings-laser-notice-35,https://www.fda.gov/media/73627/download,1985-02-05,['Center for Devices and Radiological Health'],['Laser Notice'],Final,FDA-2020-D-0957,No,
Medical Laser Delivery System Interlocks (Laser Notice 34),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-laser-delivery-system-interlocks-laser-notice-34,https://www.fda.gov/media/73634/download,1985-01-20,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
CVM GFI #13  Evaluation of Effectiveness of New Animal Drugs for Use in Free-Choice Feeds-Medicated Block,,,1984-12-31,[],"['Animal Feed','Target Animal – Effectiveness']",Final,FDA-2021-D-0624,No,
Plasma Derived from Therapeutic Plasma Exchange,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/plasma-derived-therapeutic-plasma-exchange,https://www.fda.gov/media/70938/download,1984-12-14,['Center for Biologics Evaluation and Research'],"['Blood','Blood Products']",Final,FDA-2013-S-0613,No,
CVM GFI #38 Guideline for Effectiveness Evaluation of Topical/Otic Animal Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-38-guideline-effectiveness-evaluation-topicalotic-animal-drugs,,1984-08-20,['Center for Veterinary Medicine'],['Target Animal – Effectiveness'],Final,FDA-2021-D-0625,No,
Enforcement Policy on Marketing OTC Combination Products (CPG 7132b.16).,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-marketing-otc-combination-products-cpg-7132b16,https://www.fda.gov/media/72417/download,1984-05-01,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Final,,No,
Nuclear Pharmacy Guideline Criteria for Determining When to Register as a Drug Establishment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nuclear-pharmacy-guideline-criteria-determining-when-register-drug-establishment,https://www.fda.gov/media/71007/download,1984-05-01,['Center for Drug Evaluation and Research'],['Compliance'],Final,FDA-1975-N-0008,No,
CVM GFI #37 Evaluation of Effectiveness of New Animal Drugs for Use in Poultry Feed for Pigmentation,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-37-evaluation-effectiveness-new-animal-drugs-use-poultry-feed-pigmentation,,1984-02-29,['Center for Veterinary Medicine'],"['Animal Feed','Target Animal – Effectiveness']",Final,FDA-2021-D-0626,No,
CPG Sec 430.100 Unit Dose Labeling for Solid and Liquid Oral Dosage Forms,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-430100-unit-dose-labeling-solid-and-liquid-oral-dosage-forms,,1984-01-31,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
CVM GFI #24 Drug Combinations for Use in Animals,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-24-drug-combinations-use-animals,,1983-09-30,['Center for Veterinary Medicine'],['Target Animal – Effectiveness'],Final,FDA-2021-D-0627,No,
"CPG Sec. 398.450 Applicability of Positive Beam Limitation (PBL) Requirements When PBL is Provided on ""Other than Stationary General Purpose"" Radiographic System",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-398450-applicability-positive-beam-limitation-pbl-requirements-when-pbl-provided-other,,1983-07-31,"['Center for Devices and Radiological Health','Office of Regulatory Affairs']","['Investigation & Enforcement','Radiology']",Final,FDA-2020-D-0957,No,
CPG Sec. 450.550 Control and Accountability of Labeling Associated with Tamper-Resistant Packaging of Over-the-Counter Drug Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-450550-control-and-accountability-labeling-associated-tamper-resistant-packaging-over,,1983-03-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
CPG Sec. 682.200  The Use of Antibiotic Drug Residue By-Products in Animal Feed Feed (Withdrawn 2/20/2020),,,1982-09-30,[],"['Investigation & Enforcement','Animal Feed']",Final,FDA-2021-D-0645,No,
"CPG Sec. 615.300  Responsibility for Illegal Drug Residues in Meat, Milk and Eggs",,,1982-06-30,[],"['Investigation & Enforcement','Animal Drugs','Human Food Safety']",Final,FDA-2021-D-0646,No,
Clinical Evaluation of General Anesthetics,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-evaluation-general-anesthetics,,1982-05-01,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,,No,
CPG Sec. 450.100 CGMP Enforcement Policy - OTC vs Rx Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-450100-cgmp-enforcement-policy-otc-vs-rx-drugs,https://www.fda.gov/media/72021/download,1982-04-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,None found,No,
CPG Sec. 688.100  Unapproved Additives for Exported Grains,,,1982-01-31,[],"['Investigation & Enforcement','Animal Feed','Export']",Final,,No,
Procedures for Laboratory Testing of Microwave Ovens,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/procedures-laboratory-testing-microwave-ovens,https://www.fda.gov/media/74725/download,1981-10-01,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Exemption from Reporting and Record keeping Requirements for Certain Sunlamp Product Manufacturers,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exemption-reporting-and-record-keeping-requirements-certain-sunlamp-product-manufacturers,https://www.fda.gov/media/73639/download,1981-09-16,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
CPG Sec. 430.200 Repacking of Drug Products - Testing/Examination under CGMPs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-430200-repacking-drug-products-testingexamination-under-cgmps,,1981-07-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
Investigational Medical Laser Significant Risk Device (Laser Notice 31),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-medical-laser-significant-risk-device-laser-notice-31,https://www.fda.gov/media/73645/download,1981-05-18,['Center for Devices and Radiological Health'],['Laser Notice'],Final,FDA-2020-D-0957,No,
Clinical Evaluation of Antiepileptic Drugs (adults and children),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-evaluation-antiepileptic-drugs-adults-and-children,https://www.fda.gov/media/71165/download,1981-01-01,['Center for Drug Evaluation and Research'],"['Clinical - Medical','Pediatric Product Development']",Final,,No,
CPG Sec 500.100 Additives - Labeling with Adequate Directions for Many Uses,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-500100-additives-labeling-adequate-directions-many-uses,,1980-10-01,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
CPG Sec 510.200 Brandy Containing Methyl Alcohol - Food Additive,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-510200-brandy-containing-methyl-alcohol-food-additive,,1980-10-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Beverage Bases/Conc/Nectar']",Final,,No,
"CPG Sec 510.300 Unfermented Beverages - Use of Word ""Champagne""",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-510300-unfermented-beverages-use-word-champagne,,1980-10-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Beverage Bases/Conc/Nectar']",Final,,No,
CPG Sec 515.300 Honey - Source Declaration,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515300-honey-source-declaration,,1980-10-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Candy/Gum (without chocolate)']",Final,,No,
CPG Sec 515.350 Candy - Mixed with Trinkets and Sold in Vending Machines,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515350-candy-mixed-trinkets-and-sold-vending-machines,,1980-10-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Candy/Gum (without chocolate)']",Final,,No,
"CPG Sec 515.500 Barley Sugar - Definition, and Barley Sugar Candy",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515500-barley-sugar-definition-and-barley-sugar-candy,,1980-10-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Candy/Gum (without chocolate)']",Final,,No,
CPG Sec 525.750 Spices - Definitions,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525750-spices-definitions,,1980-10-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
CPG Sec 540.475 Snapper - Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540475-snapper-labeling,,1980-10-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Seafood/Seafood Product']",Final,,No,
CPG Sec 560.450 Imported Low-Acid Canned Foods (Manufacturer Not Registered and/or No Scheduled Process Filed),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-560450-imported-low-acid-canned-foods-manufacturer-not-registered-andor-no-scheduled-process,,1980-10-01,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Import']",Final,,No,
"CPG Sec 560.500 Jams, Jellies and Related Products - Imports",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-560500-jams-jellies-and-related-products-imports,,1980-10-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Import']",Final,,No,
"CPG Sec 562.450 Identity of Foods - Use of Terms Such as Fresh, Frozen, Dried, Canned, Etc.",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562450-identity-foods-use-terms-such-fresh-frozen-dried-canned-etc,,1980-10-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Labeling']",Final,,No,
CPG Sec 578.100 Starches - Common or Usual Names,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-578100-starches-common-or-usual-names,,1980-10-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Grain/Grain Product']",Final,,No,
CPG Sec 578.350 Wheat for Human Consumption - Reconditioning,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-578350-wheat-human-consumption-reconditioning,,1980-10-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Grain/Grain Product']",Final,,No,
CPG Sec. 110.100 Certification for Exports (Withdrawn 11/04/2021),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-110100-certification-exports-withdrawn-11042021,,1980-10-01,['Office of Inspections and Investigations'],['Investigation & Enforcement'],Final,FDA-1996-D-0405,No,
"CPG Sec. 400.325 Candy ""Pills"" Representation as Drug",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-400325-candy-pills-representation-drug,,1980-10-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,None found,No,
CPG Sec. 400.600 Drugs - Declaration of Quantity of Active Ingredient by Both Metric and Apothecary Systems,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-400600-drugs-declaration-quantity-active-ingredient-both-metric-and-apothecary-systems,,1980-10-01,['Center for Drug Evaluation and Research'],"['Investigation & Enforcement','Labeling']",Final,,No,
CPG Sec. 400.800 Collection and Charitable Distribution of Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-400800-collection-and-charitable-distribution-drugs,,1980-10-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
CPG Sec. 400.900 Class I Recalls of Prescription Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-400900-class-i-recalls-prescription-drugs,,1980-10-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,None found,No,
CPG Sec. 420.400 Performance of Tests for Compendial Requirements on Compendial Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-420400-performance-tests-compendial-requirements-compendial-products,,1980-10-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
CPG Sec. 442.100 New Drugs - Export,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-442100-new-drugs-export,,1980-10-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,None found,No,
CPG Sec. 444.100 Recovery of Investigational New Drugs from Clinical Investigators,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-444100-recovery-investigational-new-drugs-clinical-investigators,,1980-10-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,None found,No,
CPG Sec. 460.100 Hospital Pharmacies - Status as Drug Manufacturer,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-460100-hospital-pharmacies-status-drug-manufacturer,,1980-10-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,None found,No,
CPG Sec. 460.300 Return of Unused Prescription Drugs to Pharmacy Stock,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-460300-return-unused-prescription-drugs-pharmacy-stock,,1980-10-01,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,None found,No,
CPG Sec. 690.400  Water and Gravy in Pet Food (Withdrawn 2/20/2020),,,1980-10-01,[],"['Investigation & Enforcement','Pet Food']",Final,,No,
CPG Sec 390.100 Definition of “Commerce” - 21 CFR 1000.3(d) 2,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-390100-definition-commerce-21-cfr-10003d-2,https://www.fda.gov/media/84821/download,1980-10-01,"['Office of Regulatory Affairs','Center for Devices and Radiological Health']",['Investigation & Enforcement'],Final,,No,
CPG Sec 555.450 Foods - Adulteration Involving Infestation and 1080 Rodenticide,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555450-foods-adulteration-involving-infestation-and-1080-rodenticide,https://www.fda.gov/media/127705/download,1980-10-01,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
CPG Sec 555.500 All Food Sanitation (Including Bacteriological) Inspections - Classification of Establishment,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555500-all-food-sanitation-including-bacteriological-inspections-classification,https://www.fda.gov/media/71965/download,1980-10-01,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
CPG Sec 578.400 Treated Grain Seed - Mercury Residue,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-578400-treated-grain-seed-mercury-residue,https://www.fda.gov/media/72102/download,1980-10-01,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Grain/Grain Product']",Final,,No,
CPG 230.120- Human Blood and Blood Products as Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-230120-human-blood-and-blood-products-drugs,,1980-09-30,['Office of Regulatory Affairs'],"['Investigation & Enforcement','Blood Products']",Final,,No,
CPG Sec 520.200 Canned Foods - Seam Defects,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-520200-canned-foods-seam-defects,,1980-09-30,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Canned Foods']",Final,,No,
CPG Sec 525.650 Labeling of Seasonings,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525650-labeling-seasonings,,1980-09-30,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dressing/Condiment']",Final,,No,
CPG Sec 527.450 Milk & Milk Products Containing Penicillin,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527450-milk-milk-products-containing-penicillin,,1980-09-30,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Dairy']",Final,,No,
CPG Sec 540.285 Crabmeat Products - Labeling; Crabmeat Products with Added Fish or Other Seafood Ingredients - Labeling,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540285-crabmeat-products-labeling-crabmeat-products-added-fish-or-other-seafood-ingredients,,1980-09-30,"['Office of Inspections and Investigations','Human Foods Program']","['Investigation & Enforcement','Seafood/Seafood Product']",Final,,No,
CPG Sec 550.550 Maraschino Cherries,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550550-maraschino-cherries,,1980-09-30,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
CPG Sec 550.575 Marmalade,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550575-marmalade,,1980-09-30,['Human Foods Program'],"['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
CPG Sec 550.625 Oranges - Artificial Coloring,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550625-oranges-artificial-coloring,,1980-09-30,"['Human Foods Program','Office of Inspections and Investigations']","['Investigation & Enforcement','Fruit/Fruit Product']",Final,,No,
CPG Sec 555.200 Adulterated Food Mixed with Good Food,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555200-adulterated-food-mixed-good-food,,1980-09-30,"['Human Foods Program','Office of Inspections and Investigations']",['Investigation & Enforcement'],Final,,No,
CPG Sec. 110.500  Food and Drug Guaranty - Imports,,,1980-09-30,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 130.100  Inspectional Authority; Refusal to Permit Inspection.,,,1980-09-30,[],"['Investigation & Enforcement','Food & Color Additives']",Final,,No,
"CPG Sec. 251.100 Schedule of Physical Examination for Donors Receiving Immunization Injections (Obsolete, Withdrawn on 11/28/2017)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-251100-schedule-physical-examination-donors-receiving-immunization-injections-obsolete,,1980-09-30,[],"['Investigation & Enforcement','Blood Products']",Final,,No,
CPG Sec. 398.400 Automatic Adjustment of the X-ray Field Size to the Selected Spot-Film Size - 21 CFR 1020.31(g)(1),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-398400-automatic-adjustment-x-ray-field-size-selected-spot-film-size-21-cfr-102031g1,,1980-09-30,[],"['Investigation & Enforcement','Radiology']",Final,,No,
CPG Sec. 420.200 Compendium Revisions and Deletions,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-420200-compendium-revisions-and-deletions,,1980-09-30,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
CPG Sec. 420.300 Changes in Compendial Specifications and NDA Supplements withdrawn on 8/30/12,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-420300-changes-compendial-specifications-and-nda-supplements-withdrawn-83012,,1980-09-30,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 460.400 Computerized Prescription Recordkeeping by Pharmacies,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-460400-computerized-prescription-recordkeeping-pharmacies,,1980-09-30,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
CPG Sec. 460.425 Prescription Status when Telephoned to Recording Machine,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-460425-prescription-status-when-telephoned-recording-machine,,1980-09-30,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
CPG Sec. 460.500 Prescription Drugs for Ship's Medicine Chests,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-460500-prescription-drugs-ships-medicine-chests,,1980-09-30,['Center for Drug Evaluation and Research'],['Investigation & Enforcement'],Final,,No,
CPG Sec. 625.200  Availability of Bulk Chemicals for Animal Drug Use (Withdrawn 4/14/2022),,,1980-09-30,[],"['Investigation & Enforcement','Animal Drugs']",Final,FDA-2021-D-0647,No,
CPG Sec. 655.200  Adequate Directions for Use - Animal Drugs & Veterinary Devices (Withdrawn 2/20/2020),,,1980-09-30,[],"['Investigation & Enforcement','Animal Devices','Animal Drugs','Labeling']",Final,,No,
CPG Sec. 660.100  Failure to Register (Withdrawn 2/20/2020),,,1980-09-30,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 682.100  Use of Drug-Contaminated Products in Animal Feed (Withdrawn 2/20/2020),,,1980-09-30,[],"['Investigation & Enforcement','Animal Feed']",Final,,No,
CPG Sec. 690.200  Pet Food Labeling (Withdrawn 2/20/2020),,,1980-09-30,[],"['Investigation & Enforcement','Labeling','Pet Food']",Final,,No,
Alternate Wording For Caution Statement (Laser Notice 30),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/alternate-wording-caution-statement-laser-notice-30,https://www.fda.gov/media/73660/download,1980-08-25,['Center for Devices and Radiological Health'],['Radiology'],Final,FDA-2020-D-0957,No,
Quality Control Practices for Compliance with the Federal Mercury Vapor Lamp Performance Standard,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-control-practices-compliance-federal-mercury-vapor-lamp-performance-standard,https://www.fda.gov/media/75030/download,1980-05-01,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Open Door Operation of Microwave Ovens as a Result of Oven Miswiring,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/open-door-operation-microwave-ovens-result-oven-miswiring,https://www.fda.gov/media/73665/download,1980-03-28,['Center for Devices and Radiological Health'],['Radiological Health'],Final,FDA-2020-D-0957,No,
"Exemption of Certain Lasers Used By DOE, NOAA and U.S. Dept. of Commerce (Laser Notice 25)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exemption-certain-lasers-used-doe-noaa-and-us-dept-commerce-laser-notice-25,https://www.fda.gov/media/73678/download,1979-09-14,['Center for Devices and Radiological Health'],['Radiological Health'],Final,FDA-2020-D-0957,No,
"Good Laboratory Practice Regulations Management Briefings, Post Conference Report, Aug 1979:  Guidance for Industry",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-laboratory-practice-regulations-management-briefings-post-conference-report-aug-1979,,1979-08-31,"['Center for Veterinary Medicine','Human Foods Program','Office of Inspections and Investigations','Center for Biologics Evaluation and Research','Center for Devices and Radiological Health','Center for Drug Evaluation and Research']","['Clinical Trials','Compliance','Food & Color Additives','Investigational New Drug Application (INDA)','Pharmacology/Toxicology']",Final,FDA-1976-N-0476-0380,No,
General Guidelines for OTC Combination Products,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-guidelines-otc-combination-products,https://www.fda.gov/media/72423/download,1978-11-01,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Final,,No,
Upgrading Category III Antiperspirants to Category I (43 FR 46728-46731),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/upgrading-category-iii-antiperspirants-category-i-43-fr-46728-46731,https://www.fda.gov/media/72221/download,1978-10-01,['Center for Drug Evaluation and Research'],['Over-the-Counter Drugs'],Final,,No,
Guidance ('Guidelines') for Evaluation of Hysteroscopic Sterilization Devices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-guidelines-evaluation-hysteroscopic-sterilization-devices,https://www.fda.gov/media/73025/download,1978-05-09,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Laser Light Shows Subject to Laser Product Performance Standard (Laser Notice 22),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/laser-light-shows-subject-laser-product-performance-standard-laser-notice-22,https://www.fda.gov/media/73704/download,1977-11-23,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Antidepressant Drugs--Clinical Evaluation,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antidepressant-drugs-clinical-evaluation,,1977-09-01,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,,No,
Hypnotic Drugs--Clinical Evaluation,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hypnotic-drugs-clinical-evaluation,https://www.fda.gov/media/71609/download,1977-09-01,['Center for Drug Evaluation and Research'],['Clinical - Medical'],Final,,No,
Procedures for Field Testing Microwave Ovens,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/procedures-field-testing-microwave-ovens,https://www.fda.gov/media/74740/download,1977-08-01,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Warning Labels For Dye And Multiple Wavelength Lasers (Laser Notice 16),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/warning-labels-dye-and-multiple-wavelength-lasers-laser-notice-16,https://www.fda.gov/media/73733/download,1977-03-02,['Center for Devices and Radiological Health'],['Radiological Health'],Final,FDA-2020-D-0957,No,
Review Guidelines for Oxygen Generators and Oxygen Equipment for Emergency Use,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/review-guidelines-oxygen-generators-and-oxygen-equipment-emergency-use,,1977-01-01,['Center for Devices and Radiological Health'],['Premarket'],Final,FDA-2020-D-0957,No,
Lasers Manufactured and Used In-House (Laser Notice 14),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/lasers-manufactured-and-used-house-laser-notice-14,https://www.fda.gov/media/73740/download,1976-11-23,['Center for Devices and Radiological Health'],['Laser Notice'],Final,FDA-2020-D-0957,No,
Manufacture and Certification of Laser Kits (Laser Notice 13),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacture-and-certification-laser-kits-laser-notice-13,https://www.fda.gov/media/73749/download,1976-10-14,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Remote Interlock Connectors (Laser Notice 11),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/remote-interlock-connectors-laser-notice-11,https://www.fda.gov/media/73756/download,1976-10-07,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Certain Military Lasers Exempt From 21 CFR 1040.10 & .11 (Laser Notice 9),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/certain-military-lasers-exempt-21-cfr-104010-11-laser-notice-9,https://www.fda.gov/media/73777/download,1976-08-23,['Center for Devices and Radiological Health'],['Radiological Health'],Final,FDA-2020-D-0957,No,
Viewing Optics - Sighting Telescope (Laser Notice 8),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/viewing-optics-sighting-telescope-laser-notice-8,https://www.fda.gov/media/73783/download,1976-08-05,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Quality Control Practices for Compliance with the Federal Laser Performance Standard,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-control-practices-compliance-federal-laser-performance-standard,https://www.fda.gov/media/75913/download,1976-03-01,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Laser Energy Source (Laser Notice 2),https://www.fda.gov/regulatory-information/search-fda-guidance-documents/laser-energy-source-laser-notice-2,https://www.fda.gov/media/73819/download,1975-11-21,['Center for Devices and Radiological Health'],,Final,FDA-2020-D-0957,No,
Guidance for the Submission of Cabinet X-Ray System Reports Pursuant to 21-CFR 1020.40,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-submission-cabinet-x-ray-system-reports-pursuant-21-cfr-102040,https://www.fda.gov/media/74944/download,1975-02-01,['Center for Devices and Radiological Health'],['Radiological Health'],Final,FDA-2020-D-0957,No,
CPG Sec. 335.300 Hypnotherapy Devices - Self-Hypnotic Tape Recordings,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-335300-hypnotherapy-devices-self-hypnotic-tape-recordings,https://www.fda.gov/media/83980/download,1900-01-01,"['Office of Regulatory Affairs','Center for Devices and Radiological Health']",['Investigation & Enforcement'],Final,FDA-2020-D-0957,No,
Chapter 1 - General,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chapter-1-general,,,[],['Investigation & Enforcement'],Final,,No,
Chapter 3 - Devices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chapter-3-devices,,,[],['Investigation & Enforcement'],Final,,No,
Chapter 4 - Human Drugs,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chapter-4-human-drugs,,,[],['Investigation & Enforcement'],Final,,No,
"CPG Sec. 257.100 Deferral of Source Plasma Donors Due To Red Cell Loss During Collection of Source Plasma by Automated Plasmapheresis (Obsolete, Withdrawn on 11/28/2017)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-257100-deferral-source-plasma-donors-due-red-cell-loss-during-collection-source-plasma,,,[],['Investigation & Enforcement'],Final,,No,
"CPG Sec. 390.100 Definition of ""Commerce"" - 21 CFR 1000.3(d)",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-390100-definition-commerce-21-cfr-10003d,,,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 420.500 Interference with Compendial Tests,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-420500-interference-compendial-tests,,,[],['Investigation & Enforcement'],Final,,No,
CPG Sec. 460.700 Controlled Release Dosage Form Drugs - Rate of Release of Active Ingredients,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-460700-controlled-release-dosage-form-drugs-rate-release-active-ingredients,,,[],['Investigation & Enforcement'],Final,,No,
"Formas posológicas orales sólidas de liberación inmediata Cambios de escala y posteriores a la aprobación: documentación química, de fabricación y controles, de pruebas de disolución in vitro y bioequivalencia in vivo.",https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formas-posologicas-orales-solidas-de-liberacion-inmediata-cambios-de-escala-y-posteriores-la,,,[],,Final,,No,
"Guía para la Industria:  Formas de dosificación oral de liberación prolongada: elaboración, evaluación y aplicación de correlaciones in vitro/in vivo",,,,[],,Final,,No,
Guía para la Industria:  Pruebas de disolución de formas de dosificación oral sólidas de liberación inmediata.,,,,[],,Final,,No,
CHAPTER 48 - 7348.809 Bioresearch Monitoring,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chapter-48-7348809-bioresearch-monitoring,https://www.fda.gov/media/75909/download,,[],,Final,,No,
Chapter 48 7348.809A Radioactive Drug Research Committee,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chapter-48-7348809a-radioactive-drug-research-committee,https://www.fda.gov/media/79759/download,,[],,Final,,No,
CPG Sec. 300.500 *Reprocessing of Single Use* Devices,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-300500-reprocessing-single-use-devices,https://www.fda.gov/media/71769/download,,[],['Investigation & Enforcement'],Final,,No,
Final In Vivo Bioavailability-Bioequivalence Studies- Analytical,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/final-in-vivo-bioavailability-bioequivalence-studies-analytical,https://www.fda.gov/media/112533/download,,[],,Final,,No,
NEPA_Final_Guidance,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nepa_final_guidance,https://www.fda.gov/media/94445/download,,[],,Final,,No,
New/Revised/Withdrawn Guidances 2014,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/newrevisedwithdrawn-guidances-2014,https://www.fda.gov/media/88642/download,,[],,Final,,No,
Sample WHO Certificate for Quality of a Pharmaceutical Product,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sample-who-certificate-quality-pharmaceutical-product,https://www.fda.gov/media/75456/download,,[],['Investigation & Enforcement'],Final,,No,